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Summary 
In this PhD project we show for the first time that novel dideoxy bicyclic pyrimidine 
nucleoside analogues (ddBCNAs) with L-chirality represent promising antiviral 
candidates for use against pox and measles viruses. We suggest a mechanism of 
action based on a cellular target. Our lead compound (Cf2642, with side chain 
C9H18–O–C5H11) is active against vaccinia virus (a surrogate poxvirus for smallpox) 
and measles virus, with IC50 concentrations of 0.19 and 7.5 µM, respectively.  This is 
a 60-fold enhancement over cidofovir (viral DNA polymerase inhibitor; IC50 of 11.5 
µM against VACV). A structure activity relationship was established, which was 
similar for both viruses, indicating a common and specific mechanism of action. 
Cf2642 does not inhibit HSV-1/2, influenza, adeno or yellow fever viruses. The 
mechanism of action for the ddBCNAs has been investigated and, though not 
defined, has been narrowed down. Based on our observations of drug activity in cell 
lines derived from various sources, we have suggested a cellular target for the 
ddBCNAs, most likely cellular membrane compartments or the proteins located 
therein. Though inhibition of vaccinia is observed within two hours of infection, we 
have shown that the ddBCNAs are unlikely to be entry inhibitors. Acidification of 
the extracellular medium was observed but, whilst it may be linked to the 
mechanism of action, this is not the cause of the antiviral effects.  With a possible 
cellular target, toxicity was carefully evaluated.  We have not observed significant 
cytotoxicity in any of our cell models. Antivirals active against cellular targets are 
less subject to viral resistance, which may develop rapidly with virus-targeting 
drugs. This could be critical since, there are currently no effective measles antiviral 
drugs available on the market, and resistance to measles RNA polymerase inhibitors 
and the potential antipoxviral drug cidofovir has already been described. 
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Chapter one - Introduction 
1.1 Di-deoxybicyclic nucleoside analogues 
Di-deoxybicyclic nucleoside analogues (ddBCNAs) are novel nucleoside analogues 
that have a bicyclic pyrimidine base with a hydrocarbon side chain at the C5 
position and lack hydroxyl groups on both the 2’ and 3’ sites of the sugar moiety 
(2’,3’-dideoxy sugar) (McGuigan et al. 2004; McGuigan et al. 2013). The general 
structure of these compounds is shown in figure 1.1. These were produced with the 
aim of developing new antiviral compounds.  
All ddBCNAs described herein were produced by the McGuigan group of Cardiff 
University, School of Pharmacy and Pharmaceutical Sciences. Initial activity of the 
ddBCNAs was discovered against human cytomegalovirus (hCMV) with the 
compound Cf1821, a D-enantiomer with an alkyl side chain of ten carbons in length. 
This compound was further optimised in order to determine the structure with the 
best activity. In the process of optimisation, it was found that switching from the D- 
to the L-enantiomer configuration produced compounds with increased activity 
against vaccinia virus (VACV). In addition, the L-configuration was later found to be 
active against measles virus.  
 
Figure 1.1 General structure of the ddBCNAs. The R group represents the 
hydrocarbon side chain which is varied to produce different ddBCNAs.  
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1.1.1 Background of BCNA nucleoside analogues as antiviral compounds 
In 1999 McGuigan et al. published data describing a new series of compounds that 
displayed highly selective antiviral activity against Varicella Zoster Virus (VZV). 
These compounds (bicyclic furano pyrimidine 2′-deoxynucleosides) were 
deoxynucleoside analogues with a bicyclic base region, (structures shown in figure 
1.2) and displayed fluorescent properties. They are unique in that other reported 
nucleoside analogues displaying activity against VZV also show activity against 
Herpes simplex virus (HSV), whereas these compounds do not. Human 
cytomegalovirus (hCMV) and VACV were also tested but were not affected. 
 
Figure 1.2 The structure of the deoxybicyclic nucleoside analogues active against 
VZV. The series produced, included alkyl side chains (R) ranging from C5 to C12. 
They were discovered as by products of the Pd-catalysed coupling of terminal 
alkynes with 5-iodo-nucleosides, the reaction used for the production of 5-alkynyl-
2’-deoxyuridines. A structure activity relationship (SAR) profile, based on the length 
of the alkyl side chain of these novel deoxynucleoside analogue compounds was 
produced, with the optimum activity being observed when the side chain was 8-10 
carbons long. These compounds were found to have 300 fold greater activity 
against VZV than the control drug acyclovir and displayed no signs of cytotoxicity in 
vitro (McGuigan et al. 1999). These compounds were not active against thymidine 
kinase-deficient strains of VZV, suggesting that they are activated by VZV kinases to 
their 5’-phosphate forms.  
In attempts at optimisation of these structures, the addition of halogen atoms (F, 
Cl, Br, I) at the end of the alkyl chain was tested though no significant differences in 
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antiviral activity was observed. No cytotoxity was observed for these compounds 
either. Furthermore, (prior to the cyclisation step) intermediate compounds in the 
synthesis of the deoxy bicyclic nucleoside analogues were also tested for activity. 
These compounds do not have the bicyclic structure and have an alkynyl group at 
the start of the side chain.  These intermediate compounds displayed reduced 
antiviral activity and showed signs of cytotoxicity against the cells tested (Brancale 
et al. 2000). 
Further analysis of the structure found that their activity could be significantly 
improved by the introduction of a phenyl ring group into the side chain of the 
compounds (McGuigan et al. 2001). The addition of an ether group in the alkyl side 
chain of these compounds significantly reduced the lipophilicity, however the 
antiviral activity was also reduced by around 1000 fold. These studies highlighted 
the requirement of the hydrophobic side chain in these compounds for optimum 
activity. Due to the high activity and low toxicity of the compounds with alkyl side 
chains, the selectivity index (toxic concentration divided by the active 
concentration) is very high at >5000. This rises to one million for the compounds 
containing a phenyl ring in the side chain. As such they represent anti-VZV drug 
candidates of great potential (McGuigan et al. 2001). Modifications elsewhere in 
the molecule were also attempted. It was found that sulphur, but not nitrogen, may 
be substituted into the furano ring in place of oxygen to maintain antiviral effect. 
However elsewhere in the molecule little variation in structure was permitted 
without loss of activity. Aryl substitutions at the C5 position of the furano ring 
abolished the activity and sugar variation (arabino- and ribo- analogues) also 
significantly reduced the antiviral activity.  
Following on from these studies, further investigations revealed that 2′,3′-dideoxy 
sugar analogues of these compounds became selective and potent inhibitors of 
hCMV but lost their activity against VZV. This confirmed that the 3’ hydroxyl group 
is required for activity against VZV. The intermediate length side chains on the 
dideoxy compounds displayed a similar range of activity to the current anti-hCMV 
drug gancyclovir. The compounds were also tested against human 
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immunodeficiency virus type 1 and type 2 (HIV-1 and HIV-2), HSV-1 and HSV-2 but 
were found to be inactive against these viruses (McGuigan et al. 2004). 
Interestingly these new compounds did not act as nucleoside analogues in their 
inhibition of hCMV. Time of addition (ToA) assays suggested that they may inhibit a 
stage of the hCMV replication cycle before DNA synthesis. The SAR profiles of the 
compounds also indicated little difference in activity between side chains of 8 and 
side chains of 12 carbons in length. In contrast, the SAR of the deoxy- compounds 
against VZV indicated that a change in side chain length of just 2 carbons altered 
the activity by 100 fold. This suggests that the new compounds are not required to 
interact with the precise kinases or DNA polymerases of hCMV (McGuigan et al. 
2004). It was the further study of these dideoxy nucleoside analogues against hCMV 
that led to the production of the ddBCNAs described in this project.  
1.1.2 D- versus L-chirality  
Chirality is the term used to describe molecules that have the same chemical 
formula but are arranged in such a way that they form mirror images of each other. 
The chirality of molecules may be described in different ways; here the D- and L- 
configuration is used. The D- or L- configuration is based on the molecule 
glyceraldehyde. Therefore, stating that the molecule of interest has D- or L- chirality 
is effectively stating that it is similar to the D- or L- form of glyceraldehyde 
respectively (Voet and Voet, 2004).To determine whether a particular molecule 
such as and amino acid should be described as D- or L- configuration the ‘CORN’ rule 
is applied. This rule states that, with the hydrogen (H) atom pointing away from the 
viewer, if the groups COOH, R and NH2 are arranged clockwise then the compound 
is the D- configuration and if they are arranged anti-clockwise then it is the L- 
configuration (Berg et al. 2006; Voet and Voet, 2004). Naturally, amino acids usually 
exist in the L- configuration while the ribose of DNA and RNA is usually in the D- 
configuration (Breslow and Cheng, 2009). 
Initial antiviral activity against hCMV was described using ddBCNAs with D-chirality. 
The initial hit for these D-compounds against hCMV with a 50% inhibitory 
concentration (IC50) of 2.6 µM was named Cf1821 which has an alkyl side chain 
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length of 10 carbons. During structure optimisation, an ether group was introduced 
into the side chain. This led to the production of Cf2095, a D-enantiomer ddBCNA 
with the side chain C9-O-C5, which displayed improved activity against hCMV (IC50 
0.5 µM) as compared to the initial lead Cf1821. This compound was also found to 
have some activity against VACV. An L-enantiomer equivalent of Cf2095 was 
produced and named Cf2642. This no longer showed activity against hCMV but 
showed much improved activity against VACV.  
Following on from this discovery, this project was initiated which included testing 
further modifications of both D- and L-ddBCNAs in order to optimise their structures 
for activity against VACV and to look into determining the mechanism of action 
(MoA) of these novel compounds. Further activity against measles virus led to a 
patent application (McGiugan et al. 2013). 
1.2 Poxvirus family  
There are two subfamilies of poxviruses within the poxvirus family: the 
Entomopoxvirinae, which contains three genera and infect only insects, and the 
Chordopoxvirinae, which contains ten genera and infects a wide range of mammals 
and birds (Haller et al. 2014).  There are two poxviruses that will infect only 
humans; Smallpox (variola virus) and Molluscum Contagiosum virus (MCV). 
However, many animal poxviruses may also cause disease in humans (Melquiot and 
Bugert, 2004; Moss, 1991).  
Poxviruses are large viruses, with a brick shaped/ovoid morphology. Their structure 
is known as complex since they are neither helical nor icosahedral, but have a 
unique dumbbell shaped core. The genome of poxviruses consists of linear double 
stranded (ds) DNA ranging between 130-360 kbp (Hughes et al. 2010). Replication 
occurs completely in the cytoplasm of the host cell and, as such, they were thought 
to be less dependent on host functions and able to replicate in cells that do not 
contain a nucleus (Schramm and Krijnse Locker, 2005).  However other studies have 
found that host nuclear proteins recruited by the virus play important roles in 
poxvirus replication (Sivan et al. 2013). This indicates that although the nucleus is 
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not the site of replication of poxviruses it is required by the virus for efficient 
replication. 
1.2.1 Vaccinia virus and its use as a vaccine  
Vaccinia virus (VACV) from the genus Orthopoxvirus is of particular interest as it 
was the first animal virus to be visualised microscopically, to be accurately titered 
and to be purified and analysed. The virus was successfully used as the smallpox 
vaccine, which lead to variola virus being the first virus to be eradicated through the 
organisation of a global vaccination campaign (Behbehani, 1983). There is evidence 
to suggest that the vaccine can induce long term protection against smallpox 
infection (Hammarlund et al. 2003). 
Despite the success of this vaccine, it can be associated with severe complications 
(Lane and Miller, 1971), especially in individuals with skin problems such as eczema 
(Engler et al. 2002) and for individuals with defective innate immunity. 
Complications were due to the high levels of VACV replication and spread from the 
initial site of inoculation (Bray, 2003). In such instances, antiviral therapies would be 
beneficial.  
First attempts at immunisation against smallpox involved the process of variolation 
where a healthy individual was inoculated using variola virus obtained from the 
lesions of an infected individual (Arita, 1979). This method was replaced by the 
safer method of using cowpox virus after it was demonstrated by Edward Jenner to 
also provide protection from smallpox. Cowpox was later replaced with VACV. The 
first VACV vaccines used included Dryvax, Lister and Copenhagen strains produced 
in the skin of live animals. Dryvax (Wyeth laboratories, Marietta, PA) for example 
was produced in calf skin infected with the NYCBH strain of VACV (Rosenthal et al. 
2001).  
Since the eradication of smallpox, other versions of VACV vaccine have been 
produced in an attempt to reduce complications associated with this virus. A new 
version produced in Vero cells (tissue culture adapted) from a plaque purified clone 
of Dryvax has been produced called ACAM2000 (Artenstein et al. 2005). Although it 
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appears that the rates of unintentional transfer are similar between the two types 
of vaccine (Tack et al. 2013).  
Other vaccine strains include Paris strain (France), Copenhagen strain (Denmark), 
Bern strain (Switzerland), Ankara strain (Turkey), Temple of Haven and Vaccinia Tian 
Tian strains (China) and the Dairen strain (Japan). Each of these stains varying in the 
levels of adverse effects. Further attempts to produce vaccines with reduced 
adverse effects have involved attenuating the virus by passaging in alternative hosts 
(e.g. Modified Vaccinia Ankara; MVA, which was passaged in chick embryo 
fibroblast cells over 570 times) and through genetic engineering (e.g. NYVAC, which 
has deletion of 18 open reading frames) (Jacobs et al. 2009). 
1.2.1.1 Vaccinia structure 
The VACV genome is about 190 000 base pairs (bp) in length, and consists of ds 
linear DNA with covalently closed ends, which is packaged into the core. VACV has 
four different forms of infectious virion. These include the intracellular mature virus 
(IMV), the intracellular enveloped virus (IEV), the cell-associated enveloped virus 
(CEV) and the extracellular enveloped virus (EEV). The most common of these is the 
IMV which remains inside the host cell until cell lysis, at which point it is then able 
to infect other cells. The IEV is the intermediate virus between the IMV and the 
CEV/EEV and is produced when the IMV is wrapped with intracellular membranes. 
The IEV is then transported to the cell membrane on microtubules. The CEV can 
induce actin tails at the surface of the cell that propel it away from the infected cell 
and allow it to spread to nearby cells. The EEV allows the virus to spread to cells 
even further away from the host cell (while the initial replication process is ongoing 
in the original cell). CEV and EEV are physically the same and differ only in their 
location in relation to the host cell. The CEV and EEV contain one less membrane 
than the IEV since one is fused with the plasma membrane when the virus particle 
is released (Smith et al. 2002). The general structures of the IMV and the EEV are 
shown in figure 1.3. 
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Figure 1.3 Structures of VACV IMV and EEV. The EEV form of the virus possesses an extra external membrane envelope. The core of 
the virus packages the ds genomic DNA (ds gDNA). The complete virus structure contains lateral bodies, the function of which is not 
entirely clear (Schmidt et al. 2013).  (Adapted from viralzone.expasy.org)
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The proteins and properties that make up the different forms of VACV vary, 
meaning that using a virus vaccine of only IMV particles does not lead to full 
protection against orthopoxvirus infection. Both EEV and IMV forms of the virus 
need to be present to initiate an adequate immune response (Roberts and Smith, 
2008). In addition inactivated forms of vaccinia vaccine do not induce sufficient 
immune response. Individuals initially treated with the inactivated virus vaccine, 
that are later treated with the live vaccine, showed similar response levels to those 
given just the live vaccine (Kaplan et al. 1965). 
The IMV is more robust than the other forms of VACV and is more effective at 
spreading the virus between hosts. However, it is less suitable for spreading the 
virus within the host when compared with the CEV and EEV forms (Townsley et al. 
2005). This is due to the fact that it remains inside the cell until cell lysis, delaying 
its opportunity to infect other cells. The other obstacle for the IMV is that it is more 
readily recognised by antibodies as it contains most of the viral membrane proteins. 
The CEV and EEV forms, on the other hand, have membranes that have been 
derived from the host and as such also contain some of the host’s membrane 
proteins. This protects the virus, to some extent, from antibody binding and 
provides the virus with increased opportunities for receptor binding with host cells 
(Smith et al. 2002). 
1.2.1.2 VACV entry 
Attempts to determine the exact mechanism of VACV entry into cells have been 
complicated by the fact that VACV exists in different infectious forms with different 
numbers of membranes (Moss, 2006). Each of the different forms contains the 
same DNA and protein core. The different forms of VACV enter the cells by different 
mechanisms (Vanderplasschen et al. 1998). In many cases of viral entry, just one or 
two fusion proteins are enough to control entry. For example measles virus requires 
only two proteins for viral attachment and fusion (measles F and H proteins, 
discussed later in the introduction, section 1.3.3). In the case of VACV this is more 
complicated as there are four proteins that have been found responsible for 
attachment to the cell and a further 12 in a complex that are involved with cell 
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entry and are conserved between poxvirus species (Moss, 2012). There are two 
different routes of entry that the IMV form may use depending on the extracellular 
pH or the pH of cellular endosomes. These include direct fusion with the cell 
membrane or uptake through endocytosis (figure 1.4).  
 
Figure 1.4 A summary of the methods of entry of the IMV and EEV forms of VACV. 
The IMV may enter the cell either through direct fusion with the membrane or by a 
form of endocytosis, the endocytosed virus particle must then fuse with the 
membrane of the vesicle to release the core into the cytoplasm. The EEV particles 
must shed their outer membrane before fusion with the plasma membrane may 
occur. Adapted from Roberts and Smith (2008).  
 
The fact that VACV have so many proteins linked to entry, combined with the fact 
that the sequences that encode them do not resemble those observed in other 
viruses, suggests that VACV enter cells by a unique method. In some instances, the 
use of inhibitors of cellular processes was found to have an effect on the ability of 
the virus to enter the host. These were mainly processes involved with actin 
remodelling/polymerisation (e.g. blebbistatin) or the tyrosine kinases that mediate 
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actin cytoskeletal changes (e.g. genistein). The overall result in these cases was that 
the virus could still attach to the cell membrane but the core could not enter the 
cell, i.e. fusion was inhibited (Laliberte et al. 2011).  
The most common form of VACV is the IMV. This form has just a single phospholipid 
bilayer that contains non-glycosylated viral proteins. For the majority of enveloped 
viruses, fusion occurs when the envelope of the virus fuses with the host cell 
plasma membrane. There is evidence to suggest that the IMV form of VACV also 
enter cells in this way (Roberts and Smith, 2008). However, evidence suggests that 
the IMV may also enter the cell by an internalisation (endocytic) method such as 
macropinocytosis (Mercer and Helenius, 2009) after the induction of blebbing at 
the cell surface through the presence of phosphatidyserine exposed on the viral 
membrane (Mercer and Helenius, 2008). The virus induces activation of p21 
activated kinase 1 (PAK1). The requirement for exposed phosphatidylserine on the 
virus membrane suggests that the virus uses apoptotic mimicry to enter the host 
cell. Cells treated with Blebbistatin (an inhibitor of myosin II preventing blebbing) 
and exposed to VACV showed significantly reduced rates of infection. This suggests 
that the blebbing caused by VACV, on contact with the host, is important for 
efficient virus entry (Mercer and Helenius 2008). This method of entry was 
observed with the Western Reserve (vWR) strain of VACV IMV, however other 
methods of macropinocytosis have been observed with different strains of VACV. 
The International Health Department-J strain of VACV (IHD-J) was found to induce 
and lengthen filopodia. The differences observed were found to be partly due to 
differences in the levels of cellular Rho GTPases (induced by the virus) between the 
different strains (Mercer et al. 2010).    
The method of entry utilised by VACV likely depends on a series of factors including 
the pH, the strain of the virus, and the type of host cell it is entering. It has been 
found that the IMV contains a set of viral fusion proteins that are conserved across 
poxvirus species, including A21, A28, H2, and L5 (Townsley et al. 2005). They are 
associated with each other, and other proteins on the membrane of the IMV. It has 
been demonstrated that knocking out any one of these proteins results in an IMV 
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that is unable to enter the cell (and is no longer infectious). This work highlighted 
the importance of these proteins in the entry process (Senkevich et al. 2005). 
VACV entry to the cell is pH dependant. VACV may enter cells through a low pH 
mediated endosomal pathway. This method of entry is inhibited by drugs that 
prevent acidification of endosomes for example balfilomycin (Townsley et al. 2006). 
Two VACV proteins A25 and A26 have been described as fusion suppressors as they 
prevent the direct fusion of the IMV with the membrane at a neutral pH. Entry 
through low pH dependent endocytosis is not inhibited by these proteins. It is likely 
that these proteins act as fusion modulators to prevent random fusion of the IMV 
with cell membranes until required for a new infection (Chang at al. 2010) and to 
allow the release of newly produced virions from the surface of the host cell. 
 The EEV form of the virus requires an additional stage for viral entry. Here, 
disruption of the fragile outer membrane of the virus occurs before the internal 
IMV is able to fuse with the host membrane (figure 1.4). This disruption of the outer 
membrane occurs after interaction with glycosaminoglycans (GAGs) on the 
membrane of the host cell. Viral proteins B5 and A34 are required for this process 
(Roberts et al. 2009). Were the EEV to fuse directly with the membrane without this 
stage, the internalised IMV would have to undergo shedding of its intact membrane 
in order to be able to release its viral core in the cytoplasm. Other evidence 
highlighting the importance of this extra stage is that viral proteins involved with 
fusion and entry, are in the membrane of the IMV (Moss, 2012). These need to be 
exposed, by disruption of the outer membrane of the EEV before entry can take 
place.  
No specific cellular receptors have been determined for the entry of VACV. 
However, evidence suggests that depletion of cholesterol inhibits VACV entry, 
suggesting that glycosphingolipid-cholesterol enriched microdomains (lipid rafts) 
are required for VACV entry (Moss, 2006). When the raft disrupting drug methyl-β-
cyclodextrin was used to treat BSC40 cells that were subsequently infected with 
VACV, it was found that the infectivity of the virus decreased with increasing 
concentrations of the drug. This indicates that the cholesterol enriched lipid rafts 
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are needed for entry of the virus into the cell. However they are not necessary for 
binding of the virus to the host cell membrane. Virus proteins interact with lipid 
rafts during penetration (Chung et al. 2005). Several cellular lipid raft associated 
proteins are required for the entry of IMV particles. These include vaccinia virus 
penetration factor (VPEF) which is detected on lipid rafts and on vesicular 
structures in the cytoplasm (Huang et al. 2008), CD98 which is required for entry 
but not attachment (Schroeder et al. 2012) and Intergin β1 which activates PI3K/Akt 
signalling and mediates endocytosis (Izmailyan et al. 2012).  
1.2.1.3 VACV life cycle 
After the viral core has entered the cell by one of the methods explained above, the 
core is transported further into the cell cytoplasm along microtubules. It enters 
what is known as a virus factory within the cytoplasm. The virus factories are made 
using specific host cell components (Wileman, 2006) recruited by the virus, plus 
proteins synthesised by the virus forming a structured specific viral organelle 
(Condit, 2007).  The core of the virus consists of structural proteins and tightly 
packaged DNA. It also contains transcription enzymes that are required to initiate 
DNA replication. Within minutes of cell entry, early transcription occurs and viral 
mRNA is released through pores in the surface of the core (Broyles, 2003). The 
genes that are expressed during early transcription are those involved with DNA 
replication, evasion of the host immune response and modification of host 
components that the virus takes advantage of. After the completion of early 
transcription, there is a stage of intermediate transcription involving genes that 
encode regulatory proteins and initiators of late transcription. The structural 
proteins that make up the core of the newly formed virus, and the enzymes that are 
required for initiating transcription in the next cell, are transcribed late in the 
replication process (Moss, 1991).  
Early VACV transcription can be induced in vitro in the absence of cells using a 
specific buffer (Bugert et al. 1998; Shand et al. 1976). This indicates that VACV 
particles contain all their necessary components for early mRNA production 
(Broyles, 2003) including DNA-dependent RNA polymerase and may initiate early 
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transcription immediately after entry into the host cell. In the cell however it has 
been shown that the early mRNAs accumulate in granular structures some distance 
from the viral cores. These mRNA granules recruit host cell translation components, 
indicating that these granular mRNA sites are where protein synthesis occurs 
(Mallardo et al. 2001).  Further to this, it has been demonstrated that the site of 
DNA replication is in a separate location within the cell, specifically at the cytosolic 
side of endoplasmic reticulum (ER) membranes. As the infection progresses further, 
ER cisternae are recruited to the site, enclosing it with membranes (Mallardo et al. 
2002).   
It has been suggested that although the virus particles contain the necessary 
components for early transcription and may undergo induced transcription in vitro 
under specific conditions, they require cellular factors for their intermediate 
transcription. The virus intermediate transcription factor 2 (VITF-2) protein, 
involved with the intermediate transcription observed in vitro may be isolated from 
uninfected HeLa cells, but not from cells that are nonpermissive to VACV. It has 
been shown that RK13 cells which are conditionally permissive do not contain the 
VITF-2 protein, however wild type strains are able to replicate in these cells. Mutant 
strains that lack the K1L gene cannot replicate in RK13 cells but may replicate in cell 
lines that contain VITF-2. This line of work suggests that VITF-2 is a cellular protein 
required by the virus for intermediate transcription and that the K1L gene is 
possibly linked to the upregulation of VITF-2 (Rosales et al. 1994). 
VACV has several host range genes that are involved with its ability to grow in 
certain cells lines. For example, the E3L, K1L, C7L and B5R genes are essential for 
growth in HeLa, RK13, MRC-5 and vero cells respectively. Often host range genes 
are involved with the evasion of the host immune responses to the virus (Chung et 
al. 1997). 
The first structures observed during the VACV replication process are oval shaped 
and package DNA within. These structures are known as immature virions (IV). The 
IV is transformed into the classic brick shaped IMV by proteolytic cleavage of core 
proteins. It is currently unclear exactly how the IMV obtains its single lipid bilayer. 
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Though evidence suggests that during the assembly of viral particles, the IMV 
obtains its membrane through an open membrane intermediate that derives its 
structure through scaffold proteins on the convex side (Suárez et al. 2013). The 
assembly of the IMV particles is a complex process involving folding of cisternal and 
tubular domains (Griffiths et al. 2001). 
At the IMV stage, replication ends for the majority of VACV particles and they are 
released from the cell upon cell lysis. For some of the particles, the next stage in 
replication is transportation from the virus factory along microtubules to the 
golgi/early ensosomes of the cell. Here they are wrapped in host cell derived 
membranes (Tooze et al. 1993) to form intracellular enveloped virions (IEV). These 
IEV are further transported along microtubules to the cell membrane. The outer 
membrane fuses with the plasma membrane of the cell, releasing the EEV form of 
the virus. The virions that remain in contact with the cell upon release are known as 
CEV and can induce the cell to produce actin tails that propel the virus particle away 
from the surface of the cell (Blasco and Moss, 1992). A summary of the lifecycle of 
VACV is shown in figure 1.5. 
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Figure 1.5 VACV lifecycle. After entry and early transcription, the construction of 
new VACV particles occurs within virus factories. Here the IMV form of VACV is 
produced. In most cases this is where the lifecycle ends and the IMV particles are 
released upon cell lysis. Some IMV particles however get transported along 
microtubules to the golgi/endosomes where they are wrapped in membranes to 
form the IEV. The IEV is transported to the plasma membrane and released by 
fusion of the outer membrane of the IEV with the plasma membrane. The released 
particles are the CEV/EEV forms of VACV. Figure adapted from Smith et al. (2002). 
 
It was discovered that the IEV form of VACV use microtubule based transport, using 
a recombinant VACV with GFP fused to the membrane protein F13L. Live 
fluorescence microscopy of this virus detected movement of the particles at a rate 
consistent with microtubule based transport (~3 µm/s). In further support of this, 
the movement of the particles can be inhibited using the microtubule 
depolymerising drug nocodazole (Geada et al. 2001). 
It was once thought that the viral gene A27L was responsible for the microtubule 
transport of IMV particles. However it has been demonstrated that mutant strains 
of VACV with this gene deleted are still capable of bidirectional transport along 
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microtubules, as the IMV are able to be transported by both kinesin and dynein 
motors (Ward, 2005). Instead the deletion of A27L leads to VACV that are unable to 
form enveloped forms of the virus. The interaction between the IMV and the motor 
proteins appears to be weaker than between the IEV and the motor proteins. The 
IEV contain the protein A36 which interacts with kinesin (Ward and Moss, 2004). It 
was noted that the intracellular microtubule based transport precedes actin based 
motility observed at the membrane of the cell only (Rietdorf et al. 2001).  
It has been shown that during VACV infection the microtubule organising centre 
becomes reorganised in a manner similar to that observed with an upregulation of 
microtubule associated proteins (MAPs). Two VACV proteins were also found to 
have properties similar to MAPs and could mediate direct binding of viral cores to 
microtubules in vitro (Ploubidou et al. 2000).   
The protein kinesin-1, but not kinesin-2, was found to have roles at several stages 
of VACV replication; including transport of the viral core to the site of DNA 
replication and assembly, then for transporting the newly formed virions to the 
golgi for wrapping and then transporting the IEV to the membrane for egress 
(Schepis et al. 2007). During the replication of VACV, newly formed IEV are 
transported from the cytoplasm of the cell to the plasma membrane on 
microtubules in a kinesin-1 dependant manner. When they reach the membrane, 
the fusion with the membrane is actin dependant (Arakawa et al. 2007). 
Autophagy is a part of the host cell innate immune response against viral infections, 
however many viruses have developed mechanisms by which they can exploit this 
system to aid their replication/spread (Kudchodkar and Levine, 2009). VACV 
however appear not to take advantage of autophagy as part of the replication cycle 
as they have been shown to be able to replicate in cells that are deficient for 
autophagy (Zhang et al. 2006). In fact VACV have been found to inhibit cellular 
autophagy, through the conjugation of ATG12 (modifier protein of autophagy) to 
ATG3 (substrate of ATG12) which in turn leads to the lipidation of LC3 (microtubule 
associated light chain-3 protein) (Moloughney et al. 2011). Therefore the virus is 
able to evade this host defence mechanism.  
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1.2.1.4 VACV spread 
In cell monolayers VACV demonstrate cytopatic effect (CPE) known as a plaque. 
Plaques are holes in the monolayer of cells where the cells have been infected by 
the virus and lysed. Each plaque is formed by one initial virus which replicates and 
spreads to form a visible plaque after 3 days (Dulbecco, 1952). The rapid rate at 
which a VACV plaque edge spreads suggests that it is not solely reliant on the rate 
of the virus’ replication cycle alone, i.e. the spread suggests that the virus spreads 
from one cell to the next every 75 minutes while the life cycle VACV is known to be 
8 hours. As such, the virus must have an alternative method of spreading from one 
cell to the next that occurs before the full replication cycle of the virus in one cell is 
complete. When cells become infected with VACV the virus expresses surface 
proteins A33 and A36, which mark the cell as infected. When another VACV comes 
into contact with a cell already expressing these proteins, actin tail formation is 
induced. VACV then binds to these tails and is propelled away from the infected 
cells and towards uninfected cells (figure 1.6). Proteins A33 and A36 are vital for the 
correct functioning of this mechanism (Doceul et. al 2010).  
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Figure 1.6 VACV spread by the activation of actin tails by A33 and A36 protein expression at the surface of infected cells. Incoming VACV 
particles are propelled away from infected cells by the actin tails towards other (uninfected) cells (figure adapted from Doceul et al. 2010).
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It has been demonstrated that actin polymerisation is greatly enhanced when CEV 
VACV recruits clathrin and a transcription factor, activating protein 2 (AP-2). 
Clathrin induces the clustering of A36 with neural Wiskott-Aldrich syndrome protein 
(N-WASP; regulator of actin polymerisation), which initiates the polymerisation of 
actin through the Arp 2/3 complex. The clustering that occurs also has the benefit 
of stabilising the N-WASP which enhances continued actin tail production 
(Humphries et al. 2012). This recruitment of clathrin is only transient and as soon as 
the actin tails are initiated, the clathrin disappears (Schmidt and Mercer, 2012). The 
clathrin recruitment is involved with the release of VACV from the host cell 
(Humphries and Way, 2013).  
F13L gene is involved in the wrapping of the IMV to form IEV. It has been found that 
deletion of this gene leads to a form of VACV that is no longer able to produce the 
EEV form of the virus and is unable to produce plaques in cell culture. This indicates 
that this gene is essential in the egress and spread of VACV (Blasco and Moss, 
1991). Mutant strains of VACV with the deletion of F13L (vRB12) may be used to 
produce recombinant forms of VACV by inserting a functional F13L gene along with 
the gene of interest (Blasco and Moss, 1995), this provides a clear selection method 
for the recombinant virus as it will produce plaques in three days. A deletion of the 
K4L gene (a homologue of F13L) was found to have no effect on the production of 
plaques and EEV formation (Blasco and Moss, 1991).  
1.2.2 Smallpox 
Small pox is a serious and, in many cases, lethal infection caused by the variola 
virus. There are two forms of the variola virus; a minor form that leads to death in 
less than 1% of cases and a major form that causes life threatening illness with a 
mortality rate of 30% (Geddes, 2006). Many of the survivors of the disease can be 
left with scarring or blindness. The infection is spread through the respiratory 
system. It is a highly infectious virus that may remain active for long periods (24 
hours) in an aerosolised form (Wehrle et al. 1970). 
This disease was declared eradicated in 1980 after a widespread vaccination 
campaign (Geddes 2006). Vaccination against this virus was stopped in 1972. 
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However recent threats of bioterrorism, specifically the event of a smallpox 
outbreak, have re-ignited interests in finding suitable treatments  (Bray, 2003). 
Smallpox was declared among the most likely candidates to be used as a 
bioweapon by a panel of Russian bioweapons experts (Henderson, 1999). In the 
meantime, the remaining stocks of the vaccine have been preserved and new 
versions are in production for fast administration should the need arise. This is 
critical since the majority of today’s population would be susceptible to the virus 
(Geddes, 2006). However it would take time for the vaccine to be administered at 
levels sufficient for protection and support from antiviral compounds would be 
essential. 
Today, there are only two laboratories in the world (one in the USA and one in 
Russia) that contain the remaining official stocks of this virus for research purposes. 
This however does not include any illegal stocks that may still exist elsewhere 
(McFadden, 2010). There is also technology available that would allow the virus to 
be regenerated in a laboratory setting as has been described using poliovirus (Cello 
et al. 2002).  
Another drawback of the vaccine is that it may lead to side effects which may be 
severe, and in some cases lethal. This is often due to over replication of VACV. In 
such instances, antiviral drugs would be beneficial. Immunocompromised 
individuals and those with skin conditions such as dermatitis and eczema are 
particularly vulnerable to complications resulting from smallpox vaccination (Bray 
2003). 
1.2.3 MCV 
Since the eradication of smallpox virus, MCV has become the most common pox 
virus of clinical significance. MCV is a member of the Poxviridae family and it has its 
own genus; Molluscipoxvirus (Esposito, 1991). MCV is a pathogen that produces 
multiple wart-like protrusions on the skin with a concave centre. These secrete 
debris that contains infectious particles. The disease is not considered serious and 
in healthy individuals it can clear up within a year without intervention. However it 
is very common in children and immune-suppressed individuals where it can persist 
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for several years with increased numbers of lesions, causing discomfort for the 
patient (Buckley and Smith, 1999). To date, there are no specific therapeutic 
treatments for this infection. In some cases the infection may be treated by physical 
removal of the growths (Van der Wouden et al. 2009). 
 MCV is a difficult pathogen to study due to the fact that it will not grow in cell 
culture. It will infect cells in culture and produce early gene transcripts but the 
infection is terminated at this stage. It is a strictly human disease, so there are no 
animal models that are able to support the infection. Other methods of studying 
this virus have been developed including a PCR quantification method and 
luciferase transcription reporter system (Sherwani et al. 2012). 
The length of the genome of MCV is similar to that of VACV, but it has a much 
higher GC content. The genome of MCV encodes around 182 proteins, 105 of which 
correspond with proteins found in the orthopoxivirus strains. (Senkevich et al. 
1997) 
1.2.4 Other poxviruses 
Human monkeypox virus is another pathogen that has recently emerged as a threat 
to human health. Monkeypox virus causes serious illness in humans, similar in 
nature to the infection caused by small pox. The disease can spread to humans 
through contact with infected animals or other humans. Incidences of it have 
increase greatly in the Democratic Republic of Congo since use of the small pox 
vaccine was stopped (Rimoin et al. 2010). 
Cowpox is another poxvirus with the ability to infect humans. Though it is rare, 
rates of infection have increased since the end of small pox vaccination (Vorou et al. 
2008). In most cases this infection is mild and self-limiting, however in the 
immunocompromised and those with skin conditions such as eczema (especially 
children) (Pelkonen et al. 2003) the disease can be more serious and in some cases 
fatal. The range of animal hosts capable of supporting this infection has also 
increased. Transmission of this virus is through animal contact (Nitsche and Pauli, 
2007).  
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1.2.5 Current antivirals against poxviruses   
Even though the most serious of poxviruses (small pox) was eradicated, the study of 
antiviral treatments against poxviruses is still very relevant today. As described, 
there is concern that this virus could re-emerge as a weapon in bioterrorist attacks. 
The vaccine would not be ideal in all cases (section 1.2.1) and would likely take time 
to be administered; therefore the support of the vaccine with antiviral drugs would 
be essential.  
Furthermore, other poxviruses (such as monkeypox virus and MCV) still cause 
infections in humans and these would benefit from antiviral treatments. Some of 
the research into antiviral compounds has been discussed below. 
Many antiviral drugs are based on nucleotide or nucleoside structures. These 
analogues may compete with standard nucleotides for incorporation into the 
growing nucleotide chain by polymerases (De Clercq and Neyts, 2009). This 
incorporation leads to termination of the growing nucleotide chain and prevents 
successful replication of the virus’ genetic material. Whilst initially effective the 
virus may develop resistance, altering the polymerase in a way that prevents the 
nucleotide/nucleoside analogue from binding.  
An example of this type of antiviral compound is cidofovir (approved for the 
treatment of hCMV in AIDS patients), which is the suggested experimental drug for 
the treatment of smallpox (in the event of an emergency outbreak). This compound 
is a nucleotide analogue; (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine. 
Cidofovir was initially discovered as a selective inhibitor of hCMV (Snoeck et al. 
1988), but was later found to have antiviral activity against other DNA viruses 
including poxviruses (Andrei and Snoeck, 2010). It is an inhibitor of viral DNA 
polymerase and therefore it prevents viral DNA replication. This drug is not ideal for 
this purpose as it has to be administered intravenously and has the severe side 
effect of nephrotoxicty (Skiest et al. 1999). Vaccinia strains that are resistant to 
cidofovir have also been described, although their virulence and growth are 
reduced in comparison to wild type strains (Becker et al. 2008). Ether lipid 
analogues of cidofovir have been produced and were found to protect mice from 
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lethal mousepox infections. They may be administered orally with improved 
bioavailability (Buller et al. 2004). 
An ether-lipid analogue of cidofovir, CMX001, has also been shown to be active 
against several DNA viruses, including poxviruses. It may be administered orally 
instead of intravenously and has been shown to cause little in the way of 
nephrotoxicity. It displays the same protective effect as cidofovir when used against 
a lethal dose of ectromilia (mousepox virus) in mice. This protective effect was still 
observed when the mice were treated up to 5 days pi (Parker et al. 2008). 
A study by Bray and Roy (2004) indicated that, in the event of an outbreak, cidofovir 
may be used as a prophylaxis against small pox to complement vaccination. With 
the addition of an alkoxyalkanol ether side-chain, which allows absorption in the 
gut, the treatment could be administered orally or aerosolized, alleviating the 
nephrotoxicity caused by the drug when given intravenously (Bray and Roy. 2004). 
Furthermore, the idea that antiviral compounds could be used as a prevention 
method for small pox was tested before its eradication using methiazone. 
Unfortunately, the drug methisazone was found to have minimal effects (Heiner et. 
al. 1971). Methisazone was the first antiviral drug used clinically against poxviruses. 
This compound inhibits a late stage in viral protein synthesis and reports suggested 
that it helped reduce the severity of the complications associated with vaccination. 
However, due to a lack of controlled trial data, its precise effects could not be 
verified (Jaroszyn, 1970). It is toxic if administered systemically and as such clinical 
use of this compound has since ceased.  
Other efforts to produce new drugs active against poxviruses have yielded ST-246 
(Yang et al. 2005), a molecule that targets the F13L protein of the virus (Duraffour 
et al. 2008). This compound has shown antiviral activity greater than that of 
cidofovir against VACV, cowpox and camelpox viruses in three dimensional cell 
culture rafts as well as monolayers, where the effect could be seen as reduction in 
the size of the plaques (Duraffour et al. 2007). It has also been found to be effective 
at protecting mice from lethal doses of VACV and ectromelia virus in vivo (Yang et 
al. 2005). Of note, ST 246 resistant strains of VACV have been characterised (Yang 
25 
 
et al. 2005). Furthermore, a study has indicated that treatment using ST-246 in 
combination with CMX001 has increased efficacy against VACV and cowpox virus 
when compared to either of these drugs alone (Quenelle et. al. 2007), indicating 
that combination therapies may be useful against poxvirus infections. 
Small interfering RNAs (siRNAs) targeting specific VACV genes B1R and G7L have 
been shown to have antiviral activity against VACV and monkeypox viruses, when 
used alone or in combination with Cidofovir. These siRNAs also display antiviral 
activity against Cidofovir resistant strains of VACV (Vigne et al. 2009).  
Another example of a drug recently described as being active against VACV and 
cowpox virus is terameprocol (a methylated derivative of nordihydroguaiaretic 
acid). This reduces the spread of the virus by inhibiting the formation of actin tails 
at the surface of infected cells (Pollara et al. 2010). Terameprocol had previously 
been associated with antiviral and anti-inflammatory effects and was recently 
shown to be safe in phase I clinical trials as a potential anti cancer therapy. It was 
generally well tolerated when administered intravenously to 25 patients with 
tumours (Smolewski, 2008) and when administered as an intravaginal ointment to 
assess its potential at interrupting transmission of HIV, HPV and HSV (Khanna et al. 
2008). The amount of virus produced by individually infected cells is not reduced by 
terameprocol, however overall virus production is reduced as the virus is unable to 
spread via actin tails to uninfected cells. It is not clear what the exact target of this 
compound is that leads to the inhibition of the actin tails (Pollara et al. 2010). 
Nigericin, a carboxylic ionophore, displays antiviral activity against VACV, with a 
50% inhibitory concentraion (IC50) of 7.9 nM. It inserts easily into biological 
membranes and facilitates the exchange of K+ ions for H+ ions, thereby altering the 
electrochemical gradient across the membranes. Its antiviral effect was not due to 
the prevention of viral entry into the host cell. Instead, it has been found to inhibit 
early and late gene transcription as well as DNA replication, though the precise 
MoA has not yet been defined. Nigericin has a selectivity index of 1038 although 
was found to be more toxic than cidofovir and ST 246 in in vivo experiments 
(Myskiw et al. 2010). 
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During those periods where vaccinations against small pox using VACV were 
necessary, it was found that therapies were required to counteract the 
complications caused by the vaccination. Several therapies were tested during this 
period although the exact effects of the therapies were not entirely clear as the 
immune response was not taken into account. Vaccinia immune globulin (VIG) was 
collected from recently vaccinated individuals to be administered to those patients 
showing complications. (Kempe, 1956) Though improvement could be seen in many 
cases, administration of the VIG treatment was required several times over several 
weeks before a full recovery was observed. However, it was unclear whether the 
improvement was due to the treatment or the patient’s own immune response.   
Research into the use of other nucleoside analogues as antiviral drugs is ongoing. 
Interferon and interferon inducers have been shown to have potential in the 
treatment of vaccinia complications (Bray 2003). Recently a new nucleoside 
inhibitor of orthopoxviruses was described named KAY-2-41. This compound is a 1’-
methyl-substituted 4’-thiothymidine nucleoside and shows activity in the 
micromolar range with little toxicity. Selected KAY-2-41 resistant strains of VACV, 
cowpox and camelpox display mutations in the viral thymidine kinase indicating 
that the MoA of this compound relies on its interaction with this enzyme (Duraffour 
et al. 2014).  
1.3. Paramyxovirus family  
The paramyxovirus family include viruses with a negative sense single-stranded 
RNA genome and a lipid envelope that is derived from the host cell membrane. 
They are generally spherical in structure with a helical nucleocapsid. Viral 
glycoproteins are inserted into the lipid envelope and extend out of the surface of 
the virus. These proteins include the hemagglutinin (H) and fusion (F) proteins, 
which are required for viral attachment and membrane fusion with the host cell 
respectively (Yanagi et al. 2006). The structure is shown in figure 1.7. 
The replication of the paramyxoviridae family is thought to occur completely in the 
cytoplasm of the host cell (Kingsbury, 1991).  
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Figure 1.7 The structure of measles virus. The envelope membrane contains the glycoproteins attachment/hemagglutinin (H) and fusion (F). 
The matrix protein (M) is located in the inner leaf of the membrane. The genome is packaged into a helical structure with the nucleocapsid (N) 
protein. The polymerase/large (L) and phopho (P) proteins are also located on the genome. (Figure adapted from Griffin, 2007).
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1.3.1 Measles virus 
The Measles virus is a member of the Paramyxovirus family, morbillivirus genus and 
spreads via the respiratory system. Measles virus is one of the most infectious 
viruses - one case of infection can lead to 12-18 subsequent infections in a 
susceptible population. Exposure of susceptible individuals to an infected individual 
leads to transfer of the infection in 90% of cases (Sabella, 2010). Measles infection 
induces long lasting immunity to the virus. Therefore in order for the virus to 
continually propagate through a population, it must consist of over 250 000 people. 
Measles virus is a strictly human pathogen and therefore could not have emerged 
until the population reached this size. Measles virus is closely related to the 
Rinderpest virus (RPV) which infects cattle. It is thought that measles virus could 
have evolved from this virus at a time when humans and cattle were often in close 
proximity (Furuse et al. 2010). 
Measles is initially acquired through the respiratory system by inhalation of 
infectious particles. At first the virus replicates in dendritic cells, lymphocytes and 
lymphatic tissues before spreading to other organs. The symptoms of measles 
infection begin around 10-12 days after initial exposure to the virus and include 
fever, coughing, coryza and conjunctivitis (Rima and Duprex, 2006). A 
maculopapular rash occurs 2-4 days after the initial symptoms present. The rash 
appears on the face and the neck area before spreading to the extremities over the 
course of around 3-7 days. Koplick’s spots may also be seen in the mouth of 
infected individuals a day before the start of the rash (Perry and Halsey, 2004). 
Whilst measles is usually a mild infection, it can lead to complications that, in some 
instances, can be lethal. Measles is one of the leading causes of child deaths 
worldwide (Hussey and Clements, 1996).  
Often measles infection can lead to pneumonia, which is the most common cause 
of measles associated deaths. The measles itself may be the direct cause of the 
pneumonia (e.g. in the case of giant cell pneumonia) or pneumonia can be caused 
by a secondary opportunistic infection that occurs as a result of a suppressed 
immune system caused by the initial measles infection. Indeed, many deaths are 
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the result of secondary infection by another virus, bacteria or parasite that occurs 
at a stage when the host is in an immunosuppressed state (Moss et al. 2004). 
Complications caused by measles virus occur at an increased rate in individuals with 
immunodeficiency (Kaplan et al. 1992) and they can affect any organ system within 
the body and range in severity from mild to fatal (Perry and Halsey, 2004). Subacute 
sclerosing panencephalitis (SSPE) is a rare complication that may be fatal and occurs 
when the virus spreads to the central nervous system and may develop years after 
the initial infection (Bellini et al. 2005). It is not treatable with any currently 
available drugs. Measles during pregnancy may also lead to severe complications 
(Atmar et al. 1992) such as premature birth, spontaneous abortion and maternal 
death (Ogbuanu et al. 2014).  
1.3.1.1 Measles genome and structure 
Measles virus has a negative sense single stranded RNA genome of 15 894 
nucleotides in length. The genome contains six genes plus small leader and trailer 
regions. The genes encoded by the measles genome are N, P/V/C, M, F, H and L 
(figure 1.7). The N gene encodes the nucleocapsid protein which forms the capsid 
structure of the virus and packages the RNA genome of the virus. Phosphorylation 
of specific sites on the nucleocapsid protein is responsible for controlling viral gene 
expression and consequently the growth rate of the virus (Sugai et al. 2013). P, V 
and C are encoded by overlapping regions of the genome. P encodes the phospho 
protein and this forms an essential part of the polymerase structure (Devaux and 
Cattaneo, 2004). V encodes the V-protein that inhibits the host interferon signalling 
response (Ohno et al. 2004). C encodes the C-protein which is involved with the 
inhibition of interferon signalling and in regulating polymerase activity (Bankamp et 
al. 2005). M encodes the matrix protein, which is situated on the inner layer of the 
membrane and is hydrophobic. It is involved with regulating RNA synthesis (Iwasaki 
et al. 2009). F encodes the fusion protein that mediates fusion of the viral envelope 
with the plasma membrane of the host, in-turn allowing entry of the viral core into 
the host cell. H encodes the hemagglutinin glycoprotein that is involved with 
attaching the virus to the host cell prior to fusion (Zhang et al. 2005). Finally L 
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encodes the large protein that provides the enzymatic activity required for the RNA 
polymerase complex (Duprex et al. 2002). 
1.3.1.2 Measles entry 
The wild type strain of measles uses the cellular receptor signalling lymphocyte 
activation molecule (SLAM), also known as CD150, to enter cells (Tatsuo et al. 
2000). The SLAM receptor is present on lymphocytes, dendritic cells and 
macrophages, and so when carrying out experiments with the wild type measles 
virus in the laboratory, the marmoset B cell line B95a is used. These cells are 
adherent and have been transformed with Epstein-Barr virus (EBV). The infection of 
these immune system cells leads to immune suppression in infected individuals 
(Yanagi et al. 2002). The vaccine strain of measles, the Edmonston strain, may use 
the SLAM receptor but also uses the CD46 receptor to enter cells (Dorig et al. 1993). 
The CD46 receptor is present on all nucleated cells and so there is a wider range of 
cells that may be used for experiments involving this strain. It has been found that 
there is another method of virus entry that does not use either the SLAM receptor 
or the CD46 receptor. SLAM negative cells showed autofluorescence when infected 
with a wild type measles virus strain expressing GFP (IC323-EGFP), indicating that 
the virus was still able to enter the cells, though less efficiently. The virus was not 
able to form syncytia in SLAM-negative cells therefore inhibiting its ability to spread 
(Hashimoto et al. 2002). The receptor PVRL4 (Nectin-4; a human tumour cell 
marker) is able to act as a receptor for binding and entry of wild type measles into 
epithelial cells of lung, colon and breast adenocarcinoma cell lines (Noyce et al. 
2011). There also exists a SLAM negative cell line that has been shown to allow 
syncytia formation by a SLAM independent mechanism in the presence of Wild type 
measles virus. This cell type is small airway epithelial cells (SAEC) (Takeuchi et al. 
2003). 
The measles virus glycoprotein complex interacts with the lipid raft domains on the 
host cell membrane. This interaction alters the recruitment and segregation of 
signalling components. This in-turn interferes with cell signalling pathways and 
leads to immunosuppression in the host because the SLAM positive immune cells 
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are no longer able to proliferate (Avota et al. 2004). In recent years, studies of the 
way that measles gets in and out of host cells have altered the assumption that the 
virus is a respiratory infection. Instead current thought suggests that it is an 
infection of the immune system through SLAM positive cells, analogous to HIV-1 
(Rima and Duprex, 2011).  
Binding, fusion and entry of measles virus are mediated by glycoprotein spikes in 
the envelope that are made up of attachment (H) and the fusion (F) proteins. The 
RNA genome, N, P, and L proteins form the nucleocapsid which is tethered to the 
envelope by the matrix protein. Binding of measles virus to the host cell membrane 
causes the activation of pH-independent fusion of the measles envelope with the 
cell membrane and subsequent entry of the nucleocapsid into the host cell.  
1.3.1.3 Measles lifecycle 
There are many stages of the virus’ life cycle that are unique to the virus and that 
don’t involve the use of host cell mechanisms. These represent potential targets for 
therapeutics.  However the virus also uses host cell components during its 
replication cycle. Sphingosine kinase (SK) is a host cell enzyme that catalyses the 
production of sphingosine 1-phosphate and regulates several cellular processes. 
This enzyme has been found to be a regulator of measles infection. Inhibition of SK 
further inhibits NF-κb activation by measles virus. This is essential for efficient 
measles replication. This indirect mechanism highlights SK as an essential cellular 
factor for measles replication (Vijayan et al. 2014). Measles proteins have been 
found to interact with a wide range of host cell proteins and in doing so, the virus 
takes advantage of the host cell machinery for its own benefit. For example, 
measles (and other viruses) phosphorylate the initiation factor eIF2α that functions 
as part of the cell’s translation machinery. This inhibits the translation of cellular 
mRNA, and allows the virus to use it for its own benefit (Rima and Duprex, 2011). 
The actin and microtubule cytoskeleton is required for replication and maturation 
of measles virus. However inhibition of either of these structures does not inhibit 
syncytia formation (Berghall et al. 2004). It has been found that using compounds 
that either disrupt or stabilise actin filaments, affects measles replication in 
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different ways. Stabilisation of actin filaments inhibited the release of newly 
produced particles, indicating that actin dynamics are required for the budding of 
measles from the cell membrane. Disruption of actin filaments results in inhibition 
of the transport of the newly formed nucleocapsids to the plasma membrane 
(Dietzel et al. 2013).  
1.3.1.4 Measles syncytia formation (virus spread) 
The fusion of measles virus with the host cell is initiated by the hemagglutinin 
glycoprotein and entry into the cell is initiated by the interaction of the fusion 
protein with the cell membrane. As the infection progresses, newly formed 
glycoproteins accumulate at the cell membrane, leading to the fusion of the cell 
with other cells in-turn resulting in the formation of syncytia (Wild et al. 1991). 
It has been shown that members of the paramyxoviridae family induce autophagy 
in the cell in order to aid virus spread to the next cell (Delpeut et al. 2012). It was 
also observed that membrane fusion is mediated by viral glycoproteins that lead to 
the induction of autophagy in the cell. The wild type and Edmonston strains of 
measles activate autophagy through different mechanisms. The Edmonston strain 
can activate early autophagy immediately upon infection through the CD46 
receptor and the scaffold protein GOPC. Replication of the virus induces successive 
waves of autophagy. Wild type (SLAM dependant) measles are unable to take 
advantage of the early autophagy, but can instead induce and exploit the late and 
sustained phase of autophagy (Richetta et al. 2013).  
1.3.1.5 Measles Vaccine 
Enders and Peebles were the first to grow measles virus in tissue culture (Enders et 
al. 1954), using primary human kidney cells, and inoculate them with the blood 
from a child with measles (David Edmonston). The primary cell lines were replaced 
with continuous monkey kidney cells lines (Vero and CV-1) for the growth of this 
virus which ultimately became the vaccine (Edmonston) strain of measles.  
The measles vaccine has been very successful and involves the use of a live-
attenuated virus. Given that this successful anti measles vaccine exists, and that 
33 
 
there is no animal reservoir for the virus to otherwise thrive in, it should 
theoretically be possible to eradicate measles (Bellini and Rota, 2011). However this 
has not occurred to date and is partly due to individuals opting against vaccination 
for themselves and/or their children. The highly infective nature of the virus means 
that it rapidly reappears when levels of vaccination decrease in the population. 
Highlighting this, only 5 to 6% of the population need be susceptible to the virus for 
it to cause outbreaks. Therefore the level of herd immunity (percentage of the 
population required to be immune to the virus to prevent outbreaks) would need to 
be over 95% (Plemper and Hammond, 2014).  
Another factor detracting from the vaccines success is that its effectiveness is 
reduced when administered to infants less than 12 months of age. This is due to the 
interference of maternal antibodies in their not-yet-developed immune systems. 
Maternal measles antibodies are often lost at 4 to 9 months and infants are 
susceptible to the virus until such a time as they are vaccinated (usually at 12-13 
months of age in the UK). Occasionally in cases where maternal antibodies persist in 
infants beyond the age of 12 months, the effectiveness of the vaccine is reduced 
(Albrecht et al. 1977). Today a second dose is recommended at the age of 40 
months to 5 years to ensure that full protection is established (Le Menach et al. 
2014).  
Prior to the development of the vaccine, 95-98% of children would catch measles 
before the age of 18 years. Indeed, individuals would make efforts to increase the 
chances of their children catching measles early in life. This was considered 
preferable to the risk of exposing their children to a disease of increased severity in 
adulthood. The introduction of the vaccine has lead to the prevention of around 5 
million child deaths per year, with the assumption that the fatality rate is 2-3% 
(Perry and Halsey, 2004). Despite the successful vaccine, outbreaks of measles virus 
are still common, and as such antiviral compounds would be of great clinical 
benefit. 
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1.3.1.6 Measles Antivirals 
At present there are no measles antiviral drugs available on the market. With the 
eradication of the virus proving difficult, the development of safe antivirals against 
measles virus would be a useful tool in the control of the virus – especially in cases 
where vaccination is not an option. Several treatments, including Ribavirin, 
interferon-alpha (IFNα) treatments, high-dose vitamin A and measles specific 
immune globin (Ig), have been shown to reduce some of the effects of the virus in 
some instances. However there are issues associated with each of these treatments 
that make them unsuitable for use in controlling measles on a larger scale (Barnard, 
2004). 
The ideal antiviral therapy for measles virus would be a small molecule inhibitor 
that is safe, effective, inexpensive to produce and stable. Attempts to produce such 
a drug have as yet failed to cover all of these criteria and, as such, there remains 
space in the market for an effective measles antiviral treatment (Plemper and 
Snyder 2009). 
Ribavirin is a guanoside ribonucleic analogue that has demonstrated antiviral 
activity against several viruses in vitro. There have been five mechanisms of action 
described for this compound including inhibition of ionosine monophosphate 
dehydrogenase, immunomodulatory effects, interference with viral RNA capping, 
inhibition of viral polymerase and mutagenesis due to incorporation of the drug 
into the viral genome (Graci and Cameron, 2006). It has been successful in treating 
some cases of measles pneumonitis (Forni et al. 1994). This compound however has 
not been accepted for clinical use against measles due to issues with side effects, 
specifically haemolytic anaemia (Lin et al. 2004). Due to the potential beneficial 
effects of this compound attempts at producing safer analogues of Ribavirin have 
been described. 
The compound 5-Ethynyl-1-β-D-Ribofuranosylimidazole-4-Carboxamide (EICAR) and 
other related compounds that are structurally similar to ribavirin have been shown 
to have broad antiviral activity, similar to but more effective than that of ribavirin. 
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The compound EICAR is thought to act on the enzyme inosine-5'-monophosphate 
(IMP) dehydrogenase, which converts IMP to xanthosine 5'-phosphate (XMP). XMP 
then catalyses the production of GTP. As expected based on this mechanism, the 
addition of GTP to the antiviral assay involving EICAR diminished its antiviral activity 
(De Clercq et al. 1991).  
A series of small molecule inhibitors of measles were designed to inhibit its entry 
into the host cell by targeting the hydrophobic pocket near the C terminal heptad 
repeat of the measles F protein. Mutation of the residue Val94 and surrounding 
residues within this hydrophobic pocket have a significant effect on the fusion of 
the virus with the host. The molecules designed, including the initial lead OX-1 
(active at 50 µM) and the optimised AS-48 (active between 600-3000 nM depending 
on virus strain), displayed inhibition of measles virus entry. During the research into 
these compounds it was also demonstrated that resistance of the virus to these 
compounds was achievable through mutations at specific locations on the F protein 
(Prussia et al. 2008).  
Peptides derived from the structure of the C terminal heptad repeat section of 
measles F protein have also demonstrated antiviral potential. They have been 
shown to protect SLAM transgenic mice from lethal measles infections (Welsch et 
al. 2013).  
A recent small molecule inhibitor of the morbillivirus polymerase has been 
described named ERDRP-0519. This molecule is orally available and has been shown 
to protect ferrets from lethal morbillivirus (canine distemper virus; CDV) infections 
(Krumm et al. 2014).   
1.4. Antiviral drugs with cellular targets 
Drugs that are produced to target a specific part of the virus have the disadvantage 
that the virus may mutate and become resistant to the drug. Therefore recently 
there has been a change in focus towards compounds that have a host target that is 
required by the virus as part of its lifecycle (Schwegmann and Brombacher, 2008). 
As well as reducing the chance of the virus developing resistance to the drug, they 
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have the added benefit of antiviral activity against other viruses that take 
advantage of the same host mechanism (Krumm et al 2011). The disadvantage of 
targeting host cell components is the increased potential for unwanted side effects 
(Yan et al. 2013).  
1.5 Aims of the PhD project: 
1. To test the activity of novel D- and L-ddBCNAs against VACV and quantify 
their activity with the aim of determining structure activity relationships. 
2. To test the lead compounds against a panel of other viruses (including 
measles) and quantify their activity in order to determine how this 
compares with their activity against VACV. 
3. To test the toxicity of the lead compounds against cell lines used in the 
antiviral assays in order to confirm that the antiviral effect is not due to loss 
of cell viability 
4. To investigate the mechanism of action of the lead ddBCNAs. 
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Chapter two - Materials and Methods 
2.1 Materials 
2.1.1 Cell lines 
 293: (ATCC, CRL-1573) - human embryonic kidney cells (HEK-293), easily 
transfectable, transformed with adenovirus 5 DNA. 
 3T3: (ATCC, CRL-1658) - Fibroblasts derived from Swiss Albino mouse 
embryo cells. 
 A431: (ATCC, CRL-1555) - Human skin (squamous carcinoma) epithelial cells 
derived from 85 year old female. 
 A549: (ATCC, CCL-185) - Human lung epithelial cells from a lung carcinoma 
derived from a 58 year old male. 
 B95a: (IZSBS – Istituto Zooprofilattico Sperimentale, Brescia, Italy) – 
Marmoset B lymphocyte cell line derived from B95 8 cells and adapted to be 
attached. Immortalised using Epstein Barr virus (EBV).  
 BJ-1: (Clontech) - Human foreskin fibroblasts derived from a newborn male. 
Stably transfected with human telomerase (Bodnar et al. 1998). 
 BJAB: (MRC – gift of Fabien Blanchet) - B cell line derived from human 
origin. Require RPMI 1640 instead of DMEM. 
 BSC-1: (ATCC, CCL-26) – Grivet monkey kidney epithelial cells. 
 CV-1: (ATCC, CCL-70) – Fibroblast cells derived from African green monkey 
kidneys. 
 HaCaT: (German cancer research centre, DKFZ) - Spontaneously 
immortalised human skin keratinocyte cells.  
 HeLa: (ATCC, CCL-2) – Human epithelial cells: established from the cervical 
adenocarcinoma of a black 31 year old female. This cell line contains Human 
Papilloma Virus 18 oncogenes (E6 and E7) (DeFilippis et al. 2003). 
 HFF: (ATCC, SCRC-1041) – Human foreskin fibroblasts, derived from 
newborn male. 
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 HFFFtc: (gift of G. Wilkinson) – Human foetal foreskin fibroblasts (HFFF tert 
car). Immortalised by human telomerase expressing the cocxsackie 
adenovirus receptor (CAR). 
 HUH7: (gift of Bartenschlager group, University of Heidelberg) - Derived 
from human liver carcinoma of 57 year old Japanese male. Epithelial 
hepatoma cells.  
 Ramos: (MRC - gift of Fabien Blanchet) - B cell line derived from human 
origin. Require RPMI 1640 instead of DMEM. 
 RK13: (ATCC, CCL-37) – Derived from 5 week old rabbit kidney epithelial 
cells. Susceptibility to several poxviruses has been reported. The cells are 
positive for keratin by immunoperoxidase staining. The cells are positive for 
bovine viral diarrhea virus (BVDV). 
 TK- 143: (ATCC, CRL-8303) - Human osteocarcoma cell line lacking the 
thymidine kinase enzyme. 
 Vero: (ATCC, CCL-81) - African green monkey kidney epithelial cells. They 
have high susceptibility to a wide range of viruses. 
2.1.2 Antiviral compounds 
2.1.2.1 ddBCNAs 
All of the ddBCNA compounds used in this project were produced/synthesized by 
the McGuigan group in the Cardiff School of Pharmacy and Pharmaceutical Sciences 
by Ranjith Pathirana and Karen Hinsinger using the methods described in a recently 
published manuscript. This describes the chemistry involved in producing these L-
enantiomer compounds and this is briefly summarised below (McGuigan et al. 
2013). The method used to produce L-ddBCNAs is more complicated than that used 
for the D-ddBCNAs. The production of the D-ddBCNAs can begin with D-5-iodo-2,3-
dideoxyuridine (D-IddU) made from D-2-deoxyuridine which is commercially 
available. L-2- deoxyuridine is not commercially available and, therefore more steps 
are required to reach the L-5-iodo-2,3-dideoxyuridine (L-IddU) starting point for the 
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various L-ddBCNAs. The starting compound used in this process is L-arabinose. Six 
further steps are required from this point to produce L-IddU. 
When the compound reaches the stage of L-IddU, the required L-ddBCNA structures 
are produced by coupling the L-IddU with a series of acetylenes using the 
Sonogashira reaction with a Palladium catalyst. Extra steps are also required for the 
production of the ether side chains as opposed to the commercially available alkyl- 
and arylacetylenes. Two alternative methods were used in the synthesis of the 
ether side chains depending on the target ethers required. The first method 
involved the mesylation of alkyl-1-ols, which were then coupled with different 
alcohols to give the final ethers. In the second method, alcohol starting materials 
were transformed into mesylated compounds and then reacted with selected 
alkynols to obtain the ethers. The final ddBCNAs were analysed spectroscopically 
and chromatographically to determine structure and purity before testing in 
antiviral assays (McGuigan et. al. 2013).  
All the ddBCNAs were assigned inventory numbers to refer to without giving away 
structural information. The use of inventory numbers ensured that IP was 
maintained and enabled double blind biological assays to prevent investigator bias. 
The inventory numbers all started with ‘Cf’ (the compounds were developed in 
Cardiff) followed by a four digit number based on the order in which the 
compounds were produced. Throughout this thesis the compounds will be referred 
to by their inventory numbers. The structure of each of the compounds is described 
in chaper 3 section 3.3.1. 
 The ddBCNAs were received from the McGuigan laboratory in a lyophilised form. In 
the Bugert laboratory each compound was dissolved in dimethyl sulphoxide 
(DMSO) to make a stock solution of 10 mM, which was stored at -20oC. The 
required concentrations of the compounds were made prior to each experiment by 
diluting relevant volumes of the stock solution in DMEM.  
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2.1.2.2 Control compounds 
 Wortmannin: (W3144; Sigma-Aldrich) – Specific covalent inhibitor of 
phosphoinositide 3-kinases (PI3Ks) (Wymann et al. 1996). 
 Cidofovir: (C5874; Sigma-Aldrich) – Viral DNA polymerase inhibitor. Used as 
antiviral treatment against CMV in AIDS patients. Also shown to be active 
against VACV (Magee et al. 2005). 
 Ribavirin: (R9644; Sigma-Aldrich) - An anti-viral drug displaying antiviral 
activity against a range of viruses in vitro and in vivo (Graci and Cameron, 
2006). 
 Cytosine arabinoside (AraC): (C6645; Sigma-Aldrich) – Chemotherapy agent 
that interferes with DNA synthesis (Grant, 1998). 
 Staurosporine: (S6942; Sigma-Aldrich) – Cytosine-β-d-arabinofuranoside 
hydrochloride, apoptosis inducer (Bertrand et al. 1994). 
 Chloroquine: (C6628; Sigma-Aldrich) – Anti-malarial drug that accumulates 
in lysosomes and raises lysosomal pH (Homewood et al. 1972). 
2.1.3 Viruses 
 vWR: (Gift from Bernhard Moss, NIH-NIAID,  to Joachim Bugert) - Vaccinia 
Western reserve strain - Wild type vaccinia virus.  
 v3: (constructed by Joachim Bugert) - Firefly luciferase expressing VACV - 
Modified VACV to express firefly luciferase under the control of the 
synthetic early/late poxviral promoter (Blasco and Moss, 1995) using pRB21-
based donor plasmid p240. Details of the production of this virus are 
described in section 2.2.4. 
 v300: (constructed by Laura Farleigh) - VACV expressing GFP - VACV 
modified to express enhanced green fluorescent protein under the control 
of the synthetic early/late promoter using the pRB21 based donor plasmid 
p300. Full details for the production of this virus are described in section 
2.2.4. 
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 vRB12: (gift from Bernhard Moss to Joachim Bugert) - Plaque-less mutant 
VACV containing faulty F13L gene (ΔF13L) responsible for producing large 
plaques. This virus will not produce visible plaques within three days pi. 
 vYFP-A3L: (Gift from Michael Way; unpublished construct) - VACV modified 
to express YFP attached to a structural (core) protein of VACV (A3L).  
 mWT Fb: (gift from Jurgen Schneider-Schaulies, Universitat Wurzburg, 
Germany) - Wild type measles virus (Erlenhofer et al. 2002). 
 mIC323: (gift from Yusuke Yanagi, NIID, Tokyo, Japan) - Wild type measles 
modified to express GFP (Hashimoto et al. 2002). 
 mEdATCC: (ATCC-VR24) - Edmonston vaccine strain of measles virus. 
 YFV: (STAMARIL, Sanofi Pasteur MSD; gift of Thomas 
Junghanss,Tropenambulanz Heidelberg) - Yellow fever virus vaccine strain.  
 Adenovirus 5: (ATCC VR-5). 
 HSV-1: (NCPV 17+) - Herpes simplex virus type 1. 
 HSV-2: (NCPV 132349) - Herpes simplex virus type 2. 
 Influenza A: (gift of Dietmar Katinger, Polymun Scientific) - Strain H1N1, NS1 
116 GFP fusion.   
 MCV: (Obtained from collection of lesions from molluscum patients, 
Heidelberg, Germany, between 1999-2003) - Samples were dounce 
homogenised prior to use. 
 HIV-X4: (Fabien Blanchet laboratory) - HIV-1 strain that uses the CXCR4 
receptor for entry. 
2.1.4 Equipment 
2.1.4.1 Plastics and glassware 
2.5 mL, 10 mL and 25 mL Stripettes (Costar). T25, T75 and T150 flasks with filter 
caps (CellStar, Greiner bio-one). 96-wp, 48-wp, 24-wp, 12-wp, 6-wp, (CellStar, 
Greiner bio-one), clear bottom black 96-wp (Corning). 25 mL universal containers 
(UC; Sterillin UK) and 7 mL Bijous (Greiner bio-one). Sterile 1.5 mL screw cap 
eppendorf tubes (Greiner, bio-one ). 1 mL cryotubes plus coloured caps (Nunc). 
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Pipette tips 10 µL, 200 µL, 1 mL, 5 mL (VWR). Falcon tubes 15 mL and 50 mL 
(Greiner). Glass 16 mm coverslips (Marienfeld, Laboratory Glassware). Glass slides 
(Superfrost, Thermo Scientific). Sterile 25 cm cell scrapers (Fisherbrand). 8.25 cm 
plastic disposable plates (Sterillin UK). 
2.1.4.2 Other equipment 
Eliptical shaker (‘The Belly Dancer’, STOVALL, life sciences incorporated). Centrifuge 
(CR412, Jouan). Microcentrifuge (IEC, MicroMax). Biosafety Class II cabinet 
(MicroFlow). Incubators (MCO-17A, Sanyo electric). Confocal miscroscope (Leica 
SP5 confocal laser scanning microscope) equipped with Ar (488 nm) and HeNe (543 
nm, 633 nm) lasers and a 63X oil immersion objective. Widefield microscope (Leica, 
SP5, DMIRB) with camera (QI Imaging Retiga Exi FAST Cooled Mono 12- bit Camera). 
Phase contrast microscope (Olympus, CK40), equipped with digital microscope 
camera (Polaroid). 96-wp plate reader (FLUOstar OPTIMA (BMG labtech). NanoDrop 
spectrophotometer (ND 1000, Thermo Scientific). Thermal cycler for PCR (PTC-100, 
Peltier Thermal Cycler). Vacuum pump (Fisherbrand). Automatic pipette (Pipetus, 
Hirschmann, Laborgerate). Incubators (MC0-17A, Sanyo Electric). Shaking incubator 
(Gallenkamp). UV transilluminator (BIORAD). Electrophoresis gel chambers 
(Hoeffer-Pharmacia). Water bath (GRANT; SUB14). Magnetic stirrer (BIBBY; HB501). 
Heat block (GRANT; QBT2). Pipettes; 10 µL, 50 µL, 200 µL, 1000 µL (BIOHIT). 
2.1.4.3 Software 
Graphs depicting results were produced in Microsoft Excel. Paired T tests 
performed using SPSS (IBM). IC50 and CC50 concentrations were calculated using 
GraphPad Prism 6. Plaque measurements and virus particle/nuclei counting 
performed using Image J (version 1.47). Leica software used to obtain images on 
the confocal microscope. FLUOstar OPTIMA plate reader software for luminescence 
readings. Nanodrop (ND 1000, V3.3) software for measuring DNA concentrations. 
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2.2 Methods 
2.2.1 Cell culture methods 
2.2.1.1 Cell maintenance  
Cells were grown in 1x Dulbecco’s Modified Eagles Medium (DMEM) containing 
4.5g/L glucose and L-glutamine without sodium pyruvate ( Gibco, Life Technologies, 
Paisley, UK) supplemented with 10% (v/v) foetal bovine serum (FBS; Gibco, life 
technologies, LOT: 41G6401K) unless stated otherwise. Cells cultured in the 
absence of antibiotics until required for assay when penicillin/streptomycin (Gibco, 
life technologies) was added. All cells stored in incubators at 37oC with 5% CO2. 
2.2.1.2 Thawing cells 
Cells were removed from the freezer and allowed to thaw quickly at 37oC. 
Immediately after thawing they were transferred into a sterile T75 flask containing 
10 mL cell medium (DMEM containing 10% FBS). These were incubated for four 
hours for the cells to settle then the cell medium was removed and replaced with 
fresh medium to remove all traces of DMSO.  
2.2.1.3 Freezing cells 
Cells were routinely frozen for storage over longer periods and to maintain stocks. 
Cells at 70-80% confluence were suitable for freezing. After trypsinising, 10 mL of 
PBS was added to the cells and they were transferred to a 25 mL UC. These were 
then centrifuged at 1000 rpm for 5 minutes. PBS was decanted from the pellet of 
cells. These were then resuspended in 2 mL of freeze medium (47.5% DMEM, 47.5% 
FBS and 5% DMSO [Sigma-Aldrich, UK]), and the cells were transferred into 2x 1mL 
cryotubes which were placed into the -70oC freezer. For long term storage after 
initial freezing at -70oC, cells were ideally transferred into liquid nitrogen (-196oC). 
2.2.1.4 Mycoplasma testing  
Mycoplasma contaminations were ruled out by routine testing by mycoplasma PCR 
(Geneflow). Over the course of the work there was one case of mycoplasma 
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contamination in B95a cells. These cells were discarded and cells at various passage 
numbers were thawed from previous stocks and retested until the results were 
negative. All other cells tested were clear of contamination over the course of the 
work. 
2.2.1.5 Sub-culturing of cells 
Cells were routinely sub-cultured for experiments/maintenance. Before reaching 
confluence (~70-80%) cells were detached from the flask using TrypLE (Gibco, life 
technologies). Cell medium was removed, cells were washed once with TrypLE (1 
mL for T25, 2 mL for T75 or 4 mL for T150 flask). This was discarded and replaced 
with fresh TrypLE (0.5 mL for T25, 1 mL for T75 and 2 mL for T150 flask). The cells 
were placed in the (37oC) incubator for ~5 minutes to allow the cells to detach 
(microscopical examination confirmed the detachment of the cells). These could 
then be removed from the flask, counted and placed into mulitiwell plates for 
experiments, or discarded for maintenance. The number of cells used were 
5x104/well in 96wp, 1x105 in 48wp, 2.5x105 in 24wp, 5x105 in 12wp and 1x106 in 6-
wp. The remaining cells in the flask were resuspended in fresh cell medium (5 mL 
for T25, 10 mL for T75, 20 mL for T150). 
2.2.1.6 Cell counting  
After trypsinisation 10 µL of evenly suspended cells (cells pipetted three times to 
ensure they were evenly dispersed) were added to 90 µL of diluted (1:5 dilution in 
sterile PBS) 0.4% trypan blue solution (Sigma). These were mixed well and 10 µL of 
the cell/trypan blue suspension was then pipetted into a hemocytometer (washed 
prior to use with 70% ethanol) and left for a few minutes to allow the trypan blue to 
stain dead cells. The hemocytometer counting grid consists of 9 large squares, the 
cells in the four corners of the grid (see figure 2.1) of the hemocytometer were 
counted and the average of the four counts was calculated. The volume in one 
corner square (consisting of 16 smaller squares) is equal to 0.1 mm3 (as it has an 
area of 1 mm2 and a depth of 0.1 mm) so the concentration of cells per mL is the 
average number of cells counted in one corner x 104/mL. This was originally diluted 
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1:10 in the trypan blue solution so the number of cells in the original stock is 10 
times greater than this (i.e the average cell count x 105/mL). 
 
Figure 2.1 Hemocytometer counting grid, the cells are counted in each of the four 
corner squares (outlined in red) and the average is calculated. The number of cells 
in the stock is the average number of cells in one corner x105/mL allowing for the 
dilution in trypan blue/PBS (figure from www.humanimmunologyportal.com). 
 
2.2.2 Virus stock production methods 
2.2.2.1 Optimisation of VACV stock production 
In order to produce stocks of VACV with high titres a time course experiment was 
carried out that determined the optimum collection time for the virus stocks. Four 
T75 flasks of each of 4 cell lines (HeLa, RK13, CV-1 and 3t3) were infected with v3 
virus at an moi of 0.1. One of each of the four flasks was then frozen after one, two, 
three or four days and the subsequent titres were calculated (by plaque assays 
described section 2.2.3.2). Separate titres were calculated for the supernatant (sn; 
containing the virus particles released from the cells into the cell medium) and the 
pellet supernatant (psn; containing the virus particles remaining within the cells) 
collected (collection protocol described in section 2.2.2.2).   
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The data generated (figure 2.2) suggests that the best time to collect VACV stocks is 
after two days for all the cells tested, with the exception of 3t3 cells where the 
optimum stock collection was four days post infection. It is noteworthy that even 
after four days the stock generated in 3t3 cells does not reach levels as high as 
those in the other cell lines tested. This is likely to be due to the fact that VACV 
does not infect and replicate as well in 3t3 cells as in the others. As such, it takes 
longer for new virus particles to be produced in this cell line. In almost all cases 
shown in figure 2.2, the supernatant shows a higher titer than the equivalent pellet 
supernatant. The supernatant v3 virus grown in HeLa cells was selected for use in 
the majority of antiviral experiments. The v3 virus grown in this way gave better 
luminescence signals in the luciferase assays compared with the virus grown in 
other cell lines (data not shown) and gave good titres of virus in both the 
supernatant and pellet supernatant although the highest titer overall was seen in 
the supernatant of RK13 cells at over 1x107 pfu /mL. 
Between the time of infection and the second day the number of viral particles 
increases as they infect the cells and fulfil their replication cycle. It appears that 
after the 2 day optimum collection time (in most cases) the titer of the virus 
decreases from this point. This observation is probably due to the fact that it takes 
two days for all of the cells in the flask to become infected. After this time there are 
no cells left to infect and the virus particles start to disintegrate, ultimately leading 
to a reduction in the number of infectious particles in the stock. This observation 
emphasises the need to collect the virus at the optimum time in order to achieve 
the highest titers for the virus stocks. 
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Figure 2.2  VACV stock production kinetic experiment in different cell lines, showing 
that the optimum time after infection for collection of the virus stocks is two days in 
the case of all cells apart from 3t3 cells where a four day incubation leads to higher 
titers. Separate titers were calculated form the supernatent (sn) and the pellet 
supernatent (psn). 
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2.2.2.2 Standard VACV stock production  
Large titers of stocks were grown in T150 flasks of HeLa cells as these produced high 
titers in both the sn and psn. The effects of the ddBCNAs appeared more apparent 
in the luciferase assays in RK13 cells when using virus produced in HeLa cells 
compared with the other stocks (data not shown). Confluent cells (~80%) were 
infected with the VACV at an moi of 0.1 and incubated for 2 days. The virus was 
collected by transferring the supernatant into a 25 mL UC and scraping the cells 
from the surface of the flask into 10 mL of PBS, this was then transferred into 
another UC. The UCs were then centrifuged at 1000 rpm for 5 minutes in order to 
pellet the cells. Cell supernatant was removed from the pellet and frozen in a 50 mL 
falcon tube to use as virus sn which contains a mixture of intracellular mature virus 
(IMV) from lysed cells and extracellular enveloped virus (EEV). The PBS from the cell 
pellet was discarded and both of the pellets of cells were resuspended into the 
same 1 mL of PBS. This cell suspension was transferred to a sterile 1 mL eppendorf 
tube and frozen and thawed 3 times in order to disrupt the cell membranes and 
release the intracellular virus. This was then centrifuged at 10 000 rpm for 5 
minutes and the supernatant was collected into another sterile eppendorf and 
frozen. This solution containing mostly IMV was designated the pellet supernatant 
(psn).  
Further purification of the virus (OPTIMEM/sucrose gradient centrifugation as 
described in Townsley et al. 2006) was only essential for the study of virion 
components and was thus not required for the antiviral experiments in this project. 
It was found that purification of VACV had no effect of the results of the antiviral 
assays and resulted in a reduced virus titer (Bugert laboratory, unpublished results). 
When making stocks of other strains of VACV the results from the same method 
was used. Stock titers were determined by plaque assay.  
2.2.2.3 Measles stock production 
In order to obtain high stocks of measles virus, stocks were grown up in a series of 
passages. Initially one T75 flask of ~80% confluent B95a cells was infected with 
measles (mWT Fb) in 2 mL volume. The flask was tilted from side to side over a 
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period of 15 minutes to allow adsorption of the virus onto the cells. The flask was 
topped up with 8 mL DMEM and the cells were left to incubate at 37oC for 48 hours. 
The cells were scraped from the flask and transferred, along with the medium into a 
14 mL falcon tube. This was frozen at -70oC and thawed at 37oC.The sample was 
centrifuged at 2000 rpm for 15 minutes at room temperature. The supernatant 
(kept on ice between steps) was collected and used for the next round of infection. 
The 10 mL collected medium was used to infect a T150 containing B95a cells at 
~80% confluency. The flask was tilted from side to side over a period of 15 minutes 
at room temperature to allow the virus to adsorb to the cells. The flask was topped 
up with a further 10 mL DMEM and left to incubate at 37oC for 48 hours. This was 
collected as before and the supernatant obtained was used to infect a further four 
T150 flasks of B95a cells at ~80% confluency (5 mL collected supernatant per flask) 
which were left for a further 48 hours at 37oC. This final stock was collected as 
before and, after the centrifugation step, FBS (20% of the supernatant volume) was 
added to the collected supernatents. These were then aliquoted into separate 1 mL 
cryotubes and frozen at -70oC for storage. The same method was also used for 
growing up stocks of mEdATCC in Vero cells. Stock titers were determined by TCID50 
assays (section 2.2.3.3) of syncytia formation in B95a/Vero cells. 
2.2.2.4 Yellow fever virus stock production 
Vero cells grown in a T75 flask at ~80% confluency were infected with 100 µL of the 
newly received vaccine stain of Yellow fever virus. This was left to incubate for 3 
days (when CPE is observed) before collection. The supernatant was used to infect a 
T150 of ~80% confluent Vero cells in order to increase the stocks. The virus stock 
was collected using the same method as was used for collection of measles virus 
stocks (section 2.2.2.3). Stock titers were determined by TCID50 assays (section 
2.2.3.3) of CPE in Vero cells. 
2.2.3 Quantification of virus stocks 
2.2.3.1 Optimisation of VACV plaque assays – Shell vial method 
It has been demonstrated that when carrying out in vitro virus assays the level of 
infection may be improved by including a centrifugation step (Osborn and Walker, 
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1968) termed shell vial. The effect of using a shell vial was tested for three vaccinia 
stocks produced in different cell lines (RK13, BSC-1 and HeLa).  
Titration of three stocks of vWR, produced in these three cell lines, was carried out 
in duplicate for each of the virus stocks. The process carried out on the first plate of 
the pair, involved applying the virus to the cells in a series of dilutions and then 
applying the overlay to the infected cells after a 45 minute incubation period. The 
second plate was treated in the same way except that during the incubation period, 
before the addition of the overlay, the plates were centrifuged at 5000 rpm for 15 
minutes (i.e. shell vial). 
This optimisation assay indicated that the stock titres generated were higher if 
treated with shell vial than they were if not. The amount by which the shell vial 
increased the titre varied depending on which cell line the VACV was produced in. 
For VACV produced in RK13 cells, the increase was over six fold, in BSC-1 cells it was 
over two and a half times increased and in HeLa cells was almost 10 fold higher 
(figure 2.3)  
This effect is likely due to centrifugation forcing the virus particles into close 
proximity to the ‘target’ cells so there is an increased chance of them binding and 
inducing an infection before the addition of the overlay. This means that the 
centrifugation step leads to more accurate calculations of the titers. Without it 
there may be more infectious particles/ plaque forming units (PFU) in the stock 
than cause plaques in the assay (i.e. the virus particles are not binding before the 
addition of the overlay to the cells). Based on these observations, the shell vial 
method was adopted for all further plaque assay titrations of VACV stocks, in an 
effort to reduce underestimation of the number of virus particles in the stocks.  
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Figure 2.3 The effect of shell vial culture on the calculated titer (as PFU/mL) for VACV produced in three different cell lines. The 
centrifugation step in the shell vial method increases the titer calculated in the three cell lines. The titer of the BSC-1 cells was 
increased by around two and a half times, the titer of the RK13 cells was increased by around 6 times and in the case of the HeLa cells 
the titer was increased by almost 10 fold by the shell vial. + denotes results generated using shell vial. - denotes results generating 
without shell vial. 
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2.2.3.2 VACV plaque assay titrations 
BSC-1 cells were seeded into a 24-wp and left to settle overnight to full confluency. 
Stock virus was prepared in a series of dilutions (1x10-2 - 1x10-7). These were applied 
to the plate in quadruplet, 500 µL per well. The plate was then centrifuged at 5000 
rpm for 15 minutes and left to incubate and allow the virus to settle for a further 30 
minutes. The wells were topped up to 1 mL with 500 µL of overlay (consisting of 
50% Avicel and 50% DMEM containing penicillin/streptomycin; Gibco). The plates 
were then left for three days before collection. After this time the sn was removed 
from the cells and the cells were gently washed twice with 1 mL PBS. The cells were 
then stained with 400 µL per well of Crystal violet solution (section 2.2.3.2.1) and 
left for 4-6 hours. The crystal violet was removed by plunging the plates into cold 
water. Excess water was shaken off and the plates were left to dry before the 
plaques in each well were counted. Titers were calculated as the average number of 
plaques in the wells (where they were countable) multiplied by ten to the power of 
the dilution factor of those wells, whilst also taking into account the original volume 
that was used to inoculate the cells (i.e. 500 µL/well).  
2.2.3.2.1 Crystal violet solution: 
5 g Crystal violet was dissolved in 100 mL 37% formalin, 200 mL 100% ethanol and 
700 mL distilled water. 35 mL 2M Tris-base and 10 g CaCl2 was added and stirred 
until dissolved the solution was then topped up to 2 L with distilled water. 
2.2.3.3 TCID50 virus quantification 
To calculate the titers of viruses that did not form plaques (i.e. mWT Fb, mEdATCC 
and YFV) the 50% tissue culture infective dose (TCID50) method was used. Cells 
(B95a for mWT Fb and Vero for mEdATCC or YFV) were grown to ~80% confluency 
in 96-wp. A series of 10 dilutions of virus plus two mocks (8 times repeated) were 
added to the cells. Cells were incubated for three days before being assessed for 
CPE. TCID50 concentrations were calculated based on the method previously 
described by Reed and Muench (1938). An estimation of the number of virus 
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particles in the stock may be made based on the average lowest dilution at which 
CPE is observed.  
2.2.4. Recombinant VACV (v300 and v3) construction details  
The construction of these viruses was based on the methods published by Blasco 
and Moss (1995). This involves the use of a virus with a faulty gene (ΔF13L) which 
renders it unable to produce large plaques. The plasmid used for the recombination 
(pRB21- ampR) includes a complete copy of the F13L gene, so any virus that takes 
up the plasmid will be able to produce large plaques. The gene of interest is 
inserted under the control of the synthetic early/late poxvirus promoter (Blasco and 
Moss, 1995). When the gene is inserted into the plasmid and recombinant virus is 
made, upon infection with the recombinant virus the gene of interest will be 
transcribed along with the F13L gene. In the case of v300 virus the eGFP gene was 
inserted into the pRB21 plasmid to produce the plasmid p300 (figure 2.4). For v3 
virus the firefly luciferase gene was inserted in order to produce the plasmid p240 
(figure 2.5). This plasmid was also used for the transcription reporter assay (chapter 
4, section 4.3.3). 
 
Figure 2.4 Plasmid p300 produced from pRB21 with the eGFP gene inserted used to 
produce v300 strain of VACV. The plasmid also contains an ampicillin resistance 
gene for selection. 
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Figure 2.5 Plasmid p240 produced from pRB21 with the firefly luciferase gene 
inserted to produce v3 virus. The plasmid also contains an ampicillin resistance 
gene for selection.  
 
2.2.4.1 PCR – gene of interest 
For the v300 virus, the eGFP gene was amplified by PCR from the plasmid pIRESneo 
eGFP, using primers designed to contain the restriction sites EcoRI and NdeI (Table 
2.1). The PCR reaction consisted of 40 µL H2O (sterile injection water; BRAUN), 5 µL 
10X Buffer I (Accuprime), 2 µL nucleotides (TaKaRa), 1 µL template (pIRESneo eGFP; 
0.01ug/ul), 0.5 µL of each primer (5’ primer Eco-K-eGFP and 3’ primer Nhe-pst-V5S-
ndeI-egfp; shown in table 2.1) and 0.5 µL Taq polymerase (Accuprime-
INVITROGEN). The cycling conditions used were two minutes at 96oC followed by 25 
cycles of one minute 96oC, two minutes at 55oC and three minutes at 72oC.  Loading 
dye (15 µL) was added to the PCR product and analysed and purified using a gel 
prep kit (see section 2.2.4.2.2). 
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Table 2.1 The sequences of the primers to amplify the GFP gene for the 
construction the v300 virus. The restriction sites are underlined and in lower case. 
 
2.2.4.2. Digestion 
The PCR product (5 µL) and plasmid vector pRB21 (5 µL) were each analysed and 
purified from an agarose gel using a Qiagen gel extraction kit (section 2.2.4.3). Both 
the PCR product and plasmid vector were digested with the restriction enzymes 
EcoRI and NdeI (2 µL each; 10 U/µL) in 10X SURECUT buffer A (5 µL; ROCHE) in a 
total volume of 50 µL (using 36 µL injection water) , incubated at 37oC for two 
hours. This was mixed with 15 µL loading buffer and analysed on a gel. The bands 
were again gel purified (QIAquick- Qiagen protocol, section 2.2.4.3), to remove 
small DNA fragments, and ligated following the protocol in section 2.2.4.4.  
2.2.4.3 Gel electrophoresis and purification 
In order to asses that the correct DNA was present at each stage of the cloning 
process, the samples were seperated by gel electrophoresis. The DNA samples were 
inserted into the wells of a 2% agarose gel housed in a vertical gel electrophoresis 
instrument (Hoeffer-Pharmacia) with 1X electrophoresis buffer used as the running 
buffer. Molecular weight ladders (1kb and 100bp) (Fermentas) were also loaded 
into the gel as markers. The running of the gel took ~60-90 minutes at 100V. 
Ethidium bromide solution (20 µL of 200 µg/mL solution in a tray of distilled water) 
was used to stain the DNA for a couple of minutes and the gel was viewed using a 
BIORAD UV transilluminator.  
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After PCR amplification and digestion of the DNA, a gel extraction kit was used to 
purify the required DNA. The samples were run on a 6 well vertical gel. In order to 
ensure that the purified DNA was not damaged, the following steps were taken to 
ensure that the required product was not exposed to UV and Ethidium bromide. 
The two centre wells were used for the DNA ladders (1kb and 100bp) while the 
adjacent wells were loaded with 10% of the DNA sample. Meanwhile the two outer 
wells were loaded with the remaining 90% of the sample. Before staining with 
ethidium bromide the two outer lanes were cut off the gel. The rest of the gel was 
stained and the bands resulting from the 10% of PCR product were used to assess 
the location of the required DNA. Based on this location, the remaining 90% of the 
DNA samples was then excised and purified using Qiagen gel extraction kit. After 
cutting the required sections out of the strips, they may then also be stained and 
viewed to ensure that the required DNA has been removed successfully.  
2.2.4.3.1 Stop buffer: 50% Sucrose (Sigma), 7 M Urea (Sigma), 0.1 M EDTA (Fisher-
scientific), 0.01% Bromphenol blue (Sigma).  
2.2.4.4 Ligation 
The digested PCR product and the vector were ligated together. This involved 
mixing 5 µL of the digested PCR product, plus 1 µL of the digested plasmid vector, 
and 2 µL glycogen with 100 µL -20oC ethanol. This mixture was centrifuged for 15 
minutes at 13 000 rpm, to pellet the DNA and bring the vector and insert into close 
proximity. The ethanol sn was discarded and the pellet was incubated at 50oC for 5 
minutes to dry. The pellet was resuspended in 10 µL ligation mix consisting of 1 µL 
T4 DNA ligase (Invitrogen), 2 µL 5X T4 DNA ligase buffer (Invitrogen) and 7 µL sterile 
injection water. The ligation reaction was stored overnight at 4oC.  
2.2.4.5 Transformation 
The product of the ligation was used to transform chemically competent Top10 
bacteria (One Shot TOP10 chemically competent E.Coli; Life Technologies) by heat 
shock transformation. This method involved thawing the bacteria slowly on ice, 
then adding 5 µL of ligated DNA to the cells on ice. The tube was placed on a heat 
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block at 37oC for 5 minutes and returned to the ice for 5 minutes. SOC buffer (250 
µL) was added to the cells and they were left to recover on the heat block at 37oC 
for one hour. The transformed bacteria (100 µL) were spread onto an Ampicillin 
(Sigma; 1 µL/mL of 100mg/mL stock) LB (Sigma) agar (Merck) plate and 50 µL was 
put into a bijou containing 1 mL LB broth containing Ampicillin. This acted as a 
control in case no colonies grew on the plates. The plates and the bijou were 
incubated overnight at 37oC and subsequent plate colonies were picked and grown 
up in 10 mL LB containing Ampicillin at 37oC overnight. One mL of the transformed 
bacteria from the grown up cultures were frozen for storage on beads (Cryobank) at 
-20oC. Plasmid from the remaining 9 mL of bacteria was purified using the MiniPrep 
kit (Qiagen). 
2.2.4.6 Preparation of agar plates and liquid bacterial growth medium:  
Agar plates were prepared by dissolving agar base (7.8g) in 200 mL of distilled 
water. The solution was sterilised in an autoclave at 121oC for 20 minutes. The agar 
was cooled in a water bath for 20 minute at 45oC, before adding ampicillin (1 µL/mL 
of 100 mg/mL stock). 20 mL was poured into each 8.25 cm plastic disposable plate. 
The plates were left overnight to cool and set before storing at 4oC. 
Liquid bacterial growth broth- Luria Bertani (LB; Sigma) was prepared by diluting 
the recommended volume in distilled water. This was sterilised by autoclaving at 
121oC for 20 minutes and was stored at room temperature. Ampicillin was added to 
the required amount of LB broth prior to use. 
2.2.4.7 Amplification and Purification of Plasmid DNA 
Purification of the plasmid DNA from the grown up bacteria was carried out using a 
MiniPrep kit (Qiagen).  Further stocks of the plasmid could be produced by growing 
up one bead in 10 mL/100 mL LB containing Ampicillin at 37oC overnight in a 
shaking incubator and purified using the QIAprep spin miniprep kit or Qiagen 
plasmid midi kit (100) (Qiagen).  
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2.2.4.8 Transfection/Infection 
This plasmid was used to transfect BSC-1 cells in 6-wp. For the transfection (200 µL) 
Opti-MEM reduced serum medium (Gibco Invitrogen) was used to dilute (2 µg) 
plasmid DNA (p300/p240). Turbofect in vitro transfection reagent (Fermentas) (4 
µL) was then added to the diluted DNA. The transfection mix was incubated at 
room temperature in the dark for 15 minutes before spotting onto the cells. The 
cells were simultaneously infected with vRB12 virus and left to settle for 1 hour. 
The wells were then topped up with 2 mL per well of low melting point (LMP) 
agarose (Bio-Rad). The plates were left at room temperature for at least 30 minutes 
to allow the agarose to set, before being returned to the incubator. The cells were 
observed over a period of three days. 
2.2.4.9 Plaque purification  
Plaques that formed over three days contained the recombinant virus and were 
selected for purification. Using a 2.5 mL pipette, a plug of the LMP agarose at the 
location of a plaque may be removed from the plate. This was transferred into a 
sterile eppendorf tube containing 500 µL DMEM which was then frozen at -70oC 
and thawed three times in order to release the virus particles from the agarose 
plug. The DMEM containing the virus was used to infect another 6-wp containing 
BSC-1 cells, and the process was repeated. This was done a total of three times to 
ensure that the final virus obtained was all recombinant from one clone. The final 
plug in 500 µL DMEM was used to grow up larger stocks of the recombinant virus 
using the method described in section 2.2.2.2. 
2.2.5 VACV (v3) firefly luciferase assay 
2.2.5.1 Optimisation of the v3 luciferase assay 
Optimisation experiments were carried out to determine the most suitable 
conditions to obtain significant luminescence signals in the luciferase assays. The 
first of these was to find out what amount of virus should be added to obtain 
sufficient measurable signals. The background signals for cells that have no v3 virus 
is an average af around 500 relative light units (RLU). Bearing this in mind, the ideal 
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signals in the presence of the virus is at least a few thousand/ tens of thousands 
RLU. If the signals are reaching the levels of hundreds of thousands then there is a 
risk of exceeding the maximum readable signal. The settings used for reading the 
luminescence signals lead to a maximum possible reading of just under 2 million. It 
was found that using an moi of 0.2 of the v3 (grown in HeLa cells) infecting RK13 
cells was sufficient to produce a signal in the range of around 25 thousand RLU 
(figure 2.6), which is around 50 times greater than the background signal (~500 
RLU). Using a small moi in the luciferase assays has the added benefit of conserving 
the virus stocks. For this reason it was possible to use the same batch of the v3 
grown in HeLa cells for all of the luciferase antiviral assays. This reduced the chance 
of error between experiments due to subtle variation between virus stocks.   
The optimum collection time for the luciferase assay has previously been 
determined by this group (data not shown). It was found that two hours was 
sufficient to produce a suitable signal from the v3 virus. This collection time has 
other advantages as it focuses solely on the early stage of the VACV lifecycle, i.e. 
cell entry and early viral transcription. Another benefit is that the assay has a short 
turn-around time, producing results within a single day. Also, the 96-wp format of 
the assay ensures that it is possible to test the effect of several compounds against 
VACV simultaneously. This assay became the standard first step for testing new 
ddBCNA compounds. Those that did not display improved activity against VACV at 
this stage were not selected for further study.   
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Figure 2.6 The luminescence signals from v3 (HeLa) at different moi after two hours 
in RK13 cells. Error bars ± 1 standard deviation.  
 
2.2.6 Microscopy methods 
2.2.6.1 Fixing cells for staining 
After the required experiment had been performed, cells were fixed onto coverslips 
by removing the medium and applying 500 µL/well 3% paraformaldehyde (PFA; 
Sigma) for 15 minutes. This was then removed and the cells were washed two times 
with PBS and stored at 4ᵒC until staining.   
2.2.6.2 Cell staining and mounting onto slides 
Coverslips were initially placed face down onto 100 µL blocking buffer (section 
2.2.6.2.1) on a sheet of parafilm (Sigma) in a box and left to block for 30 minutes at 
37oC. They were then transferred to a box containing a new sheet of parafilm with 
100 µL/coverslip of the primary antibody at the recommended dilution in blocking 
buffer and left to attach at 37oC for 1 hour. The coverslips were dipped into a 
beaker of PBS to wash off the excess primary antibody while the excess PBS was 
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carefully removed from the coverslip using a tissue. The coverslips were then 
placed into another box with fresh parafilm with 100 µL/ coverslip of the required 
secondary antibody at the recommended dilution in blocking buffer. These were 
then left at 37oC to incubate for one hour. The coverslips were rinsed again by 
dipping them into PBS, the excess PBS was removed from the coverslips by dabbing 
the edges with a tissue. Slides were prepared by placing 3 µL of Vectashield 
containing DAPI (Vector laboratories) onto them. The coverslips were then placed 
cells down onto the Vectashield on the slide. The coverslips on the slides were left 
for 5-10 minutes to dry before the edges were sealed using clear nail varnish. These 
were allowed to dry before storage at 4ᵒC. The coverslips were analysed by 
fluorescence microscopy. 
2.2.6.2.1 Blocking buffer 
Solution A: 100 ml PBS was used to dissolve 1.5 g Tris (Fisher-Scientific), the pH was 
adjusted with 2N HCl (Sigma) to pH 7. Then 1.45 g NaCl (Sigma) was added followed 
by 0.46 g EDTA (Fisher-Scientific). 125 µl Tween 20 (Fisher-Scientific) was added 
using a 200 µl pipette with the end of the tip cut off (because Tween 20 is a viscous 
liquid which does not pipette easily with a narrow tip). The solution was stirred 
using a magnetic stirrer until it had completely dissolved. Solution B: 125 ml of 1X 
PBS was heated separately in a 45oC water bath. Then 5 g bovine serum albumine 
(fraction V; Sigma) was added followed by 0.625 g gelatine (Sigma). The solution 
was stirred until dissolved.  
Solutions A and B were combined and topped up to 250 mL with 1X PBS. This was 
run through a NALGENE sterile filter (250 ml set) and stored in a sterile T75 cell 
culture flask. 
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Chapter Three – ddBCNA structure activity relationships 
against Vaccinia virus 
3.1 Introduction 
The novel compounds (ddBCNAs) used in this PhD project were synthesized from D-
IddU (for the D-ddBCNAs) using the Sonogashira reaction method, or from L-
arabinose (for the L-ddBCNAs) through 6 reaction steps to produce L-IddU. The 
required L-ddBCNAs were then produced from the L-IddU using the same method as 
for the D-ddBCNAs (McGuigan et al. 2013). The ddBCNAs were produced by the 
McGuigan group at the the School of Pharmacy and Pharmaceutical Sciences of 
Cardiff University. Previous nucleoside analogues had been shown to have antiviral 
activity (McGuigan et al. 2004). The ddBCNAs tested here are based on these 
original analogues but have been modified in an attempt to improve activity. The 
first ddBCNA compound found to show activity against hCMV was Cf1821, a D-
ddBCNA with the side chain C10 (McGuigan et al. 2004). The structure of Cf1821 
was further optimised to produce the compound Cf2095, also a D-enantiomer but 
with the side chain C9-O-C5. This modification improved the activity against hCMV. 
Cf2095 was then produced with the same general structure but in the L-enantiomer 
form. This was named Cf2642 and no longer displayed antiviral activity against 
hCMV. Critically however, it did show considerable activity against VACV (McGuigan 
et al. 2013). 
The first aim of this project was to confirm and quantify the activity of Cf2642 
against VACV. Furthermore, alternative L-enantiomer ddBCNAs (produced by the 
McGuigan group) were tested in order to determine if the structure of the ddBCNAs 
could be optimised to increase the antiviral effect against VACV. As such, another 
aim of this chapter was to test novel ddBCNA structures and compare the activity of 
the novel L- and D-enantiomers with the activity of a selection of D-enantiomers that 
had previously been produced by the McGuigan group.  
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Initially steps were taken to determine the optimum conditions for antiviral 
experiments and for the preparation of viral stocks for use in them. These 
optimisation experiments are described in chapter 2 (sections 2.2.2.1, 2.2.3.1 and 
2.2.5.1). The initial testing method for any newly produced ddBCNAs was the 
luciferase assay using v3 (VACV modified to express firefly luciferase; details in 
chapter 2, section 2.2.4) that produces firefly luciferase under the control of a 
synthetic early/late poxvirus promoter (Blasco and Moss, 1995). Using the 
luciferase assay, structure activity relationships (SAR) were established for the L-
ddBCNAs based on the length of their alkyl/ether side chains. The SAR was used to 
gain information about how the structure of the ddBCNAs relate to its antiviral 
activity. This was used to determine which specific parts of a molecule were 
responsible for the activity and to inform further optimisations.  
The luciferase assay was also used to compare the activity of the lead compound 
(Cf2642) against VACV in a variety of different cells lines. The aim of said 
experiment was to determine if the compound could inhibit the virus in a selection 
of different cellular hosts (of both human and animal origin), and if so, to what 
extent. 
A ToA assay was carried out using a luciferase reporter assay. This was done to 
determine the amount of time that the addition of the drug may be delayed before 
the antiviral effect can no longer be observed, i.e. to determine if the compound 
remains active against VACV if added at a later stage during viral infection. 
Plaque assays (carried out over 4 days) were used to determine if the ddBCNAs 
inhibited plaque formation by VACV. The effect of the active ddBCNAs could be 
seen as a reduced plaque size phenotype. Plaque sizes were measured and used to 
calculate IC50 concentrations against VACV for the compounds. The IC50 of a given 
compound is the concentration at which the compound inhibits the viral activity by 
50%, i.e. in this case the concentration at which the size of the plaque size reduced 
by 50% of the no drug control. An SAR was established for the selected L-ddBCNA 
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compounds based on their IC50 concentrations (section 3.3.5). This SAR was 
compared to the luciferase SAR for the same compounds.  
Wide field fluorescence microscopy was carried out on BSC-1 cells that had been 
infected with vYFP-A3L and either treated with Cf2642 or left untreated. The cells 
were then imaged in order to accurately visualise the effect of the ddBCNAs on the 
virus during plaque development.  
3.2 Materials and methods 
3.2.1 Luciferase assay 
RK13 cells were seeded into 96-wp and left overnight to settle and reach 
confluency. Cells were treated 30 minutes prior to viral infection, with each of the 
ddBCNAs at 10 μM and a no drug (DMEM only) control in triplicate, v3 was then 
added to the wells at a multiplicity of infection (moi) of 0.2. Cells were collected 2 
hours post infection (pi). The cell supernatant was removed and 100 μL of 1 × cell 
culture lysis reagent (CCLR) (Promega, Madison, WI) per well was added before the 
plate was agitated on an orbital shaker for 15 minutes. The plate was then frozen 
and stored at −20 °C. After thawing, 20 μL of each of the samples was transferred to 
a black 96-wp (NUNC, Roskilde, Denmark) and processed with 10 µL of the 
luciferase assay substrate and buffer II (Promega, Madison, WI). The luminescence, 
as relative light units (RLU) was measured in a 96-well luminescence plate reader 
(FLUOstar OPTIMA FL, BMG Labtech). The percentages of the treated versus the no 
drug control readings were calculated. 
 
This method was based on the technique known as poxvirus infection luciferase 
assay (PILA), described previously by Levy et al. (2010), however instead of using 
the transfection reporter system and transfecting the cells with the plasmids 
containing the luciferase gene, the VACV itself was modified to contain the firefly 
luciferase gene (v3), giving a direct firefly luciferase signal on viral entry into the 
cell. This eliminated the need for a Renilla control plasmid that is typically used to 
indicate the level of transfection.  
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3.2.2 Cell range assay 
A range of different cells were seeded in a 96-wp at 5x104 cells per well (6 wells of 
each cell type were plated). The cells selected included a range of human epithelial 
and fibroblast cells as well as cell lines derived from animals, in order to provide 
further information about the activity of Cf2642. The cells used were human 
epithelial- (HUH7, A431, A549, HeLa and HaCaT), human fibroblast (HFF, HFFFtc and 
BJ-1), marmoset B lymphocyte (B95a), monkey epithelial (BSC-1, Vero and CV-1) 
and rabbit epithelial cells (RK13) (full details of all cell lines are given in chapter 2, 
section 2.1.1).  
The panel of cells were treated 30 minutes prior to infection with 10 µM Cf2642 or 
left untreated in triplicate. The cells were then infected with v3 at an moi of 0.2. 
The cells were collected 2 hours pi (medium was removed and replaced with 100 µL 
per well of 1 x CCLR, shaken for 15 minutes on an orbital shaker and then frozen at -
20oC). The effect of the drug in each of the cell types was calculated as a percentage 
of the readings in the absence of drug.  
3.2.3 Time of Addition assay 
RK13 cells were seeded into a 96-wp and left overnight to settle and reach 
confluency. These were then treated in triplicate with 10 µM of Cf2642 at a range 
of times in relation to the time of infection (T0). These times were 30 minutes 
before infection and 2 hours, 4 hours, 6 hours, and 8 hours pi. A second 96-wp plate 
of RK13 cells was treated in the same way but with DMEM in place of Cf2642 – this 
plate acted as a control. This was carried out to compensate for the effect of the 
change in the volume at each of the time points. All cells were then collected 12 
hours pi. The medium was removed and replaced with 100 µL per well of cell (1 x 
CCLR), shaken for 15 minutes on an orbital shaker and then frozen at -20oC. 
Luminescence readings were measured using the 96-wp luminescence plate reader. 
The activity of the ddBCNAs was calculated as a percentage of the values measured 
for the DMEM control plate at each of the corresponding time points.  
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3.2.4 Statistics  
In order to determine which compounds reduced the luciferase signal by a 
statistically significant amount as compared with the no drug control, P values were 
calculated. This was done by performing paired t tests using SPSS software that 
compared the luminescence readings (RLU) from each of the drug conditions with 
the equivalent no drug control readings.  
3.2.5 Plaque size reduction assay 
BSC-1 cells were seeded in 24-wp and left overnight to settle and reach confluency. 
These were pre-treated with a series of dilutions of drug (50, 5, 0.5, 0.1, and 0.05 
μM) as well as a no drug control, in quadruplet. These were then infected with ~20 
plaque forming units (pfu) of v3 per well. The plate was centrifuged at 5000 rpm for 
15 minutes, and the virus was allowed to adsorb onto the cells for 45 minutes. The 
drug and the virus were removed and replaced with 0.5 mL DMEM containing the 
drug at double the required concentration. This was diluted to the required 
concentration by the addition of 0.5 mL Avicel overlay (50% Avicel, 50% DMEM 
containing 1% P/S). The plates were incubated for 4 days and were then rinsed 2 x 
with 1 mL/well PBS and stained with 400 µL/well crystal violet stain for 4−6 h. The 
plates were submerged in water to remove the crystal violet stain and left 
overnight to dry. After drying the plates were scanned at 600 dpi and the area of 
each plaque was measured individually using Image J software. Cidofovir (a viral 
DNA polymerase inhibitor) and AraC (a DNA synthesis inhibitor) were included in 
the assays as positive controls. 
3.2.6 IC50 calculations 
An IC50 concentration of a compound is the concentration of that compound that 
inhibits the viral activity by 50%. In this case IC50 values were defined as the 
concentration of ddBCNA that reduced plaque size (area, measured in pixels) by 
50% in comparison to cells infected in the absence of antiviral. The final IC50 values 
for all virus/antiviral combinations are each calculated as the mean of three 
repeats. IC50 values were calculated for each drug using the GraphPad Prism 
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software (GraphPad Software, Inc.). In this software the log of the concentrations 
was entered plus the average plaque size for each concentration. Since the log of 0 
cannot be defined, a theoretical concentration was used for the untreated cells i.e. 
in this instance the concentration was entered as -4, the log of 0.0001 (µM). 
3.2.7 Wide field fluorescence microscopy 
BSC-1 cells were seeded onto 12-wp containing coverslips and left overnight to 
settle and reach confluency. These were infected with ~20 pfu/well of vYFP-A3L and 
half were treated with Cf2642 at 50 µM, while the other half were treated with a 
DMEM (no drug) control. One of each of the treated and untreated coverslips was 
fixed after one day, two days and three days. The cells were stained with phalloidin-
594 to visualise the actin cytoskeleton (in red) and mounted onto slides using 
Vectashield containing DAPI to visualise the nuclei (in blue). The edges of the 
coverslips were sealed using clear nail varnish. The cells were imaged using the 
wide field fluorescence microscope and images were taken of each of the 
conditions. The exposure time required to visualise the virus was 1000 ms in the 
presence of the drug and 400 ms in its absence. 
3.2.8 Pilot in vivo assay 
The in vivo assay was carried out by Dr J Bugert and Dr A Ager, under the home 
office project licence of Dr A Ager (PPL no. 30/2635). The experiment was designed 
with the aim of determining if the lead compound Cf2642 could reduce the level of 
VACV infection in mice. The experiment involved the use of 24 black-6 female mice, 
three mice were used for each infection/treatment condition. The 8 conditions are 
summarised in table 3.1. The drug or control, as well as 2x106 pfu of v3 (grown in 
TK- cells), were injected into the peritoneal cavity of the mice. Cf2642 was dissolved 
in DMSO and mixed with the virus prior to the injection. After 3 days the mice were 
euthanized and the ovaries were collected for testing. During VACV infection of 
mice the virus accumulates in the ovaries. Therefore the reason for collecting these 
was to see if the level of virus accumulation was reduced by Cf2642. One ovary 
from each mouse was dounce homogenised. Samples of each were then used to 
  
68 
infect a 96-wp of RK13 cells. These were collected after two hours as described for 
other luciferase assays (section 3.2.1) and luminescence readings were taken.  
 
Table 3.1 The 8 conditions used in the pilot in vivo assay. The other columns 
indicate which mice received virus and which received drug (concentrations 
bracketed). 
 
3.3 Results 
3.3.1 Activity of ddBCNAs against VACV as determined by luciferase assay: 
3.3.1.1 Activity of D- versus L-ddBCNAs  
Early attempts at modifying the structure of the ddBCNAs to improve activity 
involved producing alternative compounds with D-chirality. However, recently L-
enantiomers have been studied and found to have increased activity against VACV 
(McGuigan et al. 2013). 
All ddBCNA compounds produced were tested using a two hour luciferase reporter 
assay with v3 in RK13 cells. This method provided an indication of how active these 
compounds were against VACV. Critically for experiment planning, the output of 
this assay was rapid (less than one day) (as described in section 3.2.1). 
The readouts determined which of the compounds would be further investigated 
for activity. The results also allowed for optimisation of the structure since the most 
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active compounds provided a base to work from in any attempts to improve the 
structure further. 
Initially, two L-ddBCNAs (Cf2642 and Cf2644), the original D-enantiomer lead 
Cf2095, and a series of 12 newly synthesised D-compounds were tested. The 
structures of these compounds are described in figure 3.1 and table 3.2. The 
compounds were applied to the cells at a concentration of 50 µM which was 
sufficient to ensure that the maximum effect of each could be established. 
The resulting data (figure 3.2) indicated that the two L-compounds (Cf2642 and 
Cf2644) displayed the greatest reduction in the luciferase activity of v3 in RK13 cells 
over the course of two hours. Cf2642 caused a reduction in signal from v3 to just 
20% of the luminescence signals generated in the no drug control. The reduction 
caused by Cf2644 was similar (~25%).  
Despite being inferior to the reduction observed with the L-compounds, some D-
compounds (with alternative modifications) did show improved activity against 
VACV (P <0.05) as compared to the original D-compound Cf2095. For example, 
Cf2762 reduced the luciferase signal to ~40% of that of the no drug control (P 
<0.01) whilst Cf2095 reduced the signal to only ~75% (P <0.05).   
The clear difference in activity between the best of these D-compounds compared 
to the L-compounds led to the decision that further synthesis of compounds would 
focus on the L-enantiomer form of drug, with the structures of the lead L-ddBCNAs 
Cf2642 and Cf2644 acting as the baseline for further optimisation i.e. the new 
compounds produced were similar to Cf2642/Cf2644 but had subtle alterations (for 
example, increasing/decreasing the number of carbon atoms in the hydrocarbon 
side chain). The subsequent compounds were tested in parallel to establish SAR.  
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Figure 3.1 The main chemical structure of the ddBCNAs. Variable sections are 
indicated in red and the modifications at each of these sections are described in 
table 3.2. 
 
 
Table 3.2 The structure of the side chains of the ddBCNAs.
  
                          
Figure 3.2 Luciferase signals for two L-ddBCNAs and 13 D-ddBCNAs as compared to a no drug control (Ø) Average of 3 independent luciferase 
assays as a percentage of the signal generated with the no drug control. Infection with v3 at moi 0.2 in RK13 cells pre-treated for 30 minutes 
with each of the compounds indicated in the graph at 50 µM. Collection at 2 hour pi. Error bars ± 1 standard deviation. * P <0.05, ** P <0.01, 
*** P <0.001. Although visually the data suggests that the D-ddBCNAs are not having as much of an effect against the VACV than the L-
ddBCNAs, only three of them fail to show a significant decrease in luciferase activity (Cf2643, Cf2754 and Cf2779). The remaining compounds 
correlate with varying levels of reduced signal (as indicated by decreasing P values). The compounds that reduce the virus to the greatest 
extent include both of the L-ddBCNAs described (Cf2642 and Cf2644). None of the D-ddBCNAs show as big an effect. However three of them 
(Cf2750, Cf2755 and Cf2762) do show improvement over the original D-ddBCNA (Cf2095). 
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3.3.1.2 Activity of L-ddBCNAs with alkyl and ether side chains 
The first set of modifications made to the L-ddBCNAs used the structures of Cf2642 
and Cf2644 (as described in section 3.3.1.1) as a base to work from. Cf2644 contains 
an alkyl side chain of 10 carbon atoms in length. Cf2642 contains an ether side 
chain with the structure C9-O-C5. The modifications made to these compounds 
were subtle and involved simply altering the length of the alkyl/ether side chain. In 
doing this an SAR could be established and the optimum side chain length could be 
determined. The basic structure of these compounds is shown in figure 3.3 and 
each of the modifications is listed in table 3.3. 
Figure 3.4 indicates that L-ddBCNAs with alkyl and ether side chains have a clear 
SAR. There is a correlation between increasing length of the side chain and resulting 
activity levels of the compound. However, this correlation plateau’s beyond an alkyl 
side chain length of 9 carbons. This is probably due to the fact that the lipophilicity 
of the compounds increases as the chain length increases and they become 
progressively harder to dissolve for experiments. The addition of an ether group to 
the side chain decreases the lipophilicity, thereby allowing for additional carbons to 
be added to the side chain.  
The ether series of compounds all had 9 carbon atoms before the ether group. The 
number of carbons after the ether group was then altered to determine the SAR for 
the ether series. The series portrayed an SAR with the optimum length being 4/5 
carbons after the ether group. The data also shows that the optimum ethers 
performed better than the optimum alkyls. Therefore it was decided that ethers 
would be used for further optimisation and testing against the viruses with 
particular focus on Cf2642/Cf3208. 
To avoid bias, investigators were blinded to the structures of all compounds during 
the process of optimisation. Two of the older preparations of active L-ddBCNAs 
(Cf2642 and Cf2644) were included in the assay as positive controls. When the 
structures of the new compounds were revealed, it was found that the ‘newly 
produced’ Cf3208 had the same structure as the original lead Cf2642. As expected, 
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the activity levels of newly synthesised Cf3208 were similar to the levels observed 
for Cf2642 (an older stock). This was also the case with the alkyl series; Cf3155 had 
the same structure as the original compound Cf2644, and they both showed very 
similar activity. To avoid confusion from this point forward only the original names 
of these two compounds will be used, i.e. Cf2642 and Cf2644.  
Using paired t tests in SPSS, P values were calculated for each of the compounds to 
determine which reduced the signal by a significant amount in comparison to the 
no drug controls. The compounds Cf3176 and Cf3156 were the only two that 
appeared to be inactive (P > 0.05). The remaining compounds showed significantly 
improved activity levels as compared to the untreated control - two compounds, 
Cf3177 and Cf3174, with P values less than 0.05 and all others with P values less 
than 0.01.  
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Figure 3.3 The main chemical structure of the L-ddBCNAs with alkyl and ether side 
chains. Variable sections are indicated in red and the modifications at each of these 
sections are described in table 3.3 
 
 
 
Table 3.3 The structures of each of the side chains for the alkyl and ether series of L-
ddBCNAs.
  
 
Figure 3.4 L-ddBCNAs with alkyl 
(left section) and ether (right 
section) side chains of increasing 
length. The length of carbon side 
chain is indicated above each bar. 
For the ether series the number 
above the bar represents the 
number of carbons after the ether 
group. Full structural information 
is provided in figure 3.3 and table 
3.3. Lightly shaded bars represent 
the original L-ddBCNAs included 
as positive controls. These had 
matched structures in the newly 
produced series; Cf2644 and 
Cf2642 were identical to Cf3155 
and Cf3208 respectively. As 
expected, these duplicates 
showed similar activity levels. 
 Luciferase assay in RK13 cells pre-
treated with 10 µM of stated 
compounds and infected with v3 
at moi of 0.2. Ø = no drug. 
Collection two hours pi. Error bars 
± 1 standard deviation.   
* P <0.05, ** P <0.01,  
*** P <0.001 
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3.3.1.3 Activity of further modified L-ddBCNAs  
The best performer at this stage was still Cf2642, a compound with an ether side 
chain C9-O-C5. As such this side chain structure was chosen as the basis for further 
modifications to the L-ddBCNAs. Of the resulting modified compounds, two 
maintained the same side chain structure but were altered elsewhere in the 
molecule,  four maintained the same side chain length but had the ether group 
moved to an alternative position and four had branched groups added after the 
ether group. The structures of the modified compounds are summarised in figure 
3.5 and table 3.4. 
These compounds were all tested using a two hour luciferase assay in RK13 cells. It 
was found that, barring one compound (Cf3242) which reduced the luminescence 
signal to less than 20% of the no drug control, none of them displayed better 
activity against VACV than Cf2642 (figure 3.6). As discussed later in this chapter 
(section 3.3.5), Cf3242 was ruled out as a potential drug candidate due to its 
increased toxicity against the cells. Beyond the original leads Cf2642 and Cf2644, 
four of the new compounds (Cf3242, Cf3230, Cf3231 and Cf3232) reduced the 
luciferase signals to less than 50% as compared with the no drug control (P < 0.001). 
Of the remaining compounds, all showed a significant reduction in signal compared 
to the control (Cf3253, Cf3254, Cf3392 and Cf3332 P < 0.01; Cf3393 and Cf3458 P < 
0.05).  
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Figure 3.5 The main chemical structure of the L-ddBCNAs with further 
modifications. Variable sections are indicated in red and the modifications at each 
of these sections are described in table 3.4 
 
 
 
Table 3.4 The further modified L-ddBCNAs and their structures.
  
                               
Figure 3.6 Luciferase assay in RK13 cells showing the luciferase activity of v3 in the presence of all further modified L-ddBCNAs (at 10 µM). 
Results are shown as a percentage of the no drug control readings. Cf3242 is the only other compound that showed greater antiviral activity 
than Cf2642. Error bars ±1 standard deviation. * P <0.05, ** P <0.01, *** P <0.001.
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3.3.2 Activity of Cf2642 against VACV in alternative cell lines 
The activity of Cf2642 was tested against v3 using a two hour luciferase assay in a 
variety of cell lines in order to ascertain how well it worked in an alternative host. A 
selection of human epithelial and fibroblast cells were tested as well as animal-
derived cell lines (the nature of these cell lines are described in chapter 2 section 
2.1.1). Cells were selected to cover a range of different human and animal origins in 
order to confirm an effect of the drug in relevant cell lines. The strength of the 
luminescence signals displayed in these cell lines are presented in figure 3.7A. The 
data indicate that there is considerable variability in the signals generated between 
the cell lines. Human epithelial HUH7 cells produced the largest luminescence 
signals whilst human fibroblast cell lines and monkey lymphocytic B95a cells gave 
the lowest luminescence signals.  
In order to account for the variability in luminescence signals generated by the 
various cell lines, the readings for the cells containing Cf2642 were calculated as a 
percentage of control cells (of the same origin) that received no drug. This provided 
an indication as to how well the drug worked against the virus in each of the cell 
lines tested (figure 3.7B). It can be seen that there is some level of antiviral activity 
of the compound in each cell line and that this varies from cell to cell. Of note, 
however, is the fact that the differences between the readings in the presence and 
absence of Cf2642 were significant in all the cell lines tested (CV-1, BJ-1, HaCaT and 
B95a, P <0.05; A431, A549, HUH7, HFF, HFFFtc, BSC-1 and Vero, P <0.01; HeLa and 
RK13, P <0.001). It is clear that the activity is highest in the RK13 cells. As such these 
cells were used for all downstream luciferase assays involved in compound 
optimisation. 
  
 
Figure 3.7 Luciferase assays displaying the effect of Cf2642 on v3 activity in different cells, including (human epithelial) A431, A549, HeLa, 
HaCaT, HUH7, (human fibroblast) HFF, HFFFtc, BJ-1, (monkey lymphocytes) B95a, (monkey epithelial) BSC-1, Vero, CV-1 and (rabbit epithelial) 
RK13. A: shows the average luminescence readings with and without drug. B: shows Cf2642 activity as a percentage of the no drug control. 
Error bars ± 1 standard deviation. * P<0.05, ** P<0.01, *** P<0.001.
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3.3.3 Cf2642 time of addition luciferase assay 
Another luciferase assay in RK13 cells was carried out in order to determine if the 
drug still had an effect on the virus when added at different stages of v3 infection. 
Cf2642 was added at a series of time points; prior to (30 minutes), at the same time 
as (To), and after viral infection (ranging from two to eight hours). Cells were 
collected for luciferase readings at 12 hours pi. The greatest effect on viral activity 
was observed when the drug was added before or at the same time as the virus 
(figure 3.8). However, the drug appears to still have an effect on the virus even 
when added 8 hours after the initial infection, as indicated by a ~50% reduction in 
the luminescence signal.  Whilst the latter observation is non-significant (P >0.05), 
the data is still suggestive of an effect. The results for the addition of Cf2642 at each 
of the other time points were statistically significant (P <0.01). Of note, there is no 
statistical difference in activity between cells that were pre-treated, and those 
which had the drug added at the same time as the virus (P = 0.937). 
 
 
  
             
Figure 3.8 The effect of Cf2642 (10 µM) on the luminescence signal from v3 infection in RK13 cells when added at 30 minutes prior to 
infection, To and 2, 4, 6, and 8 hours pi. Collection at 12 hours pi. The results are shown as a percentage of the DMEM time of addition control. 
Ø = no drug. Error bars ±1 standard deviation. ** P <0.01, *** P <0.001
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3.3.4 Activity of ddBCNAs in plaque size reduction assays 
Plaque assays are a well established method of studying antiviral effects in cell 
culture (Porterfield, 1959). This method was chosen as a further means of 
measuring ddBCNA activity against VACV. The effect of the ddBCNAs was observed 
as a reduction in the size of the plaques but they had no effect on the total number 
of plaques formed.  
The ether series of L-ddBCNAs were tested in four day plaque assays in triplicate. To 
demonstrate the output of the plaque assays, example data representing the 
greatest (Cf2642), smallest (Cf3210) and most toxic (Cf3242) responses to the 
compounds, are displayed in figure 3.9 along with Cidofovir as a positive anti-
poxviral control. 
Cf2642 was the most active of the compounds in the majority of the assays, 
displaying small plaques at drug concentrations of 50, 5 and 0.5 µM. Of note, this 
decrease in plaque size only occurred at Cf2642 concentrations above 0.1 µM. 
Merely by visualising the data (figure 3.9), it is evident that the concentration 
required to reduce the plaque size by 50% is between 0.1 and 0.5 µM. However, to 
confirm this, Image J software was used to accurately measure the area (in pixels) 
of each individual plaque. By inputting these measurements into curve fitting 
software (GraphPad), an accurate IC50 concentration was generated (IC50 
concentrations shown in table 3.5 and figure 3.10). This value was determined to be 
0.19 µM for Cf2642.  
Cf3210 appears the least active of the L-ddBCNAs tested, with a calculated IC50 
value of 12.9 µM. In support of this, it is clear from the plaque images that the size 
of the plaque doesn’t decrease until drug concentrations of 50 µM are used. The 
remaining L-ddBCNAs tested induced plaque size changes somewhere between 
those displayed by Cf2642 and Cf3210.  
Cf3242 appeared to have activity greater than Cf2642 in the luciferase assay (figure 
3.6) and was therefore included in the plaque assays along with three other 
compounds (Cf3230, Cf3231 and Cf3232) that were among the most active in the 
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luciferase assay (figure 3.6). Conversely, the plaque assays suggest that Cf3242 is 
not as active against VACV as Cf2642 – with plaque reduction not occurring unless 
drug concentrations of at least 5 µM are used. It had a calculated IC50 of 2.4 µM. In 
addition, it is clear that the compound displays toxicity against the host cells (figure 
3.9) as indicated by a lack of crystal violet staining (which in turn indicates a lack of 
viable cells) four days after drug addition (at a concentration of 50 µM). 
The control drug Cidofovir appears to eliminate the plaques completely at the 
highest concentration, and shows some reduction in plaque size at the 5 µM. The 
calculated IC50 for this drug was 11.45 µM. AraC which also included as a control, 
also displays reduced plaque size phenotype in the plaque assays and displays an 
IC50 concentration of 0.93 µM.  
Another observation of note when carrying out the plaque assays was that in the 
wells containing higher concentrations of ddBCNAs, the cell medium became yellow 
over the course of the experiment. This effect appeared to correlate with the 
activity of the ddBCNAs, i.e. the most active ddBCNAs changed the medium yellow 
at a lower concentration than the less active ones. This significance of this 
observation is discussed further in chapter 6 and 7.
  
                                 
Figure 3.9 Cf2642, Cf3210, Cf3242 and Cidofovir at different concentrations in BSC-1 cells infected with ~20 pfu/well v3 over four days. After 
infection, cells were stained with crystal violet and scanned in order to analyse plaque sizes. A small plaque size phenotype is observed at 
lower concentrations in the most active compounds, (e.g. at 0.5 µM in the case of Cf2642) than it is in the less active compounds (e.g. small 
plaques can only be seen at 50 µM of Cf3210). Cf3242 displays toxic effects at 50 µM, observed as a complete lack of crystal violet staining (in-
turn indicating a lack of cells in the well).
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Table 3.5 IC50 concentrations calculated using plaque size measurements for the 
ether series plus four ddBCNAs with other modifications. Cidofovir and AraC have 
also been included as positive controls. 
 
 
Figure 3.10 The calculated IC50 concentrations of the ether series of ddBCNAs 
(Cf3210, Cf3204, Cf3207, Cf2642 and Cf3209) plus four other (best performer) 
ddBCNAs (Cf3230, Cf3231, Cf3232 and Cf3242). Cidofovir and AraC were also 
included as controls.  Error bars ± 1 SD based on three independent experiments. 
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3.3.5 Fluorescence microscopy of plaque development 
BSC-1 cells were infected with ~10 pfu per well of vYFP-A3L and then were either 
treated with 50 µM Cf2642, or left untreated. Cells were fixed after one, two and 
three days pi. Cells were stained with phalloidin-594 (to visualise the actin 
cytoskeleton in red) and mounted with Vectashield containing DAPI (to visualise the 
nuclei in blue). Fluorescence microscopy images are presented in figure 3.11. 
After one day the untreated cells showed signs of the formation of small plaques 
surrounded by cells containing many virus particles. The cells that had been treated 
with Cf2642 also showed signs of plaque formation, though they appeared smaller 
than the untreated equivalents. There were some virus containing cells around the 
edge of these small plaques, however these were fewer in number than in those 
untreated.  
Another point to note is that in order to photograph the signs of the vYFP-A3L in 
the treated cells, the exposure time needed to be much longer than for the 
untreated cells, 1000 ms compared with just 400 ms. The greater exposure time 
required, indicates a reduced number of fluorescent virus particles within the 
Cf2642 treated cells i.e. suggesting that the drug is having an effect. 
Both trends noted above (i.e. smaller plaques and reduced exposure time for the 
treated cells) continued into two and three days pi, suggestive of a real and 
prolonged effect for Cf2642 against the virus.  
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Figure 3.11 BSC-1 cells seeded in a 12-wp + coverslips, infected with ~10 
pfu/well vYFP-A3 and either untreated or treated with 50 µM Cf2642. Cells 
were fixed after 1, 2 and 3 days. Cells were photographed using a fluorescence 
wild field microscope. Exposure time was 400 ms for untreated cells and 1000 
ms for Cf2642 treated cells. The intensity of the viral fluorescence is greater in 
the absence of the drug suggesting there are more viral particles present than 
in the Cf2642 treated cells. 
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3.3.6 Pilot in vivo assay  
The results of the animal experiment proved inconclusive (figure 3.12). 
Luminescence levels were used to provide an indication of the quantity of v3 
accumulation in the ovaries of the mice. Unexpectedly, the level of luminescence in 
untreated mice infected with v3 (~200 000 RLU) was lower than in some of those 
that were treated (up to ~250 000 RLU). Considering the drug dilution results alone 
for infected mice, it seems that the drug does have a slight dose dependant 
inhibitory effect on the virus (~250 000 RLU at 10 mg/kg, ~170 000 RLU at 50 mg/kg 
and ~150 000 RLU at 100 mg/kg). As expected the luminescence from the ovaries of 
the mice that were not infected with virus was equivalent to the background 
luminescence (<1000 RLU). 
In terms of toxicity, the drugs seemed to be well tolerated by the mice – with no 
indications of harm or discomfort occurring throughout the course of the 
experiment. 
  
                               
Figure 3.12 In vivo Cf2642 assay - the accumulation of v3 in the ovaries of mice. Average luminescence in relative light units from three mice 
ovary collections. Error bars ± 1 standard deviation. The uninfected mice in the presence or absence of drug display background levels of 
luminescence (<1000 RLU). The results from the Cf2642 dilution series suggest an inhibitory effect as the luminescence decreases with 
increasing concentrations. However the signals from the untreated, infected mice turned out to be lower than when treated with 10 mg/kg 
Cf2642 so the inhibitory effect of Cf2642 could not be confirmed from this assay alone.  
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3.4 Discussion 
Before commencing work on the antiviral assays in this project, certain aspects of 
the assays and virus stock production methods were optimised. The results of the 
method optimisations are described in chapter 2. All modified and optimised 
conditions were subsequently used to generate the data described here on in. 
The antiviral assays described in this chapter repeatedly demonstrate that, of the 
ddBCNAs tested, the compound Cf2642 appears the most effective at inhibiting 
VACV infection. The only exception to this was luciferase assay data generated for 
Cf3242 which showed a greater reduction in the luminescence signal (to <20% of 
the no drug control). However Cf3242 was later found to have a higher IC50 
concentration than Cf2642 and also displayed clear signs of toxicity in the plaque 
assay. Based on the overwhelming data pointing to Cf2642 having the strongest 
antiviral effect, all subsequent assays of activity against VACV focussed on this drug.  
The apparent antiviral effect of Cf2642 was tested in a variety of different cell types 
that had been infected with v3. This data indicated that Cf2642 inhibited the virus 
in all of the cell types tested, though the extent of this inhibition varied between 
them.  
In order to compare the effect of the ddBCNAs between the different cells, the 
results for the antiviral effect of the ddBCNAs in this assay were calculated as a 
percentage of no drug control for each cell type. This was particularly important in 
this assay because variation in the luminescence signal between the cell types in 
the absence of the drug could be observed. This is possibly due to the fact that 
some cells may be more easily infected with VACV than others. In cells where the 
virus can enter easily, there would likely be a greater luminescence signal produced 
than in those where the virus cannot enter so easily. Another reason for the variety 
in luminescence signals may be because the method of cell counting is not entirely 
precise, especially in cell lines that have a tendency to aggregate after 
trypsinisation. As such, although every attempt was made to ensure that equal 
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numbers of cells were placed into each well, there may have been some disparity 
between the starting numbers of cells.  
Cell size may also have been an issue. Cells that are larger will approach confluence 
at an increased rate as compared to the same number of smaller cells within wells 
of the same capacity. For example, HUH7 cells are larger than B95a cells – we 
observed that 5x104 cells per well of the former approached confluence while the 
latter did not fill the well.  
The ability of Cf2642 to function in different cell lines is an important observation. 
Previous experience has shown that the effects of novel antivirals cannot always be 
replicated in different cell lines. For example N-methanocarbathymidine ((N)-MCT) 
a carbocyclic thymidine analogue showing antviral activity against orthpoxvirus 
infection, was found to have significant variation in activity between different cell 
lines (Smee et al. 2006). The ability of Cf2642 to function in different cell types 
(albeit at different levels) supports its use as a potential novel antiviral. 
Furthermore, the data presented here can potentially provide an insight into its 
MoA. The possible MoA will be discussed further in chapters 6 and 7. 
A ToA assay was carried out to determine if the drug maintained antiviral effects 
when administered at later stages of infection.  Here Cf2642 was added at a series 
of time points relative to infection, ranging from 30 minutes prior to - 8 hours pi. 
The data ultimately suggests that adding the drug at different times made little 
difference to the antiviral effect. Whilst the signal at the 8 hour time point was not 
significantly lower than the control reaction, this is likely due to large variation 
resulting from anomalous readings. These anomalous readings are as a result of 
some of the luminescence signals generated from the later collection times 
exceeding the maximum readable signal by the luminometer  
The above findings are useful for a number of reasons. Firstly, the fact that the drug 
can be administered at various stages before and after viral infection is informative 
for future laboratory based testing. Indeed the observation that there is no benefit 
to adding the drug 30 minutes prior to infection suggests that this routine practice 
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isn’t necessary (though, for the sake of consistency, the 30 minute drug pre-
treatment step was maintained for future assays). Also, it is possible that the data 
could be clinically relevant – though it is of course difficult to extrapolate from in 
vitro data to in vivo systems.  
Relating to this though is the information the ToA data infers about the MoA of the 
drug. ToA assays have been used to gain insights as to the MoA of antiviral 
compounds (Daelemans et al. 2011). This provided information about the MoA of 
the ddBCNAs based on the time that the addition of the drug may be delayed 
before a loss of antiviral effect is observed. For example if the compound was 
inhibiting the entry stage of infection alone, this would imply that if the drug was 
added after the viral entry had already occurred there would be no antiviral effect 
observed. 
Plaque assays were carried out to determine the effect of the ddBCNAs on the 
formation of plaques by VACV. Following the observation that the ddBCNAs 
reduced the size of the VACV plaques, the area of each of the plaques was 
measured to quantify the effectiveness of each of the ddBCNAs by producing IC50 
concentrations. Again the data pointed to Cf2642 as being the compound with the 
greatest antiviral activity.  
When comparing the IC50 concentrations of the ether series of ddBCNAs to their 
luciferase activity data, there appears to be a correlation between the two. Indeed, 
the SAR profiles of each of the assays follows a similar pattern (figure 3.13). This 
pattern indicates that the activity of these compounds is specific as altering the 
structure of them by even a small amount can have a large effect on their activity. 
This effect has previously been observed with a series of deoxynucleoside 
analogues active against VZV where it was found that an alkyl side chain length of 
8-10 carbon atoms was required for optimum activity (McGuigan et al. 1999). 
Wide field fluorescence microscopy of plaques in the presence and absence of 
Cf2642 indicated a clear reduction in the number of fluorescent virus particles 
when the drug was added. This was made clear as the level of exposure needed to 
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capture the viral fluorescence in the treated cells was much higher than for the 
untreated cells with normal infection levels (1000 ms compared with 400 ms). This 
effect could be seen after one day and the trend continued over the course of the 
three days. The series of images taken during this experiment provided further 
evidence for the ddBCNAs ability to reduce infection by VACV.   
Based on the encouraging findings made in in vitro systems, a preliminary 
experiment in an animal system (specifically mice) has been carried out and is 
included here as a further discussion point. The mice appear to be unaffected by 
the presence of the drug in their system, in turn suggesting that the drug is well 
tolerated and toxicity isn’t a factor. The issue of toxicity will be discussed further in 
chapter 5. 
Though there is perhaps a trend toward decreasing virus burden as drug levels are 
increased, the data does not confirm an antiviral effect for Cf2642 in mice. Further 
tests are needed to validate this negative finding since it is possible that various 
confounding factors might have influenced the result. For example, the results 
could have been affected by the fact that some of the drug appeared to precipitate 
out of solution after injection into the mice, reducing the full antiviral effect of the 
compound. As such, further repeats involving animals would require that the drug 
be administered in a way that ensured that it remained completely in solution.
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Figure 3.13 The calculated IC50 concentrations from the plaque assays in BSC-1 cells over four days for the ether series of L-ddBCNAs 
overlaid onto previously shown data from the two hour luciferase SAR in RK13 cells for the ether series. The graph shows a similar 
trend in the SAR using the data from both assays. 
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Chapter four – Activity of ddBCNAs against measles and virus 
panel 
4.1 Introduction 
The D-ddBCNAs described in this thesis were initially developed for antiviral activity 
against hCMV. In contrast, the L-ddBCNA equivalents of these were found to not be 
active against hCMV. However they do display antiviral activity against VACV. In 
chapter 3, it was confirmed that these compounds are clearly having an inhibitory 
effect against VACV, and this effect was quantified using a series of independent 
assays. Whilst this observation is an interesting one, it is not of huge clinical 
importance. This is because the smallpox virus (the most serious of the poxviruses) 
has been declared eradicated. Despite this there is still interest in potential anti-
viral compounds against the smallpox virus due to increasing concerns about the 
possibility of bioterrorism and the release of smallpox. Indeed, whilst there are only 
two official stocks of smallpox virus remaining worldwide, there is a distinct 
possibility that unknown illegal stores exist elsewhere. For this reason the vaccinia 
vaccine, that acts against the smallpox virus, has been produced in large quantities 
for use in the event of such an outbreak.  
Beyond this, the only drug capable of protecting against an outbreak of smallpox, is 
cidofovir. However, this drug can have severe nephrotoxic side effects (Skiest et al. 
1999). Indeed, the overall aim of studying the ddBCNA’s activity against VACV was 
to act as the groundwork for determining their suitability against other poxviruses 
of greater clinical relevance, for example MCV. This is the only remaining strictly 
human poxvirus. It affects many children and immune deficient individuals (Buckley 
and Smith, 1999). It produces uncomfortable wart like protrusions on the skin that 
secrete infectious particles. In the immunosuppressed state these may persist for 
years if left untreated. 
Furthermore, if it were demonstrated that the ddBCNAs displayed activity MCV, as 
well as VACV, this would provide proof of concept of the possibility of utilising their 
antiviral effects against other poxviruses such as monkeypox (of which there are 
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increasing infections in parts of Africa) and smallpox (in case of an outbreak).  Here 
it was demonstrated that Cf2642 has an antiviral effect on MCV. 
In addition to poxviruses, the ddBCNAs were tested against a panel of other viruses. 
This was firstly to determine if they displayed activity against other viruses of 
clinical importance. It also aimed to establish if there were viruses against which 
the compound did not work. It was important to make sure that the effect of the 
compounds was specific and not just a general effect that works against any virus. 
Whilst being of obvious clinical relevance, the data yielded from this combination of 
affected and unaffected viruses might provide insights as to the MoA (e.g. is there a 
shared feature amongst the viruses that are affected by the ddBCNAs). This is 
discussed further in chapter 7. 
This chapter describes efforts to define the anti-viral activity of several ddBCNAs 
(though primarily Cf2642) against a series of viruses beyond VACV (e.g. MCV, HIV-1, 
measles (Wild type and Edmonston strains) and the vaccine strain of yellow fever 
virus (YFV)). 
The choice of viruses tested was ultimately dependent upon which ones the Bugert 
group could get access to and whether suitable assays were available or could be 
developed for testing them. The viruses tested also had to correspond with the 
permissions given for the work being carried out (details of permissions: license 
holder ‘Bugert lab’ - HSE notification GM130/07.5: testing of candidate antiviral 
compounds for activity against viruses: laboratory strains, vaccine strains, wild 
types, and recombinant viruses expressing fluorescently tagged proteins using 
classical virus titrations and reporter assays). 
Tests of Cf2642 against Influenza, Adenovirus, HSV-1 and HSV-2 had previously 
been carried out (by the Bugert group) though it was found to have no activity 
against these viruses. This chapter summarises and describes experiments carried 
out to determine activity of ddBCNAs in a series of viruses. 
Briefly, the results of this chapter describe; 
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-Test of Cf2642 against YFV where it was found to have no activity. 
-A transcription luciferase reporter assay with Cf2642 against MCV suggested anti-
viral activity. This finding provided initial evidence that the effect of the ddBCNA is 
transferable between different poxviruses. As such, it may be possible to use the 
ddBCNAs to inhibit further poxviruses. 
-Preliminary results of Cf2642 activity against HIV-1. This experiment indicated that 
Cf2642 had a possible effect against the HIV-1 virus. Although work on this virus is 
in the very early stages of development, if the antiviral effect of the ddBCNAs 
against HIV-1 could be confirmed, this too would be of clinical importance.  
-Tests of selection of ddBCNAs against measles, where activity of the L-ddBCNAs 
against this virus was discovered serendipitously, indicated by a lack of syncytia 
formation. Further testing with the ether series of L-ddBCNAs in order to establish 
SAR against this virus and compare with the SAR against VACV.  
 
4.2 Materials and Methods 
4.2.1 MCV luciferase transcription reporter assay  
This work was carried out by Ms Niamh Blythe with my technical support of cell 
culture and reporter assays (SARTRE technician post 2010).  MCV cannot be grown 
in cell culture - it is able to complete the cell entry stage of the life cycle and 
produce early gene transcripts, but cannot complete the lifecycle beyond this stage. 
For this reason, to measure the effect of Cf2642 against this virus, the transfection-
poxviral luciferase reporter system developed in 2010 by the Bugert laboratory 
(Sherwani et al. 2012) was used. This method quantitates transcription levels from 
a consensus poxviral early/late promoter (Chakrabarti et al. 1997). 
Cells were seeded into a 96-wp and left overnight to settle and reach confluency. 
The cells selected for testing were 293, 3t3, BHK21 and RK13 cells, a selection of 
cells from four different hosts (human, mouse, hamster and rabbit respectively). 
The 293 cells in particular were selected as they have been demonstrated to be 
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more easily transfected than others according to the ATCC. The cells were 
simultaneously transfected with two plasmids, one (p240 shown in figure 4.1) 
containing the firefly luciferase gene under the control of a synthetic early/late 
poxvirus promoter (to measure poxvirus entry and early transcription) (Chakrabarti 
et al. 1997), the second (p238 shown in figure 4.2) containing the renilla luciferase 
gene (to act as a transfection control). The cells were infected with MCV (collected 
from patient lesions from Heidelberg Germany, the lesions were dounce 
homogenised prior to use in assays; equivalent moi of 5, calculated using 
quantitative PCR (Sherwani et al. 2012)). They were incubated for 16 hours before 
collection to allow time for a signal to develop. This was essential since the 
transfection method using MCV is much less sensitive than the infection with v3. 
The medium was removed from the cells and replaced with 100 µL 1 X CCLR, the 
cells were agitated on an orbital shaker for 15 minutes and then frozen at -20ᵒC. 
After thawing, 20 µL of each sample was transferred into an opaque 96-wp and 
mixed with 10 µL firefly luciferase substrate. This process was done for four 
samples at a time to reduce the delay between the addition of the substrate and 
the measurements being taken. The luciferase readings measured using a 96-wp 
FLUOstar OPTIMA plate reader (set to read luminescence signals). A second set of 
luminescence readings were taken using a second 20 µL aliquot of each sample 
mixed with 20 µL Renilla luciferase. The firefly luminescence signals were 
normalised to the Renilla readings to compensate for the differing levels of 
transfection in each cell type.  
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Figure 4.1 Plasmid p240 containing the firefly luciferase gene under the control of a 
synthetic early/late poxvirus promoter. 
 
p 238 Promega
4045 bp
hRluc
amp R
HSV TK promoter
SV40 late poly(A) region
BamH I (2224)
Bgl  II (2)
Hind III (761)
Nhe  I (1025)
Xba  I (1972)
 
Figure 4.2 Plasmid p238 containing the Renilla luciferase gene to act as the 
transfection control. 
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4.2.2 Yellow fever virus assay 
Vero cells were seeded into a 48-wp and left overnight to settle and reach 
confluency. One well of these was pretreated with Cf2642 at 10 µM. Another was 
treated with Cf3625 at 10 µM. This is an anti YFV compound (produced by the 
McGuigan group) which acted as a positive control i.e. cells treated with this had a 
phenotype consistent with a positive antiviral effect and reduced CPE. Despite the 
name, it must be noted that Cf3625 is not a ddBCNA. 
Both drug treated wells were infected with YFV (moi 0.1). A further two wells were 
used and left untreated. One of these was infected with YFV while the other was 
used as a mock, to demonstrate the appearance of healthy uninfected cells. CPE of 
YFV was visible three days pi. Images of the cells were taken at this stage to assess 
the activity of the compounds. 
4.2.3 Measles assay 
A series of compounds were tested for activity against the Measles virus. The 
chosen compounds represented the best performers from the luciferase assays 
against VACV described in chapter 3 section 3.3.1. They were the L-ddBCNAs Cf2642 
(old and new stocks to compare), Cf3232, Cf3175, Cf3242, and Cf2644, In addition, 
three D-ddBCNAs (Cf2643, Cf2095 and Cf1821) were included to determine if the D-
enantiomers showed any activity against measles. 
 B95a cells were seeded into 24-wp and left overnight to settle and reach 
confluency. The cells were pretreated for 30 minutes with each of the selected 
compounds at 10, 5, 1, 0.5, 0.1 and 0 µM and infected with wild type measles virus 
(mWT Fb; moi 0.1). After 24 hours the cells were observed using an inverted phase 
contrast microscope and the activity of each of the compounds was determined by 
the absence of syncytia.  
4.2.4 Confocal microscopy 
B95a cells were seeded into an 8 well labtec slide and left overnight to settle and 
reach confluency. They were then pretreated with either a DMEM (no drug) 
control, Wortmannin (PI3 kinase inhibitor), Cf3242 or Cf2642 at 10 µM for 30 
minutes. The cells were then infected with mIC323 and v300 and left for 24 hours 
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before fluorescence confocal images of the cells in each well were captured using a 
confocal miscroscope. 
Cf3242 was included in this experiment since it was the ddBCNA compound that 
appeared to have the most improved activity against VACV in the luciferase assay 
(chapter 3 section 3.3.1.3) and it also displayed activity against measles at 
concentrations of 5 µM and above in the initial assay with mWT Fb. Cf2642 was 
included as the best performer against VACV in the luciferase assays and plaque 
assays. It also rated amongst the best performers in the initial measles assays. 
4.2.5 Phase contrast microscopy   
B95a cells were seeded into a 24-wp and left overnight to settle and reach 
confluency. These were used in two separate assays. The first tested Cf2642 at 10, 
5, 1, 0.5, 0.1 and 0 µM against both mWT Fb and mEdATCC. Ribavirin was also 
included at concentrations of 5, 2, 1, 0.5, 0.1 and 0 mM as a control. The cells were 
pretreated with the drugs for 30 minutes before the addition of mWT Fb and 
mEdATCC. Images of each condition were captured using an inverted phase 
contrast microscope at 24 and 48 hours pi. 
The second experiment was similar to the first though it tested Cf2642 against only 
mEdATCC in Vero cells. The reason mWT Fb was not used in this assay was because 
Vero cells do not have the SLAM receptor; therefore this strain cannot cause CPE in 
this cell line. Vero cells were seeded into a 24-wp and left overnight to settle and 
reach confluency. They were then pre-treated with Cf2642 and Ribavirin at the 
same concentrations as described above for 30 minutes before the addition of 
mEdATCC virus. Images of the cells were taken two days pi. 
4.2.6 Measles IC50 assay 
In order to quantify the activity of the ddBCNAs against measles virus, IC50 
experiments were carried out using a similar method to the TCID50 experiments for 
determining the titer of measles. B95a cells were seeded into a 96-wp and left 
overnight to settle and reach confluency. The cells were pre-treated for 30 minutes 
prior to infection using a variety of concentrations (100, 50, 10, 5, 1, 0 µM) of the 
alkyl series, ether series and best performers from the other modifications of L-
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ddBCNAs. The alkyl and ether series were chosen in order to compare their activity 
against measles virus with the SAR profiles previously established against VACV. The 
wells were infected with 10 µL/well mWT Fb. The presence/absence of syncytia in 
each well was analysed using phase contrast microscopy after two days pi. 
The IC50 concentration was then calculated using a similar statistical approach as 
the one described for the TCID50 method for calculating virus titers (Reed and 
Muench, 1938). The IC50 in this case is the concentration of the compound that 
inhibits the CPE (syncytia formation) by 50% in comparison to cells infected in the 
absence of antivirals as an average of three experiments. Controls consisting of 
virus and cell only (no drug) and cell only (no virus and no drug) were included in 
each experiment. 
4.2.7 HSV-1, HSV-2, Adenovirus and Influenza IC50 Assays  
The following work was carried out by Dr J. Bugert. HSV-1/2, adenovirus 5, and 
Influenza A (H1N1, NS1 116 GFP fusion ) were used to infect HFFF, BSC-1 cells, and 
MDCK cells respectively in 96-wp (10 drug dilutions, two mock, 8 times repeated) 
and evaluated 3 days pi for CPE in comparison to mock infected wells. Cells were 
grown in a 96-wp until 80% confluent. Cells were pre-treated with medium 
containing the appropriate amount of antivirals for 30 minutes prior to infection. 
Each well was infected with 100 pfu of HSV-1/2, adenovirus 5 or Influenza A and 
incubated in DMEM (without FBS or antibiotics) containing Cf2642 at 
concentrations ranging from 0 to 100 μM for 3 days. CPE was assessed by phase 
contrast microscopy. IC50 was defined as the concentration of antivirals that 
reduced the CPE by 50% (Reed and Muench, 1938) in comparison to cells infected 
in the absence of antivirals as an average of three experiments. Controls consisting 
of virus and cell only (no drug) and cell only (no virus/no virus and no drug) were 
included in each experiment.  
4.2.8 HIV-1 assay 
This work was carried out by Dr. Fabien Blanchet (Cardiff University). A pilot test of 
Cf2642 activity against the HIV-1 virus was performed in the MEDIC JBIOS CL3 
laboratory as per Blanchet laboratory protocol (Blanchet, unpublished data). This 
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preliminary experiment was done by infecting immature primary dendritic cells 
(iDC) with HIV-1 in the presence and absence of Cf2642 at 50, 5, 0.5 and 0 µM. The 
cells were harvested at two, five and nine days pi and tested for percentage of Gag 
positive cells using FACS.  The percentage of Gag positive cells provides an 
indication as to the level of HIV-1 infection as Gag is a HIV-1 viral protein that acts 
as the antigen present on the cells that are infected with the virus. Gag positive 
cells were detected with an antibody for the Gag protein. Gag positive cells were 
then counted using FACS flow cytometry. AZT is an anti-HIV-1 compound that, 
when included in the same type of assay (at 50 µg/mL,) maintains the level of Gag 
positive cells below 5% even up to 11 days pi. 
 
4.3 Results 
4.3.1 Activity of Cf2642 against HSV-1, HSV-2, Adenovirus and Influenza A 
Prior to the start of this project the activity of Cf2642 against HSV-1, HSV-2, 
Adenovirus and Influenza A had been tested using a range of assays. It was found to 
be inactive against all of them. The compound had also been tested against MCV 
and was found to have some activity.  
Tests of further viruses were carried out over the course of this project and yielded 
mixed results; Cf2642 showed no activity against Yellow Fever virus, showed 
possible activity against HIV-1, and showed definite activity against measles virus. 
All anti-viral tests and the activity scores are outlines in table 4.1. 
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Table 4.1 A summary of activity of Cf2642 against different viruses (*preliminary 
data). 
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4.3.2 Cf2642 activity against YFV 
Cf2642 activity against the vaccine strain of YFV was tested in Vero cells. In order to 
act as a positive control, a known anti-YFV compound Cf3625, was tested in 
parallel. 
A CPE of untreated cells was visible after three days pi - specifically a reduction in 
size of and rounding of the cells. In the presence of Cf2642 the levels of CPE were 
very similar (figure 4.3) to the untreated cells. This observation suggests that 
Cf2642 is not active against YFV. In contrast to this, cells administered with Cf3625 
had a normal/healthy appearance – similar to the appearance of the negative 
control (i.e. not infected) ‘mock’ cells.   
Another point of note is that in parallel with signs of CPE the YFV caused the 
medium of the infected cells to become yellow. Meanwhile, the medium of cells 
administered with anti-YFV compound Cf3625 remained pink. This is in contrast to 
what was observed in assays of Cf2642 activity against VACV and measles, where 
the medium of the treated cells did become yellow.  
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Figure 4.3 Yellow fever virus (vaccine strain) on Vero cells, three days pi. Cf2642 has 
no effect against the virus as the cells display the same level of CPE as the infected 
cells containing no drug. The positive control (Cf3625), included for comparison, 
shows no signs of CPE. The cells appear the same as the mock cells containing no 
virus. The colour of the medium in the infected wells in the absence of drug turned 
yellow with the appearance of CPE. The cells treated with Cf2642 had a similar 
appearance. The medium in the mock infected well remained pink, as did the 
medium in the well with the positive anti-YFV control Cf3625.  
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4.3.3 Cf2642 activity against MCV using a transcription reporter luciferase assay  
A transcription reporter luciferase assay system was used (by the Bugert laboratory) 
to determine Cf2642 activity against MCV. Cells were simultaneously infected with 
MCV from patient samples and transfected with two plasmids. One of these 
plasmids contained the firefly luciferase gene under the control of a synthetic 
early/late poxviral promoter. The other plasmid contained the Renilla luciferase 
gene as a transfection control. Firefly luminescence signals were normalised to 
these Renilla signals in order to compensate for differences in the level of 
transfection between different experiments or cell lines.  
The transfection method for the luciferase assay is not as sensitive as the method 
used for VACV, where the v3 virus produces its own firefly luciferase enzyme 
(described in chapter 2 section 2.2.4). For this reason the cells were allowed a 
longer incubation period in order to produce adequate luminescence signals. As 
such, the cells in this assay were collected 16 hours post infection/transfection. 
Prior to the infection and transfection, half of the cells were pre-treated with 
Cf2642 while the others were used as untreated controls.  
The luminescence readings indicated that the drug reduced the firefly luciferase 
signal suggesting that early MCV infection was inhibited by the Cf2642 (figure 4.4). 
This reduction in signal was evident in four cell lines and was found to be 
statistically significant in the 293 (P<0.01), 3t3 and RK13 cells (P<0.05).   
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Figure 4.4 Luciferase transfection reporter assay in four different cell lines (293, 
3t3, BHK21 and RK13) simultaneously infected with MCV and transfected with two 
plasmids, one containing the firefly luciferase gene under the control of a synthetic 
early/late poxviral promoter, and another containing the gene for Renilla luciferase. 
The firefly luciferase signals produced were normalised to the Renilla luciferase 
signals, in-turn giving an indication as to the level of transfection in each cell line. 
Cf2642 reduced the firefly signal in all tested cells and the reduction was found to 
be statistically significant in the 293, 3t3 and the RK13 cell lines. * P < 0.05, ** P < 
0.01. Error bars ± 1 standard deviation. The reason for the large error bars in this 
figure is that BHK21 cells have a tendancy to aggregate, meaning that there is 
increased variation in the number of cells seeded into each well. The effect in the 
BHK21 cells could have been significant if not for the large standard deviations for 
the results in this cell line as there is a trend towards a reduction in signal in the 
presence of Cf2642. (Figure adapted from IBSc dissertation by Niamh Blythe). 
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4.3.4 Cf2642 activity against HIV-1 
A pilot test of Cf2642 activity against the HIV-1 virus was attempted (by Dr Fabien 
Blanchet). Results are portrayed in figure 4.5. As expected, in untreated cells, the 
levels of viral infection increase as time goes on (4.08% at 2 days, 21.3% at 5 days 
and 44% at 9 days). This trend is apparent at all subsequent levels of drug 
concentration. 
At the lowest concentration of Cf2642 tested (0.5 µM), there is a trend towards 
decreased levels of viral infection (1.75% at two days, 14.6% at five days and 29.5% 
at nine days – a decrease of 2.33%, 6.7% and 14.5% respectively as compared to the 
no drug control), immediately suggestive of a HIV-1 antiviral effect of the drug. 
Further to this, the virus levels decrease further at a drug concentration of 5 µM at 
five (8.84%) and nine (21.4%) days post infection – a decrease of 12.46% and 22.6% 
respectively as compared to the no drug control. Of note, this is not the case at two 
days pi (2.58%, only a 1.5% decrease vs no drug and a 0.25% increase compared 
with 0.5 µM Cf2642). At 50 µM Cf2642 (the highest concentration tested) the levels 
of HIV-1 increase at two days (6.75%, a 2.67% increase vs no drug). At five days pi, 
the trend towards decreasing viral levels continues (7.64%, a 1.2% decrease as 
compared to that observed at five days). However at nine days (26%), the trend 
reverses and a 4.6% increase as compared to the five day value is observed.   
A typical level of infection observed in the presence of the HIV antiviral compound 
AZT (at 50 µg/mL) maintains the level of Gag positive cells below 5% up to 11 days 
pi. This shows that the Cf2642 is not as effective against the virus as this antiviral 
compound.  
A coincident observation of this experiment was that, in the presence of Cf2642, 
the cell medium gradually became acidic. This was indicated by an increasingly 
yellow colour of the medium over the course of the experiment. This observation 
has been noted in other assays with the ddBCNAs for example the plaque assays 
chapter 3 (section 3.3.4) and the YFV assay (section 4.3.2). Further investigations 
into this effect are discussed later in chapters 5 and 6.  
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Figure 4.5 Dose response curves of Cf2642 (at 0, 0.5, 5 and 50 µM) activity against HIV. Cells collected after two (d2), five (d5) and nine (d9) 
days pi and percentage of Gag+ cells calculated by FACS. Although not included in this assay, the dotted line indicates a typical level observed 
of Gag+ cells in the presence of the HIV-1 antiviral AZT (at 50 µg/mL, which usually maintains the level of Gag positive cells below 5% up to 
nine days pi) for comparison. All conditions were carried out in iDC cells with HIV-X4, the darkest line (and diamond points) represents data 
collected two days pi, the medium coloured line (and square points) represents data collected five days pi and the lightest line (and triangle 
points) represents data collected nine days pi. (Graph generated from data produced by Fabien Blanchet).
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4.3.5 Measles ddBCNA assay  
An initial experiment to test the activity of the ddBCNAs against measles virus was 
carried out using a selection of both L- and D-ddBCNAs at a range of concentrations 
(from 0.1 to 10 µM). Their anti-viral activity was indicated by the absence of 
syncytia in B95a cells infected with wild type measles virus. Results are depicted in 
figure 4.6. 
Here, Cf2642 (the best performing compound against VACV) showed activity 
against wild type measles virus at 1µM and above. Of note, both new and old stocks 
of Cf2642 were tested and displayed similar levels of activity from 1 µM and above. 
Activity was also observed at concentrations above 1 µM for Cf3232.  
Three other L-ddBCNAs tested (Cf3175, Cf3242 and Cf2644) were selected from the 
best performers for activity against VACV in the luciferase assays. Cf3175, Cf3242 
and Cf2644 indicated activity against the wild type measles at a concentration of 5 
µM and above.  
Finally, the D-ddBCNAs (Cf2095, Cf1821 and Cf2643) did not display any activity 
against the wild type measles virus at any of the concentrations used in this assay.  
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Figure 4.6 A selection of ddBCNAs tested against wild type measles in B95a cells over two days. Activity was determined by the absence of 
syncytia. New and old stocks of Cf2642 (the best performer against VACV) and Cf3232 are active against measles virus at concentrations of 1 
µM and above. Other selected L-ddBCNAs (Cf3175, Cf3242, Cf2644) are active against the virus from 5 µM and above. The D-ddBCNAs (Cf2643, 
Cf2095 and Cf1821) are not active against the wild type measles virus at concentrations of up to 10µM.  
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4.3.6 Fluorescence confocal microscopy with mIC323 and v300 
Described are the results of fluorescence microscopy of B59a cells, using mIC323 
and v300 with the drugs Cf3242 and Cf2642. Wortmannin was also included as a 
control.  
In the absence of any drug, the mIC323 produce large syncytia in the B95a cells, 
which are clearly visible with expression of GFP (figure 4.7 A). In the presence of the 
Wortmannin control there is a clear reduction in the levels of GFP expression 
(suggestive of a decrease in virus containing cells). Though the syncytia are not 
eradicated they are reduced in size. 
The levels of GFP expression are further reduced in the Cf3242 and Cf2642 treated 
cells – with only 5-6 and 1-2 clearly visible small syncytia respectively.  
In the wells infected with v300 there is a similar trend in GFP expression (figure 4.7 
B), although VACV does not produce syncytia. In the absence of any drug there are 
many cells containing GFP. However the number of GFP-containing cells is reduced 
in the presence of Wortmannin and reduced further still in the presence of Cf3242 
and Cf2642. 
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No drug Wortmannin cf3242 cf2642
GFP-measles IC323 on B95a cells
GFP-VACV v300 on B95a cells
No drug Wortmannin cf3242 cf2642
 
Figure 4.7 Confocal microscopy images of live B95a cells treated with no drug, Wortmannin, Cf3242 or Cf2642 (10 µM).  A: Infected with 
mIC323 B: Infected with v300.  Images taken 24 hour pi. Cf2642 and Cf3242 reduce the level of GFP expression caused by the viruses, to a 
greater extent than the control drug Wortmannin.
A 
B 
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4.3.7 Phase contrast microscopy of Cf2642 activity against measles in B95a cells 
Here the activity of Cf2642 against wild type (mWT Fb) and Edmonston (mEdATCC) 
strains of measles was tested in B95a cells, and compared with a Ribavirin control. 
Phase contrast images were taken at 24 and 48 hours pi (figure 4.8). It is clear that 
after 24 hours in the absence of drug, the measles have formed small syncytia in 
the cells. This effect can be seen for both wild type (1) and mEdATCC (2) strains of 
measles.  
(1), In the cells infected with wild type virus the syncytia are still present at 0.5 µM 
and 1 µM Cf2642 (though they do appear smaller in the latter). Above this 
concentration it appears that syncytia formation is completely inhibited. This effect 
is increasingly evident at 48 hours pi. At lower concentrations of the compound (0 – 
1 µM) the syncytia are larger in size and starting to detach from the surface of the 
plate. As the concentration increases beyond this, the cells maintain a normal and 
healthy appearance.  
The Ribavirin control appears to inhibit syncytia formation by the wild type measles 
at a concentration of 0.5 mM and above after 24 hours and after 48 hours.  
(2), In the case of the mEdATCC a similar effect is observed. Cf2642 inhibits the 
mEdATCC at the same concentrations as the wild type virus. In the case of the 
Ribavirin treated mEdATCC infections, there do not appear to be any syncytia at 
drug concentrations of 0.1 mM and above, even at 48 hours pi.  
These observations indicate that the ddBCNAs are active against measles virus as 
they inhibit the formation of syncytia at low micromolar concentrations. The 
Ribavirin control is required at higher concentrations to have an effect on the 
measles virus syncytia formation. These findings suggest that the ddBCNAs are 100 
times more active against measles than the control compound Ribavirin.  
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4.3.8 Phase contrast microscopy of Cf2642 activity against mEdATCC in Vero cells 
Interestingly Cf2642 does not appear to have the same level of anti-viral activity 
against mEdATCC infected Vero cells as it showed against the virus in infected B95a 
cells (figure 4.9). There appears to be syncytia in all of the wells containing the drug, 
even at the highest concentration of 10 µM. In contrast, Ribavirin appears to inhibit 
the formation of syncytia at concentrations of 0.5 mM and above. This is the same 
level of inhibition as observed in the B95a cells. The mWT Fb strain of measles 
cannot be tested in Vero cells as this cell line does not contain the SLAM receptor 
that the wild type measles virus uses to gain entry into the host cell.
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Figure 4.8 Activity of cf2642 and Ribavirin (concentrations displayed at the left and right of the figure respectively) against mWT Fb and mEdATCC 
strains in B95a cells. Syncytia formation is inhibited by Cf2642 at 5 µM and above. Ribavirin inhibits the formation of syncytia from 0.5 mM and above. 
Images were taken at 24 hours (left panels) and 48 hours (right panels) pi. 
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Figure 4.9 Vero cells infected with mEdATCC and treated with Cf2642 and Ribavirin 
(concentrations displayed at the left and right of the figure respectively). Images of 
the cells were taken 2 days pi. Syncytia can be seen at all concentrations of Cf2642, 
but are inhibited by ribavirin at concentrations of 0.5 mM and above. Syncytia are 
not as clearly visible in the Vero cells as in the B95a cells.
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4.3.9 IC50 concentrations of ddBCNAs against mWT Fb  
Measles IC50 values for the alkyl series, the ether series and the four best 
performers from the further modified L-ddBCNAs were generated (Table 4.2). This 
data demonstrates a clear SAR profile as the length of the side chain increases 
(figure 4.10). The SAR profiles for the alkyl and ether series of L-ddBCNAs against 
measles are very similar to those shown against VACV by the luciferase assay in 
chapter 3 section 3.3.2 The optimum alkyl L-ddBCNAs (Cf3175 and Cf3155) were 
found to have a IC50 concentration against measles of 7.5 µM, as did the lead 
compound Cf2642. Another of the compounds in the ether series (Cf3209) had an 
even lower IC50 concentration of 6.45 µM. Further to this, it appeared that one of 
the other modified L-ddBCNAs (Cf3230) had an even lower IC50 concentration of 3 
µM. Two of the alkyl L-ddBCNAs were inactive with IC50 concentrations of >100 µM. 
The control compounds cidofovir (not active against measles) and ribavirin (active 
in the mM range of concentrations) also had IC50 concentrations of >100 µM. 
It was again noticed that in this assay the colour of the cell medium became yellow 
in the presence of the active concentrations of the ddBCNAs. 
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Table 4.2 IC50 concentrations of ddBCNAs and controls against mWT Fb in B95a cells 
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Figure 4.10 Measles IC50 concentrations using the ether and alkyl series of L-ddBCNAs plus the four most active from the alternatively modified 
L-ddBCNAs. The alkyl and ether series of L-ddBCNAs show SAR against measles, similar to those seen against VACV (Chapter 3 section 3.3.1.2).
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4.4 Discussion 
The first point to note from the data presented in this chapter is that the ddBCNAs 
are not active against all viruses. It was found that there was no apparent activity of 
Cf2642 against HSV-1, HSV-2, Adenovirus and Influenza A. It was also shown that 
there is no apparent activity of Cf2642 against YFV. These findings, although not of 
clinical significance, demonstrate that the ddBCNAs don’t have a general effect that 
inhibits all viruses. Instead their activity is specific and only certain viruses are 
inhibited by whatever MoA these compounds operate through. 
It was demonstrated that Cf2642 displayed antiviral activity against MCV. This 
finding has the further implication that the compound may be a potential antiviral 
drug candidate for clinical cases of MCV. As it also works against VACV the activity 
of the ddBCNAs may possibly be transferrable to other pox viruses of clinical 
significance such as Monkeypox or Smallpox in the case of a bioterrorist outbreak. 
Considering the data generated in the experiment with HIV-1, it seems that there is 
a possible HIV-1 anti-viral effect of Cf2642 based on the trends loosely observed. 
However, it is clear that the correlation is not simple and thus, further testing is 
required. If the effect were confirmed this would be of great clinical importance 
due to the burden of HIV-1 infection. Worldwide 34 million people were living with 
HIV/AIDS at the end of 2011 (WHO website: www.who.int/gho/hiv/en/) with an 
estimated 96 000 of these in the UK (NHS website: 
http://www.nhs.uk/Livewell/STIs/Pages/HIV.aspx). AZT is a nucleoside analogue 
compound that inhibits the viral reverse transcriptase of HIV. This was the first 
approved compound to be used as a treatment against HIV. This drug slows down 
the replication of HIV in patients and can be used to prevent spread (e.g. from 
mother to baby during birth) but it does not inhibit viral replication entirely. As this 
compound has a specific viral target the virus has the potential to develop 
resistance to it. It is therefore critical that alternative compounds that act against 
the HIV-1 virus are developed (Jeeninga et al. 2001). 
The observations in HIV-1 certainly warrants further investigation in order to 
confirm and quantify the effect of the ddBCNAs against the virus. The effect could 
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potentially be confirmed by using the rest of the ether series of L-ddBCNAs to 
determine if a similar SAR can be established as was observed against VACV and 
measles. If this was the case, then it would suggest the same MoA is involved 
against all three viruses.  
The discovery of activity of the ddBCNAs against measles virus was very significant 
in terms of clinical relevance. This virus has a large impact worldwide. Even with the 
development of a successful vaccine, outbreaks still often occur due to the 
particularly high level of herd immunity (>95%) required to prevent the spread of 
this virus. Complications caused by measles infection remain one of the leading 
causes of infant mortality worldwide. There are currently no specific treatments for 
measles infection on the market. Based on this work the ddBCNAs were filed for a 
patent: US patent; Activity of ddBCNAs versus human cytomegalovirus, poxviruses 
and measles virus (2011-US patent # 13/193,343) (McGuigan et al. 2013). 
In addition, regardless of its clinical relevance, the observed activity against measles 
virus proved very useful for further investigation of the ddBCNAs. This is because 
the wild type measles virus produces a clear CPE in the form of syncytia in B95a 
cells. This tendency toward syncytia formation makes a suitable model for 
measuring the activity of the compounds against measles. 
It was found that the ether series of compounds demonstrated a clear SAR profile 
against the measles virus when plotting IC50 concentrations (figure 4.11). Critically, 
this SAR matched those previously observed against VACV using both luciferase and 
plaque assays (as described in chapter 3 section 3.4). As such, this relationship has 
now been observed in three independent cells lines infected with two different 
viruses. This offers strong evidence for the antiviral effects of these compounds. It 
also strongly suggests that they have a specific target as altering the length of the 
hydrocarbon side chain by a small amount has a significant effect on their activity. 
This also confirms that the ddBCNAs are not just having a general effect that could 
be achieved with any of their structural variations.  
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Of note, whilst the IC50 concentrations for the measles virus follow a similar trend 
to the VACV IC50 concentrations, they appear to be higher. This could imply that 
higher concentrations of the compounds are required to inhibit the measles virus to 
the same extent as VACV. However, the discrepancy could also be due to the 
timescales required for the two experiments; the measles IC50 experiments were 
collected at two days pi, whereas the VACV IC50 concentrations from the plaque 
assays were measured at four days pi.  
When using the compound against the vaccine (mEdATCC) strain of measles virus, 
the variation in the effect in different cell lines represents an interesting 
observation. It is not clear exactly why the effect of Cf2642 is different against this 
virus strain in certain cell lines. However this finding could provide insights into the 
MoA of the drug based on the differences between the two virus strains and 
between the cell lines B95a and Vero. Potential insights into the observed effect 
will be discussed further in chapter 7. 
  
 
  
 
                                                
Figure 4.11 SAR profiles of the ether series of L-ddBCNAs against measles shown as IC50 concentrations (triangle points). The IC50 
concentrations for these compounds show a similar SAR observed in VACV IC50 concentrations (square points) and luciferase assay data (bars). 
The left y-axis indicates the luciferase readings as percentage of control. The right y-axis indicates the concentrations for the measles IC50 and 
the VACV IC50 in µM. The results show that in all assays, Cf3210 is the worst performer. Taking all three assays into account the compound 
Cf2642 appears the best performer. Even though the measles IC50 concentration is slightly lower for Cf3209 the error bar on this point is larger 
and this compound did not perform so well in the luciferase assays. 
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Chapter five – Toxicity of ddBCNAs 
5.1 Introduction 
The activity of ddBCNAs against several viruses (including VACV, measles and 
possibly HIV-1) has been previously studied (as described in chapters 3 and 4). 
Regardless of the activity they show, an important consideration in the use of anti-
viral compounds is their toxicity profile. This chapter describes efforts to test the 
toxicity levels of these compounds, at active concentrations, against a series of host 
cells. An understanding of their toxicity profiles is essential if they are to have any 
chance of being considered as viable clinical antiviral candidates. The toxicity 
testing of these compounds involved several assays that tested; 
 -ATP levels – Using the cell titer-glo kit (Promega), which measures the 
viability of cells based on the level of ATP (Crouch et al. 1993). The reaction uses 
ATP in the sample to convert Beetle luciferin into oxyluciferin. This leads to the 
production of light at levels directly proportional to the amount of ATP in the 
sample, thereby providing an indication as to the number of viable cells. This is a 
very sensitive method of viability detection (Petty et al. 1995). 
 -Caspase 3/7 levels – Using the caspase-glo 3/7 kit (Promega), which 
measures the levels of caspases 3 and 7 in the sample. The kit contains a substrate 
with a tetrapeptide (DEVD) sequence that is cleaved by the caspases. The cleaved 
DEVD sequence then acts as a substrate for a luciferase enzyme, leading to the 
production of light. The level of luminescence produced provides information as to 
the level of apoptosis in the sample as the caspases are effector enzymes of 
apoptosis (Thornberry and Lazebnik, 1998). This assay was performed to confirm 
that the ddBCNAs were not leading to apoptosis of the host cells. 
 -The effect of the pH of the medium - In previous assays involving the 
ddBCNAs it has been noted that high concentrations of the compounds correlated 
with a change in the colour of the cell medium form red to yellow. Since DMEM 
contains a pH indicator (phenol red) this change in colour could suggest that the 
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ddBCNAs are acting on the cells in a way that causes them to release acidic 
substances into the cell medium. The resulting decrease in the pH could potentially 
cause the cells to lose viability. In order to determine if any loss in viability is due to 
the presence of the compounds themselves or as an indirect result of decreasing pH 
of the cell medium, a simple assay of changing the cell medium (containing fresh 
Cf2642) on a daily bases was adopted. The resulting effect on cell viability was 
observed. 
In combination, the results from these toxicity assays were used to gain insights as 
to the suitability of the ddBCNAs as drug candidates. 
5.2 Materials and Methods 
5.2.1 Cell titer-glo kit 
The method selected for measuring the viability of cells in the presence/absence of 
drug was the cell titer-glo kit (Promega). This assay sensitively determines the 
viability of cells by measuring ATP – the amount of which is directly proportional to 
the number of viable cells present. The reaction employed in this method is shown 
in figure 5.1 
 
Figure 5.1 The reaction used by the cell titer glo kit to measure the ATP present in 
the sample. The level of ATP is directly proportional to the number of viable cells in 
the sample. (Figure from Promega cell titer-glo kit protocol) 
 
This method has been described as the gold standard for viability assays as it 
determines the level of ATP present, rather than other methods such as MTT 
colourimetric assays (Petty et al. 1995). Measuring ATP provides a more accurate 
indication of the number of viable cells as the ATP is broken down very quickly after 
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cell death. In contrast, proteins may be more stable and take more time to break 
down.  
5.2.1.1 Cf2642 effect on viability using Cell titer-glo kit 
In order to determine how the ddBCNAs affect the viability of cells over a sustained 
period (here four days), a time course assay was carried out with the lead 
compound Cf2642. B95a, Vero, RK13 and BSC-1 cells (the same cell lines used in 
previous antiviral assays) were seeded into black (clear bottom) 96-wp and left 
overnight to settle and reach confluency. They were treated with different 
concentrations (50, 20, 10, 5, 1, 0 µM) of Cf2642. These concentrations were 
selected as they include the compound at active concentrations used in the 
antiviral assays (1, 5, 10 µM) and higher in order to determine the difference 
between active concentrations and toxic concentrations. Cell viability was 
measured at 6h, 12h, 24h, 48h, 72h and 96h time points using the cell titer-glo kit. 
This range of time points was selected to cover the full length of timescales used in 
previous antiviral assays. Each condition was carried out in triplicate. The aim of this 
experiment was to confirm that the apparent antiviral affects of the compounds 
was not simply due to the cells losing viability.  
5.2.1.2 CC50 calculations of the ether series of L-ddBCNAs 
Following on from the time course viability assay, the cell titer-glo kit assay was 
used again to calculate CC50 concentrations for the ether series of L-ddBCNAS 
including Cf2642. BSC-1 cells were seeded into a black (clear bottom) 96-wp and left 
overnight to settle and reach confluency. The cells were then treated with each of 
the ether series of ddBCNAs at different concentrations (0, 1, 10, 50 and 100 µM). 
The viability of the cells was measured using the cell titer-glo kit after four days and 
the values were used in GraphPad to calculate CC50 concentrations*. By using BSC-1 
cells and measuring activity over four days, it was possible to directly compare 
these CC50 concentrations with the previously generated IC50 concentrations against 
VACV (as described in chapter 3 section 3.3.5).  
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*Of note, the ether L-ddBCNAs did not reduce the viability of the BSC-1 cells to 0% 
at concentrations of up to 100 µM. In order to force the program to produce a 
curve and calculate a CC50 as the half way point between 100% and 0% viability, a 
theoretical point was included. This value was included to assume the viability 
would be zero at a high concentration of the compound (e.g. 10 000 µM or 10mM). 
The reason for including this point was because without it the program calculates 
the halfway point between the values given. This leads to a much lower calculated 
CC50 value than the bar graphs for the viability would suggest.  
5.2.2 Caspase-glo 3/7 assay 
To assess whether the ddBCNAs lead to an increase in cellular apoptosis, the 
caspase-glo 3/7 kit was used. This kit contains a substrate with a DEVD sequence 
that is recognised and cleaved by caspases 3 and 7 (effector enzymes in apoptosis). 
This releases aminoluciferin. The free aminoluciferin acts as a substrate for the 
luciferase (also in the kit) which leads to a luciferase reaction and the production of 
light. The reaction is summarised in figure 5.2. The amount of light produced is 
proportional to the activity of caspases 3 and 7, and can be used as an indicator of 
the level of apoptosis in the cells.  
 
Figure 5.2 The reaction used by the Caspase-glo 3/7 kit to detect the levels of 
Caspases 3 and 7 in the sample. These provide an indication of the level of 
apoptosis in the sample (figure from Promega Caspase-glo 3/7 kit protocol). 
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As some of the results from the first Caspase-glo 3/7 assay suggested a possible 
effect of the presence of EBV in cells, a second experiment was performed that 
included a range of B cell lines with a known presence or absence of EBV. The 
presence or absence of EBV was confirmed (by Joachim Bugert) in each of the B cell 
lines using a PCR for EBV as described by Telenti et al. (1990). HeLa and RK13 cells 
were again included so as to allow for the comparison of the two data sets. 
5.2.3 Cell medium replacement assay 
It was noted in several previous experiments (described in chapter 3 section 3.3.5 
and chapter 4 sections 4.3.2, 4.2.4 and 4.3.9) that the presence of the ddBCNAs 
correlated with a change in colour of the cell medium, possibly indicating a release 
of acidic substances from the treated cells. In order to determine if the effect of the 
ddBCNAs on the viability of the cells is a direct effect of the compounds or as an 
indirect result of decreasing pH of the medium, an assay was carried out that 
involved replacing the medium (± Cf2642) on a daily bases over the course of four 
days.  
BSC-1 and B95a cells (24 wells of each) were seeded into a black (clear bottom) 96-
wp and left overnight to settle and reach confluency. These were then pretreated 
for 30 minutes with Cf2642 (10 µM) or with a DMEM control. BSC-1 cells were 
infected with mEdATCC and B95a cells were infected with mWT Fb. Uninfected 
controls for each condition were also included and each condition was carried out 
in triplicate. Half of the wells had their medium (± Cf2642) changed every 24 hours, 
while the other half remained in the same medium. The viability of the cells was 
determined on the fourth day using the cell titer-glo assay kit.  
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5.3 Results 
5.3.1 Cell titer-glo assays and Cf2642 
To determine whether Cf2642 caused a loss in cell viability over the course of the 
antiviral assays described in previous chapters, an assay was carried out using the 
cell titer-glo kit. This involved applying Cf2642 at 50, 20, 10, 5, 1 and 0 µM of drug 
to B95a, Vero, RK13 and BSC-1 cells and measuring their viability after 6, 12, 24, 48, 
72 and 96 hours. This was to ensure that the antiviral effect of the compound is not 
simply due to a loss in cell viability. 
The cells that appeared to be most affected by the compound were the B95a cells 
(figure 5.3). For up to 24 hours, the cells appeared to maintain their viability at all of 
the included concentrations.  At 48 hours however, loss in viability is evident at 
5µM Cf2642, leading to readings that are only 40% of the no drug control. At 72 and 
96 hours, cell viability levels decrease markedly when drug concentrations of 5 µM 
and above are used, with luminescence signals decreasing to ~5% and ~0% of the 
control respectively. Of note, inhibition of syncytia formation by mWT Fb in B95a 
cells has previously been observed at 24 hours pi, suggesting that the viability loss 
observed here at 48 hours pi is not the cause of this antiviral effect. 
The Vero cells appear less affected than the B95a cells by Cf2642. As displayed in 
figure 5.4, they maintain full viability at all concentrations included in the assay for 
up to 48 hours. At 5 µM, cell viability starts to descend (to about 40%) between 48 
and 72 hours. Above this concentration the viability is greatly reduced (to around 5-
10% of the control) at 72 hours. At 96 hours the cells appear to have very little 
remaining viability (<5%) at concentrations of 5 µM and above. There also appears 
to be an anomalous peak in luminescence at the 5 µM concentration after 48 hours. 
The reason for this is not clear. 
The effect on viability of RK13 cells appears to lie somewhere in between that 
observed for the B95a and the Vero cell lines – evidenced by a ~50% reduction in 
viability at the 48 hour time point (figure 5.5). Again this loss in viability is only 
observed at concentrations of 5 µM and above. The antiviral effect against VACV in 
  
 
133 
RK13 cells can be seen at only two hours pi. Therefore, as suggested in B95a cells, 
loss in cellular viability is unlikely to be responsible for the apparent antiviral effect 
of the compounds. At the 72 and 96 hour time points, cell viability is reduced to 
around 10% and 0% of the control respectively at concentrations of 5 µM and 
above.  
Despite there being a ~20% decrease in viability levels compared with controls at 
concentrations of 5 µM and above at only 6 hours after addition, the BSC-1 cells 
appear to be less affected than the other cell lines tested (figure 5.6). They 
ultimately maintain viability at higher concentrations and longer time points i.e. the 
viability of the cells is still above 50% of the control even at the highest 
concentration (50 µM) after four days. This offers further evidence that the antiviral 
effect is not due to a loss in the viability of the cells.  
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Figure 5.3 The effect of Cf2642 at 50, 20, 10, 5, 1 and 0 µM on the viability of B95a 
cells over 6, 12, 24, 48, 72 and 96 hours. 
 
Figure 5.4 The effect of Cf2642 at 50, 20, 10, 5, 1 and 0 µM on the viability of Vero 
cells over 6, 12, 24, 48, 72 and 96 hours. The peak at 5 µM over 48 hours appears to 
be anomalous. 
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Figure 5.5 The effect of Cf2642 at 50, 20, 10, 5, 1 and 0 µM on the viability of RK13 
cells over 6, 12, 24, 48, 72 and 96 hours. 
 
Figure 5.6 The effect of Cf2642 at 50, 20, 10, 5, 1 and 0 µM on the viability of BSC-1 
cells over 6, 12, 24, 48, 72 and 96 hours.  
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5.3.2 CC50 concentrations of the ether series of L-ddBCNAs  
Further assays using the cell titer-glo kit were carried out to test the ether series of 
L-ddBCNAs in BSC-1 cells at a range of concentrations over four days. CC50 
concentrations were calculated and compared with the IC50 concentrations for the 
activity of the compounds against VACV in the same cell line over the same time 
period. This experiment was designed to calculate CC50 concentrations for the ether 
series of ddBCNAs to correspond with the IC50 concentrations against VACV 
calculated in chapter 3 section 3.3.5 This is why they were done in BSC-1 cells only 
over four days. The maximum concentration used in this assay was also increased 
as the results from the previous cell viability assays showed that in BSC-1 cells 50 
µM Cf2642 did not decrease the viability to less than 50%.  
The observed CC50 calculations are displayed in table 5.1. Interestingly the 
compounds expected to be the most active based on previous data (Cf2642, 
Cf3207, Cf3209) appear to have higher CC50 concentrations than those that 
previously showed less activity (e.g. Cf3210, Cf3204). The CC50 for the most active 
compound, Cf2642, was calculated to be 105 µM, whilst Cf3210 and Cf3204 had a 
calculated CC50 of 64.6 µM and 63.3 µM respectively. 
The CC50 concentration for Cf2642 (105 µM) as compared to its IC50 concentration 
(0.19 µM), suggests that there is a good selectivity index (>500). Wortmannin was 
included in this assay as a control and was calculated to have a CC50 concentration 
of 22 µM. This is considerably lower than that of the ether series of L-ddBCNAs and 
suggests that they are less toxic.  
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Table 5.1 The CC50 concentrations calculated for the ether series of L-ddBCNAs 
using the cell titer-glo assays in BSC-1 cells over 4 days. These results are also 
presented in the discussion section 5.4 in the form of a bar graph that compares the 
CC50 concentrations with the IC50 concentrations.
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5.3.3 Caspase-glo 3/7 assay  
To assess whether the ddBCNAs lead to an increase in cellular apoptosis, the 
caspase-glo 3/7 kit was used to test the level of these caspases in a variety of cells 
treated with Cf2642 at 10, 1 and 0 µM for 24 hours. The reason for using these 
concentrations and testing over a 24 hour timescale was to cover the 
concentrations/timescales at which antiviral activity had previously been observed. 
The initial data indicated that Cf2642 causes an increase in apoptosis in B95a cells 
(figure 5.7); 1 µM of drug increased the luminescence signal (apoptosis) by 25%, 
while 10 µM increased the signal by >100% relative to the signal in the absence of 
drug. However, in other cell lines (namely BJAB, RK13, HFFF, A549 and BSC-1) there 
is no evidence for increased apoptosis. HeLa were also included and showed some 
increase in the luminescence signal in the presence of Cf2642.
  
 
 
              
Figure 5.7 The effect of Cf2642 at 1 and 10 µM on the level of apoptosis (determined by the levels of caspases 3 and 7) in a range of cell lines. 
The values for the level of apoptosis were calculated as a percentage of the no drug readings. Cf2642 appears to double the level of apoptosis 
in B95a cells. The levels are increased by about 25% in HeLa cells, the caspase levels in the rest of the cells were relatively unaffected by 
Cf2642. Here the BJAB cells included are those from the Bugert laboratory.
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5.3.4 Caspase-glo 3/7 assay in EBV positive and negative cell lines 
B95a cells belong to a class of cell lines that have been transformed using EBV. 
Based on the positive results from the initial caspase assay (figure 5.7), it was 
suggested that the ddBCNAs may be leading to apoptosis in cell lines containing 
EBV. This was fuelled by the fact that BJAB cells included in the assay did not show 
any signs of increased apoptosis. BJAB cells are similar to B95a cells in that they are 
both derived from B cells, however BJAB are of human origin and were assumed to 
be EBV negative. To further investigate this effect, a second caspase assay was 
devised to test whether the ddBCNAs might induce apoptosis specifically in EBV 
containing cells, using a selection of B cells some of which were EBV positive and 
some EBV negative. 
Prior to this second experiment the presence or absence of EBV was confirmed in 
each of the B cell lines using a PCR for EBV using the method of Telenti et al. (2010). 
The results of this PCR led to the surprising finding that the BJAB (from the Bugert 
laboratory) were actually EBV positive. 
The cells used in the second round of testing were the B95a cells as before (EBV +), 
BJAB cells (human derived B cell line) from the Bugert laboratory (EBV +), BJAB cells 
from the MRC (EBV -), BJAB cells from MRC that have been incubated in medium 
from EBV + cells (i.e. EBV+ induced) and Ramos (another human derived B cell line 
that were EBV-). This was in an effort to confirm whether Cf2642 was leading to 
apoptosis specifically in EBV positive cell lines. This experiment involved direct 
comparison of EBV positive and EBV negative versions of the same cell line (i.e. 
BJAB). RK13 and Hela cells were also included in this assay to link the results with 
the previous apoptosis assay. Cf2642 was included at 10 µM as before but this time 
the second concentration was 20 µM instead of 1 µM in order to see if a clearer 
difference in effect could be established by using a higher concentration. 
Staurosporine (1 µM) was included in this assay as an apoptosis inducing positive 
control for comparison purposes. Results are displayed in figure 5.8. 
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All of the cells tested produced luminescence signals that were significantly 
increased by the presence of the positive control staurosporine. This result 
indicated that the caspase assay does reliably detect increases in the level of 
apoptosis. 
In contrast to the initial caspase assay, the data this time indicate no clear 
difference in the levels of apoptosis in Cf2642 treated cells as compared to those 
that were untreated, regardless of drug concentration. This included the same B95a 
cells previously tested. The caspase levels appear to be 100% of that of the control 
(i.e. there is no increase in the level of apoptosis in the presence of Cf2642 over the 
cells containing no drug). In one case (the BJAB cells from the Bugert laboratory), it 
appears that the levels of caspase are actually reduced in the presence of Cf2642 
(at 10 µM the caspase levels are ~50% of the no drug control).  
From the results of this experiment Cf2642 was ruled out as an apoptosis inducer as 
it generally did not increase the levels of caspases 3 and 7. It was also assumed that 
it was unlikely that Cf2642 induces apoptosis in B95a cells as the initial result was 
not reproducible. It was concluded that apoptosis was not the cause of the antiviral 
effect observed with the ddBCNAs. 
  
 
                 
Figure 5.8 The effect of Cf2642 at 20 and 10 µM on the level of apoptosis (caspases 3 and 7 as percentage of no drug control) in a range of cell 
lines. Cells that are EBV positive are represented with (+) and the EBV negative with (-). HeLa and RK13 cells were also included. Staurosporine 
was added to each of the cells as an apoptosis inducing positive control. Cf2642 does not appear to increase the level of apoptosis in any of the 
cells tested. BJAB JJ are BJAB cells from the Bugert laboratory, BJAB MRC are BJAB cells obtained from MRC.
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5.3.5 Cell medium replacement assay 
Coincidental observations from previous tests of the ddBCNAs raised the question 
as to whether loss of cell viability could be an indirect consequence of the effect of 
the ddBCNAs. The medium of cells in the presence of active concentrations of the 
ddBCNAs changes in colour from red to yellow, which in turn indicates a reduction 
in the pH of the cell medium (that contains phenol red indicator). Here a method 
was devised where-by the cell medium (and drug) were replaced with fresh stocks, 
on a daily basis. This experiment was carried out in B95a and BSC-1 cells (the most 
and the least affected in the viability assays with the cell titer-glo assay described 
section 5.3.1), and the viability of the cells was measured after four days using the 
cell titer-glo kit.  
The results of this experiment are presented in figure 5.9. Overall, it appears that in 
the absence of any virus the viability of both cell lines is improved when the 
medium/drug is replaced on a daily bases. For example, non-infected BSC-1 cells 
that were treated with Cf2642 and that had their medium changed daily, showed 
cellular viability levels approaching those observed in the no-drug control (123 000 
RLU compared to 162 000 RLU respectively). However, cells treated in the same 
way but that were exposed to the same cell medium for four days showed a greatly 
reduced viability as compared with the no drug control (7000 RLU compared to 166 
000 RLU). As expected, the control wells containing no drug showed little difference 
in viability whether the medium was changed or not. The latter result confirms that 
over the course of four days in DMEM, the cells are not losing viability as a result of 
their own metabolic waste products.  
The same trends were also observed in the B95a cells - those that had their 
medium changed every day produced signals of 485 000 RLU (Cf2642 treated) 
compared with 434 000 RLU (untreated). The cells that were left in the same 
medium for four days produced values of 20 000 RLU (Cf2642 treated) and 367 000 
(untreated).  
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Again, these data provide evidence that the drug itself is not leading to the loss in 
the viability of the cells. Instead, the side effect of the drug (i.e. change of pH of the 
medium) is actually the reason for the loss in viability.  
In terms of the effect of medium change on the antiviral activity, Cf2642 treated 
BSC-1 cells infected with mEdATCC did not display improved viability above that of 
the no drug control with the readings taken being 80 000 RLU compared to 99 000 
RLU respectively when the medium was changed daily. However the effect of the 
compound against mWT Fb in B95a cells suggests that treating the infected cells 
with fresh drug on a daily bases may increase the viability of the cells above that of 
the no drug control, in this case the luminescence values produced were 340 000 
RLU (Cf2642 treated) compared with only 100 000 (untreated). This suggests that 
the Cf2642 is having an antiviral effect against the virus in this assay over four days 
without causing loss in viability of the cells itself as long as it is replaced with fresh 
medium and drug on a daily bases.  
 
 
 
 
 
 
 
 
 
 
 
  
 
145 
 
  
 
Figure 5.9 Cell viability readings taken after four days. Cells were either treated 
with Cf2642 (10 µM) or untreated. Half of the cells in each condition were either 
left for the four days with no change of medium, the other half had the medium (± 
Cf2642) changed on a daily bases. A: BSC-1 cells either infected with mEdATCC or 
uninfected, B: B95a cells either infected with mWT Fb or uninfected. 
A: 
B: 
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5.4 Discussion 
The data presented here show that the ddBCNAs do not have a toxic effect on the 
host cell at active concentrations (i.e. the concentration previously shown to be 
necessary for the antiviral effect). For example, in BSC-1 cells exposed for four days, 
the CC50 concentrations of both Cf2642 and Cf3209 were calculated to be 105 µM 
and 112.6 µM respectively and the IC50 for both compounds was just 0.19 µM. 
Combined, these values produce a selectivity index for Cf2642 and Cf3209 in BSC-1 
cells of 550 and 592 respectively (i.e. the concentration of drug that causes a 50% 
reduction in viability is over 500 times greater than the concentration that causes a 
50% reduction in viral activity). However as the toxicity of the ether L-ddBCNAs 
appears to increase as the activity decreases, the selectivity index of the least active 
(Cf3210) is only 5. The intermediate compounds Cf3204 and Cf3207 display 
selectivity index values of 33 and 40 respectively. The selectivity index is an 
important consideration when developing compounds as potential drug candidates. 
The in vitro selectivity index for cidofovir against VACV has been shown to be 42 
(Nettleton et al. 2000) although was higher against parapoxviruses (198-264). 
According to this data the in vitro selectivity index for Cf2642 against VACV is much 
higher than for the control drug cidofovir. 
The CC50 concentrations generated here were plotted against the IC50 
concentrations calculated in BSC-1 cells against VACV (chapter 3 section 3.3.5) in 
figure 5.10. The fact that the CC50 and IC50 concentrations do not follow the same 
trend across the ether series of L-ddBCNAs (i.e. the most toxic of the ddBCNAs 
appears to be the least active and vice versa) provides further evidence that the 
antiviral activity of the ddBCNAs is not simply due to their effect on host cell 
viability.  
 
 
  
 
                             
Figure 5.10 CC50 concentrations (bars against the left axis) compared with IC50 concentrations (points against the right axis). The two data sets 
do not follow the same trend across the ether series of L-ddBCNAs. As the activity increases with increasing side chain length, it appears that 
the toxicity decreases.
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In addition to the cell titer-glo assays, further toxicity data was collected using an 
independent method, the caspase-glo 3/7 kit. This was to determine whether the 
loss in the viability described above was as a result of the cells entering apoptosis.  
In the first of the caspase-glo 3/7 assays HeLa cells displayed a slight increase in the 
levels of caspases 3 and 7 in the presence of drug. At 10 µM the levels appear to 
increase by around 50%. It was noted though that in the absence of drug the 
background luminescence readings for this cell line were higher than for the others 
(data not shown). This suggests that these cells have higher background levels of 
the caspases. 
The initial data also suggested that the B95a cells are sensitive to the drug after 24 
hours exposure to Cf2642 at 10 µM, with an almost doubling in the levels of 
caspases 3 and 7. Beyond this, the drug did not appear to induce apoptosis in the 
other cells tested.  
At this stage, the data points to a strong apoptotic response specifically in the B95a 
cells. Since these cells had been transformed with EBV, the next phase of caspase 
assays focused on distinguishing the difference in levels of apoptosis induced in EBV 
positive and EBV negative cells. It was thought that if it could be confirmed that the 
ddBCNAs induce apoptosis specifically in cells transformed with EBV then the 
ddBCNAs may have potential as anti-cancer agents in EBV induced cancers. 
Cidofovir has been described as having potential therapeutic use against EBV 
induced cancers; it has been shown to reduce the production of the EBV 
oncoproteins.  Another effect of cidofovir on EBV positive cells was increasing their 
sensitivity to ionising radiation, causing them to enter apoptosis (Abdulkarim et al. 
2003).  
It was hoped that the second phase of testing would be particularly informative 
since a direct comparison could be made between a selection of B cell derived cell 
lines (i.e. essentially including EBV positive and EBV negative versions of the same 
cell line). However, the results of these investigations proved to be inconclusive. 
Contrary to the initial caspase assay, the apoptotic response of the B95a cells was 
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found to remain consistent whether the drug was present or not. The reason for 
this discrepancy remains unclear. Furthermore, the two other EBV positive cell lines 
did not display increased apoptosis in response to the drug. The results of the 
second assay implied that the ddBCNAs are unlikely to be inducing apoptosis in the 
cells tested. As such, this line of investigation was terminated owing to too little 
time and money, though ideally further repeats involving more conditions would 
have been attempted. 
Interestingly, BSC-1 cells showed a decrease in the level of the caspases in the 
presence of the ddBCNAs. This work supports the conclusion that the ddBCNAs are 
having an inhibitory effect on the viruses without leading to increases in caspase 3 
and 7 levels (and resultant apoptosis) in the host cells.   
Over the course of several experiments carried out in the study of the ddBCNAs, it 
has been noted that the medium of the cells turns yellow at higher concentrations 
of the active ddBCNAs. This observation suggests a decrease in the pH of the cell 
medium at higher concentrations of Cf2642. It appears that the reduction in cellular 
viability closely corresponds to the change in pH/colour of the medium. The pH 
change had been noticed 24 hours after the addition of the drug to the cells while 
the loss in viability is seen after this point. This suggests that the drug itself is not 
leading to a loss in the viability of the cells, but is acting on the cells in a way that 
causes them to release acidic substances into the medium. It was thought that this 
decrease in pH of the medium could be the cause of the loss in cell viability.   
B95a cells appear to be particularly prone to ‘medium acidification’ in the presence 
of the ddBCNAs, possibly explaining why the viability of these cells is more affected 
than the others. It could also be the reason that these cells enter apoptosis. It has 
been shown by Park et al. (1999) that an acidic environment can lead to apoptosis 
in the cell line HL-60 as a result of upregulation in caspases 1 and 3. This occurs at a 
pH of 6.2-6.6 within a couple of hours. As it takes up to 24 hours for the Cf2642 to 
cause a visible decrease in the pH of the medium, this could be the cause of the 
increase in the caspases 3 and 7 after this time in some cases. Another group to 
show that extracellular acidity may induce apoptosis (this time in MDCK cells) was 
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Schwerdt et al. (2004). Here it was demonstrated that extracellular acidification 
increased the levels of Ochratoxin A, which in turn induced apoptosis through 
caspase 3 activation. 
To truly ascertain the effect of pH change on cell viability, an assay was devised that 
simply involved replacing the medium at regular intervals. Fresh medium (± Cf2642) 
was applied on a daily bases over the course of four days and cellular viability was 
compared between the cells with and without medium change. The data suggested 
that changing the medium did improve/extend the viability of the cells even in the 
presence of Cf2642 over the four days. This provided further evidence that the 
ddBCNAs are not directly having a toxic effect on the cells, and the loss in viability is 
due to the decrease in pH of the cell medium.  
This effect of the pH on the viability requires further study to be confirmed and 
quantified. It would be interesting to see if using a medium with a higher buffering 
capacity (more concentrated medium) could extend the viability of the cells in the 
presence of the ddBCNAs when not replenished regularly. Beyond this, it would be 
very useful to see if a dynamic cell culture system could undo the effect of the 
decrease in the pH. For example the MinuCell system can be used to examine cells 
in a 3D tissue like cell culture model and has a constant supply of fresh medium. 
This would be a closer mimic of a living/dynamic system and would provide more 
pertinent information about the survival of the cells when supplied with a constant 
flow of fresh medium (± ddBCNA).  
Following on from this model the next stage would ultimately be to study the 
toxicity effects of the ddBCNAs in animal models. This is the most accurate way of 
determining whether the compounds can be tolerated in a living system without 
causing toxicity issues.   
It has already been shown in chapter 3 section 3.3.7 that the lead compound 
Cf2642 has been tested in a small pilot animal study in mice. In this experiment, 
mice that were administered with Cf2642 (up to 100 µg/kg) were unharmed and 
displayed no signs of discomfort in comparison to the control mice over the three 
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day experiment. The compound was injected into the peritoneal cavity of the mice 
and so the fact that it was well tolerated was a positive sign as this region of the 
mice is particularly sensitive. Dissection of the mice confirmed that there were no 
signs of internal inflammation at this site.  
The discovery that the compound decreases the pH of the cell medium over time 
contributes yet further indications as to its MoA. This will be discussed further in 
chapter 6. Critically, this effect is observed in the absence of any virus and, 
therefore, it must be an effect that the compound is having on the cells that causes 
them to release acidic substances into the cell medium. It is also this effect that is 
thought to be the cause for the loss in the viability of the cells. 
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Chapter six - Mechanism of action 
6.1 Introduction 
Determining the MoA of a small molecule antiviral compound with a suspected 
cellular target is not a trivial task. For compounds that are synthesised with a target 
in mind, the MoA is potentially more obvious. The compound will either work 
against that target or not. If the target of the compound is unknown, searching for 
its precise target involves a complex process of elimination.  
Each of the experiments previously described (in chapters 3, 4, and 5) have hinted 
at the MoA of the ddBCNAs tested. The work described in this chapter highlights 
assays that specifically focused on determining this MoA. It is believed that the 
compounds have a specific target as evidenced by the clear SAR shown in chapter 3, 
sections 3.3.1.2 and 3.3.5 and chapter 4, section 4.3.9. These indicate that the 
compounds can be rendered effective or ineffective simply through the addition or 
removal of carbon atoms to/from their side chain. It is also believed that the 
compounds have a cellular rather than viral target due to the fact that they display 
the same SAR profiles for cells infected with both VACV and measles virus. Cf2642 
has been shown to work in several different cell lines but to different extents, 
pointing to a target that may be more prominent in some cells than others. This 
target is likely to be a host cell target which both VACV and measles take advantage 
of as part of their replication process. 
In order to investigate what this target might be, specific assays were carried out 
focusing on one potential cellular target at a time. This could be either affected or 
unaffected by the drug. This elimination process, whilst laborious, proved effective 
in narrowing down the MoA. 
The fact that it has been discovered that the ddBCNAs work against both VACV and 
measles viruses (shown in chapters three and four), suggests that the target of the 
ddBCNAs is cellular rather than viral since these are completely different viruses, 
VACV is from the poxvirus family while measles is from the paramyxovirus family. 
There is also some evidence that suggests that they may be active against HIV-1, 
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which is a lentivirus. It is highly unlikely that the ddBCNAs would be acting on a viral 
target within all three of these viruses. However, it is much more likely that they 
target a part of the host cell, one which all of these viruses take advantage of during 
their replication cycle.  
Here, initial experiments studied the effect of Cf2642 on the entry and the spread 
of VACV. Confocal microscopy of VACV containing YFP attached to a structural 
protein (A3L), suggested that the entry of the viruses was possibly being inhibited 
by the compound as the virus particles appeared to accumulate on the surface of 
treated cells. This was later ruled out as the antiviral effect by using an acid wash to 
remove all external virus particles and counting all particles per cell in presence and 
absence of the drug. These results indicated that there was no difference in the 
number of particles inside the cells both treated with Cf2642 and untreated. 
Another theory was that the compound was affecting the spread of the virus from 
one cell to another by inhibiting the formation of actin tails. However confocal 
images taken in the presence of the compound clearly show actin tails at the 
surface of infected cells, indicating that this is also not the cause of the antiviral 
effect. 
As mentioned in the toxicity chapter the active ddBCNAs lead to a change in colour 
of the cell medium at higher concentrations of the compounds (from red to yellow). 
The cell medium (DMEM) contains the pH indicator phenol red, which is red at a pH 
optimum for cell growth (7.4) but begins to turn orange at pH 7.2 and becomes 
bright yellow at pH 6.8 and below. This suggests that the compound is acting on the 
cell in a way that causes it to release acidic substances into the cell medium. A time 
course assay was carried out in order to determine at which point the medium 
initially visibly changes colour. This point was then used as the time scale for further 
studies based on the pH change effect. 
After consideration as to why the ddBCNAs would be causing the medium to 
become acidic, one theory put forward was the possibility of the compound causing 
the migration of intracellular acidic vesicles such as lysosomes towards the cell 
membrane, where they may fuse and release their contents extra-cellularly. In 
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order to investigate this theory, an assay was devised that focussed on Cd63, a 
transmembrane receptor located on intracellular vesicles such as lysosomes. The 
purpose of this was to establish if there was a difference in its distribution in the 
presence and absence of Cf2642.    
An ELISA for human IL-6 was carried out in order to determine if the ddBCNAs have 
an effect on the intracellular innate immune response. Most of the ddBCNAs tested 
had no effect on the levels of IL-6, with the exception of Cf3242. This compound 
was found to have increased toxicity against the cells as described in chapter 3, 
therefore this is likely to be the reason for the increase in the inflammatory 
response of the cell in the presence of this compound.  
In order to verify if the early effect of the ddBCNAs against VACV could be due to 
inhibition of transcription at the enzymatic level, a cell-free transcription assay was 
carried out. This measured the amount of mRNA production based on the signal 
from incorporation of radioactively labelled [α32P]UTP in permeabilised VACV and 
MCV virions (Bugert et al. 1998). 
 
6.2 Materials and Methods 
6.2.1 Flourescent vYFP-A3L confocal microscopy 
HeLa cells were seeded into a 12-wp containing coverslips and left overnight to 
settle and reach confluency. The cells were pre-treated for 30 minutes with 
Cf2642/no drug control before being infected with a strain of VACV modified to 
contain YFP attached to the structural protein A3L (vYFP-A3L; gift from M Way, 
2010), at an moi of 5. Cells were fixed 30 minutes pi. The cells were stained with 
phalloidin-594 to visualise the actin cytoskeleton of the cells (red) and mounted 
onto slides using Vectashield plus DAPI to visualise the nuclei of the cells (blue). The 
cells were imaged using confocal microscopy to verify if there was any difference in 
the distribution in the virus particles in relation to the cells with and without 
treatment. 
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6.2.2 Acid wash 
In order to be able to visualise just virus particles that were inside the cell, an acid 
wash step was added to the protocol prior to fixation. This removed all external 
virus particles, including those attached to the surface of the cell, allowing a clear 
view of the inside of the cell. 
The experiment was carried out as before, but an acid wash was employed 
immediately prior to the cells being fixed. The acid wash involved the following. 
Firstly the cells were placed on ice, then they were washed twice with ice cold PBS. 
After this, ice cold acid wash buffer was added to the cells on ice for one minute. 
This was then removed and they were washed three times with PBS at room 
temperature. Finally the cells were stained and mounted onto slides as usual. 
The acid wash buffer consisted of 0.2M acetic acid and 0.2M NaCl at pH 2.0. 
6.2.3 3D reconstruction confocal microscopy 
A random area of cells was selected in the field of the microscope. The top and the 
bottom of the cells were determined visually and used to define the top and the 
bottom of the stack as the points for the program to measure between. Images 
were then taken at 20 regular intervals between the top and the bottom of this 
stack, the distance between these calculated by the software based on the selected 
boundaries (i.e. the size of the cells selected, divided by 20). These images were 
then combined using the accompanying software allowing the user to view any 
specific point from above as well as from both sides. Therefore, by focussing on a 
virus particle, the combination of images allow the user to confirm that it truly lies 
within the boundaries of the cell. 
6.2.4 Virus particle and cell counting 
A, Virus counting 
Stacks of images of cell nuclei and virus particles were taken at 8 randomly selected 
areas for each of the coverslips. The images within each stack were combined using 
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Image J software, producing a single image from which a total number of virus 
particles could be counted.  The fluorescence signal for the combined stack was 
then transformed into a two tone (black and white) binary image. In order to do 
this the threshold (to decide the level of fluorescence that should be converted to 
black signal against a white background) had to be adjusted in order to determine 
what was classed as ‘signal’ and what should be ignored as ‘background’. When the 
settings had been selected for one of the stacks, the same settings were transposed 
to all remaining stacks for fair comparison. The number of particles was counted 
using Image J software.  
B, Nuclei (and cell) counting 
This process was repeated for each of the stacks but focussed on a blue DAPI signal 
in order to count the number of nuclei. Since each cell contains only one nucleus, 
the number of cells can be counted. It is important to ensure that this count is 
accurate and as such additional measures were adopted to ensure accuracy. This 
involved adjusting the signal to remove any holes in the signal areas and to 
separate nuclei that were in such close proximity that they would otherwise have 
been counted as one object (using the ‘watershed tool’). For the nuclei is was also 
important to change the settings so that only particles equal to or greater than a 
certain size were measured in order to make sure that background signals were not 
measured.  
The virus particle and cell counts from each stack were used to calculate an average 
number of virus particles per cell. This experiment was done in triplicate and the 
overall results were combined. Average counts were compared in the presence and 
absence of Cf2642. A T test was performed using SPSS to determine if there was 
any significant difference between the two sets of data.  
6.2.5 Fluorescence microscopy of actin cytoskeleton plus other markers 
The following was performed by Mr Preet Shah (from the Jones laboratory Cardiff 
school of pharmacy and pharmaceutical sciences). Hela cells were seeded into 12-
wp containing coverslips and left overnight to settle and reach confluency. These 
were pretreated for 30 minutes with Cf2642 (10 µM) plus no drug controls. They 
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were infected with vWR (at moi of 1), and one of the no drug control wells were left 
uninfected as a ‘mock’ (no drug, no virus control). The cells were collected four 
hours pi and fixed in 3% PFA for 15 minutes. The cells were stained with 
Rhodamine-Phalloidin (to visualise the actin cytoskeleton in red) and with Hoescht 
(to stain the nuclei in blue) before mounting them onto slides for confocal 
microscopy. 
This method was repeated as above substituting Rhodamine-Phalloidin with 
antibodies against a series of other cellular markers including α-Tubulin, TFR, 
TGN46, EEA1 and LAMP-2. This was also repeated using an anti-VACV antibody 
(Rabbit anti-VACV generated in the laboratory of Proffessor Bernhard Moss, 
Bethesda, USA) at 1:100 dilution, plus an Alexa Flour 488 chicken anti-rabbit IgG 
secondary antibody (Molecular Probes) at 1:400 dilution for detection.  
6.2.6 Time course – pH change of cell medium 
B95a and A549 cells were seeded into 96-wp and left overnight to settle and reach 
confluency. These were treated with Cf2642 (50, 20, 10, 5, 1 and 0 µM) and 
Chloroquine (100, 50, 20, 10, 5 and 0 µM), half the cells were infected with mWT Fb 
and the other half were left uninfected. The plates were scanned at four hour 
intervals over a 24 hour period and the subsequent images were used to visualise 
when the colour change of the medium occured.   
6.2.7 Cd63 staining 
In an effort to investigate the observation that the ddBCNAs cause the cell medium 
to become more acidic at active concentrations, A549 cells were treated with 
Cf2642 (10 µM) and fixed 16 hours after the addition of the drug. This fixation point 
was based on the time that the initial colour change (acidity exceeding the 
buffering capacity) of the medium was observed. Fixed cells were stained with a 
FITC labelled antibody for cd63 (ab18235; Abcam). Cd63 is a member of the 
transmembrane 4 family and is mainly associated with the intracellular vesicle 
membranes such as late endosomes and lysosomes (Pols and Lumperman, 2009).  
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The cells were also mounted with Vectashield containing DAPI so that the nuclei of 
the cells could be visualised via confocal microscopy. The microscope software was 
also used to produce graphs of intensity of the fluorescence through a selection of 
cells in an attempt to quantify the difference in the level/distribution of cd63 
staining in the presence/absence of Cf2642. 
6.2.8 IL-6 ELISA 
Cells were seeded into a 96-wp and left overnight to reach confluency. They were 
treated with the selected ddBCNAs (Cf3242, Cf1821, Cf2095 and the ether series) at 
10 µM for 24 hours at 37oC, and then collected for the ELISA. The ELISA assay was 
carried out according to the kit protocol (Invitrogen Hu IL-6 chemiluminescence 
ELISA kit). 
6.2.9 In vitro cell-free poxvirus transcription assay 
The following was performed by Dr. Joachim Bugert using the previously described 
in vitro poxvirus transcription method (Bugert et al. 1998). Briefly, this involves 
measuring the level of transcription by tracking the amount of UTP containing 
radioactive phosphate (P32) that is incorporated into the mRNA subsequently 
produced.  
VACV and MCV were tested for transcription levels in the presence and absence of 
Cf2642 (2 µM). This was done by incubating 50 µL of virus suspension in a total 
volume of 200 µL in vitro transcription buffer (Shand et al. 1976) at 35oC. Four 20 µL 
aliquots were taken at 0, 60, 120 and 180 minutes. The level of incorporated 
radioactivity was measured using Beckman scintillation counter.  
 
6.3 Results 
6.3.1 Cf2642 effect on vYFP-A3L entry into host cells 
In chapter 3 luciferase assay data demonstrated that the ddBCNAs can have an 
inhibitory effect on VACV within two hours of infection. This suggests that the 
target of the ddBCNAs is something that the virus requires at an early stage of its 
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lifecycle. This time period covers the entry and early transcription stages of the 
VACV lifecycle. This led to the theory that the drugs MoA might be that they inhibit 
the virus’ entry into the cell. 
In order to investigate this, Cf2642 treated/untreated cells were infected with vYFP-
A3L. The cells were fixed 30 minutes pi in order to establish the distribution of the 
virus fluorescence at the very early stages of infection. Initial confocal experiments 
with vYFP-A3L were performed, imaging cells in both the absence and the presence 
of Cf2642. 
One coincident observation made during this experiment was the presence of many 
more virus particles than predicted from the virus titres. Many of them also 
appeared to be fixed onto the glass coverslip. In the absence of drug the virus 
particles appeared to be randomly distributed throughout the cells. However, in the 
presence of Cf2642 the virus particles appeared to be much more concentrated at 
the cell surface (figure 6.1). This observation seemed to correlate with the theory 
that the ddBCNAs are inhibiting the entry stage of the virus lifecycle. i.e. the images 
suggest that whilst viral attachment is not affected, viral entry into the cell might be 
being blocked – evidenced by their accumulation at the cell membrane. 
To confirm this, the confocal assay was repeated with the inclusion of an acid wash 
step immediately prior to cell fixation. The aim of this acid wash was to remove any 
external virus particles from the cells and coverslips, including those attached to the 
surface of, but not yet internalised by, the cells. This resulted in much fewer virus 
particles being present in both the drug treated and untreated cells. Stacks of 
images were taken for random selections of the acid washed infected cells and, 
using a 3D reconstruction of the stack, it was demonstrated that fluorescent 
particles could be detected inside the cells in both the presence and absence of 
Cf2642 (figure 6.2).  
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Figure 6.1 A: HeLa cells infected with vYFP-A3L fixed 30 minutes pi, no drug control B: HeLa cells infected with vYFP-A3L fixed 30 minutes pi, 
with 30 minute pre-treatment with 10 µM Cf2642. The images suggest that in the absence of the drug the fluorescent virus particles are 
randomly distributed throughout the image, both inside and outside of the cells. In the presence of drug the localisation of the virus particles 
appears to be more concentrated at the surface of the cell. Nuclei are stained blue, the virus particles are green and the actin cytoskeleton is 
stained red.
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Figure 6.2 Using a 3D reconstruction of the images taken through a stack on the confocal microscope a view of the cells from the side and the 
bottom can be reconstructed. Using these images, it was possible to ascertain as to whether the flourescent particles were actually inside the 
cells.  Images taken in the presence and absence of Cf2642 (10 µM) are shown. The cross bars (white dotted lines) indicate the slice of the cells 
that is being viewed from the side and the bottom. The particle immediately adjacent to cross bar intersection point is visible simultaneously 
from below and from the side (as indicated by white arrows).
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Virus particles were visibly present inside the cells in both the presence and 
absence of Cf2642. However, from these images it was not evident as to whether 
there was a difference in the particle numbers between the two conditions. As 
such, this experiment was taken further in an attempt to quantify the number of 
virus particles per cell, the total number of virus particles and the total number of 
nuclei in combined stacks of images. Comparing the values generated, there was no 
apparent difference in the number of particles inside treated and untreated cells 
(figure 6.3) – with the counts from both conditions being about 5 virus particles per 
cell (P = 0.484). Contrary to the initial evidence, this data suggests that the 
ddBCNAs do not inhibit virus entry into the host cell. 
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Figure 6.3 The average number of virus particles per cell calculated from the 
average of three experiments. There is no significant difference in the number of 
particle per cell in the presence and absence of Cf2642.  P=0.484 
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6.3.2 Cf2642 effect on actin tail formation 
As previously shown in plaque assays (chapter 3 section 3.3.5), cells treated with 
the ddBCNAs exhibit a reduced plaque size phenotype. This same phenotype has 
been described by others using the drug Terameprocol (Pollara et al. 2010). They 
found that their drug causes a reduction in the size of the plaques because actin 
tails (which would normally aid virus spread) are no longer induced at the surface of 
the cells. In order to determine whether actin tails at the surface of infected cells 
were inhibited in the presence of the ddBCNAs, confocal microscopy was employed, 
specifically using HeLa cells infected with vWR and fixed four hours pi. The cells 
were stained with Rhodamine-Phalloidin to visualise the structure of actin in the 
cells and Hoechst to stain the nuclei. In the images obtained, actin tails and 
membrane blebbing are clearly visible at the surface of both the treated and 
untreated cells infected with vWR (figure 6.4 A). This finding suggests that the 
ddBCNAs are not working in the same way as Terameprocol and that they do not 
prevent the formation of actin tails. The ‘mock’ cells show no signs of blebbing or 
actin tails at the surface, therefore confirming that these are induced by the 
presence of the virus. 
Further evidence in support of this result is displayed in figure 6.4 B. This shows 
BSC-1 cells infected with vYFP-A3L in the presence of Cf2642 (50 µM). The cells 
were fixed 30 minutes pi. Actin tails can be seen at the surface of the cell.
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Figure 6.4 A: HeLa cells stained with Phalloidin-Rhodamine to visualise the actin 
cytoskeleton in red and Hoechst to visualise the nuclei in blue, untreated cells infected with 
vWR, Cf2642 (10 µM) treated and infected with vWR, ‘Mock’ untreated, uninfected control. 
Cf2642 appears to have no effect on the membrane blebbing and actin tail formation caused 
by the vWR. The blebbing and actin tails are not present in the mock cells indicating that 
these are induced by the virus. (Images from Preet Shah MSc dissertation). 
B: Wide field fluorescene image of Cf2642 (50 µM) treated BSC-1 cell infected with vYFP-A3L 
(green). Cells fixed 30 minutes pi and stained with Phalloidin-594 to view the actin 
cytoskeleton (red). The image indicates that Cf2642 does not inhibit the formation of VACV 
induced actin tails at the surface of the host cells as there appear to be many at the surface 
of the cell (two of which are indicated by white arrows). 
A 
B 
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6.3.3 Change in pH of cell medium 
In several of the assays involving the use of Cf2642 at higher concentrations 
(typically ≥ 5 µM), it has been noted that the cell medium changes in colour from 
pink to yellow, in-turn suggesting an increase in its acidity. Here, a time course 
experiment was carried out in order to determine exactly when the visible change 
in the pH of the medium occurs.  
Initially this experiment was performed using 5x103 cells per well in a 96-wp. 
Cf2642 and Choroquine were each added to the cells at a series of concentrations. 
The plates were scanned at 2 hour intervals over the course of 24 hours. Ultimately, 
this starting cell count proved too low to produce meaningful results during this 
time frame. However, a coincident observation of this plate was that, after one 
week in the incubator, A549 cells exposed to high concentrations of Cf2642 (≥ 5 
µM) did indeed show a colour change of their medium (figure 6.5). Critically, this 
effect was inhibited by the Chloroquine (i.e. the colour change became less evident 
as the Cholorquine concentration increased. This could provide evidence that 
Cf2642 acts on the lysosomes of the cells.  
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Figure 6.5 B95a and A549 cells at 5x103 cells/well, treated with Cf2642 and 
Chloroquine at a range of concentrations. Plate scans after 2 hours, 24 hours and 1 
week are shown. A change in the colour of the medium can be seen in the A549 
cells after one week at concentrations of Cf2642 ≥ 5 µM and Chloroquine ≤ 10 µM.  
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The experiment was repeated with 10 times the starting number of cells i.e. 5x104 
cells/well. This time the cells were treated with the drugs in duplicate. One half 
were left uninfected and the other half were infected with wild type measles virus. 
This was to establish whether the virus also contributed to the change in the colour 
of the medium, or if it was an effect of the drug alone. The plates were scanned at 
four hour intervals over a 24 hour period. A final scan was taken after 72 hours. 
This experiment indicated that the initial noticeable change in colour occurs 16 
hours after the addition of the drug to the cells (figure 6.6). In most of the wells it 
seemed that there was no obvious difference in the colour of the wells that were 
infected with the measles and those that were uninfected, suggesting that the virus 
is not contributing to the colour change and that it is an effect caused by the action 
of the compound on the cells. The only exception to this was in the B95a cells with 
0 and 1 µM Cf2642; after three days the wells containing the virus appeared more 
yellow than those that were uninfected. This is likely to be due to the virus infection 
killing the cells after this length of time.  
In this experiment, with the high number of cells it seemed that the Chloroquine 
did not have an effect on the colour change of the medium. Indeed, the yellow 
colour appears only in wells with higher (5 µM and above) concentrations of Cf2642 
and is the same across all concentrations of Chloroquine. It is possible that with the 
high number of cells present, Choroquine is not able to counteract the effect of the 
ddBCNA within the 16 hours it takes for the Cf2642 to cause a change in the pH.
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Figure 6.6 B95a and A549 cells at 5x104 cells/well 
treated with a range of concentrations of Cf2642 
(from 0-50 µM) and Chloroquine (from 0-100 µM). 
Plates were scanned to check for changes in colour at 
four hour intervals over 24 hours and then again after 
three days. Scans taken at 4, 16, 24 and 72 hours are 
shown. The first signs of a change in colour of the cell 
medium occur after 16 hours in the presence of 
Cf2642. 
B95a 
A549 
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6.3.4 Cd63 confocal assay   
In a further attempt to investigate the observation that the ddBCNAs cause the cell 
medium to become more acidic at active concentrations, A549 cells were treated 
with Cf2642 and fixed and stained with antibody for the detection of cd63. When 
comparing cells treated for 16 hours against untreated control cells, it appeared 
that the localisation of cd63 protein was more widespread throughout the cell in 
the former (figure 6.7). In the latter, the protein appeared to be concentrated 
around the nuclei of the cells and was typically brighter/more intense. This might 
suggest that Cf2642 is causing intracellular vesicles to migrate/fuse with the cell 
membrane and release their contents, in-turn offering a possible explanation for 
the pH change observed.  
Leica microscopy software was used in an attempt to quantify this data. A selection 
of cells were measured for the level of fluorescence intensity across their length, 
and these values were used to generate graphs of the intensity signal profiles. A 
sample of three cells in the presence and absence of drug were selected to produce 
intensity graphs of the cd63 staining (figure 6.8). In the absence of drug, the 
staining intensity appeared to be higher and the maximum intensity point observed 
was 160. In Cf2642 treated cells the intensities of the signals appeared reduced; the 
maximum intensity observed was 100. The distribution of the intensities also 
appeared to be different. In untreated samples the areas of greatest intensity 
appeared to be in close proximity to the nucleus, while in Cf2642 treated samples 
the high intensity peaks appeared more evenly distributed across the length of the 
cell cytoplasm. The corresponding cells selected for the intensity graphs are shown 
figure 6.9.
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Figure 6.7 Hela cells stained for cd63 (green) in the absence (left panel) and presence (right panel) of Cf2642 (10 µM). Cells were fixed at 16 
hours after drug addition. Confocal images show that cd63 appears more intensely clustered around the nucleus of the cells in the absence of 
the drug. However, in the presence of 10 µM Cf2642, cd63 staining is weaker and more evenly spread throughout the cell cytoplasm.
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Figure 6.8 Signal profiles for three cells (displayed as dashed green, orange and purple lines) that were either untreated (left) or treated with 
Cf2642 (10 µM, right). The x axis represents distance along the length of the cell. The y axis represents the intensity of the green staining, 
indicating the presence of cd63. The maximum intensity signal observed is represented by the black dotted line, for the untreated cells the 
maximum signal was 160 and for the Cf2642 treated cells the maximum signal was 100. The location of the nucleus of the cells is represented 
on the graph by the dark blue solid line. The cells used to generate this data, and the axes studied, are shown in figure 6.9. 
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Figure 6.9 Images of cd63 staining in HeLa cells untreated (left) or treated (right) with Cf2642 (10 µM).The green, orange and purple lines 
correspond to the signal profiles displayed in figure 6.8. Leica microscope software measures the intensity of the staining across the length of 
these lines.  
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6.3.5 Other staining experiments  
Cf2642 has also been tested in cells stained for a variety of different markers. The 
results from this project suggested no difference in the staining distribution of α-
Tubulin (staining microtubules), transferrin receptor (TFR), trans golgi network 
(TGN46) and early endosomes (EEA1), suggesting that Cf2642 has no effect on any 
of these cellular locations (data not shown). LAMP-2 staining was also performed 
and the images suggest a slight difference in its distribution with it appearing less 
intense around the nucleus when in the absence of drug (data not shown). The 
infected HeLa cells were also stained for VACV in the presence and absence of 
Cf2642 and the images suggest that there are fewer VACV containing vesicles in the 
presence of Cf2642 and an increase in staining throughout the cytoplasm figure 
6.10. 
 
 
 
 
 
 
 
 
 
 
 
 175 
 
 
      
Figure 6.10 HeLa cells infected with vWR and fixed four hours pi. Cells were stained with Hoechst (to allow visualisation of their nuclei in blue) 
and rabbit anti-Vaccinia antibody plus Alexa-488 conjugated anti-rabbit secondary antibody (to allow visualisation of virus in green). There 
appear to be fewer VACV containing vesicles in the Cf2642 treated cells than in the untreated cells. (Images from Preet Shah MSc dissertation).  
No drug Cf2642 
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6.3.6 Human IL-6 ELISA 
An ELISA was carried out to determine whether the ddBCNAs have an effect on the 
levels of human IL-6 in HeLa cells. This in turn indicated as to whether the 
compounds have an MoA that involves some effect on the intracellular innate 
immune response i.e. do they trigger an immune response in the host cell which 
acts against the virus. The results displayed in figure 6.11 indicate that the active 
ether series of L-ddBCNAs (Cf3210, Cf3204, Cf3207, Cf2642 and Cf3209) and the 
initial D-ddBCNAs (Cf2095 and Cf1821) do not alter the levels of Hu IL-6 as 
compared to the no drug control (all display levels of around 20 pg/mL). The only 
exception to this lies in the IL-6 concentration observed in the Cf3242 treated cells, 
where the levels are about double the control (i.e ~40 pg/mL). However, it has 
previously been noted (chapter 3, section 3.3.5) that this compound has a clear 
toxic effect on the cells. This observation requires further experiments, firstly 
repeats to confirm the results with statistical significance and secondly to 
investigate why cf3242 seems to trigger an IL-6 response, whereas all the others do 
not, the structure of this compound includes nitrogen methyl instead of oxygen 
(chapter 3 section 3.3.1.3).  
Taken together, it appears that alteration of the levels of IL-6 and induction of the 
intracellular innate immune response is not the MoA of the compounds.  
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Figure 6.11 Human IL-6 ELISA in HeLa cells treated with 10 µM of the shown ddBCNAs. Cf3242 is the only compound to show increased IL-6 
production (concentration calculated as ~40pg/mL). The rest of the ddBCNAs tested display similar levels of IL-6 concentrations to the no drug 
control (all were ~20 pg/mL). 
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6.3.7 Cf2642 effect on transcription 
A cell free in vitro experiment was carried out in order to verify whether the 
ddBCNAs may be having an effect on the level of viral transcription. This 
experiment studied VACV and MCV in both the presence and absence of Cf2642 (2 
µM). The results are displayed in figure 6.12. The data suggest that Cf2642 has no 
effect on the level of transcription. Indeed, transcription levels at one, two and 
three hours were almost identical in treated and untreated samples. The readings 
were higher with the MCV than with the VACV. 
For either virus, the transcription signal increases over the first two hours before 
appearing to descend. This is likely to be because the reaction is ATP dependant 
and in the isolated system, ATP would eventually be used up and mRNA production 
would cease. At this point, mRNA would break down leading to the decrease in 
signal.  
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Figure 6.12 The effect of Cf2642 (2 µM) on the level of transcription (as radioactive 
counts per minute on the y-axis) compared with no drug. A: VACV B: MCV. Cf2642 
appears to have no effect on the amount of mRNA production (Figure reproduced 
from Bugert data). 
 
A 
B 
 180 
 
6.4 Discussion 
Data from previous chapters have contributed hints as to the MoA of the ddBCNAs. 
In this chapter, the MoA has been narrowed down further. Initially confocal 
microscopy images of untreated/Cf2642 treated cells infected with vYFP-A3L 
appeared to indicate that the MoA might be inhibition of virus entry. This was 
evidenced by the localisation of virus particles on the cells; in Cf2642 treated cells, 
particles clustered at the membranes of the cells. In an extension of this study, an 
acid wash step was used to remove external virus particles. Subsequently, virus 
particles could be visualised inside cells in both the presence and absence of the 
drug. Quantification of this data confirmed that there was no significant difference 
between the two settings. The conclusion drawn from this set of data was that the 
ddBCNAs do not appear to be entry inhibitors. 
Following on from observations made in previous chapters about the change in 
colour of the medium in the presence of the ddBCNAs, further studies into this 
effect were conducted. Initially this involved a time course assay to look at cells 
treated with various concentrations of Cf2642 to determine when the initial colour 
change occurred. The first of these experiments with a lower cell count displayed a 
colour change at concentrations of 5 µM and above of Cf2642. This effect was 
reversed by chloroquine. This finding could suggest that the acidification caused by 
the ddBCNAs might be due to them causing migration and fusion of the lysosomes 
with the cell membrane and subsequent release of their acidic contents into the cell 
medium. This could be reversed by chloroquine as this drug targets the lysosomes 
of cell and raises their pH.  
The second experiment displayed an initial colour change after 16 hours in the 
presence of Cf2642 at 5 µM and above. This effect was not reversed by 
Chloroquine. This could be due to the number of cells overwhelming the capacity of 
Chloroquine to increase the pH. Ideally repeats of this experiment using a wider 
range of cell counts would need to be performed in order to confirm the effect of 
the cell numbers on acidification of the medium when ddBCNA treated. 
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Most of the cells cultured in this laboratory grow best at an optimum pH of around 
7.4. The DMEM contains phenol red indicator which has a bright red colour at this 
pH. It also contains a buffering system that maintains this pH as the cells metabolise 
and produce acidic by-products. In the presence of the compound, the release of 
acid into the medium exceeds the buffering capacity of the medium much earlier 
than would be expected when resulting from normal cell respiration alone. After 16 
hours there is already a visible colour change in the medium compared to 
untreated cells. After 24 hours the medium becomes orange, indicating a pH of 
around 7. The medium gradually turns yellow over the next 24-48 hours, indicating 
a pH of less than 6.5. This pH has an effect on the viability of the cells. 
Based on these findings, a 16 hour time period was chosen to analyse cd63 
distribution. The images produced suggest a decrease in the intensity of cd63 
staining in the presence of Cf2642 compared with the untreated cells. However it 
must be noted that these images (and the plots generated from them) are the 
result of an individual experiment that would need to be repeated for confirmation 
of the effect. Ideally repeats would also include staining with a plasma membrane 
marker or with phalloidin-594 (to stain the actin cytoskeleton) in order to more 
accurately define the boundaries of the cells.  
Experiments looking more specifically into this change in pH are necessary. This 
might include using pH trackers to detect any changes in the internal cellular pH in 
the presence of Cf2642. As viral processes can be pH dependant, changes in 
internal pH caused by the ddBCNAs could also be a potential MoA. 
It has been demonstrated that during measles infection, the virus induces 
prolonged autophagy of the cell to aid its replication (Richetta et al. 2013). If the 
drug was affecting the cellular lysosomes this may have an effect on the virus 
lifecycle. Interestingly, VACV have also been shown to adopt intracellular vesicles to 
form its own virus factories (de Castro et al. 2013). As such, were ddBCNAs to affect 
lysosomes/endosomes, this could explain the antiviral effects previously observed. 
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The images of Cf2642 treated/ untreated infected HeLa cells stained for VACV 
suggest that Cf2642 treatment appears to reduce the number of the virus factories 
forming in the cell. The cytoplasm of the treated cells appears to have a greater 
level of general green staining and fewer virus containing vesicles. This observation 
potentially provides evidence towards the theory that the ddBCNAs have an effect 
on the formation of VACV virus factories. 
In order to rule out induction of the intracellular immune response as the MoA, an 
ELISA for IL-6 was carried out. The results for this ELISA suggest that (with the 
exception of Cf3242) the ddBCNAs tested do not induce an increased 
inflammatory/immune response.  
Finally the in vitro transcription assay indicates that the ddBCNAs do not have an 
effect on the viral components of transcription as they are able to produce the 
same amount of mRNA in the presence of Cf2642 in the cell free system. This 
finding provides further evidence toward the MoA of the ddBCNAs being a cellular 
rather than a viral target.  
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Chapter seven – General Discussion 
7.1 Combining the findings of the project 
In each of the chapters of this project, the experiments performed have provided 
clues towards the MoA of the ddBCNAs. Here these results are summarised with 
further interpretation of their relevance. 
The luciferase assays have demonstrated that the ddBCNAs have an inhibitory 
effect on VACV within two hours pi. This finding implies that they have a viral or 
cellular target that is required in the early stages of infection. The first stages of the 
VACV lifecycle involve attachment and entry of the virus particles into the host cell. 
Therefore possible targets were considered within this time scale.  
Our studies using a core labelled VACV (YFP-A3L) and confocal analysis of the 
location of viral particles 30 minutes pi (chapter 6 section 6.3.1) show an equal 
amount of viral particles inside cells in the presence and absence of Cf2642. This 
finding indicates that the processes involved with viral attachment and entry, 
including lipid raft mediated pathways (Chung et al. 2005), and macropinocytosis 
(Mercer and Helenius, 2008), are unlikely inhibited by ddBCNAs.  
VACV early viral transcription is another process that occurs within the two hour 
time scale, and therefore was considered as a possible target of the ddBCNAs. The 
in vitro transcription data presented in chapter 6 section 6.3.7 suggest that viral 
early transcription is not inhibited by Cf2642. The  in vitro transcription assay 
(Shand et al. 1976) uses VACV virions containing the complete early poxviral 
transcription complex: DNA dependent RNA polymerase with nine subunits, as well 
as capping enzyme, nucleoside hydrolases, the poly A polymerase and VACV early 
transcription factor (Broyles, 2003). The assay tests this system in its entirety, 
instead of testing component parts. It is well established as an assay suitable for 
testing inhibitory effects on VACV early transcription (Melquiot and Bugert, 2004).   
However, it does not take into account the intracellular requirements for 
transcription in VACV infected cells, as the VACV virus particles are tested in a cell 
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free system.  While it is therefore possible to say that mRNA transcription from viral 
genome templates by the early transcription complex in poxviral cores is not 
inhibited by Cf2642, components contributed to VACV transcription by the cell are 
not tested.  
It has been demonstrated by Mallardo et al. (2002) that VACV cores need to be 
transported to specific locations within the cell cytoplasm for transcription to occur. 
So it is possible that the intracellular transport mechanism transporting VACV cores 
from the point of entry to the site of early transcription could be inhibited by the 
ddBCNAs. This possible MoA is the subject of ongoing work (confocal imaging of 
VACV transcription sites).   
The fact that the effect is observed within two hours pi suggests that the target is 
not specific to a process that is only required at later stages of the virus life cycle, 
e.g. virus DNA replication. This occurs from about 3-4 hrs pi at specific sites in the 
cytoplasm that are different to those where early transcription occurs (Mallardo et 
al. 2002). To distinguish ddBCNA effects at the stage of VACV transcription, from 
later stages in the viral lifecyle, we used cidofovir (Snoeck et al. 1988) as a control. 
Cidofovir is a known inhibitor of viral DNA polymerases including vaccinia DNA 
polymerase (De Clercq, 1998). In the two hour luciferase assays the ddBCNAs cause 
significant reductions in the v3 luciferase transcription luminescence signals, where 
as cidofovir does not. It is reasonable to assume that the early inhibitory effect of 
ddBCNAs is not inhibition of the VACV DNA polymerase. This is further underlined 
by the fact that the D-ddBCNAs active against hCMV (on which the compounds in 
this project are based) were also found not to be DNA polymerase inhibitors 
(McGuigan et al. 2004).  
As part of our systematic efforts to define the likely cell/viral processes affected by 
ddBCNAs, we conducted time of addition experiments. Our results (chapter 3 
section 3.3.4) show that ddBCNAs have an effect on virus transcription even if given 
up to 8 hours pi. At this point in the VACV lifecycle viruses have passed DNA 
replication and start particle assembly/egress. The sites of early transcription have 
been shown to be in different locations to the sites of DNA replication and late 
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transcription. The latter appear to occur at the cytosolic side of the endoplasmic 
reticulum (ER), and the viral DNA replication process appears to attract further ER 
cisternae, leading to the enclosure of the site in ER membranes (Mallardo et al. 
2002). It was also shown that the viral cores and mRNA associate with 
microtubules, indicating that the viral components are transported to their required 
location within the cell cytoplasm via microtubules.  
The ToA method gives an indication as to the amount of time that the addition of a 
drug may be delayed without loss of its effect. This approach has been described by 
Daelemans et al. (2011) in regards to HIV-1 antivirals. Here we used it to provide an 
indication of the MoA. Our findings imply that it is not simply an early effect. If for 
example the inhibition was of viral entry alone, then adding the compound after 
completion of the entry stage of infection would have no effect against the virus. 
From the ToA experiment we conclude that the ddBCNA target is not likely to be an 
entry inhibitor, but rather targets a process that is required throughout the lifecycle 
of VACV.  
It has been shown that antiviral compounds may exhibit differing levels of antiviral 
activity within different cell lines. An example of this effect was shown using 
poly(rI).poly(rC) (a homopolymer pair of polyriboinosinic and polyribocytidylic acid) 
which is a nucleotide inducer of interferon. This drug was tested for antiviral 
activity against bovine vesicular stomatitis virus in primary rabbit kidney (PRK) cells, 
human skin fibroblasts (HSF), mouse embryo fibroblasts (MEF), mouse L-929 cells, 
rabbit kidney (RK 13) cells, HeLa, BSC-1  and vero cells. The activity of the drug was 
found to have decreasing levels of activity through this list of cells (De Clercq and 
De Somer, 1971). Furthermore, an anti-orthopoxvirus compound, the carbocyclic 
thymidine analogue; N-methanocarbathymidine ((N)-MCT) was found to display 
differing levels of activity against VACV and cowpox in nine different cell lines 
(Smee et al. 2006). The activity of (N)-MCT was discovered to be dependent on 
cellular thymidine kinase. 
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We tested for such a difference using a cell range assay (chapter 3, section 3.3.2) 
which indicated that there was an antiviral effect of Cf2642 in a range of different 
cell lines of both human and animal origin. This finding confirms that the activity of 
the ddBCNAs is not specific to a single cell line. Of note, human lung cell line (A549) 
and skin keratinocytes (HaCaT) were both included in the assay and each represents 
an area of entry for natural infection with both pox and measles viruses (airborne 
route/direct contact). As such, our results contribute evidence that the drug may 
perform well as a measure against clinical infection. They also suggest that the 
target of the ddBCNAs could be cellular since the level of antiviral activity varies 
between different cells. The target of the ddBCNAs may also vary in abundance 
between cell lines.  
In order to follow up with this line of thought, the ddBCNAs would need to be 
further tested in an animal model. The compounds and virus would be 
administered through different routes in order to determine the activity in a model 
that better simulates natural infection. Only more extensive animal testing would 
answer the question as to whether the ddBCNAs are suitable for development as 
drug candidates. This work has been proposed as the subject of a follow-up Phd 
/postdoctoral project.   
The VACV assay giving the best indication of ddBCNA activity over the whole 
lifecycle of the virus are plaque assays. VACV plaques reach a size of ~3 mm in 
diameter in BSC-1 cell culture over a period of 3 days (Doceul et al. 2010). Plaque 
size is dependent on morphogenesis proteins (e.g. F13L, the VACV protein present 
of the outer envelope of the EEV form of the virus) being present (Blasco and Moss, 
1991) and functionality of the cell cytoskeleton, especially the formation of actin 
tails to facilitate viral spread (Doceul et al. 2010).  
In VACV plaque assays the effect of the ddBCNAs was observed as a reduced plaque 
size phenotype (chapter 3, section 3.3.4). This small plaque phenotype has been 
described for other VACV antiviral compounds such as ST-246. This compound 
targets the viral protein F13L leading to the reduced plaque size (Duraffour et al. 
2008). As this compound targets a specific viral protein, the virus may mutate and 
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develop resistance to the drug. Indeed, strains of VACV that are resistant to ST-246 
have already been described (Yang et al. 2005).  
Another experimental antiviral active against VACV that causes a reduction in 
plaques size is Terameprocol (Pollara et al.2010). The reduction was found to be 
due to the inhibition of actin tail formation in-turn reducing the spread of the virus 
from one cell to the next. Actin tail formation propels incoming virus particles from 
already infected cells to cells further away, in the manner of a conveyor belt 
(Doceul et al. 2010).  Actin tail formation is not inhibited at the surface of VACV 
infected cells in the presence of Cf2642 (chapter 6, section 6.3.2) ruling out an 
effect on actin polymerisation.  
Blebbing has been described by Mercer and Helenius (2009) as a VACV triggered 
method for entry into host cells. Blebbing of the membrane was apparent in 
infected cells both in the presence and absence of Cf2642 (chapter 6, section 6.3.2). 
The question at this point was to assess whether a cellular target is affected, rather 
than a VACV specific viral function. One way to answer this question was by 
investigating the effect of ddBCNAs/Cf2642 against a series of other viruses. A 
panel of viruses was chosen that represented a wide variety of different types. It 
included DNA viruses with and without envelopes i.e. HSV-1/HSV-2 and Adenovirus 
respectively, and the RNA viruses measles and Influenza. Assay systems for all of 
these viruses were established in the Bugert laboratory and high titer stocks were 
available. Yellow fever virus and HIV-1 were added to the panel at a later stage of 
the project. 
The results, as presented in chapter 4, revealed significant antiviral activity against 
measles virus, while all other viruses in the panel were not affected. The measles 
virus lifecycle and gene products are sufficiently different from VACV, to rule out a 
virus specific target at this point. This is further evidenced by the fact that the 
ddBCNAs, in measles virus infected cells, inhibit the formation of syncytia, a CPE 
that is not observed in VACV infected cells. Syncytia formation is brought about by 
 188 
 
the measles virus fusion (F), and hemagglutinin (H) proteins (Cattaneo and Rose, 
1993), both of which have no correlates among known poxviral gene products.  
This would support the notion of a ddBCNA cellular target relevant in the lifecycle 
of both VACV and measles viruses, but not the other viruses tested. Unfortunately, 
finding the MoA of a cell targeting drug is not trivial (Yan et al. 2013). With the vast 
number of cellular processes possibly affected, one way to show whether a 
compound has any specific activity versus a cryptic target is to determine SAR. SAR 
can establish whether specific chemical modifications have an effect on biological 
activity. Medicinal chemists use the method to improve the potency of a bioactive 
compound by chemical modification. The specificity of antiviral activity based on 
side chain length of other nucleoside analogues (against VZV) has previously been 
demonstrated through the establishment of an SAR (McGuigan et al. 1999). 
In this project experiments were carried out in order to define SAR using the 
compound’s activity versus VACV and measles viruses as biological readouts 
(chapter 3, sections 3.3.1 and 3.3.4 and chapter 4, section 4.3.9). This work was 
done in depth, using five of the L-ddBCNA compounds (including Cf2642) with 
specific modifications to the length of the ether side chain. Although not all 
ddBCNAs produced were tested in all antiviral assays they were all tested using 
luciferase assays in triplicate (a total of 38 compounds with various modifications), 
to establish the most active structures. 
The two principal findings of the SAR study are: 1) that only L-ddBCNAs (and not D-
ddBCNAs) nucleoside analogues have significant antiviral activity versus both VACV 
and measles virus and 2) that the most effective chemical modification was the 
lengthening of a hydrophobic side chain, with solubility aided by the presence of an 
ether bridge. Cf2642 emerged from this study as the lead ddBCNA, an L-enantiomer 
with the ether side chain C9-O-C5. Both the effects of chirality and the existence of 
an optimal side chain modification indicate a sterically specific molecular 
interaction as the cause of Cf2642 antiviral activity. This is demonstrated by the fact 
that altering the length of the side chain by just one or two carbon atoms can 
render the L-ddBCNAs less active. 
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Critically, the SAR established for the ether series of L-ddBCNAs follows the same 
trend in three very different biological assays: VACV luciferase assays at two hours 
pi, VACV plaque assays (IC50 of plaque size reduction) over four days, and measles 
virus IC50 assays two days pi (inhibition of syncytia inhibition). This indicates that the 
same target is affected in cells infected by either virus, over a period of two hours 
to four days pi, giving more credence to the hypothesis of one cellular target 
required for mRNA transcription, virus spread/ plaque formation, and syncytia 
formation of two very different viruses.   
This work was used to make EU / US patent applications in 2012 (filed and upheld 
by Cardiff University) and published as an SAR study (McGuigan et al. 2013). 
As all of the above processes involve intracellular transport and membrane 
trafficking, this work points at a cellular membrane compartment as the ddBCNA 
drug target. This is all the more plausible as the long hydrophilic side chain with 
specific length requirements suggest a membrane interaction/insertion of the L-
ddBCNAs. An example of a drug that interacts with membrane bound 
compartments is chloroquine which in an unprotonated form may cross the lipid 
membrane. The compound accumulates in acidic lysosomes as once it has passed 
through the membrane into them it becomes protonated and with the positive 
charge it is unable to cross back through the membrane. Chloroquine has been 
shown to have potential as an antiviral compound as it inhibits pH dependant 
stages of viral lifecycles (Savarino et al. 2003). The MoA of chloroquine (increasing 
endosomal vesicle pH) turns out to be of special interest in light of our further 
findings regarding ddBCNA cellular toxicity and pH changes. We have addressed the 
question of cellular toxicity in depth as described in chapter five. 
For evaluation of toxic effects on our cell lines the CELLTiter-glo assay was used, an 
extremely sensitive luminescence based test (Petty et al. 1995), which is now the 
accepted gold-standard for toxicity testing of biologically active compounds prior to 
testing in animal models. Four different cells lines were tested including B95a, Vero, 
RK13 and BSC-1 selected as the cells used in the majority of the antiviral assays. We 
have shown that loss in viability (ATP production) caused by the lead ether series of 
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L-ddBCNAs is not occurring at active concentrations within the timescale at which 
activity is observed (chapter 5, section 5.3.1). This implies that the activity is not 
simply a result of a loss in cell viability.  
To our knowledge, this study exceeds other published work in terms of range of 
cells tested, and observation time for possible toxic effects in vitro. Indeed, cell 
viability was measured at four days post treatment, when most cell lines require 
medium changes sooner than that, especially at high cell densities. Usual timescales 
for published toxic effects do not exceed 72 hours. 
Further to this, CC50 concentrations were calculated using BSC-1 cells (used for the 
four day VACV plaque assay). The most active ddBCNAs (Cf2642 and Cf3209), were 
found to have CC50 concentrations over 500 times greater than the IC50 
concentrations (VACV) in the same cell line over the same time frame (i.e. they 
display a selectivity index of over 500).  The in vitro selectivity index for Cidofovir 
against VACV has been shown to be 42 in experiments that used semi continuous 
foetal lamb muscle (FLM) cells (Nettleton et al. 2000).   
It was also demonstrated that the CC50 concentrations calculated for the ether 
series of L-ddBCNAs do not follow the same trend as the IC50 concentrations for the 
same compounds. This is encouraging as it suggests that the loss in viability of the 
cells observed in some of the cell titer-glo assays (after 24 hours) is not the reason 
for the antiviral activity of the compounds. So loss of cell viability observed as a 
result of our lead series of ddBCNA compounds are independent of drug activity in 
SAR, indicating that the MoA is not an effect leading to cell toxicity between zero 
and four days post treatment. 
This does however not correlate with the theory that the pH change of the medium 
is linked to the MoA. This theory requires that the pH would become more acidic 
when more active compounds are used. This is exactly what we observe: the colour 
change of the medium occurs at the same concentrations at which activity is 
observed (dose effect), and the more active compounds turn the medium yellow at 
lower concentrations than the less active ones (SAR pH effect). This effect is clearly 
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evident in images taken of the plates as part of the measles IC50 assays 
(supplementary material).  
In order to find out if extracellular acidity as a cause for loss of viability, a medium 
replacement assay was devised (chapter 5, section 5.3.5). The results demonstrate 
that, by replacing the drug and medium with fresh aliquots on a daily basis, the 
viability of the cells over the four days is improved without a concomitant reduction 
in antiviral activity.  
We interpret the above observations as follows: the cells tested (least and most 
sensitive BSC-1 and B95a, respectively) show reduced loss of viability after four 
days if the extracellular acidity is removed on a daily bases. This, along with the fact 
that antiviral activity can be observed within two hours, indicates that while 
extracellular acidity affects cell viability, it is not the cause of the antiviral effect, 
but is a side effect of the MoA of the ddBCNAs. The fact that there is a difference in 
the trend of the CC50 concentrations and the IC50 concentration suggests that 
extracellular acidity is not the sole reason for the loss in viability, and that the 
compounds with lower activity have other possible unwanted side effects.   
At this point it is reasonable to conclude that increased extracellular acidity is a side 
effect that may lead to loss of cell viability, but is not the actual MoA. The 
mechanisms however, leading to increased extracellular acidity may still be linked 
to the MoA. Preliminary work into intracellular pH effects, looking at a lysosomal 
marker (cd63) at fixed time points (chapter 6, section 6.3.4), suggested that there 
was a reduction in cd63 staining in the presence of Cf2642. However this effect was 
difficult to accurately quantify and, therefore, further work using pH tracker dyes 
and live cell microscopy is currently ongoing. 
In order to rule out apoptosis as a side effect of the ddBCNAs, Cf2642 was tested in 
a selection of cells using the caspase-glo 3/7 kit (chapter 5, sections 5.3.3 and 5.3.4) 
which measures the levels of effector caspases 3 and 7 (i.e. the level of apoptosis 
triggered through the caspase cascade (Thornberry and Lazebnik, 1998).  
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Initial results for caspase 3/7 levels in HeLa and B95a cell lines indicated a dose 
dependent induction of apoptosis by Cf2642. However, these results could not be 
repeated, and later experiments suggested both cell lines were completely 
unaffected. Some studies have shown that a decrease in the extracellular pH may in 
some cases lead to apoptosis (Park et al. 1999; Schwerdt et al. 2004). As discussed 
in chapter 6 section 6.3.3, the pH change time course assays indicate that the time 
of change in the pH brought about by the ddBCNAs is dependent on cell density. If 
there were slight differences in the number of cells in the wells between the two 
caspase-glo 3/7 assays (pipetting margin of error), this could be the reason for the 
differences in the level of caspases between the different assays i.e. a slight 
increase in the number of cells in the first assay could have been enough to tip the 
pH over the threshold before cells enter apoptosis.  
This finding however also raised the possibility that at least in the case of measles 
virus syncytium inhibition (24 hrs pi) the antiviral effect may actually be preceded 
by cell apoptosis. To make sure that apoptosis is not actually the cause of the 
antiviral effect against measles, Cf2642 was tested in a human B cell line BJAB 
(derived from human Burkitt lymphoma), where it did not induce apoptosis in 
either of the caspase assays, but still inhibited syncytia formation by mWT Fb and 
mEdATCC (supplementary material).  
Based on the combined data we feel confident to say that the antiviral effect of the 
ddBCNAs is not due to apoptosis or a loss in viability of the host cells, especially as 
initial antiviral activity against VACV can be observed after 2 hours pi (earlier than 
any loss in viability and/or apoptosis is observed).  
The pH effects following ddBCNA treatment are the most interesting current lead 
for ddBCNA MoA. It is thought that the effect of the ddBCNAs may be linked to 
effects on cellular lysosomal vesicle turnover (chapter 6, section 6.3.4) and by 
extension another interesting and topical cellular effect: autophagy.  
Measles have been described as inducing successive waves of autophagy (where 
lysosomes fuse with autophagosomes to form autolysosomes), leading to the 
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formation of syncytia, which aids dissemination of the infection (Richetta et al. 
2013). Therefore if the action of the ddBCNAs on lysosomes were to inhibit 
autophagy, this could be the reason that the ddBCNAs inhibit syncytia formation in 
measles infection. A difference in autophagy induction between measles wild type 
and vaccine strains and the measles receptors involved is also described (Richetta 
et al. 2013). H protein adaptation to the cellular receptor Cd46 allows measles 
vaccine viruses to induce an initial wave of autophagy immediately upon infection 
of non-B cell types (e.g. Vero).  Cd150 dependant wild-type measles strains are not 
able to induce early autophagy, but rather exploit the late and sustained phase of 
autophagy (Richetta et al. 2013). The difference in the way that these two receptors 
may induce autophagy may account for the differences observed between the 
effect of the ddBCNAs against the Edmonston strain of measles in B95a and Vero 
cells (chapter 4, sections 4.3.7 and 4.3.8).  
We hypothesize, that early/pre-treatment with ddBCNAs leads to total suppression 
of syncytia and late autophagy in wild type strains, but is not always successful in 
the case of the vaccine strain, where autophagy starts sooner.   
If the same MoA were assumed to apply to all viruses affected by ddBCNAs, this 
case is harder to make for VACV. VACV has been described as being able to 
replicate in cells deficient for autophagy, implying that they do not require 
autophagy for their replication (Zhang et al. 2006).  
However this does not exclude lysosomes as a possible target for the MoA of the 
ddBCNAs against VACV. VACV require ER and other intracellular membrane 
compartments for their assembly and to set up virus factories (de Castro et al. 
2013). It has also been found that VACV envelopes contain phospholipids typically 
found in lysosomal membranes (Hiller et al. 1981), suggesting that they may derive 
part of their envelope from lysosomal membranes.  
While virus factories and the assembly of the VACV particles including the envelope 
are all occurring late in virus infection, effects on the setup of early transcription 
sites would also explain, how the ddBCNAs are able to inhibit VACV within two 
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hours of infection. Mallardo et al. (2002) describe specific intracellular sites of VACV 
early transcription which are distinct from DNA replication and virus assembly sites. 
Movement of viral cores to these sites is dependent on dynamic parts of the 
cytoskeleton, specifically microtubules. 
It is well documented, that VACV use actin tails to spread between cells, however 
this appears not to be affected by the ddBCNAs (chapter 6, section 6.3.2).  This 
leaves other (presumably membrane based) transport mechanisms within the cell 
that may affect the virus’ ability to transport themselves to their required locations 
within the cell.  
So we hypothesise that ddBCNAs are having an effect on the cellular trafficking of 
VACV components through interference with or disruption of lysosomes within the 
ddBCNA treated cells. 
It has been shown that both measles (Berghäll et al. 2004) and VACV (Schepis et al. 
2007) require the use of microtubule based transport during their replication 
cycles. Transport along microtubules is also required for the clustering of lysosomes 
in the region of the microtubule-organising centre (Matteoni and Kreis, 1987). From 
confocal images staining for the marker α-tubulin it appeared that the distribution 
of microtubules was not affected by Cf2642 (Prett Shah MSc data not shown). 
Also, if microtubules themselves were the target of ddBCNAs, this would affect all 
viruses using this cellular transport system. However, the viruses that have been 
described as unaffected by the ddBCNAs also use microtubules for intracellular 
transport, including Adenovirus (Kelkar et al. 2004) Influenza (De Conto et al. 2012) 
and HSV (Mabit et al. 2002).  
The ddBCNAs may affect viral/intracellular membranes (lysosomal/autophagosome 
compartments) in a way that makes them unable to bind with microtubule 
transport proteins.  
From the cell range assay it was apparent that the antiviral effect against VACV was 
strongest in RK13 cells (chapter 3, section 3.3.2). Information provided on this cell 
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line from ATCC states that these cells are positive for keratin by immunoperoxidase 
staining. Keratin could be another possible target to consider. Keratin-like proteins 
have been found to associate with VACV factories (Murcia-Nicolas et al. 1999). It 
has also been shown that in cells infected with respiratory syncytial virus (related to 
measles), cytokeratin 17 is expressed and localises to sites of syncytia formation 
(Domachowske et al. 2000). We are following up the leads and hypotheses outlined 
above one by one. 
Ongoing work on intracellular pH imaging and high resolution/EM imaging of 
poxviral factories, is testing the hypothesis that the cellular target is the 
lysosomal/autophagosome compartment, which is known to be involved in measles 
virus syncytia formation and presumably also affects poxviral assembly in factories.    
7.2 Future work with the ddBCNAs 
A number of leads for MoA of the ddBCNAs have been developed based on a 
cellular target which we would like to follow up with the following planned 
experiments:  
1. Intracellular pH tracker live microscopy experiments ± Cf2642 using U2OS 
FYVE gfp cells (these cells are derived from human osteosarcoma and are 
stably express the FYVE finger fused to GFP, this is thought to localise FYVE-
finger proteins with early endosomes; Thermo scientific) and lysotracker 
RED (selective marker for acidic organelles). The distribution of the green 
and red stained vesicles will be observed in the presence and absence of 
Cf2642. The effect of chloroquine on the results will also be established to 
see if this drug counteracts the effects of Cf2642. This work is currently in 
progress by Angela Williams and Elizabeth Roquemore at GE Healthcare 
Whitchurch. 
2. An in vitro syncytia assay has recently been established using plasmids 
containing the genes for the Edmonston strain measles F and H proteins 
(from Caltech). Transfection of HeLa cells with these two plasmids has been 
shown to produce syncytia in the absence of the virus (supplementary 
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material). This effect is to be tested in the presence of Cf2642 to see if the 
effect can be reversed. This will establish if the ddBCNAs are able to inhibit 
syncytia formation in the absence of virus in different cell lines. Plasmids 
containing the wild type strains of measles F and H proteins are also in the 
process of being produced. 
3. Depending on the results of the in vitro syncytia assay, it may be beneficial 
to test the effect of the ddBCNAs against the wild type measles virus in an 
alternative cell type e.g. cord blood cell (COBL) (Kobune et al, 2007). 
4. The ddBCNAs will ultimately need to be tested to confirm antiviral activity in 
animal models for both VACV using black 6 mice (as used in chapter 3, 
section 3.3.6) and for measles using  the cotton rat model (Niewiesk, 1999) 
which has been found suitable as a model for antiviral testing (Wyde et al, 
2000). The compound would be administered through different routes in 
order to see if the level of infection may be reduced. The testing would need 
to be extended including administering repeated doses to ensure that no 
toxic effects occur at any stage during treatment with the compound. 
5. The ddBCNAs should be tested against other viruses to find out if there are 
other viruses that may be inhibited by the drug. Further experiments against 
HIV-1 are necessary to to confirm if there is a clear effect against this virus. 
6. Further medium replacement assays would need to be carried out to 
determine if maintaining the cell medium pH has an effect on the IC50 and 
CC50 concentrations. 
7. Autophagosome assays to, firstly, determine the effects of Cf2642 on cells 
treated with either autophagy inhibitors (e.g. balfilomycin, wortmannin or 
chloroquine) or autophagy inducers (e.g. rapamycin) and secondly for use 
with fluorescence microscopy using markers for autophagosomes such as 
p62 and/or LC3B during measles infection in the presence/absence of 
Cf2642. 
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7.3 Addressing the aims of the project 
In the introduction (section 1.5) a list of aims for the PhD project were presented. 
These aims have been addressed over the course of the project as follows: 
1. All of the novel ddBCNAs were tested using luciferase assays and statistical 
significance was assessed in order to ascertain their levels of activity. SAR 
profiles were established for the alkyl and ether series of L-ddBCNAs (based 
on their side chain length) using the luciferase assay data. Similarly, SAR 
were also established for the same ether series using the IC50 concentrations 
developed from the plaque assays. 
2. The ddBCNAs were found to be inactive against YFV, HSV-1, HSV-1, 
Adenovirus and Influenza. Possible activity was displayed against MCV and 
HIV-1. Activity of the L-ddBCNAs was established against measles. IC50 
concentrations against measles virus of the ether series displayed similar 
SAR profiles to those previously established against VACV. 
3. The ddBCNAs were found to not cause loss in viability at the active 
concentrations over the time scales at which activity is observed. The 
calculated CC50 concentrations for the ether series of L-ddBCNAs did not 
show the same trend as the SAR shown against measles and VACV. The 
selectivity index for Cf2642 was 500 as based upon the CC50 and IC50 
concentrations for this compound. It was also demonstrated that it is 
unlikely that the ddBCNAs are inducing cellular apoptosis. 
4. Experiments focussing solely on the MoA have ruled out certain targets for 
the MoA of the ddBCNAs. These include: viral entry, viral transcription, viral 
DNA polymerisation, cellular actin polymerisation and cellular innate 
immune responses. Combined, these suggest a specific cellular target which 
requires further investigation. 
7.4 Merit of the project results 
In summary this project has investigated the potential of novel compounds (the 
ddBCNAs) as antiviral drug candidates against pox and measles viruses. Structure 
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activity relationships have been established and revealed the most active of the 
compounds to be Cf2642. Initial toxicity testing has been successful and not ruled 
these out as drug candidates. The MoA has also been narrowed down by a series of 
experiments.  
The MoA of the ddBCNAs is thought to involve a cellular target. Drugs that have 
cellular rather than viral targets are sometimes not preferred due to the increased 
likelihood of toxic side effects in the host. However in this project, it has been 
demonstrated that the ddBCNAs have an acceptable selectivity index in vitro and as 
long as these compounds can be proved safe in future in vivo assays, they may have 
potential for use as clinical antiviral drugs. A benefit of a cellular rather than viral 
target is that the capacity of the virus to become resistant to the drug is limited. It 
also has been demonstrated that the compounds display activity against more than 
one type of virus, presumably any virus that uses the target of the ddBCNAs as part 
of their replication cycle may also be inhibited by them.  
The ddBCNAs are worth pursuing as antiviral compounds as there are currently no 
approved specific treatments for measles infection and the only recommended 
treatment against pox viruses in an emergency is cidofovir. Despite the existence of 
a successful vaccine, measles is still causing outbreaks worldwide and in many cases 
causes severe side effects. For example, in 2013 an outbreak in Swansea led to 
1200 cases of infection, 88 of these individuals required hospital treatment for 
complications and 1 person died due to giant cell pneumonia caused by the 
infection (Griffith, 2013). An antiviral candidate for treatment in these situations 
would be of great benefit.  
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Supplementary material 
1. IC50 calculation graphs (GraphPad) 
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2. Transfection with measles F and H proteins – syncytia formation in the absence of 
virus 
HeLa cells transfected with plasmids containing measles F and H proteins, in the 
absence of virus. Syncytia could be observed 24 hours post transfection.  
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3. Measles IC50 experiment – Image of plates with medium colour change  
Measles IC50 experiments showing that the medium in the wells containing active 
concentrations of the ddBCNAs become acidic (yellow), those where antiviral activity is not 
observed remain neutral (pink). The control compounds to not change the pH/colour of the 
cell medium.  
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4. Cf2642 activity against measles in BJAB cells 
 
 
 
A: mEdATCC, B: mWT Fb 
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ABSTRACT: Dideoxy bicyclic pyrimidine nucleoside analogues (ddBCNAs) with D-chirality have
previously been described by us to inhibit replication of human cytomegalovirus. We herein report for
the ﬁrst time that activity against vaccinia virus (VACV) was achieved using novel L-analogues. A
structure−activity relationship was established: Antiviral activity versus VACV was highest with an ether
side chain with an optimum of n-C9H18−O−n-C5H11. This gave an IC50 of 190 nM, a 60-fold
enhancement over the FDA-approved antiviral cidofovir. Interestingly, L-ddBCNAs also inhibit wild
type measles virus syncytia formation with a TCID50 of 7.5 μM for the lead compound. We propose
that L-ddBCNAs represent signiﬁcant innovative antiviral candidates versus measles and poxviruses, and
we suggest a mechanism of action versus one or more cellular targets that are essential for viral
replication.
■ INTRODUCTION
Small pox variola was declared eradicated in 1979. However,
threats of bioterrorism have reignited interest in ﬁnding suitable
treatments that could be used in case of a small pox outbreak.1
At present, the only drug that has been approved for treatment
of poxviruses is cidofovir.2 This drug is not ideal, as it has severe
side eﬀects. Vaccinia virus (VACV) is a convenient surrogate
poxvirus for the development of new antipoxviral agents in
vitro; VACV strains that are resistant to cidofovir have also
been described.3 Alternative treatments would also be useful for
related infections with molluscum contagiosum virus4 and
human monkey pox virus.5
A number of new potential antipoxviral agents have recently
been reported. These include ST-246, a molecule that targets
the F13L protein of the virus,6 although resistance to this drug
has already been described,7 and terameprocol, which reduces
the spread of the virus by inhibiting the formation of actin tails
at the surface of infected cells (cellular target).8
Human measles is usually a mild childhood infection but is a
known cause of severe pneumonia in developing countries with
over 1 million fatalities worldwide in 2005. The live measles
vaccine is not given to infants under 12 months of age and
maternal measles virus antibodies are lost at 4−9 months, so
individuals are susceptible to the virus before the vaccination is
given.9 The ideal antiviral therapy for measles would be a small
molecule inhibitor that is safe, eﬀective, inexpensive to produce,
and stable. Having a host target may oﬀer the additional beneﬁt
of reducing the emergence of rapid resistance. Ribavirin inhibits
measles virus in vitro only at supraphysiological levels (IC50 =
1160 μM), but it is not eﬀective for the treatment of measles
virus infections.10 At present there are no measles antiviral
drugs on the market.
Previously, we have reported novel potent and selective
inhibitors of human cytomegalovirus based on D-dideoxy
bicyclic furanopyrimidine nucleoside analogues (D-ddBCNAs)
bearing alkyl side chains at the C5-position, with action
suggested early in the virus lifecycle.11 Further potency of D-
ddBCNAs versus VACV12 suggested a non-virus-speciﬁc
mechanism of action and possibly a cellular target.
In order to further increase potency and explore the
structure−activity relationships (SARs), we were interested in
other unusual sugars and particularly in unnatural L-
conﬁguration nucleosides. Indeed, several L-nucleosides have
emerged as potent antiviral agents,13,14 which include β-L-[2-
(hydroxymethyl)-1,3-oxathiolan-4-yl]cytosine (lamivudine,
3TC),15 5-ﬂuoro-β-L-2′,3′-dideoxy-3′-thiacytidine (emtricita-
bine, FTC),16 5-ﬂuoro-β-L-2′,3′-dideoxycytidine (L-FddC),17
β-L-2′-ﬂuoro-5-methylarabinofuranosyluracil (clevudine, L-
FMAU),18 2′,3′-dideoxy-2′,3′-didehydro-β-L-5-ﬂuorocytidine
(elvucitabine, β-L-Fd4C),19 and carbocyclic nucleoside L-
Cd4U.20 Moreover, it has been reported that some of them
have more potent antiviral activity than their D-enantiomers
with reduced toxicity.21,22
Therefore, it was of particular interest to synthesize and
study the antiviral activity of L-dideoxy bicyclic furanopyr-
imidine nucleoside analogues (L-ddBCNAs) with diﬀerent side
chains.
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■ RESULTS AND DISCUSSION
Chemistry. We previously presented the successful syn-
thesis of diﬀerent D-BCNAs.11,23−26 For the D-dideoxy family,
the bicyclic nucleosides were obtained from the key synthon D-
5-iodo-2′,3′-dideoxyuridine (D-IddU) via Sonogashira reaction
with diﬀerent acetylenes followed by an intramolecular
cyclization.11 The described formation of the D-IddU started
from the D-2′-deoxyuridine. We wanted to apply our method-
ology for the synthesis of the L-ddBCNAs. However, the L-2′-
deoxyuridine is not commercially available. Thus, we sought a
new route, illustrated in Scheme 1, starting from L-arabinose 1.
First, reaction of the carbohydrate 1 with cyanamide,
according to the methodology reported by Ladureé et al.,27
aﬀorded the corresponding bicyclic oxazoline 2. Treatment
with methyl propiolate in methanol yielded the 2,2′-anhydro-
nucleoside 3 which via a bromoacetylation reaction28 with
acetyl bromide in acetonitrile gave the nucleoside 4 in good
yield. Reductive β-elimination with activated zinc powder in the
presence of glacial acetic acid29 aﬀorded the 5′-O-acetyl-2′,3′-
didehydro-2′,3′-dideoxyuridine 5, which gave almost quantita-
tively the dideoxy nucleoside 6 upon catalytic hydrogenation.
The L-5-iodo-2′,3′-dideoxyuridine 7 was obtained after ﬁrst
iodination at the C5-position of the base with iodine in the
presence of ammonium cerium(IV) nitrate (CAN)30 and then
deacetylation using sodium methoxide, in 60% yield over two
steps. Palladium-catalyzed Sonogashira coupling of the key
synthon 7 with a series of acetylenes gave the corresponding 5-
alkynyl nucleosides. Addition of copper(I) iodide in situ with
heating of the reaction resulted in their intramolecular
cyclization to aﬀord the desired furanopyrimidine compounds
8a−u with alkyl, aryl, or ether side chains. Indeed, we have
reported in the case of D-deoxy BCNAs that aryl and ether
groups decrease the lipophilicity of nucleosides and improve
their activity.24,26
The alkyl- and arylacetylenes needed for the Sonogashira
reaction were commercially available. However, the ether
alkynes were synthesized following two diﬀerent pathways
depending on the target ethers (Scheme 2). The ﬁrst method
(pathway A) started with the mesylation of alkyn-1-ols to
obtain the intermediates 9a−c, which were then coupled with
diﬀerent alcohols to give the ethers 10a−j. In the second
method (pathway B), the starting materials were alcohols,
which were ﬁrst transformed into the mesylated compounds
11a and 11b and then reacted with selected alkynols to obtain
the ethers 12a and 12b.
The structure and the purity of all L-ddBCNAs were
conﬁrmed by spectroscopic, chromotographic, and analytical
data before they were tested for inhibition of viral infections.
Antiviral Activity. The L-ddBCNAs 8a−u were evaluated
by luciferase assay for their ability to inhibit the early stages of
VACV replication from entry to early gene transcription in RK
13 cells (Table 1), following the initial notion of an eﬀect early
in the viral lifecycle.11
Luciferase inhibition was observed in compounds 8a−h
bearing alkyl and aryl chains, with an optimum at the analogue
8d (n-C9H19 chain). The apparent reduction in activity for
longer alkyl chain derivatives 8e (n-C10H21 chain) and 8f (n-
C12H25 chain) may be caused by their low water solubility
(clogP data of 4.72 and 5.77). This led to the synthesis of ether
compounds with a nonyl chain prior to oxygen (8i−q). The
best reduction of luciferase values was then identiﬁed among
the L-ddBCNAs 8j−m with linear ether side chains, and a SAR
regarding the length of the chain emerged; the best activity was
found for compounds 8k and 8l with butyl and pentyl termini.
Using the length of the side chain in 8l, alteration of the oxygen
atom position toward the base (analogues 8r−u) did not
improve the activity. However, the good luciferase values of
derivatives 8r (n-C8H16−O−n-C6H13 chain) and 8s (n-C4H8−
O−n-C10H21 chain) in spite of high calculated log P data (of
4.89) shows that the lipophilicity of compounds is only one
parameter in their mechanism of action.
These results were followed up for the most potent ether
compounds by plaque assay and determination of IC50 in BSC-
Scheme 1. Synthetic Route to Target L-ddBCNAsa
a(i) NC−NH2, NH4OH, MeOH, rt, 3 days (70%); (ii) methyl
propiolate, EtOH, reﬂux, 3 h (69%); (iii) AcBr, CH3CN, reﬂux, 2 h
(75%); (iv) Zn, glacial AcOH, EtOH, reﬂux, 2 h (53%); (v) H2, Pd/C,
MeOH, rt, 18 h (97%); (vi) (1) I2, CAN, CH3CN, reﬂux, 6 h, (2)
MeONa, MeOH, rt, 18 h (60% over two steps); (vii) acetylenes,
Pd(PPh3)4, CuI, DIPEA, DMF, rt, 18 h and then addition of Et3N,
CuI, 80 °C, 8 h (7−53%).
Scheme 2. Synthetic Routes to Alkynyl Ethers 10a−j and
12a,ba
a(i) MsCl, Et3N, THF, rt, 18 h; (ii) alcohol, NaH, THF, 70 °C, 24 h;
(iii) alkynol, NaH, THF, 60 °C, 36 h.
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1 cells with data shown in Table 2. The eﬀect of L-ddBCNAs on
cell viability (CC50) was tested by measuring ATP levels in live
BSC-1 cells (CellTiter-Glo Luminescent Cell Viability Assay).
The IC50 values from 4 day plaque assays of ethers with
increasing chains (compounds 8i−m) followed a similar SAR
to that identiﬁed for the 2 h luciferase activity data. Both assays
showed the same trend, perhaps implying the same mechanism
of action. The 2 h luciferase assay was used as a predictor of
compound eﬃcacy. Moreover, all L-ddBCNAs with the
exception of 8i performed better than the cidofovir control.
The IC50 of nucleosides 8l and 8m of 0.19 μM is a 60-fold
improvement of activity.
The ether series L-ddBCNAs have a mild eﬀect on BSC-1 cell
viability with a selectivity index of >500 for the lead compound
8l (IC50 = 0.19 μM and CC50 > 100 μM). BSC-1 cells did not
show visible cytotoxicity in phase contrast microscopy after 2 h
in the luciferase reporter assays or after 4 days at CC50 in the
plaque reduction assays. The mild toxicity observed in BSC-1
cells for some compounds does not follow the SAR of the ether
series L-ddBCNAs and is not predictive of antiviral activity. No
cytotoxic eﬀects of L-ddBCNAs 8i−m were observed in HFFF
cells up to 100 μM.
The lead bicyclic nucleoside 8l was then evaluated by
TCID50 assay for its ability to inhibit formation of
cytopathogenic eﬀect of adenovirus, herpesvirus (types 1 and
2), and vaccine and wild type measles viruses (Table 3).
Nucleoside 8l was unable to suppress the cytopathogenic
eﬀects of adeno, herpes simplex, and measles vaccine viruses in
BSC-1 and HFFF cells. However, it inhibits wild type measles
virus syncytia formation by 50% at 7.5 μM. This is a 150-fold
improvement over ribavirin in vitro (IC50 of 1160 μM;
10 Figure
1). When L-ddBCNAs 8i−m of the ether series were tested
versus wild type measles virus in B95a cells (Figure 1), the SAR
was found to follow closely the one found previously for VACV
in RK13 (luciferase assay) and BSC-1 (plaque assay) cells.
Cidofovir, a DNA polymerase inhibitor active against VACV,
shows no eﬀect in this assay, as expected. The ribavirin IC50
(1.2 mM, data not shown) is out of the range of this ﬁgure.
Wortmannin, a furanosteroid inhibitor of PI3 like kinases,31
inhibited measles wild type virus in this assay with an IC50 of 75
μM. (data not shown).
The SAR observed versus both vaccinia and wild type
measles viruses is highly suggestive of a drug interaction with a
speciﬁc target. While measles wild type viruses are only able to
utilize the CD150 receptor found on human and simian B cells,
the vaccine strain of measles virus uses the ubiquitous CD46
receptor. CD150 and CD46 receptors are located in diﬀerent
membrane microdomains, so a diﬀerential eﬀect of L-ddBCNAs
is possible. Membrane microdomains are involved in both
measles and vaccinia virus replication.32,33
Is it possible that the reduction of VACV plaque size herein
observed could be due to an eﬀect on the dissemination of
VACV in cell culture via the “conveyor belt”.34
The phenolic antioxidant terameprocol8 shows a similar
activity proﬁle to L-ddBCNAs, where the target of the antiviral
Table 1. L-ddBCNA Structures, clogP, and Luciferase
Reporter Assay Versus VAVC
compd R clogPa luciferase reporterb (%)
8a n-C6H13 2.60 70.7
8b n-C7H15 3.13 43.2
8c n-C8H17 3.68 41.9
8d n-C9H19 4.19 38.1
8e n-C10H21 4.72 45.7
8f n-C12H25 5.77 96.4
8g Ph-n-Bu 3.64 43.7
8h Ph-n-C5H11 4.17 73.6
8i n-C9H18−O−n-Et 3.30 79.9
8j n-C9H18−O−n-Pr 3.83 46.8
8k n-C9H18−O−n-Bu 4.36 27.5
8l n-C9H18−O−n-C5H11 4.89 27.7
8m n-C9H18−O−n-C6H13 5.42 35.7
8n n-C9H18−O−i-Pr 3.61 79.9
8o n-C9H18−O−s-Bu 4.14 69.9
8p n-C9H18−O−i-Bu 4.23 64.3
8q n-C9H18−O−t-Bu 4.01 70.7
8r n-C8H16−O−n-C6H13 4.89 37.2
8s n-C4H8−O−n-C10H21 4.89 26.1
8t CH2−O−n-C13H27 5.46 43.9
8u n-C13H26−O−Me 5.03 60.5
cidofovir −2.39 94.6
aclogP values calculated with Chemdraw ultra 12.0. bLuciferase
reporter activity as percent of no drug control (100%) in RK13 cells.
Table 2. IC50 and CC50 Data Versus VACV of Selected Ether
L-BCNAs
compd R
IC50
a
(μM)
CC50
a
(μM)
CC50
b
(μM)
8i n-C9H18−O−n-Et 12.9 79.4 >100
8j n-C9H18−O−n-Pr 1.9 89.1 >100
8k n-C9H18−O−n-Bu 1.8 >100 >100
8l n-C9H18−O−n-C5H11 0.19 >100 >100
8m n-C9H18−O−n-C6H13 0.19 74.1 >100
8r n-C8H16−O−n-C6H13 1.7 − −
8s n-C4H8−O−n-C10H21 2.2 − −
8t CH2−O−n-C13H27 3.4 − −
cidofovir 11.5 >100 >100
aIn BSC-1 cells. bIn HFFF cells.
Table 3. TCID50 (μM) of Compound 8l versus Other Viruses
HFFF BSC-1 B95a
adenovirus 5 >50 >50 nd
HSV 1 NCPV 17+ >50 >50 nd
HSV 2 NCPV 132349 >50 >50 nd
measles virus Edmonston (vaccine) nda >50 >50
measles virus wild type mWTFb nda nda 7.5
aCells not susceptible. nd: not determined.
Figure 1. SAR of ether series of L-ddBCNAs versus wild type measles
virus.
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activity is the actin-cytoskeleton, clearly a cellular target. The
main eﬀect is a quantiﬁable reduction in plaque size, just as
observed with the L-ddBCNAs. With a cellular target of this
nature, viral infection in the host would not be completely shut
down, but rather, the dissemination of the virus would be
aﬀected. Inhibiting speciﬁc aspects of a virus lifecycle induces
the virus to develop resistance to the drug by altering the target
of the drug. Targeting cellular processes means that there may
be a possibility of increased toxicity but reduction in the
opportunity for resistance. Antivirals versus cellular targets are
not subject to viral resistance, which may develop quickly with
all virus-targeting drugs.
■ CONCLUSION
In summary, we have described the successful synthesis of
substituted L-dideoxy bicyclic furanopyrimidine nucleoside
analogues in eight steps starting from L-arabinose.
A series of ether-substituted compounds has been shown to
induce suppression of orthopox and measles virus replication in
vitro. Actually, early (2 h p.i.) luciferase reporter assays against
VACV and plaque/syncytium reduction assays against VACV
and measles virus highlighted a SAR regarding the length of the
chain. Notably, the lead L-ddBCNA 8l with n-C9H18−O−n-
C5H11 side chain possessed an IC50 value of 0.19 μM against
VACV, with good selectivity index, and a TCID50 value of 7.5
μM against measles virus.
We propose that interactions between L-ddBCNAs and
membrane microdomains are involved in the inhibition of virus
replication. This kind of host targeting action would prevent
drug resistance issues. Further studies about the mechanism of
action of L-ddBCNAs are currently under investigation in our
laboratory.
■ EXPERIMENTAL SECTION
Chemistry. The numbering of the bicyclic ring follows the
recommended IUPAC nomenclature guidelines. The naming of the
compounds follows IUPAC nomenclature and/or standard accepted
nomenclature for nucleoside chemistry.
All solvents used were anhydrous and used as supplied by Aldrich.
All nucleosides and solid reagents were dried for several hours under
high vacuum over potassium hydroxide. All glassware was oven-dried
at 130 °C for several hours or overnight and allowed to cool in a
desiccator or under a stream of dry nitrogen. TLC was performed on
precoated aluminum-backed plates (60 F-54, 0.2 mm thickness;
supplied by E. Merck AG, Darmstadt, Germany) and spots visualized
by UV (at 254 or 336 nm depending on the compound). Column
chromatography was performed with silica gel supplied by Fisher
(60A, 35−70 μm). 1H and 13C NMR spectra were recorded in a
Bruker spectrometer (500 and 125 MHz, respectively) and
autocalibrated to the deuterated solvent reference peak. All 13C
NMR spectra were proton-decoupled. Coupling constants (J) are
measured in Hertz. The following abbreviations are used in the
assignment of NMR signals: br (broad), s (singlet), d (doublet), t
(triplet), q (quartet), m (multiplet), dd (doublet of doublet), ddd
(doublet of doublet of doublet), dt (doublet of triplet). Low-resolution
and accurate mass analysis were performed by the service at the
Department of Chemistry, University of Wales, Cardiﬀ, U.K., with
electrospray (ES). The ≥95% purity of all the ﬁnal compounds was
conﬁrmed using analytical HPLC analysis. HPLC experiments were
done on a Thermo Fisher Scientiﬁc Spectra System SCM1000
provided with a System Controller SN4000, a pump Spectra System
P4000, and a Spectra UV2000 detector set (detection at 254 nm) and
using a 5 μM Hypersil GOLD (150 × 4.6 mm) reverse phase column
eluting with the indicated mobile phase with a ﬂow rate of 1 mL/min.
2-Amino-[1,2-d]arabinosyloxazole (2). A suspension of L-arabi-
nose 1 (17 g, 113 mmol), cyanamide (10 g, 238 mmol, 2.1 equiv) in
anhydrous MeOH (30 mL), and 6 M NH4OH (5 mL) was stirred at
room temperature for 65 h. The solvents were then evaporated from
the resulting suspension under reduced pressure. The crude was
triturated with MeOH to give a white solid (13.16 g, 66%). 1H NMR
(500 MHz, DMSO-d6): δ 6.27 (2H, br s, NH2), 5.67 (1H, d, J = 5.5
Hz, H-1′), 5.39 (1H, br s, OH-3′), 4.68 (1H, bs, OH-5′), 4.53 (1H, d,
J = 5.5 Hz, H-2′), 4.02−3.99 (1H, m, H-3′), 3.67−3.62 (1H, m, H-4′),
3.31−3.23 (2H, m, H-5′). 13C NMR (125 MHz, DMSO-d6): δ 162.18
(C-2), 99.95 (C-1′), 88.04 (C-2′), 84.58 (C-4′), 75.62 (C-3′), 6.55
(C-5′).
2,2′-Anhydrouridine (3). A solution of 2-amino-[1,2-d]-
arabinosyloxazole (2) (24.0 g, 137.81 mmol) and methyl propiolate
(23 mL, 275.62 mmol, 2 equiv) in 50% aqueous ethanol solution (350
mL) was reﬂuxed for 2 h. The solvent was removed under reduced
pressure to obtain a residue that was dissolved in acetone (400 mL)
and left at 0 °C overnight. The resulting precipitate was ﬁltered and
washed with acetone to obtain a white solid (23.06 g, 74%). 1H NMR
(500 MHz, DMSO-d6): δ 7.83 (1H, d, J = 7.4 Hz, H-5), 6.31 (1H, d, J
= 5.8 Hz, H-1′), 5.87 (1H, d, J = 4.3 Hz, OH-3′), 5.84 (1H, d, J = 7.4
Hz, H-6), 5.20 (1H, d, J = 5.5 Hz, H-2′), 4.97 (1H, t, J = 5.0 Hz, OH-
5′), 4.41−4.37 (1H, m, H-3′), 4.08 (1H, t, J = 4.1 Hz, H-4′), 3.31−
3.25 (1H, m, H-5′), 3.23−3.16 (1H, m, H-5′). 13C NMR (125 MHz,
DMSO-d6): δ 171.10 (C-4), 159.77 (C-2), 136.77 (C-5), 108.59 (C-
6), 89.97 (C-1′), 89.16 (C-4′), 88.71 (C-2′), 74.71 (C-3′), 60.81 (C-
5′).
5′,3′-Diacetyl-2′-bromo-2′-deoxyuridine (4). 2,2′-Anhydrouridine
(3) (22.0 g, 97.26 mmol) was suspended in CH3CN (400 mL) and
heated under reﬂux. Acetyl bromide (64.7 mL, 875.37 mmol, 9 equiv)
was added dropwise. The mixture was stirred at reﬂux for 2 h. The
solvent was removed under reduced pressure, and the residue obtained
was dissolved in dichloromethane (400 mL), washed with a solution,
dried over MgSO4, and evaporated to obtain the title compound as a
brown oil (33.0 g, 87%). 1H NMR (500 MHz, CDCl3): δ 8.99 (1H, s,
NH), 7.45 (1H, d, J = 8.4 Hz, H-6), 6.22 (1H, d, J = 5.21 Hz, H-1′),
5.82 (1H, dd, J = 7.4 Hz, 1.57 Hz, H-5), 5.16 (1H, t, J = 5.04 Hz, H-
3′), 4.61 (1H, t, J = 5.6 Hz, H-2′), 4.46−4.41 (1H, m, H-4′), 4.42−
4.36 (1H, m, H-5′), 3.31−3.25 (1H, m, H-5′), 2.22 (3H, s, CH3), 2.16
(3H, s, CH3).
13C NMR (125 MHz, CDCl3): δ 171.04 (CO), 169.69
(CO), 162.50 (C-4), 149.93 (C-2), 138.92 (C-5), 103.29 (C-6), 91.01
(C-1′), 80.11 (C-4′), 70.76 (C-3′), 62.55 (C-5′), 48.41 (C-2′), 20.78
(CH3), 20.61 (CH3). MS (ES
+) m/z 413−415 (M + Na+).
5′-Acetyl-2′,3′-dideoxy-2′,3′-dehydrouridine (5). Glacial acetic
acid (1.5 mL, 26.20 mmol, 1.6 equiv) was added dropwise at 0 °C
to a stirred suspension of zinc (4.20 g, 64.23 mmol, 4 equiv) and 5′,3′-
diacetyl-2′-bromo-2′-deoxyuridine 4 (6.2 g, 15.85 mmol) in ethanol
(195 mL). The resulting mixture was stirred at room temperature until
the TLC (3% methanol in ethyl acetate) showed that the starting
material had completely reacted. The mixture was ﬁltered through a
sintered funnel packed with Celite to remove zinc, and triethylamine
(1.4 mL) was added to the ﬁltrate. The solvent was removed under
reduced pressure and the residue obtained was extracted with ethyl
acetate (250 mL). Removal of solvent under reduced pressure gave a
brown oil which was puriﬁed by column chromatography (1%
methanol in ethyl acetate) to aﬀord the title compound as a yellow oil
(2.24 g, 53%). 1H NMR (500 MHz, DMSO-d6): δ 11.37 (1H, br s,
NH), 7.44 (1H, d, J = 8.1 Hz, H-6), 6.79 (1H, m, H-1′), 6.42 (1H, dt,
J = 6.1 Hz, 1.7 Hz, H-3′), 6.00 (1H, ddd, J = 6.1 Hz, 2.3 Hz, 1.3 Hz, H-
2′), 5.66 (1H, d, J = 8.1 Hz, H-5), 4.97 (1H, m, H-4′), 4.17 (2H, d, J =
3.4 Hz, H-5′), 2.00 (3H, s, CH3). 13C NMR (125 MHz, DMSO-d6): δ
170.07 (CO), 163.09 (C-4), 150.72 (C-2), 140.52 (C-6), 133.85 (C-
3′), 126.37 (C-2′), 101.90 (C-5), 89.34 (C-1′), 83.80 (C-4′), 64.48
(C-5′), 20.56 (CH3). MS (ES+) m/z 275 (M + Na+).
5′-Acetyl-2′,3′-dideoxyuridine (6). To a solution of 5′-acetyl-2′,3-
dideoxy-2′,3′-dehydrouridine (5) (4.88 g, 19.34 mmol) in anhydrous
methanol (80 mL) was added 10% Pd on carbon (0.23 g, 5% wt). The
mixture was stirred under a hydrogen atmosphere for 6 h. The reaction
was monitored by NMR analysis. The mixture was then ﬁltered
through a Celite pad. The solvent was removed under reduced
pressure to aﬀord the title compound as a pale brown oil (5.0 g, 99%).
1H NMR (500 MHz, DMSO-d6): δ 11.27 (1H, br s, NH), 7.66 (1H, d,
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J = 8.0 Hz, H-6), 5.98 (1H, dd, J = 7.2 Hz, 3.8 Hz, H-1′), 5.64 (1H, d,
J = 8.0 Hz, H-5), 4.21−4.18 (3H, m, H-5′, H-4′), 2.34−2.22 (1H, m,
H-2′), 2.06−1.95 (5H, m, H-2′, H-3′, CH3), 1.81−1.72 (1H, m, H-3′).
13C NMR (125 MHz, DMSO-d6): δ 170.21 (CO), 163.08 (C-4),
150.48 (C-2), 140.43 (C-6), 101.51 (C-5), 85.24 (C-1′), 77.95 (C-4′),
64.88 (C-5′), 30.8 (C-2′), 25.56 (C-3′), 20.60 (CH3). MS (ES+) m/z
277 (M + Na+).
L-5-Iodo-2′,3′-dideoxyuridine (7). To a solution of 5′-acetyl-2′,3′-
dideoxyuridine (6) (2.00 g, 7.86 mmol) in anhydrous acetonitrile (8
mL) were added I2 (1.20 g, 4.72 mmol, 0.6 equiv) and CAN (2.16 g,
3.94 mmol, 0.5 equiv). The mixture was stirred at reﬂux for 3 h
(progress of the reaction was monitored by TLC using 1% methanol
in ethyl acetate as the eluent). The solvent was removed under
reduced pressure and the residue was dissolved in dichloromethane
(300 mL) and washed with a saturated solution of sodium bicarbonate.
The two phases were separated, and the organic layer was dried over
sodium sulfate and evaporated under reduced pressure to obtain the
5′-acetyl-2′,3′-dideoxy-5-iodouridine intermediate as a brown solid.
This residue was dissolved in MeOH (60 mL), and MeONa (0.63 g,
11.66 mmol, 1.5 equiv) was added. The solution was stirred for 21 h.
As the reaction was not complete, an additional amount of MeONa
(0.21 g, 3.88 mmol, 0.5 equiv) was added, and the resulting mixture
was stirred for further 1 h. Amberlite IR 120 was then added until the
pH of the solution became 6.0 and the mixture was ﬁltered. The
solution was evaporated and the solid was washed with diethyl ether to
yield the title compound (oﬀ-white solid, 1.57 g, 60%). 1H NMR (500
MHz, DMSO-d6): δ 11.27 (1H, br s, NH), 8.57 (1H, s, H-6), 5.87
(1H, dd, J = 6.6 Hz, 2.8 Hz, H-1′), 5.22 (1H, t, J = 5.0 Hz, OH), 4.05
(1H, m, H-4′), 4.72−4.53 (2H, m, H-5′), 2.26−1.83 (4H, m, H-2′,
H3′). 13C NMR (125 MHz, DMSO-d6): δ 160.59 (C-4), 150.05 (C-
2), 145.19 (C-6), 85.83 (C-1′), 82.10 (C-4′), 68.11 (C-5), 61.20 (C-
5′), 32.45 (C-2′), 23.93 (C-3′). Reverse HPLC eluting with H2O/
MeOH (gradient from 90:10 to 0:100 in 30 min): tR = 08.96 min.
General Procedure A: Formation of Mesylates (9a−c and
11a,b). To a stirred solution of alcohol in THF (0.7 mL/mmol) was
added triethylamine (1.3 equiv) and methanesulfonyl chloride (1.3
equiv) dropwise at 0 °C under a nitrogen atmosphere. The reaction
was left stirring for 18 h at room temperature. The solvent was
evaporated; water was added to the reaction mixture and then
extracted with dichloromethane. The organic layer was dried over
sodium sulfate, ﬁltered, and evaporated under reduced pressure to
obtain the desired product.
10-Undecynyl Mesylate (9a). Procedure A was carried out using
10-undecyn-1-ol (10 g, 59.42 mmol) to give the desired compound as
a yellow oil (15.5 g, 100%). 1H NMR (500 MHz, CDCl3): δ 4.26 (2H,
t, J = 7.1 Hz, OCH2), 3.05 (3H, s, CH3), 2.20 (2H, dt, J = 7.1 Hz, 2.6
Hz, α-CH2), 1.97 (H, t, J = 2.5 Hz, HCC), 1.60−1.28 (14H, m, 7 ×
CH2).
9-Decynyl Mesylate (9b). Procedure A was carried out using 9-
decyn-1-ol (2.50 g, 16.21 mmol) to give the desired compound as a
yellow oil (3.10 g, 82%). 1H NMR (500 MHz, CDCl3): δ 4.24 (2H, t, J
= 6.6 Hz, OCH2), 3.02 (3H, s, CH3), 2.01 (2H, dt, J = 7.1 Hz, J = 2.6
Hz, α-CH2), 1.96 (1H, t, J = 2.6 Hz, HCC), 1.58−1.31 (12H, m, 6
× CH2).
13C NMR (125 MHz, CDCl3): δ 84.64 (HCC), 70.13
(OCH2), 68.19 (HCC), 37.39 (CH3), 29.13, 2 × 28.89 (double
intensity), 28.57, 28.39, 25.38 (6 × CH2), 18.38 (α-CH2).
14-Pentadecynyl Mesylate (9c). Procedure A was carried out using
14-pentadecyn-1-ol30 (1.80 g, 8.022 mmol) to give the desired
compound as a pale brown oil (2.07 g, 85%). 1H NMR (500 MHz,
CDCl3): δ 4.24 (2H, t, J = 6.1 Hz, OCH2), 3.01 (3H, s, CH3), 2.20
(2H, dt, J = 7.1 Hz, 2.7 Hz, HCCCH2), 1.95 (1H, t, J = 2.7 Hz,
HCC), 1.76 (2H, m, CH2), 1.56 (2H, m, CH2), 1.43 (2H, m, CH2),
1.40−1.23 (16H, m, 8 × CH2). 13C NMR (125 MHz, CDCl3): δ 84.79
(HCC), 70.18 (OCH2), 68.03 (HCC), 37.65 (CH3), 29.59,
29.55, 29.47, 29.40, 29.13, 29.09, 28.89, 28.85, 28.74, 28.49, 25.73 (11
× CH2), 18.63 (CCCH2).
Tridecyl Mesylate (11a). Procedure A was carried out using 1-
tridecanol (5.00 g, 24.95 mmol) to give the desired compound as a
pale brown oil (6.39 g, 93%). 1H NMR (500 MHz, CDCl3): δ 4.25
(2H, t, J = 6.6 Hz, OCH2), 3.03 (3H, s, CH3), 1.76 (2H, m,
OCH2CH2), 1.47−1.23 (20H, m, 10 × CH2), 0.91 (3H, t, J = 7.0 Hz,
CH3).
13C NMR (125 MHz, CDCl3): δ 70.19 (OCH2), 37.38 (CH3),
31.91, 29.64, 29.62, 29.60, 29.51, 29.41, 29.34, 29.13, 29.03, 25.42 (10
× CH2), 22.68 (CH2CH3), 14.10 (CH3).
Decyl Mesylate (11b). Procedure A was carried out using 1-decanol
(8.6 mL, 45 mmol) to give the desired compound as a pale brown oil
(11.00 g, 100%). 1H NMR (500 MHz, CDCl3): δ 4.24 (2H, t, J = 6.6
Hz, OCH2), 3.03 (3H, s, CH3), 1.78 (2H, m, OCH2CH2), 1.46−1.23
(14H, m, 7 × CH2), 0.91 (3H, t, J = 7.0 Hz, CH3).
13C NMR (125
MHz, CDCl3): δ 70.19 (OCH2), 37.38 (CH3), 31.85, 29.46, 29.41,
29.25, 29.13, 29.02, 25.42 (7 × CH2), 22.66 (CH2CH3), 14.08 (CH3).
General Procedure B: Synthesis of Alkyloxyalkyne (10a−j
and 12a,b). To a stirred solution of alcohol (1.2 equiv) in THF (2.5
mL/mmol) at 0 °C under a nitrogen atmosphere was added slowly
NaH (dispersion, 60%, 1.25 equiv). After 5 min, the mesylate was
added and the reaction was heated at 70 °C for 19 h. Then the solvent
was removed under reduced pressure and the residue was dissolved in
dichloromethane (100 mL) and washed with water (2 × 100 mL). The
organic layer was dried over sodium sulfate, evaporated to dryness, and
puriﬁed by column chromatography to obtain the desired compound.
11-Ethyloxy-1-undecyne (10a). Procedure B was carried out using
ethanol (0.448 g, 9.735 mmol) and 10-undecynyl mesylate (9a) (2.04
g, 8.28 mmol). The crude product was puriﬁed by column
chromatography (5% ethyl acetate in hexane) to give the product
10a as a colorless oil (0.87 g, 69%). 1H NMR (500 MHz, CDCl3): δ
3.54−3.36 (4H, m, OCH2), 2.20 (2H, m, α-CH2), 1.95 (1H, ddd, J =
3.1 Hz, 2.2 Hz, 1.0 Hz, HCC), 1.64−1.27 (8H, m, 4 × CH2), 1.21
(3H, dt, J = 7.4 Hz, 1.1 Hz, CH3).
13C NMR (125 MHz, CDCl3): δ
84.76 (CH-C), 70.76 (OCH2), 68.03 (CH−C), 66.04 (OCH2CH3),
29.81, 29.77, 29.43, 29.03, 28.72, 28.48, 28.25 (7 × CH2), 18.39 (α-
CH2), 15.24 (CH3).
11-Propyloxy-1-undecyne (10b). Procedure B was carried out
using propanol (0.75 mL, 9.936 mmol) and 10-undecynyl mesylate
(9a) (2.04 g, 8.28 mmol). The crude product was puriﬁed by column
chromatography (5% ethyl acetate in hexane) to give the product 10b
as a colorless oil (1.06 g, 61%). 1H NMR (500 MHz, CDCl3): δ 3.50−
3.36 (4H, m, 2 × OCH2), 2.21 (2H, m, α-CH2), 1.95 (1H, ddd, J = 3.1
Hz, 2.2 Hz, 1.0 Hz, HCC), 1.65−1.48 (8H, m, 4 × CH2), 1.46−1.20
(8H, m, 4 × CH2), 0.94 (3H, dt, J = 7.4 Hz, 1.1 Hz, CH3).
13C NMR
(125 MHz, CDCl3): δ 84.75 (CH-C), 72.55 (OCH2), 70.94 (OCH2),
68.01 (CH−C), 29.78, 29.69, 29.42, 29.03, 28.72, 28.48, 26.17, 22.94
(8 × CH2), 18.38 (α-CH2), 10.57 (CH3).
11-Butyloxy-1-undecyne (10c). Procedure B was carried out using
butanol (0.77 mL, 8.44 mmol) and 10-undecynyl mesylate (9a) (1.60
g, 6.49 mmol). The crude product was puriﬁed by column
chromatography (5% ethyl acetate in hexane) to give the product
10c as a colorless oil (0.83 g, 57%). 1H NMR (500 MHz, CDCl3): δ
3.47−3.38 (4H, m, 2 × OCH2), 2.20 (2H, m, α-CH2), 1.95 (1H, t, J =
2.6 Hz, HCC), 1.65−1.26 (18H, m, 9 × CH2), 0.94 (3H, t, J = 6.5
Hz, CH3).
13C NMR (125 MHz, CDCl3): δ 84.75 (HCC), 70.93
(OCH2), 70.63 (OCH2), 68.01 (HCC), 31.88, 29.77, 2 × 29.42
(double intensity), 29.03, 28.72, 28.48, 26.17, 19.37 (9 × CH2), 18.38
(α-CH2), 13.91 (CH3).
11-Pentyloxy-1-undecyne (10d). Procedure B was carried out
using pentanol (0.84 mL, 7.79 mmol) and 10-undecynyl mesylate (9a)
(1.60 g, 6.49 mmol). The crude product was puriﬁed by column
chromatography (5% ethyl acetate in hexane) to give the product 10d
as a colorless oil (1.00 g, 66%). 1H NMR (500 MHz, CDCl3): δ 3.48
(4H, m, 2 × OCH2), 2.20 (2H, dt, J = 7.1 Hz, 2.7 Hz, α-CH2), 1.95
(1H, t, J = 2.7 Hz, HCC), 1.67−1.22 (20H, m, 10 × CH2), 0.92
(3H, t, J = 7.3 Hz, CH3).
13C NMR (125 MHz, CDCl3): δ 84.75
(HCC), 70.96 (OCH2), 70.94 (OCH2), 68.01 (HCC), 31.59,
29.78, 29.49, 29.36, 29.04, 28.73, 28.49, 28.39, 26.17, 22.65 (10 ×
CH2) 18.39 (α-CH2), 14.03 (CH3).
11-Hexyloxy-1-undecyne (10e). Procedure B was carried out using
hexanol (0.98 mL, 7.79 mmol) and 10-undecynyl mesylate (9a) (1.60
g, 6.49 mmol). The crude product was puriﬁed by column
chromatography (5% ethyl acetate in hexane) to give the product
10e as a colorless oil (0.98 g, 60%). 1H NMR (500 MHz, CDCl3): δ
3.41 (4H, t, J = 6.7 Hz, 2 × OCH2), 2.19 (2H, dt, J = 7.1 Hz, 2.6 Hz,
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α-CH2), 1.95 (1H, t, J = 2.7 Hz, HCC), 1.65−1.24 (22H, m, 11 ×
CH2), 0.92 (3H, t, J = 7.2 Hz, CH3).
13C NMR (125 MHz, CDCl3): δ
84.75 (HCC), 70.97 (OCH2), 70.93 (OCH2), 68.02 (HCC),
31.73, 29.78, 2 × 29.76 (double intensity), 29.43, 29.03, 28.73, 28.48,
26.18, 25.88, 22.63 (11 × CH2), 18.39 (α-CH2), 14.03 (CH3).
11-(Isopropyloxy)-1-undecyne (10f). Procedure B was carried out
using 2-propanol (0.372 mL, 4.86 mmol) and 10-undecynyl mesylate
(9a) (1.00 g, 4.06 mmol). The mixture was heated for a total of 24 h at
70 °C, with a further 0.75 equiv of NaH added after the ﬁrst 7 h. After
treatment, the crude product was puriﬁed by column chromatography
(5% ethyl acetate in hexane) to give the product 10f as a colorless oil
(0.484 g, 56%). 1H NMR (500 MHz, CDCl3): δ 3.56 (1H, m, J = 6.1
Hz, CH), 3.41 (2H, t, J = 6.8 Hz, OCH2), 2.20 (2H, dt, J = 7.1 Hz, 2.7
Hz, α-CH2), 1.96 (1H, t, J = 2.7 Hz, HCC), 1.58−1.52 (4H, m, 2 ×
CH2), 1.44−1.29 (10H, m, 5 × CH2), 1.18 (3H, s, CH3), 1.17 (3H, s,
CH3).
13C NMR (125 MHz, CDCl3): δ 84.81 (HCC), 71.23
(OCH), 68.23 (OCH2), 68.02 (HCC), 30.18, 2 × 29.44 (double
intensity), 29.04, 28.73, 28.48, 26.18 (7 × CH2), 22.16 (double
intensity, 2 × CH3), 18.39 (α-CH2).
11-(sec-Butyloxy)-1-undecyne (10g). Procedure B was carried out
using sec-butanol (0.447 mL, 4.87 mmol) and 10-undecynyl mesylate
(9a) (1.00 g, 4.06 mmol). The crude product was puriﬁed by column
chromatography (5% ethyl acetate in hexane) to give the product 10g
as a colorless oil (0.372 g, 38%). 1H NMR (500 MHz, CDCl3): δ
3.50−3.29 (3H, m, CH2OCH), 2.20 (2H, dt, J = 7.1 Hz, 2.6 Hz, α-
CH2), 1.96 (1H, t, J = 2.7 Hz, HCC), 1.62−1.27 (16H, m, 8 ×
CH2), 1.14 (3H, d, J = 6.1 Hz, CHCH3), 0.92 (3H, t, J = 7.4 Hz,
CH2CH3).
13C NMR (125 MHz, CDCl3): δ 84.79 (HCC), 76.59
(OCH), 68.47 (OCH2), 68.01 (HCC), 30.21, 29.44 (double
intensity), 29.26, 29.04, 28.74, 28.49, 26.18 (8 × CH2), 19.30
(CHCH3), 18.39 (α-CH2), 9.86 (CH2CH3).
11-(Isobutyloxy)-1-undecyne (10h). Procedure B was carried out
using isobutanol (0.450 mL, 4.87 mmol) and 10-undecynyl mesylate
(9a) (1.00 g, 4.06 mmol). The mixture was heated for a total of 28 h at
70 °C, with a further 0.75 equiv of NaH and 0.6 equiv of isobutanol
added after the ﬁrst 18 h. After the treatment, the crude product was
puriﬁed by column chromatography (5% ethyl acetate in hexane) to
give the product 10h as a light yellow oil (0.480 g, 52%). 1H NMR
(500 MHz; CDCl3): δ 3.41 (2H, t, J = 6.7 Hz, CH2CH2O), 3.19 (2H,
d, J = 6.7 Hz, OCH2CH), 2.20 (2H, dt, J = 7.1 Hz, 2.6 Hz, α-CH2),
1.96 (1H, t, J = 2.7 Hz, HCC), 1.92−1.85 (1H, m, CH), 1.59−1.53
(4H, m, 2 × CH2), 1.36−1.28 (13H, m, 2 × CH2), 0.93 (3H, s, CH3),
0.91 (3H, s, CH3).
13C NMR (125 MHz, CDCl3): δ 84.80 (HCC),
77.86 (OCH2CH), 71.07 (OCH2CH2), 68.03 (HCC), 29.76, 2 ×
29.44 (double intensity), 29.05, 28.75, 28.50, 28.45, 26.15, 25.89,
22.63 (10 × CH2), 18.39 (α-CH2), 14.04 (CH3).
11-(tert-Butyloxy)-1-undecyne (10i). Procedure B was carried out
using tert-butanol (0.925 mL, 9.74 mmol) and 10-undecynyl mesylate
(9a) (2.00 g, 8.12 mmol). The mixture was heated for a total of 28 h at
70 °C, with a further 0.75 equiv of NaH added after the ﬁrst 18 h.
After treatment, the crude product was puriﬁed by column
chromatography (5% ethyl acetate in hexane) to give the product
10i as a colorless oil (0.478 g, 26%). 1H NMR (500 MHz; CDCl3): δ
3.41 (2H, t, J = 6.7 Hz, OCH2), 2.21 (2H, dt, J = 7.1 Hz, 2.7 Hz, α-
CH2), 1.96 (1H, t, J = 2.7 Hz, HCC), 1.58−1.52 (4H, m, 2 × CH2),
1.41−1.28 (10H, m, 5 × CH2), 1.21 (9H, s, 3 × CH3). 13C NMR (125
MHz, CDCl3): δ 84.81 (HCC), 72.97 (OC(CH3)3), 70.97 (OCH2),
68.05 (HCC), 29.79, 2 × 29.45 (double intensity), 29.06, 28.76,
28.50, (6 × CH2), 27.61 (3 × CH3), 26.20, 18.42 (2 × CH2).
10-Hexyloxy-1-decyne (10j). Procedure B was carried out using
hexanol (1.2 mL, 9.29 mmol) and 9-decynyl mesylate (9b) (1.8 g, 7.74
mmol). The mixture was heated for a total of 55 h at 70 °C, with a
further 1.2 equiv of NaH added after the ﬁrst 19 h and again 0.5 equiv
of NaH and 0.5 equiv of 9-decynyl mesylate (9b) added after 40 h.
After treatment, the crude product was puriﬁed by column
chromatography (5% ethyl acetate in hexane) to obtain the product
10j as a pale brown oil (0.572 g, 35%). 1H NMR (500 MHz, CDCl3):
δ 3.41 (4H, t, J = 6.6 Hz, 2 × OCH2), 2.20 (2H, dt, J = 7.1 Hz, 2.6 Hz,
α-CH2), 1.96 (1H, t, J = 2.7 Hz, HCC), 1.70−1.26 (20H, m, 10 ×
CH2), 0.92 (3H, t, J = 7.2 Hz, CH3).
13C NMR (125 MHz, CDCl3): δ
84.75 (HCC), 70.98 (OCH2), 70.91 (OCH2), 68.04 (HCC),
31.73, 2 × 29.76 (double intensity), 29.34, 29.05, 28.70, 28.47, 26.15,
25.89, 22.63 (10 × CH2), 18.39 (α-CH2), 14.04 (CH3).
15-Methoxy-1-pentadecyne (10k). Procedure B was carried out
using methanol (0.36 mL, 8.76 mmol) and 14-pentadecynyl mesylate
(9c) (2.04 g, 6.74 mmol) at 60 °C for 4 h. Some methanol (1.3 equiv)
and NaH (1.35 equiv) were then added, and the mixture was heated
further 3 h at 60 °C. After treatment, the crude product was puriﬁed
by column chromatography (5% ethyl acetate in hexane) to obtain the
product 10k as a colorless oil (1.11 g, 69%). 1H NMR (500 MHz,
CDCl3): δ 3.40 (2H, J = 6.7 Hz, OCH2), 3.35 (3H, s, CH3), 2.20 (2H,
dt, J = 7.1 Hz, 2.7 Hz, CH2CC), 1.95 (1H, t, J = 2.7 Hz, HCC),
1.64−1.50 (6H, m, 3 × CH2), 1.46−1.23 (16H, m, 8 × CH2). 13C
NMR (125 MHz, CDCl3): δ 84.79 (HCC), 72.98 (OCH2), 68.01
(HCC), 58.51 (CH3), 31.58, 2 × 29.66 (double intensity), 29.61,
29.58, 29.50, 29.11, 28.76, 28.50, 26.14, 22.65 (11 × CH2), 18.40
(CH2CC).
3-Tridecyloxy-1-propyne (12a). Procedure B was carried out using
2-propyn-1-ol (0.56 g, 10.00 mmol) and tridecyl mesylate (11a) (4.2
g, 15.0 mmol). The mixture was heated for a total of 36 h at 60 °C
with a further 1.0 equiv of NaH added after the ﬁrst 24 h. After
treatment, the crude product was puriﬁed by column chromatography
(5% ethyl acetate in hexane) to give the desired compound as a pale
brown oil (0.90 g, 22%). 1H NMR (500 MHz, CDCl3): δ 4.17 (2H, d,
J = 2.6 Hz, OCH2CC), 3.54 (2H, t, J = 7.1 Hz, OCH2CH2), 2.43
(1H, t, J = 2.6 Hz, HCC), 1.62 (2H, m, OCH2CH2), 1.62−1.22
(20H, m, 10 × CH2), 0.91 (3H, t, J = 7.1 Hz, CH3).
13C NMR (125
MHz, CDCl3): δ 80.09 (HCC), 73.97 (HCC), 70.32
(OCH2CH2), 57.99 (OCH2CC), 31.92, 29.67, 29.65, 29.60, 29.57,
29.52, 29.44, 29.35, 26.21, 26 09 (10 × CH2), 22.68 (α-CH2), 14.10
(CH3).
6-Decyloxy-1-hexyne (12b). Procedure B was carried out using
hexyn-1-ol (0.66 mL, 6.11 mmol) and decyl mesylate (11b) (2.17 g,
9.17 mmol, 1.5 equiv). The mixture was heated for a total of 90 h at 60
°C, with a further 1 equiv of NaH added after the ﬁrst 24 h and
another 1 equiv of NaH and 1 equiv of decyl mesylate added after 48
h. After treatment, the crude product was puriﬁed by column
chromatography (5% ethyl acetate in hexane) to obtain the desired
compound as a brown oil (1.2 g, 82%). 1H NMR (500 MHz, CDCl3):
δ 3.47−3.36 (4H, m, 2 × OCH2), 2.24 (2H, dt, J = 7.0 Hz, J = 2.6 Hz,
CH2), 1.96 (1H, t, J = 2.6 Hz, HCC), 1.76−1.53 (6H, m, 3 × CH2),
1.38−1.21 (14H, m, 7 × CH2), 0.89 (3H, t, J = 7.0 Hz, CH3). 13C
NMR (125 MHz, CDCl3): δ 84.36 (HCC), 71.01 (OCH2), 70.17
(OCH2), 68.29 (HCC), 31.90, 29.80, 29.32, 29.11, 28.81, 26.20,
25.28, 24.85, 22.67, 22.64 (10 × CH2), 18.23 (α-CH2), 14.08 (CH3).
General Procedure C: Synthesis of 3-(2′,3′-Dideoxy-ribo-β-L-
furanosyl)-6-substituted-furo[2,3-d]pyrimidin-2(3H)-one ana-
logues (8a−u). To a solution of L-5-iodo-2′,3′-dideoxyuridine 7 in
DMF (5.5 mL/mmol) was added the alkyne (3 equiv), tetrakis-
(triphenylphosphine) palladium(0) (0.1 equiv), CuI (0.2 equiv), and
DIPEA (2 equiv). The mixture was stirred at room temperature for 16
h, and further CuI (0.2 equiv) and triethylamine (5.5 mL/mmol) were
added. The mixture was stirred at 80 °C for 8 h. The solvent was
removed under high vacuum and the residue was puriﬁed by ﬂash
column chromatography.
3-(2′,3′-Dideoxy-ribo-β-L-furanosyl)-6-hexylfuro[2,3-d]pyrimidin-
2(3H)-one (8a). Procedure C was carried out using 1-octyne (0.29 g,
2.66 mmol), which gave the desired alkyne intermediate (0.130 g,
0.374 mmol, 34%). This compound was dissolved in DMF (5 mL),
and to this solution Et3N (5 mL) and CuI (0.014 g, 0.075 mmol, 0.2
equiv) were added. The resulting solution was heated at 80 °C for 8 h.
Solvent was removed under high vacuum. The product 8a was then
obtained as an oﬀ-white solid (0.026 g, 22%) after puriﬁcation by
preparative thin layer chromatography using 20% chloroform in ethyl
acetate as the eluent. 1H NMR (500 MHz, CDCl3): δ 876 (1H, s, H-
4), 6.20 (1H, m, H-1′), 6.15 (1H, s, H-5), 4.31 (1H, m, H-4′), 4.16
(1H, ddd, J = 11.9 Hz, 4.2 Hz, 2.9 Hz, H-5′), 3.89 (1H, ddd, J = 11.9
Hz, 3.0 Hz, H-5′), 2.69−2.54 (3H, m, CH2, H-2′), 2.25−2.16 (1H, m,
H-2′), 1.99−1.90 (2H, m, H-3′), 1.72 (2H, m, J = 7.1 Hz, CH2), 1.41−
1.22 (6H, m, 3 × CH2), 0.90 (3H, t, J = 6.3 Hz, CH3).
13C NMR (125
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MHz, CDCl3): δ 171.74 (C-7a), 159.47 (C-6), 155.05 (C-2), 135.98
(C-4), 107.25 (C-4a), 99.10 (C-5), 89.00 (C-1′), 82.93 (C-4′), 62.81
(C-5′), 33.79 (C-2′), 31.43, 28.69, 28.25 (3 × CH2), 26.78 (C-3′),
23.89, 22.50 (2 × CH2), 14.01 (CH3). MS (ES
+) m/z 321 (M + H+).
Accurate mass: C17H25N2O4 requires 321.1814, found 321.1824.
Reverse HPLC eluting with H2O/MeOH (gradient from 100:0 to
0:100 in 25 min): tR = 21.81 min.
3-(2′,3′-Dideoxy-ribo-β-L-furanosyl)-6-septylfuro[2,3-d]pyrimidin-
2(3H)-one (8b). Procedure C was carried out using 1-nonyne (0.275 g,
2.22 mmol), which gave, after puriﬁcation by ﬂash column
chromatography (5% methanol in ethyl acetate), the product 8b as
an oﬀ-white solid (0.128 g, 53%). 1H NMR (500 MHz, CDCl3): δ
8.84 (1H, s, H-4), 6.20 (1H, dd, J = 6.7 Hz, 2.5 Hz, H-1′), 6.16 (1H, s,
H-5), 4.30 (1H, m, H-4′), 4.18 (1H, m, H-5′), 3.91 (1H, m, H-5′),
3.16 (1H, t, J = 5.4 Hz, OH), 2.70−2.54 (3H, m, α-CH2, H-2′), 2.21
(1H, m, H-2′), 1.97 (2H, m, H-3′), 1.69 (2H, m, J = 7.1 Hz, CH2),
1.44−1.22 (8H, m, 4 × CH2), 0.90 (3H, t, J = 6.5 Hz, CH3). 13C NMR
(125 MHz, CDCl3): δ 171.72 (C-7a), 159.43 (C-6), 155.06 (C-2),
136.12 (C-4), 107.25 (C-4a), 99.15 (C-5), 89.00 (C-1′), 83.01(C-4′),
62.74 (C-5′), 33.81 (C-2′), 31.68, 28.98, 28.91, 28.25 (4 × CH2),
26.83 (C-3′), 23.87, 22.59 (2 × CH2), 14.04 (CH3). MS (ES+) m/z
335 (100%, M + H+), 373 (9%, M + K+), 398 (81%, M + CH3CN +
Na+). Accurate mass: C18H27N2O4 requires 335.1971, found 335.1958.
Reverse HPLC eluting with H2O/MeOH (gradient from 100:0 to
10:90 in 15 min and with 10:90 for 10 min): tR = 17.91 min.
3-(2′,3′-Dideoxy-ribo-β-L-furanosyl)-6-octylfuro[2,3-d]pyrimidin-
2(3H)-one (8c). Procedure C was carried out using 1-decyne (0.31 g,
2.22 mmol). After puriﬁcation by ﬂash column chromatography (2%
methanol in ethyl acetate) to obtain a pale brown oil and trituration
with ethyl acetate, the product 8c was obtained as an oﬀ-white solid
(0.060 g; 23%). 1H NMR (500 MHz, DMSO-d6): δ 8.83 (1H, s, H-4),
6.42 (1H, s, H-5), 5.97 (1H, m, H-1′), 5.15 (1H, t, J = 5.1 Hz, OH),
4.14 (1H, m, H-4′), 3.80 (1H, m, H-5′), 3.60 (1H, m, H-5′), 2.61 (2H,
t, J = 7.2 Hz, α-CH2), 2.42 (1H, m, H-2′), 1.97 (1H, m, H-2′), 1.88−
1.56 (2H, m, H-3′), 1.6 (2H, m, J = 7.5 Hz, CH2), 0.84 (3H, t, J = 6.7
Hz, CH3).
13C NMR (125 MHz, DMSO-d6): δ 170.99 (C-7a), 158.01
(C-6), 153.76 (C-2), 137.00 (C-4), 107.33 (C-4a), 99.72 (C-5), 88.02
(C-1′), 83.00 (C-4′), 61.33 (C-5′), 33.03 (C-2′), 31.16, 28.55, 28.50,
28.29, 27.29 (5 × CH2), 26.35 (C-3′), 23.61, 22.00 (2 × CH2), 13.88
(CH3). MS (ES
+) m/z 349 (M + H+). Accurate mass: C19H29N2O4
requires 349.2127, found 349.2141. Reverse HPLC eluting with H2O/
MeOH (gradient from 100:0 to 0:100 in 25 min and then at 0:100 for
5 min): tR = 26.04 min.
3-(2′,3′-Dideoxy-ribo-β-L-furanosyl)-6-nonylfuro[2,3-d]pyrimidin-
2(3H)-one (8d). Procedure C was carried out using 1-undecyne (0.405
g, 2.66 mmol), which gave, after puriﬁcation by ﬂash column
chromatography (40% dichloromethane in ethyl acetate), the product
8d as an oﬀ-white solid (0.150 g, 47%). 1H NMR (500 MHz, CDCl3):
δ 8.76 (1H, s, H-4), 6.20 (1H, dd, J = 6.8 Hz, J = 2.6 Hz, H-1′), 6.15
(1H, s, H-5), 4.31 (1H, m, H-4′), 4.17 (1H, m, H-5′), 3.91 (1H, m, H-
5′), 2.83 (1H, t, J = 5.5 Hz, OH), 2.70−2.55 (3H, m, α-CH2, H-2′),
2.24 (1H, m, H-2′), 1.95 (2H, m, H-3′), 1.70 (2H, m, J = 7.2 Hz,
CH2), 1.45−1.21 (12H, m, 6 × CH2), 0.90 (3H, t, J = 6.7 Hz, CH3).
13C NMR (125 MHz, CDCl3): δ 171.75 (C-7a), 159.49 (C-6), 155.02
(C-2), 135.89 (C-4), 107.22 (C-4a), 99.07(C-5), 88.99 (C-1′), 82.88
(C-4′), 62.87 (C-5′), 33.78 (C-2′), 31.84, 29.45, 29.26, 29.04, 28.26 (5
× CH2), 26.83 (C-3′), 23.91, 22.64 (2 × CH2), 14.08 (CH3). MS
(ES+) m/z 363 (53%, M + H+), 426 (80%, M + CH3CN + Na
+).
Accurate mass: C20H31N2O4 requires 363.2284, found 363.2289.
Reverse HPLC eluting with H2O/MeOH (gradient from 100:0 to
10:90 in 15 min and then at 10:90 for 10 min): tR = 21.57 min.
3-(2′,3′-Dideoxy-ribo-β-L-furanosyl)-6-decylfuro[2,3-d]pyrimidin-
2(3H)-one (8e). Procedure C was carried out using 1-dodecyne (0.516
g, 3.11 mmol), which gave, after puriﬁcation by ﬂash column
chromatography (40% dichloromethane in ethyl acetate), the product
8e as an oﬀ-white solid (0.100 g, 33%). 1H NMR (500 MHz, CDCl3):
δ 8.75 (1H, s, H-4), 6.21 (1H, m, H-1′), 6.15 (1H, s, H-5), 4.32 (1H,
m, H-4′), 4.17 (1H, m, H-5′), 3.90 (1H, m, H-5′), 2.86 (1H, t, J = 5.4
Hz, OH), 2.68−2.57 (3H, m, α-CH2, H-2′), 2.21 (1H, m, H-2′), 1.96
(2H, m, H-3′), 1.72 (2H, m, J = 7.0 Hz, CH2), 1.44−1.21 (14H, m, 7
× CH2), 9.00 (3H, t, J = 6.4 Hz, CH3).
13C NMR (125 MHz, CDCl3):
δ 171.75 (C-7a), 159.49 (C-6), 155.03 (C-2), 135.90 (C-4), 107.23
(C-4a), 99.07 (C-5), 88.99 (C-1′), 82.88 (C-4′), 62.86 (C-5′), 33.78
(C-2′), 31.87, 29.56, 29.50, 29.29, 29.27, 29.05, 28.26 (7 × CH2),
26.83 (C-3′), 23.91, 22.66 (2 × CH2), 14.09 (CH3). MS (ES+) m/z
377 (16%, M + H+), 399 (6%, M + Na+), 415 (8%, M + K+), 440
(100%, M + CH3CN + Na
+). Accurate mass: C21H33N2O4 requires
377.2440, found 377.2426. Reverse HPLC eluting with H2O/MeOH
(gradient from 100:0 to 0:100 in 30 min and then at 0:100 for 5 min):
tR = 33.00 min.
3-(2′,3′-Dideoxy-ribo-β-L-furanosyl)-6-dodecylfuro[2,3-d]-
pyrimidin-2(3H)-one (8f). Procedure C was carried out using 1-
tetradecyne (0.345 g, 1.77 mmol), which gave, after puriﬁcation by
ﬂash column chromatography (40% dichloromethane in ethyl acetate),
the product 8f as an oﬀ-white solid (0.100 g, 42%). 1H NMR (500
MHz, CDCl3): δ 8.77 (1H, s, H-4), 6.23 (1H, dd, J = 6.6 Hz, 2.5 Hz,
H-1′), 6.16 (1H, s, H-5), 4.32 (1H, m, H-4′), 4.18 (1H, m, H-5′), 3.90
(1H, m, H-5′), 2.90 (1H, br s, OH), 2.67−2.56 (3H, m, α-CH2, H-2′),
2.21 (1H, m, H-2′), 1.94 (2H, m, H-3′), 1.69 (2H, m, J = 7.5 Hz,
CH2), 1.43−1.20 (18H, m, 9 × CH2), 9.00 (3H, t, J = 6.5 Hz, CH3).
13C NMR (125 MHz, CDCl3): δ 171.74 (C-7a), 159.48 (C-6), 155.03
(C-2), 135.95 (C-4), 107.24 (C-4a), 99.08 (C-5), 88.99 (C-1′), 82.91
(C-4′), 62.83 (C-5′), 33.79 (C-2′), 31.90, 29.64, 29.61, 29.51, 29.33,
29.28, 29.06, 28.26 (9 × CH2), 26.84 (C-3′), 23.90, 22.67 (2 × CH2),
14.10 (CH3). MS (ES
+) m/z 405 (M + H+). Accurate mass:
C23H37N2O4 requires 405.2753, found 405.2739. Reverse HPLC
eluting with H2O/MeOH (gradient from 100:0 to 10:90 in 15 min,
then at 10:90 for 10 min and another gradient from 10:90 to 0:100 in
5 min): tR = 28.99 min.
3-(2′,3′-Dideoxy-ribo-β-L-furanosyl)-6-(4-n-butylphenyl)furo[2,3-
d]pyrimidin-2(3H)-one (8g). Procedure C was carried out using 4-n-
butylphenylacetylene (0.351 g, 0.39 mL, 2.22 mmol). The obtained
residue was puriﬁed by column chromatography (5% methanol in
dichloromethane) to give the product 8g as an oﬀ-white solid (0.110 g,
40%). 1H NMR (500 MHz, CDCl3): δ 8.90 (1H, s, H-4), 7.63 (2H, d,
J = 8.2 Hz, Ph), 7.22 (2H, d, J = 8.3 Hz, Ph), 6.71 (1H, s, H-5), 6.25
(1H, dd, J = 6.7 Hz, 2.3 Hz, H-1′), 4.32 (1H, m, H-4′), 4.2 (1H, m, H-
5′), 3.92 (1H, m, H-5′), 2.92 (1H, t, J = 5.0 Hz, OH), 2.70−2.59 (3H,
m, α-CH2, H-2′), 2.25 (1H, m, H-2′), 2.00 (2H, m, H-3′), 1.65 (2H,
m, CH2), 1.39 (2H, m, CH2), 0.98 (3H, t, J = 6.6 Hz, CH3).
13C NMR
(125 MHz, CDCl3): δ 171.58 (C-7a), 155.58 (C-6), 155.00 (C-2),
144.80 (C-para Ph), 136.79 (C-4), 128.96 (Ph), 125.98 (C-ipso Ph),
124.82 (Ph), 107.81 (C-4a), 97.22 (C-5), 89.11 (C-1′), 83.03 (C-4′),
62.79 (C-5′), 35.53 (CH2), 33.85 (C-2′), 33.36 (CH2), 23.83 (C-3′),
22.32 (CH2), 13.91 (CH3). MS (ES
+) m/z 369 (44%, M + H+), 407
(70%, M + K+), 432 (50%, M + CH3CN + Na
+). Accurate mass:
C21H25N2O4 requires 369.1814, found 369.1830. Reverse HPLC
eluting with H2O/MeOH (gradient from 100:0 to 0:100 in 35 min): tR
= 33.29 min.
3-(2′,3′-Dideoxy-ribo-β-L-furanosyl)-6-(4-n-pentylphenyl)furo-
[2,3-d]pyrimidin-2(3H)-one (8h). Procedure C was carried out using
4-n-pentylphenylacetylene (0.382 g, 0.43 mL, 2.18 mmol). The
obtained residue was puriﬁed by column chromatography (5%
methanol in dichloromethane) to give the product 8h as an oﬀ-
white solid (0.102 g, 36%). 1H NMR (500 MHz, CDCl3): δ 8.80 (1H,
s, H-4), 7.68 (2H, d, J = 8.2 Hz, Ph), 7.26 (2H, d, J = 8.3 Hz, Ph), 6.70
(1H, s, H-5), 6.26 (1H, dd, J = 6.67 Hz, 2.26 Hz, H-1′), 4.35 (1H, m,
H-4′), 4.20 (1H, m, H-5′), 3.90 (1H, m, H-5′), 2.65 (3H, m, α-CH2,
H-2′), 2.30−2.18 (2H, m, H-2′, OH), 1.95 (2H, m, H-3′), 1.61 (2H,
m, CH2), 1.42−1.29 (4H, m, 2 × CH2), 0.91 (3H, t, J = 6.5 Hz, CH3).
13C NMR (125 MHz, CDCl3): δ 170.10 (C-7a), 156.00 (C-6), 155.50
(C-2), 144.91 (C-para Ph), 136.36 (C-4), 128.99 (Ph), 126.00 (C-ipso
Ph), 124.87 (Ph), 125.98, 106.60 (C-4a), 97.04 (C-5), 89.10 (C-1′),
82.76 (C-4′), 63.04 (C-5′), 35.83 (C-2′), 33.78, 31.45, 30.92 (3 ×
CH2), 23.91 (C-3′), 22.51 (CH2), 13.99 (CH3). MS (ES+) m/z 383
(14%, M + H+), 405 (3%, M + Na+), 421 (7%, M + K+), 446 (62%, M
+ CH3CN + Na
+). Accurate mass: C22H27N2O4 requires 383.1971,
found 383.1988. Reverse HPLC eluting with H2O/MeOH (gradient
from 100:0 to 10:90 in 15 min and then at 10:90 for 10 min): tR =
21.00 min.
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3-(2′,3′-Dideoxy-ribo-β-L-furanosyl)-6-ethyloxynonylfuro[2,3-d]-
pyrimidin-2(3H)-one (8i). Procedure C was carried out using 11-
ethyloxy-1-undecyne (10a) (0.348 g, 1.775 mmol). The obtained
residue was puriﬁed by column chromatography (4% methanol in
ethyl acetate) to give the product 8i as an oﬀ-white solid (0.102 g,
42%). 1H NMR (500 MHz, CDCl3): δ 8.71 (s, 1H, H-4), 6.21 (1H,
dd, J = 6.7 Hz, 2.2 Hz, H-1′), 6.13 (1H, s, H-5), 4.33−4.28 (1H, m, H-
4′), 4.18−4.43 (1H, m, H-5′), 3.86 (1H, dt, J = 11.9 Hz, 3.8 Hz, H-5′),
3.49 (2H, q, J = 7.0 Hz, CH3CH2O), 3.42 (2H, t, J = 6.8 Hz,
CH2CH2O), 2.65 (2H, t, J = 7.4 Hz, α-CH2), 2.63−2.58 (1H, m, H-
2′), 2.53 (1H, t, J = 4.7 Hz, OH), 2.26−2.19 (1H, m, H-2′), 1.99−1.90
(2H, m, H-3′), 1.72−1.65 (2H, m, β-CH2), 1.62−1.54 (2H, m,
CH2CH2O), 1.40−1.25 (10H, m, 5 × CH2), 1.22 (3H, t, J = 7.0 Hz,
CH3).
13C NMR (125 MHz, CDCl3): δ 171.79 (C-7a), 159.47 (C-6),
154.98 (C-2), 135.70 (C-4), 107.15 (C-4a), 99.02 (C-5), 88.98 (C-1′),
82.76 (C-4′), 70.77 (CH2CH2O), 66.06 (CH3CH2O), 62.93 (C-5′)
33.76 (C-2′), 29.69, 29.39, 29.35, 29.09, 28.88, 28.21, 26.73, 26.15 (8
× CH2), 23.91(C-3′), 15.24 (CH3). MS (ES+) m/z 429 (M + Na+).
Accurate mass: C22H34N2O5Na requires 429.2365, found 429.2365.
Reverse HPLC eluting with H2O/MeOH (gradient from 100:0 to
0:100 in 35 min and then at 0:100 for 10 min): tR = 33.25 min.
3-(2′,3′-Dideoxy-ribo-β-L-furanosyl)-6-propyloxynonylfuro[2,3-
d]pyrimidin-2(3H)-one (8j). Procedure C was carried out using 11-
propyloxy-1-undecyne (10b) (0.466 g, 2.218 mmol). The obtained
residue was puriﬁed by column chromatography (4% methanol in
ethyl acetate) to give the product 8j as an oﬀ-white solid (0.105 g,
34%). 1H NMR (500 MHz, CDCl3): δ 8.84 (1H, s, H-4), 6.18 (1H,
dd, J = 6.5 Hz, 2.0 Hz, H-1′), 6.15 (1H, s, H-5), 4.31−4.26 (1H, m, H-
4′), 4.18−4.10 (1H, m, H-5′), 3.87 (1H, dt, J = 12.0 Hz, 3.0 Hz, H-5′),
3.50 (1H, m, OH), 3.40 (2H, t, J = 6.7 Hz, OCH2), 3.40 (2H, t, J = 6.8
Hz, OCH2), 2.63−2.54 (3H, m, α-CH2, H-2′), 2.21−2.16 (1H, m, H-
2′), 2.02−1.89 (2H, m, H-3′), 1.69−1.50 (6H, m, 3 × CH2), 1.40−
1.21 (10H, m, 5 × CH2), 0.92 (3H, t, J = 7.4 Hz, CH3).
13C NMR
(125 MHz, CDCl3): δ 171.68 (C-7a), 159.33 (C-6), 155.10 (C-2),
136.32 (C-4), 107.24 (C-4a), 99.21 (C-5), 89.00 (C-1′), 83.10 (C-4′),
72.55 (OCH2), 70.88 (OCH2), 62.57 (C-5′), 33.82 (C-2′), 29.74,
29.39 (double intensity), 29.13, 28.93, 28.20, 26.76, 26.13 (8 × CH2),
23.83 (C-3′), 22.91 (CH2), 10.56 (CH3). MS (ES+) m/z 443 (M +
Na+). Accurate mass: C23H36N2O5 requires 443.2522, found 443.2539.
Reverse HPLC eluting with H2O/MeOH (gradient from 100:0 to
0:100 in 35 min and then at 0:100 for 10 min): tR = 34.04 min.
3-(2′,3′-Dideoxy-ribo-β-L-furanosyl)-6-butyloxynonylfuro[2,3-d]-
pyrimidin-2(3H)-one (8k). Procedure C was carried out using 11-
butyloxy-1-undecyne 10c (0.497 g, 2.217 mmol). The obtained residue
was puriﬁed by column chromatography (4% methanol in ethyl
acetate) to give the product 8k as an oﬀ-white solid (0.090 g, 28%). 1H
NMR (500 MHz, CDCl3): δ 8.76 (1H, s, H-4), 6.20 (1H, dd, J = 6.7
Hz, 2.4 Hz, H-1′), 6.14 (1H, s, H-5), 4.34−4.28 (1H, m, H-4′), 4.20−
4.12 (1H, m, H-5′), 3.88 (1H, dt, J = 11.9 Hz, 3.5 Hz, H-5′), 3.41 (4H,
q, J = 6.1 Hz, 2 × OCH2), 2.88 (1H, t, J = 4.5 Hz, OH), 2.64 (2H, t, J
= 7.3 Hz, α-CH2), 2.60 (1H, m, H-2′), 2.24−2.18 (1H, m, H-2′),
1.99−1.90 (2H, m, H-3′),1.71−1.61 (2H, m, β-CH2), 1.61−1.50 (4H,
m, 2 × CH2), 1.44−1.24 (12H, m, 6 × CH2), 0.93 (3H, t, J = 7.4 Hz,
CH3).
13C NMR (CDCl3): δ 171.75 (C-7a), 159.42 (C-6), 155.02 (C-
2), 135.94 (C-4), 107.18 (C-4a), 99.09 (C-5), 88.99 (C-1′), 82.90 (C-
4′), 70.94 (OCH2), 70.66 (OCH2), 62.80 (C-5′), 33.79 (C-2′), 31.85,
29.76, 29.39, 29.37, 29.12, 28.92, 28.21, 26.75, 26.14 (9 × CH2), 23.87
(C-3′), 19.36 (CH2), 13.93 (CH3). MS (ES+) m/z 457 (M + Na+).
Accurate mass: C24H39N2O5 requires 435.2859, found 435.2839.
Reverse HPLC eluting with H2O/MeOH (gradient from 100:0 to
0:100 in 35 min and then at 0:100 for 10 min): tR = 35.15 min.
3-(2′,3′-Dideoxy-ribo-β-L-furanosyl)-6-pentyloxynonylfuro[2,3-d]-
pyrimidin-2(3H)-one (8l). Procedure C was carried out using 11-
pentyloxy-1-undecyne (10d) (0.465 g, 1.952 mmol). The obtained
residue was puriﬁed by column chromatography (4% methanol in
ethyl acetate) to give the product 8l as an oﬀ-white solid (0.102 g,
35%). 1H NMR (500 MHz, CDCl3): δ 8.76 (1H, s, H-4), 6.20 (1H,
dd, J = 6.7 Hz, 2.5 Hz, H-1′), 6.14 (1H, s, H-5), 4.33−4.29 (1H, m, H-
4′), 4.18−4.13 (1H, m, H-5′), 3.88 (1H, dt, J = 12.0 Hz, 3.9 Hz, H-5′),
3.41 (4H, dt, J = 6.7 Hz, 0.9 Hz, 2 × OCH2), 2.90 (1H, br s, OH),
2.64 (2H, t, J = 7.5 Hz, α-CH2), 2.63−2.56 (1H, m, H-2′), 2.25−2.18
(1H, m, H-2′), 2.00−1.91 (2H, m, H-3′), 1.72−1.63 (2H, m, β-CH2),
1.61−1.55 (4H, m, 2 × CH2), 1.35−1.28 (14H, m, 7 × CH2), 0.91
(3H, t, J = 6.9 Hz, CH3).
13C NMR (125 MHz, CDCl3): δ 171.75 (C-
7a), 159.41 (C-6), 155.01 (C-2), 135.96 (C-4), 107.18 (C-4a), 99.09
(C-5), 88.99 (C-1′), 82.91 (C-4′), 70.98 (OCH2), 70.94 (OCH2),
62.79 (C-5′), 33.79 (C-2′), 29.76, 29.45, 29.39, 29.38, 29.12, 28.92,
28.36, 28.21, 26.75, 26.14 (10 × CH2), 23.87 (C-3′), 22.54 (CH2),
14.04 (CH3). MS (ES
+) m/z 449 (11%, M + H+), 471 (M + Na+).
Accurate mass: C25H41N2O5 requires 449.3015, found 449.3033.
Reverse HPLC eluting with H2O/MeOH (gradient from 100:0 to
0:100 in 35 min): tR = 26.13 min.
3-(2′,3′-Dideoxy-ribo-β-L-furanosyl)-6-hexyloxynonylfuro[2,3-d]-
pyrimidin-2(3H)-one (8m). Procedure C was carried out using 11-
hexyloxy-1-undecyne (10e) (0.448 g, 1.775 mmol). The obtained
residue was puriﬁed by column chromatography (4% methanol in
ethyl acetate) to give the product 8m as an oﬀ-white solid (0.120 g,
44%). 1H NMR (500 MHz, CDCl3): δ 8.76 (1H, s, H-4), 6.21 (1H,
dd, J = 6.7 Hz, 2.3 Hz, H-1′), 6.14 (1H, s, H-5), 4.33−4.29 (1H, m, H-
4′), 4.19−4.13 (1H, m, H-5′), 3.87 (1H, dt, J = 12.0 Hz, 3.9 Hz, H-5′),
3.41 (4H, dt, J = 6.7 Hz, 1.3 Hz, 2 × OCH2), 2.87 (1H, t, J = 4.9 Hz,
OH), 2.64 (2H, t, J = 7.3 Hz, α-CH2), 2.63−2.57 (1H, m, H-2′),
2.24−2.19 (1H, m, H-2′), 1.98−1.92 (2H, m, H-3′), 1.71−1.65 (2H,
m, β-CH2), 1.69−1.53 (4H, m, 2 × CH2), 1.38−1.26 (16H, m, 8 ×
CH2), 0.90 (3H, t, J = 6.9 Hz, CH3).
13C NMR (125 MHz, CDCl3): δ
171.75 (C-7a), 159.41 (C-6), 155.01 (C-2), 135.93 (C-4), 107.17 (C-
4a), 99.08 (C-5), 88.98 (C-1′), 82.89 (C-4′), 71.00 (OCH2), 70.94
(OCH2), 62.80 (C-5′), 33.79 (C-2′), 31.71, 29.76, 29.73, 29.39, 29.38,
29.12, 28.92, 28.21, 26.75, 26.15, 25.86 (11 × CH2), 23.87 (C3′),
22.62 (CH2), 14.03 (CH3). MS (ES
+) m/z 463 (5%, M + H+), 485
(100%, M + Na+), 501 (8%, M + K+). Accurate mass: C26H43N2O5
requires 463.3172, found 463.3163. Reverse HPLC eluting with H2O/
MeOH (gradient from 100:0 to 10:90 in 15 min, then at 10:90 for 10
min and another gradient from 10:90 to 0:100 in 5 min): tR = 26.91
min.
3-(2′,3′-Dideoxy-ribo-β-L-furanosyl)-6-isopropyloxynonylfuro-
[2,3-d]pyrimidin-2(3H)-one (8n). Procedure C was carried out using
11-isopropyloxy-1-undecyne (10f) (0.280 g, 1.330 mmol). The
obtained residue was puriﬁed by column chromatography (4%
methanol in ethyl acetate) to give the product 8n as an oﬀ-white
solid (0.019 g, 10%). 1H NMR (500 MHz, CDCl3): δ 8.80 (1H, s, H-
4), 6.20 (1H, dd, J = 6.6 Hz, 2.2 Hz, H-1′), 6.14 (1H, s, H-5), 4.30
(1H, ddt, J = 9.2 Hz, 6.0 Hz, 3.0 Hz, H-4′), 4.16 (1H, d, J = 11.8 Hz,
H-5′), 3.88 (1H, dd, J = 12.0 Hz, 3.2 Hz, H-5′), 3.55 (1H, m, J = 6.1
Hz, OCH), 3.40 (2H, t, J = 6.7 Hz, OCH2), 3.16 (1H, br s, OH), 2.63
(2H, t, J = 7.5 Hz, α-CH2), 2.60−2.57 (1H, m, H-2′), 2.23−2.18 (1H,
m, H-2′), 1.97−1.93 (2H, m, H-3′), 1.67 (2H, m, J = 7.2 Hz, β-CH2),
1.55 (2H, m, J = 7.0 Hz, OCH2CH2), 1.38−1.26 (10H, m, 5 × CH2),
1.17 (3H, s, CH3), 1.15 (3H, s, CH3).
13C NMR (125 MHz, CDCl3):
δ 171.72 (C-7a), 159.38 (C-6), 155.05 (C-2), 136.10 (C-4), 107.21
(C-4a), 99.15 (C-5), 89.00 (C-1′), 83.00 (C-4′), 71.29 (OCH), 68.24
(OCH2), 62.68 (C-5′), 33.83 (C-2′), 30.16, 29.41, 29.39, 29.13, 28.92,
28.21, 26.75, 26.19 (8 × CH2), 23.85 (C-3′), 22.19 (double intensity,
2 × CH3). MS (ES
+) m/z 443 (100%, M + Na+), 863 (30%, MM +
Na+). Reverse HPLC eluting with H2O/CH3CN (elution with mixture
0:100 for 35 min, then gradient from 0:100 to 90:10 in 2 min and at
90:10 for 3 min): tR = 36.18 min.
3-(2′,3′-Dideoxy-ribo-β-L-furanosyl)-6-sec-butyloxynonylfuro[2,3-
d]pyrimidin-2(3H)-one (8o). Procedure C was carried out using 11-
secbutyloxy-1-undecyne (10g) (0.197 g, 0.877 mmol). The obtained
residue was puriﬁed by column chromatography (4% methanol in
ethyl acetate) to give the product 8o as an oﬀ-white solid (0.032 g,
36%). 1H NMR (500 MHz, CDCl3): δ 8.84 (1H, s, H-4), 6.19 (1H,
dd, J = 6.6 Hz, 2.3 Hz, H-1′), 6.14 (1H, s, H-5), 4.33−4.29 (1H, m, H-
4′), 4.16 (1H, d, J = 11.0 Hz, H-5′), 3.87 (1H, dt, J = 12.0 Hz, 3.9 Hz,
H-5′), 3.49−3.28 (4H, m, OCH2, OH, OCH), 2.63 (2H, t, J = 7.6 Hz,
α-CH2), 2.59−2.56 (1H, m, H-2′), 2.23−2.18 (1H, m, H-2′), 2.02−
1.90 (2H, m, H-3′), 1.69−1.63 (2H, m, β-CH2), 1.59−1.25 (14H, m, 7
× CH2), 1.12 (3H, d, J = 6.1 Hz, CH3), 0.09 (3H, t, J = 7.4 Hz, CH3).
13C NMR (125 MHz, CDCl3): δ 171.70 (C-7a), 159.33 (C-6), 155.08
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(C-2), 136.28 (C-4), 107.21 (C-4a), 99.19 (C-5), 89.00 (C-1′), 83.09
(C-4′), 76.64 (OCH), 68.48 (OCH2), 62.58 (C-5′), 33.86 (C-2′),
30.19, 29.41 (double intensity), 29.25, 29.12, 28.94, 28.22, 26.77,
26.22 (9 × CH2), 23.82 (C-3′), 19.31 (CH3), 09.87 (CH3). MS (ES+)
m/z 457 (100%, M + Na+), 891 (51%, MM + Na+). Reverse HPLC
eluting with H2O/CH3CN (mixture 0:100 for 35 min, then gradient
from 0:100 to 90:10 in 2 min and with 90:10 for 3 min): tR = 36.71
min.
3-(2′,3′-Dideoxy-ribo-β-L-furanosyl)-6-isobutyloxynonylfuro[2,3-
d]pyrimidin-2(3H)-one (8p). Procedure C was carried out using 11-
isobutyloxy-1-undecyne (10h) (0.297 g, 1.319 mmol). The obtained
residue was puriﬁed by column chromatography (4% methanol in
ethyl acetate) to give the product 8p as an oﬀ-white solid (0.047 g,
41%). 1H NMR (500 MHz, CDCl3): δ 8.69 (1H, s, H-4), 6.22 (1H,
dd, J = 6.7 Hz, 2.5 Hz, H-1′), 6.13 (1H, s, H-5), 4.34−4.29 (1H, m, H-
4′), 4.16 (1H, d, J = 11.5 Hz, H-5′), 3.88 (1H, d, J = 12.0 Hz, H-5′),
3.41 (2H, t, J = 6.7 Hz, OCH2), 3.19 (2H, d, J = 6.7 Hz, OCH2), 2.65
(2H, t, J = 7.6 Hz, α-CH2), 2.63−2.59 (1H, m, H-2′), 2.42 (1H, s,
OH), 2.25−2.20 (1H, m, H-2′), 1.97−1.92 (2H, m, H-3′), 1.87 (1H,
m, CH), 1.69 (2H, m, β-CH2), 1.58 (2H, m, OCH2CH2), 1.36−1.31
(10H, m, 5 × CH2), 0.92 (3H, s, CH3), 0.91 (3H, s, CH3).
13C NMR
(125 MHz, CDCl3): δ 171.79 (C-7a), 159.51 (C-6), 154.97 (C-2),
135.67 (C-4), 107.18 (C-4a), 99.01 (C-5), 88.99 (C-1′), 82.75 (C-4′),
77.87 (OCH2), 71.07 (OCH2), 62.98 (C-5′), 33.76 (C-2′), 29.74,
29.40 (double intensity), 29.14, 28.93 (5 × CH2), 28.43 (CH), 28.24,
26.77, 26.16 (3 × CH2), 23.93 (C-3′), 19.31 (double intensity, 2 ×
CH3). Reverse HPLC eluting with H2O/MeOH (gradient from 90:10
to 0:100 in 40 min and then at 0:100 for 5 min): tR = 37.72 min.
3-(2′,3′-Dideoxy-ribo-β-L-furanosyl)-6-tert-butyloxynonylfuro-
[2,3-d]pyrimidin-2(3H)-one (8q). Procedure C was carried out using
11-tert-butyloxy-1-undecyne (10i) (0.296 g, 1.319 mmol). The
obtained residue was puriﬁed by column chromatography (4%
methanol in ethyl acetate) to give the product 8q as an oﬀ-white
solid (0.011 g, 7%). 1H NMR (500 MHz, CDCl3): δ 8.67 (1H, s, H-4),
6.22 (1H, dd, J = 6.7 Hz, 2.5 Hz, H-1′), 6.13 (1H, t, J = 1.1 Hz, H-5),
4.34−4.29 (1H, m, H-4′), 4.16 (1H, d, J = 12 Hz, H-5′), 3.88 (1H, dt,
J = 11.9 Hz, 3.5 Hz, H-5′), 3.35 (2H, t, J = 6.8 Hz, OCH2), 2.66 (2H,
t, J = 7.5 Hz, α-CH2), 2.64−2.59 (1H, m, H-2′), 2.27−2.21 (1H, m, H-
2′, OH), 1.99−1.89 (2H, m, H-3′), 1.72−1.66 (2H, m, β-CH2), 1.55−
1.50 (2H, m, OCH2CH2), 1.39−1.28 (10H, m, 5 × CH2), 1.21 (9H, s,
3 × CH3).
13C NMR (125 MHz, CDCl3): δ 171.81 (C-7a), 159.53 (C-
6), 154.94 (C-2), 135.54 (C-4), 107.16 (C-4a), 98.98 (C-5), 88.99 (C-
1′), 82.68 (C-4′), 72.48 (OC(CH3)3), 63.04 (C-5′), 61.69 (OCH2),
33.75 (C-2′), 30.72, 29.44, 29.39, 29.11, 28.89, 28.22 (6 × CH2), 27.61
(3 × CH3), 26.73, 26.22 (2 × CH2), 23.96 (C-3′). MS (ES+) m/z 457
(100%, M + Na+), 891 (13%, MM + Na+). Reverse HPLC eluting with
H2O/MeOH (gradient from 90:10 to 0:100 in 40 min and with 0:100
for 5 min): tR = 36.23 min.
3-(2′,3′-Dideoxy-ribo-β-L-furanosyl)-6-hexyloxyoctylfuro[2,3-d]-
pyrimidin-2(3H)-one (8r). Procedure C was carried out using 10-
hexyloxy-1-decyne 10j (0.352 g, 1.48 mmol, 2.5 equiv). The obtained
residue was puriﬁed by column chromatography (4% methanol in
ethyl acetate) to give the product 8r as an oﬀ-white solid (0.080 g,
30%). 1H NMR (500 MHz, CDCl3): δ 8.73 (1H, s, H-4), 6.21 (1H,
dd, J = 6.1 Hz, 1.8 Hz, H-1′), 6.13 (1H, s, H-5), 4.34−4.27 (1H, m, H-
4′), 4.19−4.12 (1H, m, H-5′), 3.88 (1H, dt, J = 7.6 Hz, 4.0 Hz, H-5′),
3.41 (4H, t, J = 6.1 Hz, 2 × OCH2), 2.71 (1H, t, J = 4.7 Hz, OH),
2.67−2.56 (3H, m, α-CH2, H-2′), 2.26−2.18 (1H, m, H-2′), 2.00−
1.91 (2H, m, H-3′), 1.77−1.64 (2H, m, β-CH2), 1.62−1.52 (4H, m, 2
× CH2), 1.42−1.23 (14H, m, 7 × CH2), 0.90 (3H, t, J = 6.8 Hz, CH3).
13C NMR (125 MHz, CDCl3): δ 171.76 (C-7a), 159.44 (C-6), 154.99
(C-2), 135.83 (C-4), 107.17 (C-4a), 99.05 (C-5), 88.99 (C-1′), 82.83
(C-4′), 71.00 (OCH2), 70.89 (OCH2), 62.88 (C-5′), 33.77 (C-2′),
31.71, 29.73, 29.32, 29.19 (double intensity), 28.94, 28.23, 26.78,
26.14, 25.86 (10 × CH2), 23.90 (C-3′), 22.62 (CH2), 14.04 (CH3).
MS (ES+) m/z 449 (11%, M + H+), 471 (64%, M + Na+), 487 (100%,
M + K+). Accurate mass: C25H41N2O5 requires 449.3015, found
449.3033. Reverse HPLC eluting with H2O/MeOH (gradient from
100:0 to 0:100 in 35 min and then at 0:100 for 10 min): tR = 38.17
min.
3-(2′,3′-Dideoxy-ribo-β-L-furanosyl)-6-methyloxytridecylfuro[2,3-
d]pyrimidin-2(3H)-one (8s). Procedure C was carried out using 15-
methoxy-1-pentadecyne (10k) (0.423 g, 1.774 mmol). The obtained
residue was puriﬁed by column chromatography (3% methanol in
ethyl acetate) to give the product 8s as an oﬀ-white solid (0.050 g,
19%). 1H NMR (500 MHz, CDCl3): δ 8.75 (1H, s, H-4), 6.20 (1H,
dd, J = 6.7 Hz, 2.4 Hz, H-1′), 6.15 (1H, s, H-5), 4.35−4.27 (1H, m, H-
4′), 4.19−4.13 (1H, m, H-5′), 3.88 (1H, dt, J = 12.0 Hz, 4.0 Hz, H-5′),
3.38 (2H, t, J = 6.7 Hz, OCH2), 2.35 (3H, s, OCH3), 2.84 (1H, J = 4.8
Hz, OH), 2.64 (2H, t, J = 7.5, α-CH2), 2.62−2.57 (1H, m, H-2′),
2.24−2.15 (1H, m, H-2′), 1.98−1.92 (1H, m, H-3′), 1.71−1.65 (2H,
m, β-CH2), 1.61−1.54 (2H, m, γCH2), 1.40−1.23 (18H, m, 9 × CH2).
13C NMR (125 MHz, CDCl3): δ 171.75 (C-7a), 159.47 (C-6), 155.02
(C-2), 135.90 (C-4), 107.22 (C-4a), 99.08 (C-5), 88.99 (C-1′), 82.88
(C-4′), 72.99 (OCH2), 62.83 (C-5′), 58.52 (OCH3), 33.77 (C-2′),
29.63, 29.56, 29.54, 29.48 (double intensity), 29.45 (double intensity),
29.23, 29.01, 28.25, 26.81, 26.12 (12 × CH2), 23.91 (C-3′). MS (ES+)
m/z 449 (100%, M + H+), 471 (68%, M + Na+), 487 (84%, M + K+).
Accurate mass: C25H40N2O5 requires 449.3015, found 449.2997.
Reverse HPLC eluting with H2O/MeOH (gradient from 100:0 to
10:90 in 15 min, then at 10:90 for 5 min and another gradient from
10:90 to 0:100 in 5 min): tR = 24.29 min.
3-(2′,3′-Dideoxy-ribo-β-L-furanosyl)-6-tridecyloxymethylfuro[2,3-
d]pyrimidin-2(3H)-one (8t). Procedure C was carried out using 3-
tridecyloxy-1-propyne 12a (0.352 g, 1.776 mmol). The obtained
residue was puriﬁed by column chromatography (4% methanol in
ethyl acetate) to give the product 8t as an oﬀ-white solid (0.024 g,
10%). 1H NMR (500 MHz, CDCl3): δ 8.87 (1H, s, H-4), 6.45 (1H, s,
H-5), 6.21 (1H, dd, J = 6.8 Hz, 2.0 Hz, H-1′), 4.48 (2H, s,
CH2OCH2CH2), 4.34−4.29 (1H, m, H-4′), 4.20−4.15 (1H, m, H-5′),
3.90−3.87 (1H, m, H-5′), 3.56 (2H, t, J = 6.65 Hz, OCH2CH2), 2.68−
2.57 (1H, m, H-2′), 2.28−2.18 (1H, m, H-2′), 1.98−1.89 (2H, m, H-
3′), 1.67−1.58 (2H, m, J = 6.9 Hz, OCH2CH2), 1.40−1.22 (20H, m,
10 × CH2), 0.90 (3H, t, J = 6.7 Hz, CH3).
13C NMR (125 MHz,
CDCl3): δ 171.78 (C-7a), 159.36 (C-6), 154.75 (C-2), 137.60 (C-4),
107.62 (C-4a), 102.36 (C-5), 88.13 (C-1′), 82.92 (C-4′), 71.49
(OCH2CH2), 64.95 (CH2OCH2CH2), 62.79 (C-5′), 33.79 (C-2′),
31.91 (double intensity), 29.65, 29.61, 29.58 (double intensity), 29.47,
29.35, 26.06 (double intensity) (10 × CH2), 23.74 (C-3′), 22.68
(CH2), 14.10 (CH3). MS (ES
+) m/z 449 (24%, M + H+), 471 (36%,
M + Na+), 512 (100%, M + CH3CN + Na
+). Accurate mass:
C25H41N2O5 requires 449.3015, found 449.3024. Reverse HPLC
eluting with H2O/MeOH (gradient from 100:0 to 10:90 in 15 min,
then at 10:90 for 5 min and another gradient from 10:90 to 0:100 in 5
min): tR = 24.87 min.
3-(2′,3′-Dideoxy-ribo-β-L-furanosyl)-6-decyloxybutylfuro[2,3-d]-
pyrimidin-2(3H)-one (8u). Procedure C was carried out using 6-
decyloxy-1-hexyne (12b) (0.352 g, 1.776 mmol). The obtained residue
was puriﬁed by column chromatography (4% methanol in ethyl
acetate) to give the title compound as an oﬀ-white solid (0.070 g,
26%). 1H NMR (500 MHz, CDCl3): δ 8.72 (1H, s, H-4), 6.21 (1H, br
d, J = 6.1 Hz, H-1′), 6.14 (1H, s, H-5), 4.34−4.28 (1H, m, H-4′),
4.19−4.12 (1H, m, H-5′), 3.91−3.86 (1H, m, H-5′), 3.45 (2H, t, J =
6.3 Hz, 2.1 Hz, OCH2), 3.41 (2H, t, J = 6.7 Hz, 2.1 Hz, OCH2), 2.69
(2H, t, J = 7.4 Hz, α-CH2), 2.64−2.57 (2H, m, H-2′, OH), 2.23−2.19
(1H, m, H-2′), 1.98−1.92 (2H, m, H-3′), 1.81−1.73 (2H, m, β-CH2),
1.69−1.62 (2H, m, CH2), 1.60−1.54 (2H, m, CH2), 1.35−1.24 (12H,
m, 6 × CH2), 0.90 (3H, t, J = 6.5 Hz, CH3).
13C NMR (125 MHz,
CDCl3): δ 171.75 (C-7a), 159.11 (C-6), 154.97 (C-2), 135.87 (C-4),
107.10 (C-4a), 99.23 (C-5), 89.00 (C-1′), 82.81 (C-4′), 71.15
(OCH2), 70.23 (OCH2), 62.92 (C-5′), 33.77 (C-2′), 29.74, 29.60,
29.57, 29.49, 29.31, 29.12 (6 × CH2) 28.08 (α-CH2), 26.18 (CH2),
23.90 (C-3′), 23.68 (β-CH2), 22.67 (CH2), 14.10 (CH3). MS (ES+)
m/z 449 (17%, M + H+), 471 (6%, M + Na+), 487 (4%, M + K+), 512
(100%, M + CH3CN + Na
+). Accurate mass: C25H41N2O5 requires
449.3015, found 449.3028. Reverse HPLC eluting with H2O/MeOH
(gradient from 100:0 to 10:90 in 15 min, then at 10:90 for 5 min,
another gradient from 10:90 to 0:100 in 5 min and then at 0:100 for
10 min): tR = 26.45 min.
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Antiviral Assays. L-ddBCNAs were then prepared as 10 mM stock
solutions in dimethyl sulfoxide (DMSO) to do the antiviral assays.
Wortmannin (W3144; Sigma−Aldrich) was obtained as a 10 mM, 0.2-
μm-ﬁltered, ready-made solution in DMSO. Ribavirin (R9644;
Sigma−Aldrich) and Cidofovir (C5874; Sigma−Aldrich) were
prepared as 100 mM stock solution in water.
Cell Culture. Hela cells (ATCC CCL-2) were used for VACV
stock production. BSC-1 cells (ATCC CCL-26), RK13 cells (ATCC
CCL-37), HFFF (gift of G. Wilkinson), and B95a simian B cells
[IZSBS−Istituto Zooproﬁlattico Sperimentale (Brescia, Italy)] were
used for antiviral and proliferation assays. All cells were grown in
Dulbecco’s modiﬁed Eagle medium (DMEM; Invitrogen, Life
Technologies, Paisley, U.K.) with 4.5g/L glucose and L-glutamine
without sodium pyruvate 1× (Gibco, Life technologies, Paisley, U.K.),
supplemented with 10% (v/v) heat-inactivated fetal bovine serum
(FBS; Gibco; lot 41G6401K), used for the culture of all cells. Cells
were cultured in the absence of antibiotics prior to assay, when
penicillin/streptomycin was added (Gibco). Visibly contaminated
cultures were discarded, mycoplasma contamination was ruled out by
mycoplasma PCR (Geneﬂow).
Virus Culture. Vaccinia viruses were propagated in adherent HeLa
cells, and mature intracellular virus (MV) was prepared using the
method described by Townsley and co-workers35 Vaccinia virus WR
(VACV-WR) is a kind gift of Dr. Bernhard Moss, NIH, NIAID, LVD,
to Joachim J. Bugert. VACV-WR luciferase reporter virus v3 was
constructed to express ﬁreﬂy luciferase under the control of the
synthetic−optimized early/late poxviral promoter using the pRB21-
based donor plasmid p240.36 The VACV-WR gfp reporter virus v300
was constructed to express enhanced green ﬂuorescent protein
(EGFP) under the control of the synthetic−optimized early/late
poxviral promoter using the donor plasmid p300.37
Wild type measles viruses were propagated and titered in B95a cells
and prepared as described by Hashimoto and co-workers38 Wild type
measles virus mWTFb is a kind gift of Jürgen Schneider Schaulies
(Universitaẗ Würzburg, Germany). Wild type measles virus mIC323
expressing green ﬂuorescent protein (GFP) is a kind gift of Yusuke
Yanagi (NIID, Tokyo, Japan).
Measles virus vaccine strain Edmonston was purchased from ATCC
(ATCC-VR24).
Measles virus Edmonston, adenovirus 5 (ATCC VR-5), and herpes
simplex viruses type 1 (NCPV 17+) and type 2 (NCPV 132349) were
propagated in Vero cells.39
VACV Luciferase Assays. RK13 cells in 96-well plates were
pretreated for 30 min with each of the drugs at 10 μM and a DMSO
control in triplicate. Luciferase producing vaccinia virus (v3) was then
added to the wells at a multiplicity of infection (moi) of 0.2. The cells
were collected 2 h p.i. A 100 μL portion of 1× passive lysis buﬀer
(Promega, Madison, WI) per well was added to each well and the plate
was agitated on a Bellydancer for 15 min. The plate was then frozen at
−20 °C. After thawing, 20 μL of each of the samples was transferred to
a black 96-well plate (NUNC, Roskilde, Denmark) and processed
using the luciferase assay substrate and buﬀer II (Promega, Madison,
WI). The luminescence was measured in a 96-well luminescence plate
reader (FLUOstar OPTIMA FL, BMG Labtech). The percentages of
the treated versus the no drug control readings were calculated.
VACV Plaque Reduction Assays (IC50). BSC-1 cells grown to
conﬂuency in 24-well plates were pretreated with a series of dilutions
of drug (50, 5, 0.5, 0.1, and 0.05 μM and no drug control) in
quadruplicate. These were then infected with 30 plaque forming units
(pfu) of vaccinia virus WR per well. The virus was left to adsorb onto
the cells for 1 h, before the drug and the virus was removed and
replaced with 1 mL of Avicel overlay (50% Avicel, 50% DMEM
containing 1% P/S and drug to the required concentration). The
plates were incubated for 4 days and were then rinsed with PBS and
stained with crystal violet stain for 4−6 h. The plaque sizes were
analyzed by scanning the plates at 600 dpi and measurement of the
area of each of the plaques using Image J software. IC50 values were
deﬁned as the concentration of antiviral that reduced the size of
plaques by 50% in comparison to cells infected in the absence of
antiviral. The ﬁnal IC50 values for all virus/antiviral combinations are
each a mean from three experiments. The IC50 values were calculated
for each drug using the GraphPad Prism software (GraphPad Software,
Inc.).
TCID50 Assays. Ten-fold dilutions of HSV-1/2, adenovirus 5, and
measles viruses were used to infect HFFF, BSC-1 cells, and B95a cells
in 96-well plates (10 dilutions, two mock, 8 times repeated) and
evaluated 3 days postinfection for cytopathic eﬀects in comparison to
mock infected wells. Cells were grown in 96-well plates (NUNC) until
80% conﬂuent. Cells were pretreated with medium containing the
appropriate amount of antivirals for 30 min prior to infection. Each
well was infected with 100 pfu of HSV-1/2 and adenovirus 5 or 100
syncytia forming units (sfu) of measles virus WTFb and incubated in
DMEM without FBS or antibiotics containing no antivirals or
antivirals at concentrations ranging from 1 to 100 μM for 3 days.
Cytopathogenic eﬀects were assessed by phase contrast microscopy.
TCID50 was deﬁned as the concentration of antivirals that reduced the
CPE by 50% in comparison to cells infected in the absence of antivirals
as an average of three experiments. Controls consisting of virus and
cell only (no drug) and cell only (no virus/no virus and no drug) were
included in each experiment. TCID50 values were calculated using the
method of Reed and Muench.40
Cell Viability. L-ddBCNAs were tested for eﬀects on cell viability
over a period of 4 days in BSC-1 cells using a range of drug
concentrations according to the manufacturer’s instructions (G7571
CellTiter-Glo Luminescent Cell Viability Assay; Promega, Madison,
WI). The assay measures the number of viable cells in culture based on
quantitation of the ATP present, which signals the presence of
metabolically active cells. CC50 values were calculated for each drug
versus no drug using the GraphPad Prism software (GraphPad
Software, Inc.).
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 New Method for the Assessment of Molluscum 
Contagiosum Virus Infectivity 
 Subuhi  Sherwani ,  Niamh  Blythe ,  Laura  Farleigh , 
and  Joachim  J.  Bugert  
 Abstract 
 Molluscum contagiosum virus (MCV), a poxvirus pathogenic for humans, replicates well in human skin 
in vivo, but not in vitro in standard monolayer cell cultures. In order to determine the nature of the replica-
tion de fi ciency in vitro, the MCV infection process in standard culture has to be studied step by step. The 
method described in this chapter uses luciferase and GFP reporter constructs to measure poxviral mRNA 
transcription activity in cells in standard culture infected with known quantities of MCV or vaccinia virus. 
Brie fl y, MCV isolated from human tissue specimen is quantitated by PCR and used to infect human HEK293 
cells, selected for ease of transfection. The cells are subsequently transfected with a reporter plasmid encod-
ing  fi re fl y luciferase gene under the control of a synthetic early/late poxviral promoter and a control plasmid 
encoding a renilla luciferase reporter under the control of a eukaryotic promoter. After 16 h, cells are har-
vested and tested for expression of luciferase. MCV genome units are quantitated by PCR targeting a 
genome area conserved between MCV and vaccinia virus. Using a GFP reporter plasmid, this method can 
be further used to infect a series of epithelial and  fi broblast-type cell lines of human and animal origin to 
microscopically visualize MCV-infected cells, to assess late promoter activation, and, using these parameters, 
to optimize MCV infectivity and gene expression in more complex eukaryotic cell culture models. 
 Key words:  Molluscum contagiosum virus ,  Luciferase reporter construct ,  Eukaryotic cells ,  Infection , 
 Transfection ,  Quantitative PCR 
 
 Molluscum contagiosum virus (MCV) does not produce a 
quanti fi able cytopathic effect and does not produce viral progeny 
in infected standard cell cultures. But small amounts of viral mRNA 
and protein expression can be detected indicating that MCV virions 
are transcriptionally active  ( 1– 3 ) . Many investigators have observed 
 1.  Introduction
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that poxvirus transcription complexes can drive luciferase reporters 
under the control of poxviral promoters in plasmids in poxvirus-
infected cells. A recent paper uses this as a method to diagnose 
orthopoxvirus infections  ( 4 ) . 
 In the assay described in this chapter, the same principle is 
used. We introduce a luciferase reporter expression in trans as a 
new surrogate marker of infectivity and gene expression for MCV. 
To compare the infectivity of MCV with other poxviruses ( 11 ), the 
number of virions must be determined. Quantitation by EM or 
OD300 can be used  ( 5 ) , but requires relatively large amounts of 
gradient puri fi ed virons. However, currently, MCV can only be 
isolated from clinical specimens and thus is dif fi cult to obtain 
amounts suf fi cient for gradient puri fi cation  ( 5 ) . PCR is an alterna-
tive method of quantitation of smaller amounts of poxviruses from 
clinical specimens, which is both reliable and highly speci fi c for 
individual poxviruses. The method described in this chapter uses a 
novel PCR target in an area with signi fi cant DNA homology 
(~65%) between MCV and vaccinia virus strain WR (VACV-WR). 
The MCV gene is mc129R, which is homologous to the VAVWR144 
(also called A24R gene encoding RPO132, the large subunit of the 
DNA-dependent RNA polymerase). The method provides a means 
to quantitate poxviral genome units in the same virus preparations 
used to compare transcriptional activity and infectivity of MCV 
and VACV-WR. 
 
  1.  OPTIMEM, stored at 4°C. 
  2.  Plasmids described in Subheading  2.3 (see Note 1). 
  3.  Lipofectamine 2000, stored at 4°C until used. 
  4.  Human HEK 293 cells (ATCC CRL1573) (see Note 2). 
  5.  Dulbecco’s modi fi ed Eagle medium: DMEM, high glucose 
with glutamine, stored at 4°C until  used. 
  6.  Fetal calf serum: FCS, stored in aliquots at −70°C until used. 
  7.  Cell growth medium: DMEM with 10% FCS. 
 
  1.  Dual Luciferase Assay Substrate (lyophilized) stored at −20°C 
for up to 6 months reconstituted. 
  2.  10 ml Luciferase Assay Buffer II, stored in a 1-ml aliquots at 
−20°C for up to 6 months until used. 
  3.  Stop and Glo Substrate (50×) stored at −20°C. 
 2.  Materials
 2.1.  MCV Luciferase 
Reporter Assay
 2.1.1.  Infection–
Transfection 
of Cell Cultures
 2.1.2.  Luciferase Assay 
(The Dual-Luciferase ® 
Reporter Assay System 
from Promega)
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  4.  10 ml of Stop & Glo Buffer, stored in a 1-ml aliquots at −20°C 
for up to 6 months until used. 
  5.  30 ml of Passive Lysis Buffer (5×) stored at −20°C, then diluted 
to 1× using sterile water, and kept at 4°C until used. 
  6.  Clear  fi lm plate protectors (to prevent evaporation from 
wells). 
  7.  FLUOStar Luminometer. 
  1.  Primers outlined in Table  1 suspended in injection-grade 
water to a  fi nal concentration of 100 pmol/ m l and stored at 
−20°C. 
  2.  MCV isolated from human skin biopsy material as described 
previously  ( 5 ) and kept in 100- m l aliquots frozen at −70°C in 
PBS (see Note 3). 
  3.  VACV-WR, vaccinia virus, strain WR (kind gift of B. Moss) 
was prepared and puri fi ed from infected HeLa cells, titrated in 
BSC-1 cells, and kept in 100- m l aliquots frozen at −70°C in 
PBS (see Note 3). 
  4.  DNAse at 1 mg/ml. 
  5.  DNAse/BamHI buffer: 78  m l water, 2  m l DNAse, 20  m l 10× 
BamHI buffer from New England Biolabs. 
  6.  High Pure viral nucleic acid (HPVNA) kit (e.g., Roche). 
  7.  Nanodrop-Spectrophotometer. 
 2.2.  MCV and VACV 
Quantitative PCR 
Assay
 Table 1 
 MCV–VACV quantitative PCR assay primers 
 Primer ID  Primer sequence (nhb) 
 Primer 
length 
 Product size (nucleotide 
position), GenBank Acc. # 
 Mcv129 
1-2F149275 
 5 ¢ -CC G CACTA C 
TC C TGGATGCAGAA-3 ¢ 
 23  576 bp (149,275–149,850), 
U60315 
 Mcv129 
1-3R149850 
 5 ¢ -CTG G ATGTC
 G GAGAA G GTCATG-3 ¢ 
 22 
 VACV-WR 
1-2F132482 
 5 ¢ -CC T CACTA T 
TC A TGGATGCAGAA-3 ¢  ( 3 ) 
 23  573 bp (132,482–122,054), 
AY243312 
 VACV-WR 
1-3R133054 
 5 ¢ -CTG A ATGTC 
A GAGAA T GTCATG-3 ¢  ( 3 ) 
 22 
 nhb nonhomologous bases underlined (number of mismatches) 
 Primers were designed using BLAST2 (NCBI:  http://blast.ncbi.nlm.nih.gov/ ) alignment of MCV (GenBank accession 
# U60315) and VACV-WR (GenBank accession # AY243312) genome sequences and Vector NTI vs. 4.0, 1994–1996 
InforMax Inc. 
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  8.  ImageJ (Wayne Rasband (wayne@codon.nih.gov) Research 
Services Branch, National Institute of Mental Health, Bethesda, 
Maryland, USA). 
  9.  Injection-grade water. 
  10.  AmpliTaq 360 polymerase (5 U/ m l). 
  11.  dNTP (0.2 mM). 
  12.  10× PCR buffer. 
  13.  2% Agarose gel. 
  14.  Ethidium bromide solution: 10 mg/ml stock solution in 
demineralized water and used at 20  m l per 200 ml. 
  1.  PCR control plasmid . The complete MCV-1 genome was 
cloned  ( 6 ) and sequenced  ( 7,  8 ) and the redundant MCV 
genome fragment library of MCV type 1 was submitted to 
 2.3.  Plasmids 
( See Fig.  1 )
 Fig. 1.  Plasmid constructs. VectorNTI drawings for the recombinant plasmids ( a ) pyMCV1-EcoRI-fragment C (pyMCV1-E-C; 
available from ATCC molecular section), ( b ) phRG-TK (Promega; Internal lab reference number p238), ( c ) pRB21-pE/L-FF 
luciferase (p240), and ( d ) pRB21-pE/L-EGFP-SFX (p300). 
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ATCC for safekeeping in 2003 and 2008. For the quantitative 
PCR assay, the genomic MCV-1  Eco RI fragment C (25,516 bp) 
cloned into bacterial plasmid vectorp pACYC184 was used as a 
MCV target control (pyMCV1-E-C, see Fig.  1a ). 
  2.  Transfection control plasmid . Plasmid phRG-TK (Promega 
GenBank accession number AF362545: 4,045 bp), expressing 
renilla luciferase under the control of the herpes simplex virus 
TK gene promoter. In this protocol, this plasmid is called p238 
and used as plasmid transfection control (p238 Promega; see 
Fig.  1b ). 
  3.  Poxviral luciferase reporter plasmid . The coding sequence of 
 fi re fl y luciferase ( Photinus pyralis GenBank accession number 
M15077) was ampli fi ed with a modi fi ed Kozak sequence by 
PCR and ligated into the pRB21 donor plasmid (kind gift of 
B. Moss  ( 9,  10 ) ) using the EcoRI and HindIII restriction sites 
in the donor plasmid multiple cloning site, resulting in the 
pRB21-E-Koz-Fire fl y luciferase-H (also called pRB21-pE/L-FF 
luciferase) construct of 7,178 bp with the internal lab designa-
tion p240 (p240, see Fig.  1c ). 
  4.  Poxviral EGFP reporter plasmid . The coding sequence of EGFP 
was ampli fi ed from a commercially available plasmid with a 
modi fi ed Kozak sequence by PCR and ligated into the pRB21 
donor plasmid using the EcoRI and NheI restriction sites in 
the donor plasmid multiple cloning site, resulting in the 
pRB21-E-Koz-EGFP-X- fl ag-strepII-N construct (also called 
pRB21-pE/L-EGFP-SFX) of 6,333 bp with the internal lab 
designation p300 (p300, see Fig.  1d ). 
 
  1.  Prepare enough 12-well plates containing HEK 293 cells in 
growth media to allow for infection/transfection in triplicate 
for each experimental condition (including a mock that will be 
transfected but not infected, as well as wells that will be har-
vested at 16 h and wells that will be continued to be incubated 
for days) (see Note 4). 
  2.  Thaw virus aliquots, sonicate, and keep on ice. 
  3.  Thaw plasmid DNA and keep on ice. 
  4.  Bring OptiMEM and Lipofectamine 2000 to room tempera-
ture (RT). 
  5.  Prepare transfection mixes by adding a dilution of 2  m l of 
Lipofectamine 2000 in 50  m l of OptiMEM to a dilution of 
0.3  m g of each plasmid DNA (p240 FF reporter and p238 
 3.  Methods
 3.1.  Infection–
Transfection: 
Luciferase Assay
 3.1.1.  Infection/
Transfection
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transfection control plasmid, p300 EGFP reporter) in 50  m l of 
OptiMEM. Mix gently for 15 min at RT in the dark to allow 
formation of transfection complexes. 
  6.  Remove growth media from HEK293 cells and put 100  m l of 
transfection mix in each well. 
  7.  Combine 100  m l each of ice-cold virus in PBS and 100  m l of 
transfection mix at RT and transfer the mixture into appropri-
ate wells of HEK293 cells (see Note 5). 
  8.  Incubate for 16 h at 37°C in 5% CO 2 atmosphere (see Note 6). 
  1.  At 16 h post infection (p.i.), inspect cells transfected with the 
GFP reporter plasmid using live cell microscopy. Document 
GFP-positive cells noting that MCV does not show GFP-
positive cells after 16 h, whereas WR shows multiple GFP-
positive cells. 
  2.  Upon further incubation for another 4 days (5 days p.i.), some 
individual cells in the MCV-infected wells will show medium 
to strong GFP signals (see Note 7). At the same time point, 
the WR-infected wells will show extensive plaques and cell 
degradation (see Fig.  2a–d ). 
  3.  For luciferase assay, at 16 h p.i., wash adherent cells in wells 
once with PBS and add 100  m l of 1× passive lysis buffer to each 
well (see Note 8). 
 3.1.2.  Microscopy 
and Collection of Cells 
for Luciferase Assay
 Fig. 2.  Images of luciferase and GFP in infected/transfected cells and quanti fi cation of luciferase output.  Panels ( a – d ) show 
HEK 293 cells infected with MCV ( a and  c ), and vWR ( b and  d ). Inserts in  c show individual GFP-positive cells.  Panel  e 
shows a histogram of luciferase data giving chemiluminescence in RLU. HEK 293 cells were infected with MCV or vWR at 
the indicated moi, and collected at 16 h  p.i. 
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  4.  Cover the 12-well plate with clear  fi lm plate protectors to stop 
evaporation and incubate with agitation on a belly-dancer at 
RT for  15 min. Plates are then frozen at −20°C for at least 
15 min or stored overnight or for up to 2 weeks before 
assayed. 
  5.  Cell lysates are tested for luciferase activity by adding 100  m l 
Dual Luciferase Assay Substrate to each well (see Note 9). 
  6.  Luciferase activity is then measured in a FLUOStar 
Luminometer. 
  7.  Data is compiled in a Microsoft EXCEL  fi le and evaluated 
using standard statistical protocols (average, standard devia-
tion, Student’s  P test). A typical result is shown in Fig.  2e 
(see Notes 6, 10, and 11). 
  1.  Incubate equal volumes of freshly thawed virions (100- m l ali-
quot) in 100  m l DNAse/BamHI buffer for 30 min at 37°C. 
  2.  Extract viral genomic DNA using a HPVNA kit following the 
manufacturer’s instructions. The control plasmid pyMCV1-E-
C (see Fig.  1a ) is prepared using the same procedure. 
  3.  Determine the DNA concentration of the control plasmid 
using a Nanodrop-Spectrophotometer or a similar device. 
  4.  Calculate molecule numbers using the average molecular 
weight of DNA molecules and Avogadro’s number 
(6.02 × 10 23 per mole). The molecular weight of a plasmid (in 
Daltons) can be estimated as MW of a double-stranded DNA 
molecule ( http://www.epibio.com/techapp.asp ) = (# of base 
pairs) × (650 Da/base pair). The plasmid pyMCV1-E-C has 
29,760 bp. Thus, the molecular weight is calculated as 
19.344 MDa and thus 19.344 ng of plasmid would be 
6.02 × 10 8 mol. The actual plasmid concentration was 21 ng/ m l 
(±1.7) and, thus, represented 6.5 × 10 8 mol/ m l. From this 
value, the molecule numbers for the pyMCV1-E-C twofold 
dilution series are calculated (see Fig.  3d ). The molecule 
numbers are then correlated to the pixel numbers of bands on 
a gel quantitated by ImageJ (see Fig.  3d ). 
  1.  Prepare twofold dilutions of viral genomic DNA and plasmid 
control in injection-grade water and store at −20°C. 
  2.  Prepare PCR assays as outlined in Table  2 . PCR reaction con-
ditions are included in the table. 
  3.  Visualize PCR bands by loading a 2% agarose gel with 10  m l 
from each PCR reaction and run for 1 h at 100 V (constant 
voltage). Stain with ethidium bromide, photograph with a dig-
ital unit, and export into a jpeg  fi le (see Note 13). 
  4.  To quantitate the PCR product, one can use the captured 
bands on the jpeg photograph with a series of identical gates 
 3.2.  Quantitative PCR 
Assay
 3.2.1.  Virus and DNA 
Preparation
 3.2.2.  PCR Reaction 
( see  Note 12 )
 Fig. 3.  PCR quanti fi cation of puri fi ed DNA.  Panels  a – c show twofold dilutions of poxviral genomic DNA puri fi ed from 
DNAse-treated virions ( b and  c ) and plasmid DNA repuri fi ed using the HPVNA kit ( a ). Lane numbers at the top of the  fi gure 
refer to log 2 dilutions from 1 to 10.  Panel  d tabulates the calculated molecular number for the reference plasmid pyMCV1-
E-C (pyMC) (1,000× by nanodrop in 10  m l of original DNA prep) and the ImageJ pixels for each band in gels  a to  c . ImageJ 
(Wayne Rasband (wayne@codon.nih.gov) Research Services Branch, National Institute of Mental Health, Bethesda, 
Maryland, USA) was used to quantitate pixel densities in boxes of 212 × 42 pixels. 
 Table 2 
 PCR reaction 
 Volume ( m l) 
 Primer 1-2F a (100 pmol/ m l)  0.5 
 Primer 1-3R a (100 pmol/ m l)  0.5 
 Injection-grade water  36.8 
 10× PCR buffer  5.0 
 TaKaRa dNTP (0.2 mM)  2.0 
 Template (series of twofold dilutions)  5.0 
 AmpliTaq 360 polymerase (1 unit of 5 U/ m l)  0.2 
 Total  50.0 
 PCR reaction: 2 min of denaturation at 96°C; and then 45 cycles of 
1 min at 96°C, 2 min at 55°C, and 3 min at 72°C. Block and then cool 
to 10°C
aFor MCV Primer 1-2F and Primer 1-3R, use Mcv129 1-2F149275 and 
Mcv129 1-3R149850, respectively. For WR Primer 1-2F and Primer 1-3R, 
use VACV-WR 1-2F132482 and VACV-WR 1-3R133054, respectively 
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using IMAGEJ software to produce a quanti fi ed pixel output 
that can be imported into a Microsoft EXCEL  fi le. 
  5.  Plot quantitative results of digital imaging (quanti fi ed pixel 
output) of a twofold dilution series of plasmid pyMCV1-E-C 
against molecule numbers using Microsoft EXCEL software. 
  6.  Take molecule/genome equivalent numbers from the calibra-
tion plot and compare to the pixel readings obtained for 
VACV-WR. Tabulate results and evaluate using standard statis-
tical protocols (average, standard deviation, Student’s  P test). 
  7.  Results from a PCR reaction and the corresponding mole 
numbers and pixels are shown in Fig.  3d . In that  fi gure, for gel 
a, lane 9, the signal (27,779 pixels) for the dilution of the MCV 
control plasmid (pyMCV1-E-C) correlates to 1.586 × 10 6 plas-
mid units. The band in gel c (MCV PCR) with comparable 
pixel density (i.e., within 10%) is in lane 4 with a pixel value of 
28,726 pixels. If the 1.586 × 10 6 mol are multiplied by the 
dilution factor (16×), the MCV aliquot of 100  m l used for 
genomic DNA preparation contained 2.5 × 10 7 mol/genome 
units. If the pixel values obtained for vWR in gel b, lane 4 
(71,008), are used in the same way and related to gel a, lane 8 
(67,495 pixels), after multiplying by the dilution factor (16×), 
a molecule number of 5 × 10 7 is obtained. This can then be 
used to relate to the pfu. If WR was at 1.6 × 10 6 pfu in 100  m l, 
the pfu-to-genome unit ratio is 1:31  (see Notes 14–16). 
 
  1.  All plasmid DNA should be puri fi ed using 100- m g capacity 
midiprep-columns (HPVNA) and then stored in elution buffer 
at −20°C until used. 
  2.  The assay depends to a signi fi cant degree on the transfectabil-
ity of the cell cultures involved. Human keratinocytes and 
 fi broblast cell lines are most interesting as possible natural hosts 
for MCV, but they are also hard to transfect. We found HEK 
293 cells to be the best transfected cell line. However, while 
this cell line shows robust reporter signals, it is clearly not the 
type of cell MCV naturally infects. 
  3.  We prepare vaccinia virus and MCV preparations in 1 ml PBS 
and then immediately make ten 100- m l aliquots and freeze. 
The vaccinia virus stock was generated by infecting one T150 
 fl ask containing adherent HeLa cells. Harvest of the infected 
cells and resuspending them in 1 ml PBS yielded a titer of 
2 × 10 7 pfu/ml. Thus, each of the ten 100- m l aliquots of vaccinia 
virus used here contained 2 × 10 6 pfu. The 100- m l aliquot MCV 
 4.  Notes
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contained an unknown number of MCV particles, but is 
quanti fi ed using the described PCR method. 
  4.  Transfection ef fi ciency can vary considerably from cell batch to 
cell batch. Passage number (best low), cell con fl uence (best 
below 60%), and time of culture prior to experiment (best no 
longer than 24 h) are determinant factors. 
  5.  While in this protocol we transfect adherent cells, we have 
found that for some harder-to-transfect cells (e.g., human 
 fi broblasts) we can get higher transfection ef fi ciency when cells 
are in  suspension. 
  6.  The incubation time of 16 h allows for a robust signal from the 
transfection control plasmid p238, so  fi re fl y signal readings can 
be adjusted to renilla transfection ef fi ciency readings between 
experiments. 
  7.  Transfected plasmids with poxviral transcription signals can be 
transcribed by the poxviral transcription complex produced by 
transcriptionally active cores after entry. It is not clear whether 
the transcription complex is accessed inside partially uncoated 
virions, with plasmid DNA getting inside cores, or by tran-
scription complex that is released into the cytoplasm. MCV-
infected cells produce a robust luciferase signal after 16 h. 
However, GFP is only visibly expressed in a small number of 
individual cells, detectable after 5 days of incubation. Potentially, 
other cells may express GFP at a level undetectable by micros-
copy. The process where cores are accessible for the reporter 
plasmids may be delayed in MCV-infected cells. 
  8.  The samples for the luciferase assay are collected at 16 h post 
infection. This allows the control plasmid ILR#238 to get to 
the nucleus and be expressed to yield a robust control signal. 
In 293 cells, the Renilla luciferase signal can be seen in vac-
cinia-infected cells after 2 h, and is seen in the MCV signal 
after 8 h. 
  9.  If one does not have instrumentation that can add 100  m l of 
PROMEGA Dual luciferase  fi re fl y substrate one can hand, 
pipet series of four samples in a row, then load the plate, and 
read. The reading time, including the initial shake for four 
samples, is 20 s. Doing this results in a signal loss per reading 
of <1%, which is less than the sample-to-sample variation in 
triplicate samples, when compared to machine pipetting sam-
ple per sample. 
  10.  The signal from early poxviral promoters can be used as a sur-
rogate parameter of viral infectivity. 
  11.  The signal can be further dissected and used to look at early 
and late transcription activity using transfected plasmids with a 
reporter gene behind the respective promoters in isolation. 
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  12.  The conventional PCR assay described has the problem of 
assay-to-assay variation due to agarose gel and staining arti-
facts. Future advances may be the development of a real-time 
PCR assay using molecular Taqman probes speci fi c to either 
VAVC-WR or MCV and binding in the internal section of the 
rather large PCR product  (550 bp). 
  13.  The source template of the PCR products produced can also 
be determined by XhoI digest, which cleaves the MCV prod-
uct into 227- and 349-bp subfragments but does not cleave 
the VAVC-WR PCR product. 
  14.  It is unclear to which extent the different GC content of the 
two virus genomes would affect the PCR product. This was 
not further investigated. 
  15.  It is clear that vaccinia plaque-forming units cannot be directly 
compared to MCV virion units because of the different nature 
of their biological activity. However, the PCR method 
described in Subheading  3.2 allows a relative quanti fi cation 
of MCV genome equivalents to VAVC-WR infectious units 
measured in pfu/ml based on ampli fi able genomic DNA 
units/molecule numbers calculated for a relatively large 
plasmid containing 25,517 bp of MCV sequence. As described 
in Subheading  3.2.2 ,  step 7 , the pfu-to-molecule ratio for 
vaccinia virus (mature virions) comes out as 1:31, in keeping 
with previously published ratios  ( 12 ) . The PCR data can be 
used to calculate an MCV multiplicity of infection equivalents 
in relation to the control plasmid molecule numbers as well as 
in the form of pfu equivalents in relation to a titered vaccinia 
stock for comparison purposes. We have found this approach 
to be both more reproducible and more speci fi c than electron 
microscopy or OD quanti fi cations of virions. 
  16.  The biological activity of virions can be assessed using an 
in vitro transcription reaction  ( 1,  5,  13 ) . 
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Abstract
Molluscum contagiosum virus (MCV) is a significant but underreported skin pathogen for children and adults.
Seroprevalence studies can help establish burden of disease. Enzyme linked immunosorbent assay (ELISA) based studies
have been published for Australian and Japanese populations and the results indicate seroprevalences between 6 and 22
percent in healthy individuals, respectively. To investigate seroprevalence in Europe, we have developed a recombinant
ELISA using a truncated MCV virion surface protein MC084 (V123-R230) expressed in E. coli. The ELISA was found to be
sensitive and specific, with low inter- and intra-assay variability. Sera from 289 German adults and children aged 0–40 years
(median age 21 years) were analysed for antibodies against MC084 by direct binding ELISA. The overall seropositivity rate
was found to be 14.8%. The seropositivity rate was low in children below the age of one (4.5%), peaked in children aged 2–
10 years (25%), and fell again in older populations (11–40 years; 12.5%). Ten out of 33 healthy UK individuals (30.3%; median
age 27 years) had detectable MC084 antibodies. MCV seroconversion was more common in dermatological and
autoimmune disorders, than in immunocompromised patients or in patients with multiple sclerosis. Overall MCV
seroprevalence is 2.1 fold higher in females than in males in a UK serum collection. German seroprevalences determined in
the MC084 ELISA (14.8%) are at least three times higher than incidence of MC in a comparable Swiss population (4.9%).
While results are not strictly comparable, this is lower than Australian seroprevalence in a virion based ELISA (n = 357; 23%;
1999), but higher than the seroprevalence reported in a Japanese study using an N-terminal truncation of MC133 (n = 108,
6%; 2000. We report the first large scale serological survey of MC in Europe (n = 393) and the first MCV ELISA based on viral
antigen expressed in E. coli.
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Introduction
After the eradication of smallpox, MCV is the principal
poxvirus causing human disease [1–4]. MCV is classified as a
member of the family Poxviridae, in its own genus Molluscipoxvirus
[5]. It has unique features that are distinct from other poxviruses
pathogenic for humans, including smallpox and monkeypox [6].
MCV shares the highest level of amino acid (aa) similarity and
unique proteins with parapoxviruses such as Orf viruses [7].
MCV infects the human skin and Molluscum contagiosum
(MC) is a sexually transmitted disease, with infections occurring
worldwide [1,8–10]. Clinical infection is characterized by a
variable number of papules, each forming a central crater filled
with a waxy plug of cell debris mixed with a large numbers of virus
particles. Histopathologically, MC causes a benign epidermal
hyperproliferation, known as an acanthoma [11]. MC is most
common in young children and teenagers. MC in immunocom-
promised patients results in more numerous and extensive lesions
[12]. In immune-competent patients, lesion may persist for up to
12 months [11]. Spontaneous regression of MC lesions is
commonly preceded by clinical signs of inflammation [13],
indicating a vigorous immune response [14].
The true prevalence of MC has probably been underestimated
because of the benign clinical manifestation and rare complica-
tions. Development of assays which could assist in seroprevalence
studies has been hampered by unsuccessful attempts to cultivate
MCV efficiently in vitro [15–18]. The viral genome was sequenced
in 1996 [2].
In the first known MCV antibody study in 1952, Mitchell found
three out of 14 MC patients with complement-fixing antibody to
an antigen prepared from human MC lesions [19]. Shirodaria
et al. used MCV cryostat sections in an immunofluorescence study
of MCV antibodies, reporting IgM class of antibodies only in
MCV patients and IgG antibody responses in 16.7% of healthy
control subjects (n = 30) [20]. Only two seroprevalence studies
using ELISA, have been reported; one by Konya and Thompson
[21] in 1999 and another by Watanabe et al. in 2000 [22].
Konya and coworkers described in 1992 a virion based enzyme
linked immunosorbent assay [23]. MCV virions were isolated from
human lesion material. The antigen was extracted from pooled
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lesions of different genotypes with epidermal protein extract used
as a control. Their 1999 serological survey of a healthy Australian
population (n= 357) revealed an overall seroprevalence of 23%
and up to 77% in MCV infected HIV negative individuals [21].
Based on MCV sequence information then available, in 1998
Watanabe et al. identified two immunodominant proteins of 70
and 34 kDa and mapped them to the ORFs mc133L and mc084L,
respectively [24]. The proteins are homologues of vaccinia virus
proteins H3L and A27L, and major antigenic peptides of the
virion particle [1,24].
Using this information they developed an ELISA, based on an
N-terminal truncation of MCV virion protein MC133 produced in
a Sendai virus expression system [22]. Their survey of a Japanese
population of 508 subjects found mc133 specific antibodies only in
Figure 1. Bioinformatics. (A) Transmembrane plot (TMHMM Server v.2.0) [25] of mc084 amino acids 1–318; (B) hydropathy plot of MC084 protein
with predicted high hydrophilic/antigenic regions indicated by black boxes. The full length ORF (MC084 1–318; predicted molecular weight 34.2 kD;
shown on top) was cloned into vRB12 using specific primers tailed with restriction enzyme sites BamHI-HindIII) and C-terminal StrepII epitope tag. The
resulting plasmid p319 was sequenced and the recombinant vaccinia virus v319 isolated on BSC-1 cells using the plaqueless mutant system [26]. N-
and C-terminal (in yellow) truncations were subcloned from the original full length MCV gene into pGEX-2TK for overexpression in E. coli BL21 (RIL+).
TMHMM was used to determine transmembrane regions [26] whereas the Kyte-Doolittle plot was used to identify hydrophilic regions with predicted
high antigenicity [27].
doi:10.1371/journal.pone.0088734.g001
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58% of patients with MC, and in only 6% of healthy controls
(n = 108).
The objective of our current study was to develop a
recombinant MCV ELISA using water soluble and highly
antigenic truncations of MC084L expressed in E. coli and to
establish seroprevalence in a German and a UK serum collection.
Materials and Methods
Ethics Statement
The study has ethical approval for the use of German tissues
and sera (Ethikvotum S-091/2011 Hautklinik Heidelberg. Ethical
approval was given by the Heidelberg University board in charge
of ethical approvals, the ‘Ethikkommission’. Ethical approval for
UK samples was part of ‘An Epidemiological study of Multiple
sclerosis and other neuroinflammatory demyelinating disorders in
South Wales’, 05/WSE03/111. Ethical approval was given by the
Cardiff University ‘Biobank Ethics Board’. All patients provided
prospective informed consent in writing upon admission. All
children’s’ parents/guardians provided informed consent in
writing. Class 2 GM work was notified to HSE with the project
number GM 130/10.3.
pGEX-2TK Expression of Truncated MCV –GST Fusion
Proteins
The plasmid pGEX-2TK was used for expression of truncated
and epitope tagged MCV ORFs mc084 (V33-G117V5), MC084
(V123-R230 StrepII), and MC133 (M1-N370 StrepII) in E. coli
with Glutathione S-Transferase (GST) fusion protein at the N
terminus. Recombinant plasmids were constructed by PCR using
specific primers tailed with restriction enzyme sites (BamHI-EcoRI)
and C-terminal epitope tags.
Expression and Purification of MC084S (V123-R230)
Protein
pGEX 2TK GSTmc084S (ILR#332; MC084 specific insert
107 amino acids; 14 kD) was transformed into E. coli BL21
(RIL+).Cultures were induced with Isopropyl b-D-1-thiogalacto-
pyranoside (IPTG) and fractions analysed for fusion protein
expression by SDS-PAGE and StrepII tag expression by western
blotting. Cultures were incubated at 37uC for 4 h after which the
cells were harvested by centrifugation at 10,0006g for 20 min and
lysed by sonification in buffer B (8 M urea, 0.1 M NaH2PO4,
0.01 M and Tris-HCl, pH 8.0). Lysate containing the protein of
interest was added to glutathione sepharose beads and GST-
MC084S was bound to beads using batch purification. The fusion
protein was cleaved using Precision protease at RT overnight.
AKTA-FPLC of the resulting 14 kD sized protein was done using
size exclusion Superdex S200 column (GE Healthcare).
SDS-PAGE, Western Transfer and Immunodetection
Protein preparations were separated using denaturing sodium
dodecyl sulphate polyacrylamide electrophoresis (SDS-PAGE) in
NuPAGE Novex 4–12% Bis-tris Gels (Life technologies) and
MOPS SDS running buffer (Invitrogen). Protein bands were
visualised by staining with 0.01% Coomassie Brilliant Blue R-250.
For immunodetection proteins prepared by SDS-PAGE were
electrotransferred onto nitrocellulose and probed with Strep MAB
Classic HRP conjugate (IBA). Detection by chemiluminescence
was performed using Super Signal West Pico Chemiluminescent
Substrate (Thermo Scientific) according to the manufacturer’s
recommendations.
Human Serum/Tissue Samples
314 serum samples and lesion material from patients with
molluscum contagiosum were collected at University Hospital
Heidelberg, Germany, between 2007–2011. 79 UK sera samples
Figure 2. pGEX 2TK construct. (A) Schematic of recombinant plasmid p332 with a MC084 specific insert of 107 amino acids (V123-R230); predicted
molecular weight 14 kD (B) Schematic of fusion protein of GST (green), followed by Thrombin kinase site (red), MC084 V123-R230 (grey), and strep II
tag (blue); predicted antigenic site (black) (C) Western blot giving 40 kD GST fusion protein GST-MC084S (V123-R230) detected using Strep MAB-
Classic HRP conjugate (IBA-lifesciences). Vector NTI (vNTI) was used to produce virtual molecules and schematic diagrams of constructs prior to
molecular cloning (InforMax, Inc).
doi:10.1371/journal.pone.0088734.g002
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were collected at Cardiff University. Twelve serum samples were
collected from MCV patients (10 from Dr P N Behl Skin Institute
and School of Dermatology, New Delhi, India; two from UK;
aged 2–62 years) as diagnostic specimens.
MCV Direct Binding ELISA
Ninety six well Maxisorp ELISA plates (Nunc) were coated with
3 mg/ml of FPLC purified recombinant truncated MC084S (aa
123–230) protein per well in 100 ml of 0.05 M carbonate-
bicarbonate buffer (pH9.6) and incubated at 37uC for 2 h and
then overnight at 4uC. Plates were washed with PBS and blocked
with 5% skim milk. Test sera, diluted 1:100 in dilution buffer, and
were coated across the plate (100 ml/well). The plates were
incubated at 37uC for 2 h and washed ten times with PBS-T.
Secondary anti-human IgG conjugated to horseradish peroxidase
(GE Healthcare), diluted 1:2000 in dilution buffer was subse-
quently added (100 ml/well). After incubation at 37uC for 2 h the
plate was washed ten times with PBS-T and 100 ml of BD
OptEIATM substrate reagents (BD Biosciences) was added to each
well. 50 ml of 1 M H2SO4 was used to stop the enzyme reaction
after 20 min incubation at RT. The OD of the reaction product
was read at 450 nm on an FLUROSTAR OPTIMA - ELISA
plate reader (BMG Labtech).
Plate Description
42 serum samples were tested in duplicate on each plate along
with a panel of four control sera consisting of two negative and two
positive as well as four blanks, all in duplicate. The results were
expressed as dODU (dODU=mean of duplicate wells minus
mean of the blank wells).
ELISA Performance
Plate to plate variation was monitored by comparing the control
panel results between the different wells of the same plate; same
sera samples run on different plates on the same day as well as on
different days.
Immunofluorescence and Immunohistochemistry
Paraffin embedded sections were deparaffinized and rehydrat-
ed. Dako Cytomation EnvisionH+Dual Link System-HRP (DAB+)
kit (Dako) was used as per manufacturer’s instructions. For staining
of tissue with human sera, ECL Anti-human IgG (1:2000) (GE
Healthcare) was used. Staining was completed with Mayers
haematoxylin and eosin counterstaining. All sections were
analysed using an Olympus BX51 light microscope. Vaccinia
virus infected HaCaT cells were grown on glass coverslips and
fixed with 3% paraformaldehyde for 10 min, followed by staining
with human serum antibodies (1:100) and an anti-human
AlexaFluor 488 secondary antibody (Invitrogen).
Figure 3. Protein purification. Characterisation of over expressed recombinant fusion protein GST-MC084S and FPLC purified recombinant
MC084S protein by SDS-PAGE and Western Blot. M: Molecular weight markers expressed in kDa. (A) Over-expressed 40 kDa Recombinant GST-
MC084S fusion protein separated in a 4–12% Bis-Tris gel. (B) FPLC purified 14 kDa protein separated in a 15% Bis-Arylamide gel. Both gels were
stained with Coomassie Brilliant Blue R-250. (C) GST-MC084S fusion protein after transfer to nitrocellulose (D) FPLC purified MC084S. The membranes
were probed with Strep MAB-Classic HRP conjugate (IBA-lifesciences). Arrow heads indicate the locations of proteins.
doi:10.1371/journal.pone.0088734.g003
Figure 4. Sensitivity. Absorbance plot of twelve sera from patients clinically diagnosed with MCV (India n = 10; UK n= 2; control group of 0–1 year
old individuals n = 17).
doi:10.1371/journal.pone.0088734.g004
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Statistical Analysis
Serological data was stratified by age or diagnosis. Statistical
significance of differences between the ELISA responses of
different groups was assessed by one way ANOVA. Tukey post
hoc anova was used to identify and compare statistically significant
means and differences of different groups.
Additional information on material and methods is shown in
supporting information.
Results
Selection of MC084 Antigen, Cloning and Purification
Amino acid sequences of MC084 (298 aa, 34 kD) were analysed
to determine overall homology with related proteins in the
GenBank and identify transmembrane regions and region of high
hydrophilicity/high antigenicity. Two transmembrane regions
predicted in the C-terminal end of the protein [26], were excluded
to avoid solubility issues in the E. coli expression system (Figure 1A).
Of the remaining amino acids, a N-terminal region (V33-G117)
and a C-terminal region (aa V123-R230), both containing one
region of high hydrophilicity in the Kyte–Doolittle plot (Figure 1B)
[28] were further analysed for subcloning.
Figure 5. Tissue stain details. Microscopy (46) of a Molluscum contagiosum lesion section (17315/11) stained with MC patient positive serum
(CF2012-1) and haematoxylin-eosin counterstain (upper left hand corner). Three insets showing details at various magnifications [inset 1-(106), inset
2-(206) and inset 3-(206)].
doi:10.1371/journal.pone.0088734.g005
Figure 6. HaCaT Immunofluorescence. (A) HaCaT cell culture infected with recombinant vaccinia virus expressing MC084S (v319). Reactivity of
high titre human serum HDV0901071 and secondary antibody AlexaFluor 488 (Green) goat anti-human IgG (H+L). (B) HaCaT cell culture infected with
recombinant vaccinia virus expressing MC084S (v319). Reactivity of low titre human serum HDV0900040 and secondary antibody AlexaFluor 488
(Green) goat anti-human IgG (H+L). (C) Mock infected cells. Reactivity of high titre human serum HDV0901071 and secondary antibody AlexaFluor 488
(Green) goat anti-human IgG (H+L). Nuclei are stained with DAPI (Hoechst) and shown in blue. Samples were analysed for fluorescence emission
properties by using confocal scanning laser microscopy Leica TCS SP2 AOBS.
doi:10.1371/journal.pone.0088734.g006
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The C-terminal truncation of mc084 (V123-R230, predicted
MW 14 kD), comprising 107 aa, has the lowest homology to
orthopoxvirus proteins and contains a region of high antigenicity
(218-NELRGREYGASLR-230) with no significant homology to
vaccinia/cowpox virus. The C-terminal truncation MC084 (V123-
R230) was then subcloned into the pGEX-2TK vector (Figure 2A)
with a Strep II tag and in frame with glutathione S-transferase
separated by a thrombin kinase site (Figure 2B) and overexpressed
as a GST fusion protein in codon optimized E. coli (BL21 RIL+).
The GST fusion protein was identified with an apparent
molecular weight (MW) similar to the predicted MW of 40 kD in
IPTG induced cultures (Figure 3A) and was absent in the
uninduced cultures. The protein was protease cleaved and the
C-terminal truncation of MC084 with an apparent MW of 14 kD
was further purified via FPLC using a size exclusion Superdex
S200 column (Figure 3B). The Strep II tag was identified in
Western Blot in both the fusion protein and the cleaved MC084
(V123-R230)-Strep II truncation (Figures 3 C and D). Additional
data on antigen selection and optimization can be found in Figures
S1 and S2.
ELISA Sensitivity, Cut-off, and Specificity
MC084S (V123-R230) antigen coated ELISA plates were
produced as described in material and methods. Serum samples
were diluted 1:100.
To establish sensitivity a panel of 12 sera from patients with
known and clinically active MCV was first screened in comparison
to sera from 0–1 year old individuals from the neonatal screening
program of the Heidelberg University Clinics. In the group of sera
from patients with diagnosed Molluscum contagiosum (n= 12) the
ELISA gave high readings for all (median dODU 1.5), with the
most recent sample from Cardiff (CF2012-1) giving the highest
(Figure 4). The control group of seventeen neonates from the
Heidelberg University Clinics showed low readings with a mean of
0.1 dODU as shown in Figure 4, with one outlier (0.61 dODU).
The confidence interval for the difference between positive and
negative control groups was highly significant (Figure 4). Sensitiv-
ity was 100% for MC patients.
The cut-off for ELISA was calculated based on 66 sera from
infants seen in the neonatal unit aged 0–1 years. The mean of
dODU readings was 0.12043 and the SD was 0.08300. In
Figure 7. German seroprevalence. Distribution of anti-MC084S antibodies in a German population tested by direct binding ELISA (A) Serological
responses to MCV antigen MC084 in a German population (n = 289; ages 0–40 years) expressed as the dODU value of an individual serum sample. The
horizontal bar within each group represents the median absorbance measurement. (B) Percent seropositivities in different age groups after cut–off of
0.36 (i) 0–1 years (4.5%), (ii) 2–5 years (25%), (iii) 6–10 years (23.4%), 11–20 years (12.5%), and 21–40 years (13.5%).
doi:10.1371/journal.pone.0088734.g007
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comparison the mean dODU for 12 MCV infected patients was
0.833 and the S.D. 0.571. The infant group was used to define
negativity with the upper limit being the mean dODU plus 3 SD
(i.e. 0.36). Assuming that these values are indicative of a negative
response to the recombinant protein, we defined a positive
antibody response as being a value greater than mean plus 3 SDs
i.e. dODU 0.36. Two more outliers were identified in this group
(dODU 0.36 and 0.35). The MCV status of these subjects (aged 2
months, 9 months and 11 months) could not be determined. Inter-
well, intra-assay and inter-assay variability was found to be 3%,
5.2% and 6.7%, respectively.
In order to establish ELISA specificity, human MCV infected
tissue section obtained from the Heidelberg University Dermatol-
ogy Unit were tested with high and low titre sera form our serum
collections (Figure S3). Reactivity of high titre sera are shown on
the left (Figure S3 1A, B/transverse section-perpendicular to level
skin and 2A, B/plane section-parallel to level skin). High titre sera
show strong MC084 specific staining of cellular debris and MC
bodies extruded from and in the centre of lesions, as well as
infected cells in lobules extruding infectious virus into the centre of
the lesion and upwards. Molluscum rich lipid debris areas are well
preserved in these lesions. There is much weaker staining with low
titre sera (same lesions in transverse and plane sections; Figure S3
1C, D and 2C, D).
Specific reactivity (MCV positive UK patient CF2012-1) is
demonstrated in more detail in Figure 5. The section shows a
dome-shaped contour with cup shaped lesions with central
invagination, representing a typical MCV lesion consisting of
two inverted lobules of hyperplastic squamous epithelium (red
arrows) with several sub-lobules. The MC lesion shows acanthosis
with the appearance of intraepidermal lobules with enlarged
basophilic nuclei filled with cellular debris and molluscum bodies
(black arrows). Intraepidermal lobules are separated by septa
consisting of compressed dermis (dotted arrow). MCV inclusion
bodies stain strongly golden-brown with the human polyclonal
serum CF2012-1 taken from a patient with clinical MCV
infection. The stain is confined to areas where MCV cores,
mature and released virus particles would be expected. In a
number of tissue sections stained, the pattern was repeatable and
sensitive to tissue preparation. Interestingly, the debris areas filled
with mature MCV particles and lipid debris are also sensitive to
removal by xylene/ethanol treatment of paraffin sections. The
area’s most consistently stained are the suprabasal and spinous
layers.
To further establish antigen specificity we also infected human
HaCaT keratinocytes with a vaccinia virus expressing full length
mc084 (v319; aa 1 to 318) as shown in Figure 6. Infected
keratinocytes were tested with the high titre serum HD V0901071.
Virus infected cells show a vesicular stain similar to an endosomal/
lysosomal pattern. Uninfected cells show no background signal,
indicating the human polyclonal does not recognize keratinocyte
antigens in cultured HaCaT cells.
Antigen optimization and comparisons are described in
supporting information (Figures S1 and S2).
ELISA Population Studies
Sera from 289 individuals aged 2 months to 40 years (median
age 21 years) were randomly selected from frozen ‘normal control
sera’ collected at the University of Heidelberg, Germany, and
tested for the presence of anti-MC084S (aa 123–230) antibodies
(Figure 7 A). Healthy subjects are divided into groups on the basis
of age: 0–1 years (n = 66), 2–5 years (n = 52), 6–10 years (n = 47),
11–20 years (n = 72) and 21–40 years (n = 52). The reactivity in
infants was significantly lower than in other groups. Based on the
minimum cut-off value of dODU 0.36, 43 (14.8%) sera of the 289
sera from a representative healthy German population tested
positive in the MC084S (123–230) ELISA. Positive antibody
responses in the age groups were as follows: 4.5% (n= 3) 0–1 year
olds, 25% (n= 13) in 2–5 year olds, 23.4% (n= 11) in 5–10 year
olds, 12.5% (n= 9) in 10–20 year olds and 13.5% (n= 7) in 20–40
Table 1. Summary of seroprevalences in German and UK populations.
Groups Total sera Positive sera $ cut-off =Mean+3*SD (0–1 yr+outlier) 0?36
German sera
0–1 years 66 3 (4?5%)
2–5 years 52 13 (25%)
6–10 years 47 11 (23?4%)
11–20 years 72 9 (12?5%)
21–40 years 52 7 (13?5%)
289 Seropositivity in healthy subjects
14?87%
Psoriasis 10 2 (20%)
SLE* 3 1 (33?3%)
Autoimm{ 12 2 (16?6%)
UK sera
Healthy Humans 33 10 (30.3%)
PPMS# 9 1 (11?1%)
RRMS 37 6 (16?2%)
Total 393 65 (16.5%)
*SLE – Systemic Lupus Erythematosus.
{Autoimm. – General autoimmune conditions.
#PPMS – Primary progressive multiple sclerosis.
RRMS – Relapsing remitting multiple sclerosis.
doi:10.1371/journal.pone.0088734.t001
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year olds (Figure 7 B). A one way anova was used for preference
differences between the different age groups. The test statistic (F
value) is 4.587 and the p value is 0.001. Further post hoc analysis
was done using Tukey test to identify and measure statistically
significant difference between groups of data as pairs. From the
multiple comparisons it can be concluded that there is a sharp
increase in positive sera responses between 0–1 year olds and 2–5
year olds which are statistically significant at p value = 0.001. The
differences in the sera responses between 0–1 year olds and 6–10
year olds are also statistically significant (p = 0.011). Differences in
sera responses between all other groups are not statistically
significant. The results of the serological survey in members of the
German populations are shown in Table 1.
We analysed 25 patients (8–40 years of age) with dermatological
conditions such as Systemic lupus erythematosus (n = 10), Psoriasis
(n = 3) and general autoimmune conditions (n = 12), including
patients with Autoimmune haemolytic anaemia, Autoimmune
cerebilitis and Autoimmune hepatitis diagnosed at the University
of Heidelberg. The findings are summarized in Table 1. MCV
seroprevalence is above the average rate in skin specific
autoimmune conditions, but similar in general autoimmune
conditions.
79 serum samples from a UK population (aged 21–40 years;
median age 27 years) were analysed which had been collected as
part of a study on Multiple sclerosis (MS) at Cardiff University.
These subjects were grouped as Primary progressive multiple
sclerosis (n = 9), relapsing remitting multiple sclerosis (n = 37) and
healthy humans (n = 33) (Figure 8A).
Using the same cut-off of 0.36, MCV antibodies were detected
in 10 of 33 healthy UK serum samples (30.3%). In patients with
primary progressive multiple sclerosis seroprevalence was 11.1%
(n= 1/9), as compared to 16.2% (n= 6/37) in patients with
relapsing remitting multiple sclerosis (Figure 8B). A one way anova
was used for preference differences between the different groups.
The test statistic (F value) is 1.756 and the p value is 0.180. Further
post hoc analysis was done using Tukey test to identify and
measure statistically significant difference between groups of data
as pairs. From the multiple comparisons it can be concluded that
Figure 8. UK seroprevalence. Distribution of anti-MC084S antibodies in a UK population tested by direct binding ELISA. (A) Serological responses
to MCV antigen MC084S (V123-R230) in UK population (n = 79) expressed as the dODU value of an individual serum sample in different groups (i)
Primary progressive multiple sclerosis (PPMS; n = 9), (ii) Relapsing remitting multiple sclerosis (RRMS; n = 33) and (iii) Healthy humans (n = 37). The
horizontal bar within each group represents the median absorbance measurement (B) Percent positivity in individual groups for MC084S after cut-off
of 0.36 (i) PPMS (11.1%), (ii) RRMS (16.2%) and (iii) healthy humans (30.3%).
doi:10.1371/journal.pone.0088734.g008
Molluscum contagiosum Virus Burden of Disease
PLOS ONE | www.plosone.org 9 February 2014 | Volume 9 | Issue 2 | e88734
differences in sera responses between groups are not statistically
significant. An overall gender ratio (M: F) of 1.4:1 (183:131) was
found in the German serum collection, as compared to 1:2.1
(25:54) in the UK population. The results of the serological survey
in members of all UK populations are shown in Table 1.
Discussion
We describe here for the first time a seroepidemiological study
of MCV in Europe, the largest survey reported so far (n = 393) and
the first MCV ELISA based on viral antigen expressed in E. coli.
Previously reported MCV ELISAs used antigen from human
lesion material or Sendai virus expressed N-terminal amino acid
sequences of MC133, raising issues with background skin antigens
and posttranslational antigen processing. To improve water
solubility and provide an expression platform more suitable for
commercial production of a MCV ELISA, we decided to use
hydrophilic antigenic regions of MC084 expressed in E. coli. On
the basis of previous work by Watanabe et al. [22] and our own
homology analyses we chose a C-terminal truncation of MC084
(V123-R230), upstream of A238-Q298 previously found non-
reactive in ELISA by Watanabe [22], as our candidate ELISA
antigen. Our choice of antigen minimizes the possibility of cross
reactivity with vaccinia virus specific antibodies, exclude the
membrane spanning domains of mc084, but include a possible
major antigenic site, identified by hydrophilicity plotting (MC084
N218-R230).
The ELISA is sensitive (100%) and specific, with low inter- and
intra-assay variability. This is in comparison to the lower
sensitivities of 71% and 58%, in the ELISAs reported by Konya
et al. [21] and Watanabe [22], respectively. We have determined
specificity in MCV tissue sections, similar to Konya et al. [21]. To
determine specificity quantitatively, a collection of sera would be
needed.
We have calculated cut-off for our ELISA to include outlier
results from our neonatal control group. The MC status of the
outliers could not be determined, as the data was anonymised.
Any comparisons of our findings with previous ELISA results
must be fundamentally flawed, because different antigen and
expression systems were used. However, no other data are
available, so with the above reservations, we compared the
findings of our serological survey to results reported for Northern
Ireland and two previous ELISA studies in Australia and Japan
[20,21–22]. We find an overall seropositivity in a general German
population of 14.8% and 30.3% in the UK. This correlates well
with previous findings of 16.7% in Ireland (n= 30; IgG responses)
[20], 23% in an Australian population [21] and less so with 6%
reported in a Japanese survey [22].
The age profile determined using the MC084 ELISA
correspond well with our understanding of the natural history of
MCV infections, with low exposure of very young children and a
high prevalence among toddlers and preschool children, where
MCV smear infections is most likely to be transmitted among
larger numbers of children. Our data confirm previously reported
findings of stronger antibody responses in acute MC [21], mostly
in the 2–10 age group [25,28], with waning antibody levels being
detectable as the population ages. This would suggest very little re-
exposure in older age groups.
In contrast to Konya et al. [21], who report a very high
seropositivity rate in their 0–6 month old population of 31%,
explaining this with maternal antibodies, our data do not indicate
a high seropositivity rate in very young children. Seroprevalence
with the mc084 (V123-R230) ELISA is below 5% in 0–1 year olds
and only increases in the age group of 2–5 year olds, not exceeding
25%. Watanabe et al. explained their low overall seropositivity
(n = 108, 6%) [22] in healthy subjects in comparison to the prior
Australian study (n= 357; 23%) [21], with their mc133 ELISA
failing to pick up sera with mc084 antibodies as shown in
immunoblots, indicating that mc133 may not be the best choice of
antigen, underestimating seroprevalence.
The findings in immunocompromised patients and patients with
skin and other inflammatory disorders indicate an increased
seroprevalence in skin disorders, and a decrease in generally or
therapeutically immunocompromised populations, but lack statis-
tical power because of low sample numbers. The gender ratios
calculated, indicate a higher seroprevalence (2.1 fold) in females
than males of in the UK serum collection, but a lower ratio in the
German collection.
In summary, we propose MC084 (V123-R230) is a suitable
antigen for MCV serological surveys when expressed in E. coli. It
includes a probable highly antigenic site at amino acid position
N219-R230. Importantly, the MC seroprevalence of 14.8% in our
German population is a threefold increase over the reported
incidence of MC in a comparable Swiss population of 4.9% [29],
supporting the notion, that MC is an underreported infection. The
assay will allow further investigations into the seroprevalence of
MCV in other geographical areas, including the US, China, Japan
and Australia.
Ongoing work includes possible use of a subpeptide of MC084
(N218-R230) comprising only the highly antigenic site for a
capture ELISA and T cell studies, and the development of an IgM
MC084 (V123-R230) ELISA. We are also in the process of
investigating the MC084 (V123-R230) peptide for its potential to
compete with MCV/VACV entry in a MCV/VACV reporter
assay [30].
Supporting Information
Figure S1 MC084 antigen optimization. The figure shows
the antigenicity of MC084S (aa123–230) as determined by direct
binding ELISA using high titre human serum (HD V0901071). (A)
Saturation was achieved at 3 mg/ml. (B) A maximum of 80%
inhibition of anti-serum antibodies with MC084S as inhibitor was
observed whereas negligible inhibition was observed with BSA and
human IgG.
(TIF)
Figure S2 Comparison of antigen reactivity. The N-
terminal truncation of MC084 i.e. MC084v5 (33–117), C-terminal
truncation of MC084 i.e. MC084S (123–230), N-terminal
truncation of MC133 i.e. MC133S (1–370) and GST tested as
uncleaved fusion proteins on a GST affinity plate to compare
antigen affinity and seroreactivities. The relative absorbance of
individual sera was the same against all antigens tested with only
minimal differences in absorbance.In direct antigen comparison
there was no significant difference between truncations of mc084
and mc133, and no serum showed prevalent reactivity against one
or another of the antigen used. A strep tag was used for detection
of recombinant antigen in western blots. The tag did not interfere
with ELISA results in a serum study of 149 serum samples.
(TIFF)
Figure S3 Tissue staining with high and low litre sera.
Tissue sections stained with high (HD V0901071 (1A, B), HD
V0903005 (2A, B) and low titre sera (HDV0900471 (1C, D),
HDV0900040 (2C, D) in two magnifications (4x and 10x). High
titre sera stained the spinous layers as well as cellular debris and
MC bodies in and around the intraepidermal lobules golden-
brown. The same section stained with low titre sera as determined
Molluscum contagiosum Virus Burden of Disease
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in MC084S ELISA showed much reduced or no reactivity in the
same tissue areas.
(TIFF)
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